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β-catenin overexpression was investigated in transgenic mouse skin carcinogenesis to 
determine at which stage β-catenin deregulation became causal in co-operation with ras and 
fos oncogene activation and/or loss of tumour suppresser genes p53, p21 and PTEN. β-catenin 
has two major functions in being a major node for canonical Wnt signalling, nuclear relocation 
regulates transcriptional targets LEF/TCF and increased nuclear β-catenin expression 
associates with tumour progression; whilst membranous β-catenin binds to E-cadherin to form 
cell-cell adhesion complexes and their failure is associated with invasion. Thus, in cutaneous 
squamous cell carcinoma [SCC], β-catenin mutations result in constitutive overexpression via 
mutations in exon 3, the site for removal via ubiquination, or failures in genes that regulate β-
catenin, such as APC and GSK3β. However, despite the clear relevance of β-catenin in SCC, 
few studies have directly explored constitutive β-catenin overexpression employing classic 
multi-stage mouse skin carcinogenesis to help unravel the mechanism of β-catenin 
deregulation. Therefore, to investigate stage-specific roles in skin carcinogenesis, β-catenin 
overexpression was targeted to transgenic mouse epidermis employing RU486-inducible 
cre/lox and expression of an exon 3-ablated β-catenin transgene [K14creP.Δ3β-cat]. The effect 
of β-catenin overexpression was assessed in co-operation with activated Ras [HK1.ras] and 
Fos [HK1.fos] and loss of PTEN-regulated AKT activation [Δ5PTEN], together with p53 and 
p21 ablation.  
Initial experiments targeted β-catenin overexpression to K14creP.Δ3β-catflx/wt mouse epidermis 
and showed HF anomalies, and alterations to keratinocyte differentiation observed in previous 
studies; and discovered that K14creP.Δ3β-catflx/wt mice displayed compensatory p53/p21 
expression in response to β-catenin that may inhibit spontaneous papillomatogenesis. Indeed, 
creation of the HK1.ras.K14creP.Δ3β-catenin genotype was expected to give typical HK1.ras 
papillomas and as Δ3β-catenin expression was now independent of PTEN/AKT/GSK3β 
signalling this may have given malignancy. However, HK1.ras-K14creP.Δ3β-catflx/wt mice lacked 
papillomas, yet possessed Δ3β-catenin-associated HF abnormalities, skin keratosis and altered 
epidermal differentiation observed previously; typified by patchy keratin K1 but a unique lack of 
hyperproliferation marker K6 expression. HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia also 
expressed membranous β-catenin in basal layers, unlike supra-basal expression typical of control 
3 
 
hyperplasia; and this triggered compensatory p53/p21 responses that may underlie this 
paradoxical lack of tumours. 
These novel findings challenged current dogma that β-catenin overexpression facilitates 
carcinogenesis and were further compounded by a lack of tumours in HK1.ras/Δ3β-catenin co-
operation experiments with conditional p53 loss. Importantly, in K14creP.Δ3β-catflx/wt .p53flx/flx  
mice, p53 loss inhibited Δ3β-catenin phenotypes indicating that p53-mediated responses 
played major roles in development of these skin phenotypes. In addition, HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx  mice also lacked these early phenotypes and exhibited 
differentiation abnormalities typified by an absence of K1/K6 expression; with elevated p21 
and novel expression of p53 family members p63/p73. In particular, strong p73 expression in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis and HFs, suggests that at these early stages 
of papillomatogenesis, oncogenic Δ3β-catenin could be blocked/circumvented by 
p63/p73expression. That these epidermal responses to β-catenin deregulation depended upon 
p53 was further confirmed by p21 knockout, which failed to block responses to Δ3β-catenin. 
 
Although the majority of HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice lacked tumours, four individuals did develop tumours and shared a 
specific characteristic whilst most individuals expressed K14creP.Δ3β-catflx/wt due to leakage 
of K14.creP activity in these rare individuals, the epidermis developed normally into 
adulthood as K14.cre had not leaked. This absence of Δ3β-catenin responses in juvenile 
epidermis requiring RU486-mediated β-catenin overexpression in adults apparently allowed 
these individuals to establish an epidermal context permissive for papilloma formation; as 
originally theorised. Moreover, whilst HK1.ras-K14creP.Δ3β-catflx/wt mice developed 
papillomas, HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours rapidly progressed to aggressive 
SCC due loss of p53, despite the presence of p21. Such HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
conversion to SCC involved reduced membranous β-catenin expression and increased nuclear 
β-catenin, together with E-cadherin loss at the invasive front. This reinforces the idea that β-
catenin deregulation in juvenile development can be overcome by p63 or p73 [but not p21]; 
however, in papillomas, p53 loss in conjunction with nuclear β-catenin induces conversion and 
additional E-cadherin loss facilitates collective invasion. 
This paradoxical tumour block also manifests in Δ3β-catenin co-operation with HK1.fos and 
K14creP-Δ5PTEN genotypes [HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt]. In this context, a 
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novel skin phenotype was also observed; typified by a keratotic, folded, scale-like skin 
exhibiting numerous cysts, increased HF abnormalities, and a disturbed premature/accelerated 
epidermal differentiation. This [dubbed pangolin-like] skin maybe the first to demonstrate 
direct co-operation between fos and β-catenin deregulation, resulting in anomalous 
differentiation consistent with roles such as keratinocytes commitment to differentiation, and 
possibly the decision-making of stem cells in their various niches. These data suggest that the 
block to tumourigenesis following β-catenin activation maybe relatively generic, appearing in 
both fos and fos/PTEN genotypes. Furthermore, p53 loss failed to elicit papillomas, however 
HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx mice again displayed a striking lack of the pangolin 
skin phenotype which clearly indicates responses to β-catenin overexpression were dependent 
on p53 function or responses to p53 loss.  
In vitro analysis of primary transgenic keratinocytes and cell lines produced results more 
consistent with expectations for β-catenin overexpression in terms of inducing resistance to 
calcium-induced differentiation indicative of a transformed phenotype; and the ability to grow 
from clonal density, which suggests a malignant phenotype in HK1.ras-K14creP.Δ3β-catflx/wt 
and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt cell lines. Indeed, migration and cell seeding 
experiments highlighted that β-catenin overexpression may return K14creP.Δ3β-catflx/wt cells 
to a more juvenile/neonatal state, as they exhibited a seeding potential similar to neonatal 
primary keratinocytes; consistent with previous observations that demonstrated β-catenin 
regulates keratinocyte signalling to alter the dermal extra cellular matrix in neonatal skin.  
Overall, this study shows β-catenin roles in developing papillomas and progression to SCC 
was more complex and context dependent than originally anticipated. Logically, in being 
exposed to environmental carcinogens, an epidermis has evolved options to prevent benign 
tumour formation, which becomes lost as papillomas progress to SCC. The findings of this 
study were intriguing and identified potent responses to β-catenin deregulation in juvenile 
epidermis that maybe quite general given they appeared in ras/β-catenin/p53; fos/β-
catenin/p53; ras/p53 and fos/p53 models and maybe applicable to internal epithelia. These 
models highlight several aspects to be pursued in future to gain understanding and fill the void 
concerning causal roles for β-catenin overexpression in cutaneous carcinogenesis. In the final 
analysis the discovery of the mechanism underlying this tumour inhibition may identify targets 
for new treatments.   
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General Introduction: The development of transgenic mice that accurately mimic the 
multistage nature of carcinogenesis provides an ideal opportunity to study the molecular 
mechanism underlying tumour progression (Ogilvie et al., 2017; Lampreht Tratar et al., 2018; 
Tuveson, 2021). These models offer a tractable approach to verify causal roles for mutations 
commonly associated with skin carcinogenesis; explore how progression mechanisms unfold 
in vivo; and also have the potential to identify systems that have evolved to inhibit 
carcinogenesis at each specific stage (Ogilvie et al., 2017; Lampreht Tratar et al., 2018; 
Tuveson, 2021). In clinical terms, the most significant events from the patient viewpoint are 
those that drive the malignant conversion of benign tumours to carcinomas and subsequent 
progression to tumours with increasing metastatic potential (Hanahan and Weinberg, 2011); 
and this aspect of tumour progression is a particular strength of this model (Greenhalgh and 
Roop, 1994).  
The project builds upon an established, well-characterised carcinogenesis model, with a 
flexibility to explore a variety of pathways; whilst gaining valuable insights on mechanisms 
inhibiting/driving tumour progression. Hence, analysis of how the progression mechanism 
unfolds in vivo helps validate suspected driver mutations and identify changes to additional 
key oncogenes and/or TSGs. This will advance the understanding of how normal molecular 
processes fail and provide insight for the potential to inhibit this process in proof-of–principal 
genotypes. By default, this approach also provides novel information regarding normal 
epithelial differentiation, e.g., effects of β-catenin on keratinocyte differentiation and roles in 
epidermal barrier maintenance. 
Many human carcinomas exhibit mutations in β-catenin, a component of the adhesion 
complex, which moves to the nucleus to help integrate membrane signals and alter critical 
gene expression during cell growth (Morin, 1999; Doglioni et al., 2003; Grigoryan et al., 
2008; Krishnamurthy and Kurzrock, 2018). Thus stage-specific loss or overexpression may 
drive or inhibit both malignant conversion and the early stages of malignant progression 
(Malanchi, et al., 2008; Grigoryan et al., 2008). Therefore, in this study inducible expression 
of a stabilised [exon 3-ablated] β-catenin was used to investigate whether canonical β-
catenin/Wnt signalling is key to driving skin carcinogenesis (Doglioni et al., 2003) and further 
investigate whether temporal failures in cell-cell adhesion facilitate invasion during the early 
stages of malignant progression (Morin, 1999; Doglioni et al., 2003; Grigoryan et al., 2008; 
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Krishnamurthy and Kurzrock, 2018). This study may therefore provide valuable insights into 
the complex molecular interplay involved in skin carcinogenesis, and a platform to evaluate 
potential therapeutic value of β-catenin/Wnt signalling interdiction. 
 
1.1 Carcinogenesis  
Carcinogenesis can be defined as the time taken for normal cells to acquire cancer cell abilities 
that allow survival, uncontrolled proliferation and invasion thorough the affected organ to 
become metastatic and ultimately fatal (Hanahan and Weinberg, 2011). Often, these abilities 
are driven by DNA mutation that effects gene expression or gene function that eliminate or 
alter their roles to induces excess proliferation, facilitate invasion and impair cell-cell 
adhesion. The most fundamental capability that cancerous cells first acquire is a sustained 
proliferation state due to inherited [i.e. Cowden’s disease (Liaw et al., 1997)] or acquired 
genetic mutation [i.e. from sun exposure (Zeigler et al., 1994)] that disturb the normal 
homeostasis of cell signalling and deregulate subsequent cell growth via maintained cell cycle 
vitality (Hanahan and Weinberg, 2011). These functions and capabilities can be acquired in 
various types of tumours through different mechanisms and act as drivers or failed inhibitors 
at different times in the different contexts of multistep tumorigenesis. Thus, once generated, a 
specific tumour can remain benign, regress or eventually convert to malignancy depending 
upon the stage-specific responses deployed to inhibit this process.   
Several pathways are common to many tumour types. For instance, a common example is a 
mutation that affects the ras family of oncogenes (Hanahan and Weinberg, 2011; Fernández-
Medarde and Santos, 2011; Hobbs et al., 2016). Here mutations in the GTPase activity that 
govern the negative feedback loop to inhibit ras activity results in a sustained active state of 
ras signalling [see below], which affect a plethora of downstream cell signalling pathways that 
promote proliferation, cell migration, and cell cycle vitality (Hanahan and Weinberg, 2011; 
Fernández-Medarde and Santos, 2011; Hobbs et al., 2016). In addition, once an overt tumour 
is formed in clinical terms for the patient the most important stage is the progression to 
malignancy and increasing invasive potential. In this aspect the failure of cell-cell adhesion 
signalling is a vital component; thus, another common pathway involves somatic mutations in 
the β-catenin gene, that affect its degradation or the molecules that regulate its removal via 
ubiquination which leads to overexpression and amplification of canonical Wnt signalling. 
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This results in deregulation of several crucial transcriptional targets and additional failures in 
direct cell-cell adhesion via β-catenin interactions with E-cadherin (Morin, 1999; Grigoryan et 
al., 2008; Krishnamurthy and Kurzrock, 2018). 
The failure in appropriate responses is often in the domain of tumour suppressor genes. Whilst 
both of these exemplary pathways are common in many types of cancer as highlighted below, 
cancerous cells acquiring a sustained proliferation state is not enough for tumorigenesis as 
they need to acquire another vital ability to evade or overcome the tumour suppresser genes 
responses such as p53 which is part of the p53 protein superfamily that includes p53, p63 and 
p73 (Mollereau and Ma, 2014). The guardian of the genome p53 was found to be defective in 
more than half of human cancers cases, as it acts as DNA repair mechanism via either 
apoptosis or cell-cycle arrest in response to cellular stress signals such as excess proliferation 
(Mollereau and Ma, 2014; Kastenhuber and Lowe, 2017). In the absence of these protective 
responses or if the DNA repair mechanism is not sufficient to halt cancerous cell growth due 
to irreversible DNA damage, this would result in facilitating tumourigenesis as cancerous cells 
acquire several other capabilities including resisting apoptosis, immortal replication, 
angiogenesis and finally invasion and possibly metastasis (Hanahan and Weinberg, 2011). 
The ability of cancerous cells to maintain sustained proliferation and overcome tumour 
suppresser responses are both essential steps in the process of a multistage carcinogenesis, 
which will be explored in this study in the context of cutaneous squamous cell carcinoma. 
This intricate process of carcinogenesis requires a multi-staged step for tumourigenesis and 
one of the most valuable tools to study this complicated mechanism is the use of transgenic 
mice models. This study utilizes the classic skin model of carcinogenesis that involves 3 
stages: the initiation and promotion stages to form a benign tumour [papilloma] which may or 
may not undergo malignant conversion to squamous cell carcinoma [SCC] (Huang and 
Balmain, 2014; Balmain and Yuspa, 2014). 
In this study one logical candidate that fits this profile for a multi-stage carcinogenesis study is 
β-catenin. The deregulation of membrane adhesion and proliferation mediated by failure to 
regulate β-catenin has been implicated in skin and many alternate tumour types (Morin, 1999; 
Grigoryan et al., 2008). However, although β-catenin’s roles were implicated in SCC due to 
Wnt/β-catenin activation being central for activation of several proto-oncogenes and also 
being a integral protein in maintaining cell-cell adhesion, to date no study directly investigated 
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constitutive activation of β-catenin involvement in developing SCC and this study aims to fill 
that void in literature. 
1.2 Skin layers  
The skin is the largest organ of the body and its main function is to act as a barrier from 
physical harm, as well as preventing loss of body fluids. Skin is comprised of different layers 
all geared to maintain a protective barrier that helps regulate body temperature and is one of 
the largest bio reactors e.g. Vitamin D production. Skin can be divided into three layers; the 
epidermis separated by the basement membrane from the dermis with all the appendages such 
as sebaceous and sweat glands and hair follicles and finally beneath it is the subcutaneous 
layer comprised mainly of fat, blood and muscle cells (Alonso and Fuchs, 2003; Blanpain and 
Fuchs, 2006). 
The epidermis can be further subdivided into four layers compartments [Fig. 1.1]; stratum 
basale [Basal layer], spinous layer [suprabasal layer], granular layer and cornified 
layer/envelope (Alonso and Fuchs, 2003; Blanpain and Fuchs, 2006). Each layer is formed by 
keratinocytes that differentiate outwards from the previous layers and express specific 
keratins, as they commit to terminal differentiation and collectively form a mature stratified 
epithelium (Alonso and Fuchs, 2003; Blanpain and Fuchs, 2006).  
The stratum basale, also known as the basal layer is the innermost layer of the epidermis 
which is attached to the basement membrane that separate epidermis from the dermis. This 
layer is the proliferative layer composed of proliferative transit amplifying keratinocytes and 
occasional interfollicular epidermal stem cells, whereas most pluripotent stem cells residue in 
the bulge region of the hair follicle (Watt and Collins, 2008). Together these sets of cells feed 
the proliferation required to maintain the epidermis as a stem cell divides into a stem and 
daughter cell; in turn the transit amplifying keratinocytes divide into a TA and a daughter cell 
that commits to the terminal differentiation programme (Rangel-Huerta and Maldonado,  
2017). Hence the epidermis is continually renewed and mutation containing postmitotic or 
virally infected cells are eventually sequestered into the environment. This the process of 
maintaining correct epidermal homeostasis, hair follicle self-renewal and response to skin 
wounding is under complex control of Wnt signalling as it contributes to the maintenance of 
hair follicles, sebaceous gland and transit amplifying keratinocytes needed for epidermal 
differentiation. (Alonso and Fuchs,2003; Blanpain and Fuchs, 2006; Watt and Collins, 2008) 
23 
 
[Fig. 1.2]. As outlined in detail below, this brings in one of the main reasons for investigating 
the roles of β-catenin in skin cancer as β-catenin helps govern the homeostasis of hair follicle 
morphogenesis and differentiation via their integral role in Wnt signalling (Morin, 1999; 
Grigoryan et al., 2008).  
 
The proliferative basal layer expresses keratin14 [K14] and keratin 5[K5] (Yuspa et al., 1989; 
Yuspa, 1994), whilst the hair follicle express other keratins such as K15 (Blanpain and Fuchs, 
2006), in addition to keratin K6 which is also a marker for wounding or hyperproliferation in 
the epidermis (Rothnagel et al., 1999) [Fig. 1.1]. Moving upward as proliferative cells in the 
basal layer commit to differentiate to the spinous layer or supra-basal layer, which express 
early differentiation markers K1 and K10 (Blanpain and Fuchs, 2006). These keratins are 
connected through a framework of intermediate filaments that anchor the basal cells to the 
basement membrane via hemidesmosomes and connect the keratins to intracellular junctions 
via desmosomes (Blanpain and Fuchs, 2006). These desmosomes are made up mainly of 
cadherin proteins and found to be highly abundant in the supra-basal layer which gives this 
layer the ability to withstood mechanical stress, whilst the basal layer possess a more dynamic 
frame- work of cell-cell adherent junctions with microtubules and actin filaments mediated via 
β-catenin and E-cadherin proteins (Young et al., 2003; Blanpain and Fuchs, 2006). This 
involvement of β-catenin in maintaining cellular adhesion or focal adhesion between the cells 
in the epidermis is the major reason for investigating β-catenin deregulation in the processes of 
skin cancer invasion.  
Further, to maintain correct adhesion and signalling between epidermal cells the anchorage of 
both desmosomes and hemidesmosomes requires attachment of cytoplasmic intermediate 
filaments formed from the correct expression of keratins (Green and Jones, 1996; Jones et al., 
2017). These intermediate filaments span from the nucleus and extend to the protein structure 
of desmosomes and hemidesmosome. Thus, providing epidermal cells with tissue integrity and 
elasticity to withstand mechanical stress whilst maintaining cellular adhesion and signalling 
via binding to cadherin meditated desmosomal arrangements at the cell membrane (Green and 
Jones, 1996; Jones et al., 2017) [Fig. 1.1]. 
Following on subsequently in keratinocyte differentiation, the cells of the supra-basal layer 
migrate into the granular layer which contains keratohyalin granules that help to produce one 
24 
 
of the late-stage differentiation markers, filaggrin and other markers in this layer include 
structural proteins such as loricrin and keratinocyte transglutaminase (Candi et al., 2005). The 
outmost layer known as the cornified envelope is formed via filaggrin collapsing and flatting 
the shape of cells giving it the cornified characteristic and reinforcing this layer by process of 
cross linking several proteins including loricrin regulated by transglutaminase (Candi et al., 
2005; Blanpain and Fuchs, 2006). 
Another major component of the process of epidermal terminal differentiation is the signalling 
controlled by Calcium ions (Ca2＋), also known as calcium dependent terminal differentiation 
(Hennings et al., 1980; Lee and Lee, 2018). The influx of Ca2＋ ions into keratinocytes drives 
terminal differentiation as the concentration of Ca2＋ ions gradually increases from low levels 
in basal layers that increases in supra-basal to higher concentrations up until cornification 
(Hennings et al., 1980; Lee and Lee, 2018). This process also serves as valuable tool allowing 
the culture of primary keratinocytes in vitro under low calcium conditions as well as 
controlling the induction of terminal differentiation by increasing the concentration of Ca2+; 
which is strategy used in this study to investigate oncogenic transformation as this induces 
resistance to normal terminal differentiation (Hennings et al., 1980; Greenhalgh et al., 1989). 
Finally, its needs to be noted that since this study is conducted on mouse model, the epidermis 
of animals with fur are normally very thin [1-2~layers thick] compared to humans (Sundberg 
and King, 1996). However, at neonatal stage[3-4~days] mice epidermis is thicker as it is 
hyperplastic until hair follicle is formed, then it will start to thin out and remain constant in 
adult mice unless hyperplasia is triggered via genetic mutation or wounding (Sundberg and 
King, 1996). This neonatal hyperplasia makes new-born mice ideal to produce primary 







Figure 1. 1: Schematic diagram of normal stratified epidermis with different markers 
expressed in each layer.  
Basal layer cells express K5-K14 and they are anchored to the basement membrane via 
hemi-desmosomes [red junctions] and cells are connected to each other via desmosomes 
[green junction] as well as adherent junctions [blue junctions]. Desmosomes and adhesions 
junctions also connect and surround the supra-basal layer cells which expresses early 
differentiation markers K1-K10 as basal layer commit to differentiation, whilst late-stage 
differentiation markers such as loricrin and filaggrin are expressed in granular layer and 
cornified envelope. The cytoplasmic intermediate filaments [purple lines] emerge from the 
nucleated cells [orange circle] and links to hemi-desmosomes and desmosomes at cells 
membrane. The epidermis terminal differentiation program is influenced by concentration of 
Ca2＋as the concentration gradually increases from low levels in basal layer to highest 








Figure 1. 2: Schematic diagram of normal hair follicle compartments.  
Hair follicles are formed in the dermis and at the base of the HF is the dermal papilla [DP], 
that attached to outer root sheath [ORS], the inner root sheath [IRS] and the developing HF in 
between IRS. Within The ORS, the bulge region of the HF is located just underneath the 
sebaceous gland [SG]. As the HF develop to form the hair shaft at the surface of the skin it 
gradually releases itself from the surrounding sheath to form the hair shaft, thus completing 
the hair cycle. The bulge region contains the pluripotent stem cells regulated via 
Wnt/β‐catenin signalling and contribute to the maintenance of HFs, SGs and transit 









1.3 Skin cancer and squamous cell carcinoma     
Skin cancer is the most prevalent type of malignancy in humans worldwide and more is 
predominant in the Caucasian population with growing estimation of over a million cases 
reported each year (Simões et al., 2015). Skin cancers can be divided into two types:  
melanomas and non-melanoma skin cancers [NMSC], which represent the vast majority of 
cases. Although NMSC considered to be relatively less fatal than melanomas, the increasing 
number of cases which represent nearly 90% of skin cancer cases burden the health care 
providers to give patients the best prognosis and treatment. (Simões et al., 2015; Jones et al., 
2020).  
Non-melanomas can be also subcategorised into two major types known as basal cell 
carcinoma [BCC] representing majority of cases and squamous cell carcinoma [SCC], where 
SCC is the aggressive type out of the two with higher chance of metastasis and associated with 
a higher mortality rate (Huang and Balmain, 2014; Barton et al., 2017). Although BCC cases 
are higher, the mechanism of developing BCC is well documented to be mostly associated 
with deregulation of Wnt/sonic hedgehog pathway, whilst SCC could arise from a wide range 
of signalling irregularities (Clifford and DiGiovanni, 2010; Huang and Balmain, 2014).  
Squamous cell carcinomas cases are generally associated with skin exposure to UV light, 
however recent studies have found that developing SCC could be a consequence of hereditary 
diseases such as multiple self-healing squamous epithelioma, and dyskeratosis congenita or 
sporadic mutation in several key genes (Huang and Balmain, 2014), which found to be 
frequently associated with SCC cases including Ha-RAS, K-RAS, p53, NOTCH1 and NOTCH2 
(Huang and Balmain, 2014). Mutations in these genes were implicated in many types of 
cancers, but in the context of SCC they highlighted the recurrence of these mutations in 
different types of Squamous tumours found in skin, neck, head and lung (Huang and Balmain, 
2014). This finding also suggests that individual developing SCC might be susceptible to other 
types of diseases or it might be a feature of an underlying illness due to carrying these 
mutations (Barton et al., 2017). 
The treatment of SCCs usually requires surgical treatment with or without chemotherapy 
depending on the seriousness of the condition, however metastasised SCCs are associated with 
poor long-term prognosis, adding to that the number of new cases each year which burden the 
health care providers worldwide (Clifford and DiGiovanni, 2010; Huang and Balmain, 2014; 
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Barton et al., 2017). This highlights the importance of providing a better understanding of the 
mechanism of developing SCCs to help design a better countermeasure to this disease. To 
achieve that goal, the use of animal models has proven to be a valuable tool in studying the 
multistep process of carcinogenesis as expanded on in the next section.  
 
1.4 Genetic engineering of animals to study carcinogenesis. 
The use of animal models, specifically mice, are one of the most useful tools employed in 
studying and understanding human cancer for the past century (Tuveson, 2021). In terms of 
cellular and molecular characteristics that govern carcinogenesis the tumour biology between 
humans and mice shares an estimate of 80% similarity in mutated genes (Waterston et al., 
2002). This has led to the current great advancement in developing mouse models that offer 
tractable systems to understand cancer molecular biology via inducing mutations into the 
transgenic mouse genome in a spatially or/and temporal expressed manner (Ogilvie et al., 
2017; Lampreht Tratar et al., 2018; Tuveson, 2021). 
The creation of transgenic mice can generally be accomplished via three methods involving 
insertion of new DNA into the mouse genome (Lampreht Tratar et al., 2018). The methods 
are retroviral infection of mouse embryos at different developmental stages, the standard 
method of microinjection of DNA constructs directly into the pronucleus of fertilized mouse 
oocytes or lastly via a gene-targeted transgene approach that involves mouse embryonic stem 
[ES] cell manipulation at specific loci (Lampreht Tratar et al., 2018). These different 
approaches have been used over the years to mimic human cancer biology by creating 
transgenic mice carrying a gain of function [GOF] mutation or a loss of function [LOF] 








1.4.1 Loss of function mutations in transgenic mice 
Inducing a LOF mutation in a transgenic mouse that causes silencing or depletion of specific 
gene function is a useful tool to investigate possible therapeutic targets and understanding the 
cause and effect of the gene function in cancer development (Lampreht Tratar et al., 2018). 
This approach has been applied to study different types of genes including oncogenes [e.g. ras, 
fos], tumour suppresser genes [e.g. p53, p21, PTEN] and even housekeeping genes [e.g actin] 
(Walrath et al, 2010). The knockout of specific gene function or expression was typically 
accomplished via two methods: either by constitutive knockout, where gene expression is 
inactivated in every cell or via conditional knockout where the gene expression is inactivated 
in specific tissues and/or is inducibly modified at specific stages of mouse development or in 
adults (Kersten et al., 2017). 
The constitutive knockout also known as generic or conventional knockout uses a gene-
targeted transgene approach to create the transgenic mouse (Jiang, 2013). Briefly, in this 
approach genetically modified embryonic stem cells with the targeted transgene are 
microinjected into mouse embryos and then transferred to pesudopregrant mice. The mice give 
birth to chimeric offspring carrying both genetically modified cells and normal cells. These 
chimeric offspring would then be mated with wild type or ICR mice and PCR testing would 
reveal successful inheritance of the targeted transgene (Agarwal et al., 2009). The TSGs p21 
and p53 are excellent examples of the constitutive knockout approach [See Chapter 6] as this 
knock out method tested their general effect on body homeostasis as well as carcinogenesis 
due to the loss of gene expression with other activated oncogenes such as ras and fos 
(Donehower et al., 1992; Greenhalgh et al., 1996). However, this approach suffers from two 
major disadvantages, as it does not mimic the sporadic mutations that frequently appear in 
human carcinogenesis (Maddison et al., 2005) and this method is also not applicable to genes 
that induce embryonic lethality (Eisener-Dorman et al., 2009) such as β-catenin and E-
cadherin (Grigoryan et al., 2008; Tian et al., 2011). 
On the other hand, employing an inducible element to the conditional knockout method offers 
a gateway to overcome the limitations of the constitutive knockout approach e.g., animal 
viability. Thus, inducible knockout can mimic the sporadic mutations in human carcinogenesis 
more accurately by inducing the mutation both spatially and temporally at the chosen time and 
avoiding embryonic lethality or reduced viability in adults (Walrath et al, 2010).  
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The application of the conditional knockout method requires use of bacterial Cre [Cre-loxP] or 
yeast FLP enzyme [FLP-FRT] technologies, where both function as a tissue specific 
recombinase to catalyze recombination of a targeted DNA segments encoding specific gene 
function flanked by loxP sites or FRT sites (Branda and Dymecki, 2004; Saunders, 2015; 
Lampreht Tratar et al., 2018). This technology can be used to either inactivate or activate a 
gene function depending on the placement and the orientation of the targeted flanked sequence 
by loxP or FRT (Saunders, 2015; Kim et al., 2018). For instance, to create a cre-loxP mouse 
targeting a specific gene expression in specific tissue [e.g., skin], separate Cre and loxP mice 
would be created. For example for keratinocytes Cre recombinase can be expressed by 
promotors such as keratin 14 [K14] or Keratin 5 [K5] (Brown et al., 1998; Berton et al., 2000; 
Zhou et al., 2002; Huang and Balmain, 2014 Kim et al., 2018) to create [K14.creP] or K5 
driven cre [K5.creP].  
Creating this transgene requires a standard transgene insertion method via microinjection of 
DNA constructs directly into the pronucleus of fertilized mouse oocytes, where offspring are 
screened for successful inheritance of the incorporated transgene (Gordon and Ruddle, 1981; 
Lampreht-Tratar et al., 2018). On the other hand, the mouse carrying the flanked sequence by 
loxP is frequently generated using the gene-targeted transgene approach discussed in the 
constitutive knockout method. However, here the embryonic stem cells are manipulated to 
incorporate loxP sites between targeted sequences via selective recombination, where ES 
resistant clones are inserted into zygotes to create chimeric offspring these are screened for 
carriers of the loxP transgene known as the Floxed allele (Lampreht Tratar et al., 2018). Once 
the transgene of promotor driven Cre [i.e. K14.creP] and the loxP flanked sequence transgene 
[i.e PTEN exon 5 or p53 exon 2-10; see chapter 6/7] are generated, they are crossed to create 
the conditional knockout mouse under the control of cre activation, where this activation could 
be either non-inducible or inducible (Saunders, 2015; Lampreht Tratar et al., 2018). 
Employing the inducible Cre.loxP technology utilizes the full potential of this approach by 
having a tissue specific spatial and temporal control over cre activation that consequently 
activates the targeted mutation flanked by loxP at intended times by the investigator 
(Kellendonk et al., 1996; 1999; Whitfield et al., 2015; Saunders, 2015; Kim et al., 2018; 
Lampreht Tratar et al., 2018). The inducible system of cre recombinase requires the use of a 
hormonal binding domain of steroids receptors which include progesterone, estrogen, 
glucocorticoid, mineralocorticoid and androgen receptors (Kellendonk et al., 1996; 1999; 
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Whitfield et al., 2015; Saunders, 2015; Kim et al., 2018; Lampreht Tratar et al., 2018). The 
cre recombinase DNA sequence is fused to a mutated form of a hormonal binding domain of 
choice depending on the type and requirement of the experiment (Kellendonk et al., 1996; 
1999; Whitfield et al., 2015). For instance, progesterone and estrogen based receptors are both 
frequently used to provide temporal control yet differ in application.  
Thus, cre activity is regulated by fusion to a mutated form of human progesterone ligand 
binding domain [PLBD] known as Cre.PR1 and can only be activated once a synthetic anti 
progesterone treatment RU486 is applied to the transgenic animal (Kellendonk et al., 1996; 
1999) otherwise Cre is sequestered in the cytoplasm. This treatment results in dimerization of 
the PLBD element and translocation into the nucleus, where the cre component binds to DNA 
at loxP sites, which result in an irreversible ablation of loxP -flanked [floxed] DNA sequences 
(Kellendonk et al., 1996; 1999). Thus, providing a useful tool to study LOF or GOF mutations 
at different stages of development and avoids the possible embryonic lethality or genetic 
defect that may arise from embryonic stage activation. In addition to studying compensatory 
elements and phenotypes development in response to the induced mutation (Kellendonk et al., 
1996; 1999; Saunders, 2015; Lampreht Tratar et al., 2018). 
This briefly summarises the evolution of inducing germline mutations in transgenic mice and 
below the differences between the constitutive and conditional LOF approach are outlined 
together with some similarity in inducing GOF mutations. 
 
1.4.2 Gain of function 
The GOF approach in transgenic mice is widely used to study the roles of oncogenes 
overexpression in driving cancer development (Lampreht Tratar et al., 2018). Thus, to achieve 
this purpose several methods of inducing GOF mutation in transgenic mouse have been 
developed. 
One of which is the classical constitutive random insertion model, where the transgene gene is 
incorporated randomly into the genome causing GOF of a specific gene expression (Iwakuma 
and Lozano, 2007; Konishi et al., 2007). This can be achieved by viral vector-based 
transfection of mouse early embryos and implantation of these embryos into female mice 
where offspring are crossed with ICR mice and can be screened for carriers of the transgene 
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(Lampreht Tratar et al., 2018). More commonly This is achieved via microinjection of DNA 
constructs directly into the pronucleus of fertilized mouse oocytes where offspring of the 
mated mice are screened for carriers of the incorporated transgene (Greenhalgh et al., 1993a; 
Greenhalgh et al., 1993b; Lampreht Tratar et al., 2018) [e.g. HK1.ras or HK1.fos see section 
1.5]. Here the main drawback is random incorporation of the transgene which may yield 
unwanted results or birth defects due to uncontrollable expression levels and random 
integration (Lampreht Tratar et al., 2018). 
To overcome this limitation, a Knock-in Permissive Locus Model can be employed where a 
more stable GOF is induced using a known genetic loci called ROSA26 (Hohenstein et al 
2008; Casola, 2010). This loci lacks the expression of any essential genes for body hemostasis 
and is devised to integrate the GOF transgene under a more controlled expression in 
conjunction with Cre recombinase to utilize spital and temporal control as well (Hohenstein et 
al 2008; Casola, 2010). 
Alternatively, the cre.loxP system can incorporate a STOP sequence [ strong transcription and 
translation termination sequence], where the STOP cassette  is flanked by loxP site and placed 
in between the promoter and coding sequence of the target gene (Jackson et al., 2001). Thus, 
the gene of interest cannot be transcribed without cre activation that excises the STOP 
sequence flanked by loxP resulting in expression of the gene of interest in the targeted tissue 
in spital and temporal manner (Jackson et al., 2001; Masre et al., 2017; 2020). 
This briefly summarises some common technologies used in recent years and this study 
utilized a variety of the discussed approaches as illustrated in sections 1.6-1.8 and Chapters 3-
7 below. However, before the evolution of genetic engineering of transgenic mice, a 
steppingstone in the use of animal models to study carcinogenesis was the use of the classic 




1.5 The classic mouse model of two-stage chemical carcinogenesis 
The animal model of two-stage chemical carcinogenesis is one of the most valuable tools used 
over the last 100 years that led to a better understanding of cancer development overall 
(Balmain and Yuspa, 2014). This model helped in defining the classical stages of cancer 
development known as the initiation stage, promotion stage given it the name the two-stage 
chemical carcinogenesis which result in tumour formation that may or may not progress to 
malignancy (Yuspa et al., 1991; Yuspa, 1994; Balmain and Yuspa, 2014). 
The model works via applying doses of chemical mutagen that induces mutations resulting in 
establishing a pool of cancerous cells and applying another dose of a mutagen at separate time 
that induces mutations resulting in prompting cancerous cells which could be used together in 
this fashion or independently from each other in this model (Yuspa, 1994). One of the most 
common initiator mutagens is 7,12-dimethyl-benzanthracene [DMBA], which at low doses 
leads to inducing several mutations resulting in irreversible DNA damage such as HRAS 
mutation at codon 61 (Balmain, et al 1985; Roop et al., 1986). This specific mutation of HRAS 
has been identified to be the main initiating mutation in this model and recent studies have 
reported this mutation as well to be the most common RAS mutation found in human SCCs 
(Huang and Balmain, 2014). The targeted regions of the epidermis in the initiating step are the 
proliferative basal layer and bulge region of the hair follicle where most of the stem cells 
residue (Huang and Balmain, 2014).  
However, a low-level dose of DMBA is usually not sufficient to produce a tumour therefore 
promotion is needed via applying another mutagen such as 12-O-Tetradecanoylphorbol-13-
acetate [TPA], that induces several other mutations resulting in activation of other pathways 
including c-fos which is highly involved in epidermal proliferation and differentiation 
(Greenhalgh and Yuspa., 1988; Greenhalgh et al., 1990). 
Two stage chemical carcinogenesis involving DMBA initiation and TPA promotion leads to 
formation of squamous cell papilloma with the earliest appearing at 10-12 weeks and are 
usually TPA independent (Hennings et al., 1993) with the majority appearing over the next 20 
-60 weeks and are usually dependent on continued TPA promotion. Thus, the first sets usually 
persist and 10% to 20% progress to squamous cell carcinoma; whist the later cohort typically 
regress on cessation of TPA promotion (Hennings et al., 1993). However, the rate of 
progression and conversion is highly dependent on the type of mutagens used as initiator and 
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to some extent on the promoter employed, as well as the level of dose applied to the animal 
(Hennings et al., 1993; Yuspa, 1994 Balmain et al., 1994).  
Briefly, in the DMBA/TPA two-stage chemical carcinogenesis model, the sub-carcinogenic 
dose employed in initiation induced multiple mutations mainly HaRAS at codon 61 which led 
to sustained proliferation due to activation of the ras pathway [see below]. Subsequent 
promotion with TPA amplified the proliferation rate by activating the fos oncogene which is 
downstream of the ras pathway. This led to formation of squamous papillomas that may or 
may not progress to carcinoma.  
Although the two-stage chemical carcinogenesis model has provided a valid system to study 
carcinogenesis (Hennings et al., 1993; Yuspa, 1994 Balmain et al., 1994), it suffers from a 
major flaw, as the use of such mutagens induces numerus mutations that may be irrelevant to 
the carcinogenic process. Therefore, as outlined below in this study an animal model was 
employed that mimics the classic two-stage chemical carcinogenesis resulting in papillomas 
and carcinomas but without the need to use mutagens. 
 
1.6 The HK1 transgenic mouse model of multistage carcinogenesis  
Transgenic mouse models of carcinogenesis have evolved greatly over the last 30 years, and 
one of the great advances in this field is the ability to mimic the two-stage chemical 
carcinogenesis model via the use of keratin promotors [modified keratin targeting vectors] to 
achieve exclusive epidermal expression of an oncogene [i.e. HaRAS, C-FOS] to initiate 
carcinogenesis instead of using mutagens (i.e. DMBA). Thus, in cancer studies, the ability to 
stably introduce genes into the germline of mice has greatly enhanced prospects for the 
generation of relevant animal models to explore the molecular mechanism of neoplastic 
disease in vivo (Stewart et al., 1984; Rothnagel et al., 1993; Greenhalgh and Roop, 1994). 
Aside from investigating a known genetic insult, transgenic mice offer the possibility to 
determine the influence of factors critical for tumour progression, such as blood supply, an 
intact immune system, hormonal and cell-mediated growth controls, and physical barriers to 
cell growth. These parameters are absent in cell culture systems, however once developed, 
cells derived from transgenic models are easily exploited for further in vitro experimentation. 
A useful transgenic model system must be able to assess relevant multiple, stage-specific 
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genetic or epigenetic insults. In this respect, mouse skin is an ideal target tissue, being the 
classical laboratory animal model for multi-stage carcinogenesis for the last 50 years, with an 
inherent discrete series of well-defined tumour pathologies and well characterised molecular 
biology (Balmain and Yuspa, 2014). This fact, coupled to the well characterised molecular 
biology of skin makes, it an ideal tissue to couple to the latest in inducible gene switch 
technology to explore oncogene and TSG synergism in vivo with typically a minimal threat to 
the viability of the animal. 
  
In the design of these studies, a strength in terms of animal research is that by employment of 
epidermal-specific expression vectors coupled to an inducible cre/lox system (Berton et al., 
2000), disease is prevented in internal organs or during embryogenesis and development- but 
as this project evolved, this was not the case. Moreover, in addition to being able to localise 
disease to a specific skin site, use of inducible systems gives breeder animals that are non-
phenotypic until application of the inducer hormone, a significant feature of the refinement 
category of the 3Rs during breeding. As found in this β-catenin model, such internal 
expression can compromise animal viability particularly when assessing multiple insults.  
 
Another major advantage of skin is the accessibility which facilitates application of the 
inducer hormone to localize the disease and allows macroscopic observation of neoplastic 
events without invasive procedures. Once established each parental genotype becomes a 
comparison control in the exploration of transgene synergism in bi-genic and tri-genic genotypes 
to help minimize numbers.  
 
In this study the model uses a modified human keratin 1 (HK1) as targeting vector to achieve 
exclusive epidermal expression of HaRAS and C-FOS oncogenes (Greenhalgh et al., 1993 a-
c). The HK1 vector is a truncated form of the human K1 gene that is missing several 
regulatory elements in comparison to the mouse K1 (MK1) gene, which results in the HK1 
being expressed in 30-40% of the basal layer keratinocytes with proliferative potential, whilst 
the indigenous MK1 is only expressed in rare basal cells as they commit to differentiation 
(Rothnagel et al., 1991; 1993) [Fig. 1.3]. Further this HK1 vector 1 targets exclusively to the 
interfollicular epidermis [IFE] [Fig. 1.3], which for ras and/or fos activation resulted in 
formation of benign papillomas that do not spontaneous convert to carcinoma (Greenhalgh et 
al., 1993a-c; 1995; Greenhalgh and Roop, 1994). On the other hand, using basal layer keratin 
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as promoter such as Keratin5 that also targeted HaRAS expression to the outer sheath of the 
hair follicle and bulge region where most of the epidermal stem cells reside; which resulted in 
the formation of malignant SCCs and spindle carcinomas (Brown et al., 1998).  
 
 
This expression in the basal layer, made this truncated HK1 clone an ideal vector to achieve 
expression exclusive to the epidermis and target the proliferating basal layer keratinocytes 
with activated oncogenes (Rosenthal et al., 1991). Thus, mimicking the two-stage chemical 
carcinogenesis, the initiating and promotion stages to form papilloma in this model can be 
done by expressing activated ras and fos oncogenes with HK1 as vector [HK1.ras] and 
[HK1.fos] to achieve the expression in the keratinocyte basal layer of the intra-follicular 
epidermis without the use of mutagens (Greenhalgh et al., 1993 a-c; 1995; Greenhalgh and 
Roop, 1994). Given that these papillomas do not convert to malignancy without additional 
oncogene or TPA promotion (Greenhalgh et al., 1995) it makes them ideal to study causal 
roles of other oncogenes involved in tumour progression and conversion to carcinoma 
(Greenhalgh et al., 1995; Wang et al., 1995; 1998; Yao 2006; 2008; Macdonald et al., 2014; 








Figure 1. 3: Confirmation of the expression profile of the HK1 vector:  
[A] Diagram of human keratin 1 [HK1] targeting vector. This is based on the 12-kb EcoRl 
clone of the human keratin 1 gene which proved to be truncated; missing the 3’ flanking 
sequences that contain the Ca2+-responsive regulatory elements for correct supra-basal 
expression and is expressed in proliferative basal cells. This enabled the targeting of 
transgene expression exclusively to basal layer keratinocytes [but not follicles] and also 
following conversion to malignancy HK1 vector expression is detectable in SCC (Greenhalgh 
et al., 1995). In this model activated v-rasHa or FBR/J v-fos genes were inserted at the Bam Hl 
and Cla l sites (Greenhalgh et al, 1993a; 1993b). [B] Introduction of the LacZ reporter gene in 
HK1.β-gal mice and staining newborn frozen sections with X-gal, confirms HK1 vector 
expression in the basal layers of interfollicular epidermis but not hair follicles. [C] Wild type 




1.6.1 Phenotypes produced in HK1.ras transgenic mice  
The ras family of oncogenes including Ha-ras, K-ras and N-ras are one of the first oncogenes 
to be discovered over the last 30 years. This family play a crucial role in cellular proliferation, 
cell cycle vitality, cells migration, apoptosis and senescence. This can be attributed to ras 
being the gate keeper of a plethora of downstream effectors that a play major role in cellular 
proliferation and differentiation (Fernández-Medarde and Santos, 2011; Hobbs et al., 2016).  
The ras gene activation is governed by GTPases activation cycle between ras-GDP binding 
inactive state and ras-GTP binding active state, which is the process that is conveniently found 
to be defective in mutated ras leading constitutive activation of ras pathway [Ras-GTP binding 
active state on ras (Huang and Balmain, 2014; Hobbs et al., 2016). In skin ras can be activated 
via epidermal growth factor receptor [EGFR] signalling, which plays a vital role in skin 
homeostasis (Kern et al., 2011; Doma et al., 2013). EGFR signalling leads to downstream 
switching of ras-GDP [inactive] binding to ras-GTP [active] starting the ras pathway cascade 
known as Ras/MAPK pathway, where ras activates RAF which phosphorylates MEK and 
activates ERK leading to activation of several transcriptional targets such as AP-1 complex via 
activating fos/jun component [Fig. 1.4] (Deng and Karin, 1994; Roberts and Der, 2007; Doma 
et al., 2013). Ras also activates other pathways such as the phosphoinositide-3 kinases 
(PI3K)/AKT pathway (Martini et al., 2014; Hopkins and Parsons, 2014) that induces cellular 
proliferation and resistance to apoptosis [Fig. 1.4] (Martini et al., 2014; Hopkins and Parsons, 
2014). This pathway is of interest in this study as the  PI3K/AKT pathway is negatively 
regulated by tumour suppresser gene PTEN (Hopkins and Parsons, 2014) and deregulation of 
this pathway could induce β-catenin overexpression through AKT associated phosphorylation 
of GSK3-β that is responsible for down regulating β-catenin [Fig. 1.4] [see β-catenin section], 
which is a mechanism hypothesized to be highly associated with the result seen in co-
operation between ras, fos and PTEN loss (Yao et al., 2006;2008; Macdonald et al., 2014) 






Figure 1. 4: Schematic diagram of RAS activation and downstream signalling [green 
highlighted pathways are of interest in this study].  
EGFR Signalling triggers GTPase activity of ras from the resting GDP-bound state to the 
active GTP-bound state resulting in activating several pathways downstream of the MAPK 
pathway cascade including activation of transcription of Fos/Jun family members [i.e., C-fos] 
leading to active expression of AP-1 which induces cellular proliferation and differentiation. 
Ras activation also interacts with PI3K/AKT pathway which is also inhibited by PTEN 
regulation. This failure of PTEN [as in the HK1 model] leads to oncogenic activation of AKT 
that phosphorylates GSK3-β to inactivate roles in β-catenin degradation and thus activating 
Wnt/β-catenin pathway resulting in increased cellular proliferation. 
 
The implications of ras in all of these pathways has increased the research attempting to find 
an anti-ras therapy, since ras mutations are found in approximately 30% of all types of human 
tumours. Most of ras mutations are missense found in three hotspot codons 12,13 and 61 
(Fernández-Medarde and Santos, 2011; Hobbs et al., 2016). In human SCCs cases including 
skin, head, neck and lung, Ha-Ras mutations are the most prevalent, where according to most 
recent studies the specific mutation at codon 61 is the most common (Huang and Balmain, 
2014).   
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This specific mutation is known as the initiating mutation in the DMBA treated mouse model 
of two-stage chemical carcinogenesis and the codon 61 mutation is also the mutation that 
activates  v-rasHA [ Harvey murine sarcoma virus (Ha-MSV)]. When this v-rasHA gene was 
infected into mouse primary keratinocytes the results showed a transforming phenomena in 
terms of resistance to calcium induced terminal differentiation (Hennings et al., 1980) and 
increased proliferation in response to v-rasHA activation (Roop et al., 1986). Furthermore, 
when these infected cells were grafted onto nude mouse skin this resulted in formation of 
benign papillomas (Roop et al., 1986). Thus, this study established the ability of v-rasHA to 
mimic the initiation step of DMBA-mediated two-stage chemical carcinogenesis but, it still 
required a promotion agent in the form of wounding to form the papilloma (Roop et al.,1986). 
This study has facilitated the ability of driving ras activation in skin using a keratin promoter. 
The model uses the HK1 promoter (Rosenthal et al., 1991) to drive exclusive epidermal 
expression of v-ras, creating HK1.ras transgene (Greenhalgh et al., 1993a). There are two 
transgenic mouse strains of HK1.ras in this study, known as HK1.ras1205 and HK1.ras1276 
(Greenhalgh et al., 1993a). Mice carrying HK1.ras1205 are capable of developing a stable 
benign papilloma, within 6-7 weeks in response to wounding promotion, whilst the 
HK1.ras1276 line is insensitive to wound promotion and needs the promotion stimulus from 
HK1.fos to produce papillomas (Greenhalgh et al., 1993c). This project employs HK1.ras line 
1205 not 1276, and is thus referred to as HK1.ras   throughout the text.  
Mice carrying the HK1.ras transgene can be identified grossly at neonatal stage [~3-5day] by 
having a wrinkly skin phenotype, that disappears during neonatal development via a massive 
hyperkeratosis beginning by d10 such that by d21 these mice start to maintain a normal 
looking skin indistinguishable from wildtype mice at adulthood. Of importance, these 
papillomas formed by HK1.ras expression did not convert to malignancy unless treated 
repeatedly with TPA, which make this model ideal to study the genetic mutations that drive 







1.6.2 Phenotypes produced in HK1.fos transgenic mice    
 Fos is a family of genes [c-fos, fosB, Fra-1, Fra-2] that form a heterodimer with jun family of 
genes [c-jun, junB, and junD] and bind to DNA to regulate transcription of the activator 
protein 1 [AP-1]. This plays a crucial role in skin homeostasis, cellular proliferation, 
differentiation and apoptosis. In skin homeostasis AP-1 transcriptional factors are highly 
implicated in regulating terminal differentiation (Fisher et al., 1991; Greenhalgh et al., 1993b; 
Basset-Seguin et al., 1994; Angel et al., 2001; Eckert et al., 2013). AP-1 is one of the 
transcriptional targets of the ras-MAPK pathway as mentioned earlier, and it was reported that 
increased expression of AP-1 associated transcriptional factors promote tumorigenesis (Young 
et al., 1999) which was associated with a significant increase in AP-1 transcription genes 
specially C-FOS (Greenhalgh and Yuspa., 1988; Greenhalgh et al., 1990; Schlingemann et al., 
2003). The roles of fos in skin was also investigated in transgenic mouse skin using LacZ/fos 
fusion which illustrated that fos is expressed in all layers of the intrafollicular epidermis [IFE] 
including hair follicle (Smeyne et al., 1992).  
Similarly, in adult humans the expression of fos was also normally found in basal layer and 
upper differentiated layers of the epidermis (Fisher et al., 1991; Greenhalgh et al., 1993b; 
Basset-Seguin et al., 1994; Angel et al., 2001). This indicate that fos is an essential component 
in maintaining epidermal differentiation and deregulation of its function could result in 
facilitating tumorigenesis. To test fos roles in tumourigenesis, an in-vitro study tested inducing 
transfection of the FBJ murine osteosarcoma virus v-fos gene into a papilloma LINE SP1  
(Strickland et al., 1997) derived from DMBA/TPA promotion and thus expressing  an 
activated rasHA (Greenhalgh and Yuspa, 1988). This experiment resulted in formation of 
malignant SCC when grafted into nude mice skin (Greenhalgh and Yuspa, 1988) Further 
experimentation confirmed the co-operation of v-fos and v-rasHA   via infection into primary 
mouse keratinocytes and grafting into nude mice skin which again resulted in highly 
aggressive SCCs (Greenhalgh et al., 1990). In this study primary keratinocytes carrying v-fos 
alone resulted in a hyperplastic skin in grafts, whilst cell lines carrying v-rasHA produced 
benign papilloma (Greenhalgh et al., 1990). Both of these studies highlighted that 
overexpression of fos alone was insufficient to produce skin tumours, however co-operation 
with ras activation enable tumorigenesis and malignant conversion which highlight the 
promotion potential of fos as an oncogene. 
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The roles of c-fos in SCCs using HK1 promoter tested the effect of driving c-fos expression 
exclusively in the epidermis. This was conducted in a similar manner to HK1.ras, where the 
viral form of aggressive v-fos driven from Finkel-Biskis-Jenkins (FBJ) osteosarcoma virus 
(Greenhalgh et al., 1990) was used to construct HK1.fos transgene; (Greenhalgh et al., 
1993b). In the absence of other events, tumour development in HK1.fos mice took 8-12 
months post ear-tag wounding for HK1.fos mice to develop benign, highly keratotic 
papillomas (Greenhalgh et al., 1993b) and as outlined below required the initiating elements 
of rasHa activation (Greenhalgh et al., 1990; 1993c) as a prior event to papilloma formation. 
Of note in the in vitro grafting experiments (Greenhalgh et al., 1988; 1990) this led to 
metastatic SCC, whereas in vivo the more relevant HK1 transgenic mouse model led to stable 
autonomous papillomas without spontaneous malignant conversion (see below; Greenhalgh et 
al., 1993c). 
 Indeed, in the HK1 model TPA promotion was often required to induce malignancy and 
HK1.fos mice required applying TPA treatment for over 12 months which eventually resulted 
in papillomas that converted to SCC (Greenhalgh et al., 1995) and here endogenous c-rasHa 
was found to be activated (Sutter et al., 1994; Greenhalgh et al., 1995). Thus, again ras and 
fos with extended TPA promotion was required for conversion to malignancy. These data 
indicate that unlike in vitro models and graft assays, even HK1.fos combined with amplified 
expression of c-fos alone was insufficient for tumour progression (Greenhalgh et al., 1993b) 
and other multiple oncogenic events are needed such as HK1.ras (Greenhalgh et al., 1995) or 
long-term promotion from wounding or TPA to elicit even a benign papilloma- hence these 
mice are ideal to study the requirements for papilloma formation and malignant conversion.   
Additionally, in other transgenic mouse studies conducted on constitutive expression of fos 
resulted in osteosarcomas and chondrosarcomas due to fos roles in promoting bone growth, 
whilst fos null studies showed several defects including osteoporosis, lymphopenia and 
delayed gametogenesis (Saez et al., 1995). However, on an epidermal level c-fos null mice 
showed a fairly normal epidermal differentiation pattern indistinguishable from normal mouse 
(Saez et al., 1995). This suggests that c-fos absence in the early stages of tumour promotion 
could be taken over by other oncogenes in response to TPA treatment [v-ras/c-fos null], but 




1.6.3 Phenotypes of HK1.ras/fos mice and tumour development 
To develop squamous cell benign papilloma in the HK1.ras genotypes, wound promotion was 
required, which was activated via tagging the mice ear. Hence HK1.ras[1205] develop a 
benign a papilloma within 8-10 weeks post ear tag wounding in 100% of animals; whilst 
HK1.fos genotypes develop a delayed papilloma  8 -12 moths post tagging (Greenhalgh et al., 
1993a; 1993b). One aspect of the HK1.ras 1205 strain was their acute sensitivity to wound or 
TPA promotion. Given this observation and experiments performed in the USA, this indicated 
that use of this line crossed with HK1.fos mice could exceed the limits of animal 
experimentation in the UK ; thus as outlined above the alternate HK1.ras 1276 strain was 
employed in these co-operation experiments (Greenhalgh et al., 1993c). HK1.ras 1276 mice 
never develop papillomas however when crossed with HK1.fos mice in the UK, the bi-genic 
HK1.ras1276/fos progeny now develop papillomas over a slower 4-6 month period (Greenhalgh 
et al., 1993c)[Fig. 1.5] and these were subsequently employed in HK1.ras, HK1.fos and PTEN 
loss experiments (Yao et al., 2006; 2008; Macdonald et al., 2014).   
 
The HK1 promoter enabled HK1.ras/fos to be expressed at a late stage of embryonic 
development [day ~19] thus avoiding any lethality in utero and the exclusive epidermal 
expression driving constitutive expression of ras and fos oncogenes which elicits a notable 
increase in changes to the overt appearance of these mice. Again, mice carrying the HK1.ras 
transgene can be identified grossly at the neonatal stage [~3-5day] by having a wrinkly skin 
phenotype, that shortly disappears via a massive hyperkeratosis by d10 and by d21 HK1.ras 
mice of either strain maintain a normal looking skin indistinguishable from adult wild type 
mice. The overt appearance of these mice is shown in Fig. 1.5, and here the HK1.ras1276/fos 
mice initially exhibit a greater degree of wrinkled skin resulting in a greater hyperkeratosis 
which can persist into early adulthood but then returns to normal. With respect to 
papillomatogenesis the wound sensitive HK1.ras line produces larger papillomas compared to 
age matched HK1.ras1276/fos, but if the tag is lost in HK1.ras 1205 line papillomas typically 
regress whereas 1276/fos papillomas persist- however these papillomas did not spontaneously 
convert to malignancy even when maintained for over 12 -16 months, unlike in many other 






Figure 1. 5: Overt appearance of HK1.ras and or fos mice from neonatal stage to 
formation of benign ear papillomas at tagged ear sites.  
[A] Normal mouse neonatal skin. [B] HK1.ras[1276]/fos neonatal skin shows a wrinkly skin 
phenotype with slightly increased severity of phenotype in the 2 middle neonates compared 
to fos [left ] and the two 1205 alone [right]. [C] shows Normal tagged ear, whilst [D] HK1.fos 
mouse eventually exhibits bi-lateral keratotic ears beginning in the tagged ear but no overt 
papillomas until 10 -12 months and not in all mice. [E] HK1.ras[1205] developed benign 
papillomas typically within 6-10 weeks in 100% of animals that are prone to regress if the tag 
is lost; and similarly HK1.ras[1276]/fos mice developed smaller  papillomas initially at 
wounding site that occasionally became bi-lateral.  
 
Histologically, in HK1.fos mice the epidermis showed no significant abnormalities compared 
to normal [Fig. 1.6]  except for a mild hyperplasia that arises around at 3-4 month after birth in 
tagged ears (Greenhalgh et al., 1993b) similar to the hyperplasia produced in neonatal 1205 
neonatal mice consistent with wrinkled skin appearance; whilst co-operation of HK1.ras1276 
and HK1.fos showed histologically similar phenotypes but with increased severity such as 
degree of hyperplasia and hyperkeratosis [Fig. 1.6] (Greenhalgh et al.,1993c). With time 
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HK1.ras and HK1.ras/fos mice exhibited papilloma histotypes with little evidence of 
malignant conversion [Fig. 1.6].  
In order to confirm this histotype and assess effects on differentiation, HK1.ras/fos mice were 
assessed by double-labelled immunofluorescence staining to investigate the epidermal changes 
in differentiation via keratin expression and this also served as a valuable tool to assess the 
degree of tumour invasiveness in these genotypes. For instance, assessing the expression of 
K14 provide a good mapping of the epidermis, as it is a basal layer keratin expressed in hair 
follicles and throughout the epidermis due to its high stability as a protein. This made K14 the 
standard counterstain[red] in analysing different genotypes in this model to highlight the 
epidermis, hair follicles and tumour (Greenhalgh et al., 1993a; 1993b). In addition analysing 
the expression of the early differentiation marker K1 that is normally expressed in supra-basal 
layers becomes reduced as papillomas convert to malignancy and is lost during progression to 
aggressive SCC and thus served as one of the main tools to assess the differentiation pattern 
and the benign nature of the papillomas formed. As shown in Fig. 1.6 analysis of UK biopsies 
also confirms these original data, in normal epidermis, keratin mK1[green] against K14[red] is 
expressed in the supra basal epidermis; whilst mK6α is confined to the HFs together with K14 
[Fig. 1.6B&C.]  
In epidermal hyperplasia HK1.ras/fos [HK1.ras1205 identical] [not shown] IF analysis showed 
that K1[green] maintains this normal expression again confined to the now expanded supra-
basal layers, with a delay in its onset due to expansion of the proliferative layer as highlighted 
by the thicker K14 positive basal layers throughout the epidermis [Fig. 1.6E]. This K1 
expression is maintained in the supra-basal layer in typical benign papillomas formed in this 
model, again confirming their benign nature and indicting that differentiation remains 
relatively ordered despite ras and fos expression in this model (Greenhalgh et al., 1993a; 
1993b; 1995).  Similarly, in the HK1 model the hyperproliferation marker K6α 
[green]/K14[red], normally only expressed in hair follicles or in response to epidermal stress 
such as wounding or psoriasis, was expressed strongly in the hyperplasia in addition to the 
normal hair follicle expression [Fig. 1.6 C]. Hyperplastic genotypes displayed strong and 
uniform mK6α expression in the interfollicular basal and supra-basal layers [Fig. 1.6] which 
was also the case in benign papillomas regardless of genotype (Greenhalgh et al., 1993a-b; 




Figure 1. 6: Histotype and expression of keratin K1 and K6α expression in HK1.ras/fos 
hyperplasia and papilloma  
[A] H&E staining of normal mouse skin shows the thin nature of the epidermis being only one 
or two cells in depth; also visible are typical telogen [resting] follicles with associated 
sebaceous glands. [B] Double-labelled IF analysis of early differentiation marker keratin K1 
(green) expression against keratin K14 (red) shows normal K1 expression is confined to the 
supra-basal layers, whereas [C] shows K6α expression normally expressed in hair follicles 
only. [D] Typical pre-neoplastic epidermal hyperplasia in HK1.ras/fos mice is typified by 
expansion of supra-basal layer [acanthosis] due to increased proliferation in the expanded 
basal layers that give rise to a papillomatous [folded] epidermis consistent with the 
appearance of wrinkled skin. [E] Analysis of K1 in hyperplasia maintains a normal expression 
in the expanded supra-basal layer, whist K14 expression is more prominent in the expanded 
basal layer. [F] In response to the stress signals of epidermal hyperplasia, mK6α is expressed 
strongly in both basal and supra-basal layers. [G] Histology of typical HK1.ras/fos papillomas 
again show an ordered nature to differentiation where K1 expression remains strongly supra-
basal confirming the benign nature of the tumour, whilst [H] mK6α also remains strongly 
expressed in both basal and supra basal layers. Scale bars: A,D,E&F: 50µm; B: 25µm; 
D,G,H&I: 100µm [confirmatory experiment to illustrate the HK1.ras/fos model] 
 
To help investigate the mechanism driving stage-specific tumour progression in this model, 
the phenotypes produced by the combination of genotypes also involved assessing tumour 
suppresser gene expression at different stages from the early hyperplasia through the benign 
papilloma intermediates and eventual malignant carcinomas (Yao et al., 2006;2008; 
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Macdonald et al., 2014). In particular, given their frequency of inactivation in human 
carcinogenesis, the tumour suppresser genes [TSG] p53 and P21 were of great importance in 
assessing changes to the epidermal differentiation and the causality of their overexpression in 
response to ras and fos activation and potential consequences of their inactivation at each 
specific stage of tumour progression.  
 
In humans, p53 is the most mutated tumour suppresser gene in cancer, as it is responsible for 
inducing protective cellular mechanism such as DNA repair, cell cycle arrest and apoptosis, in 
response to cellular stress signals including genetic instability and excess proliferation 
(Kastenhuber and Lowe., 2017). In human spontaneous SCC, p53 was found to be frequently 
mutated and in DMBA/TPA mice model, p53 was found to be commonly mutated or lost in 
SCCs (Huang and Balmain, 2014). This enforces the roles of p53 in epidermal homeostasis 
and tumour prevention in SCCs; however, the story is far more complex as in this model loss 
of p53 induced an intriguing paradox of blocking papilloma formation the HK1.ras mice 
(Greenhalgh et al., 1996) that is explored further in this study. The p21 is one of the major 
downstream effectors of p53 and plays a crucial role in DNA repair, cell cycle arrest, 
apoptosis and epidermal differentiation as a counter mechanism to tumorigenesis and genetic 
instability (Topley et al., 1999). This is clearly exemplified below in HK1.fos-∆5PTEN mice 
and the aetiology of keratoacanthoma (Yao et al., 2008); and also in HK1.ras/fos-∆5PTEN  
mice as it appeared to antagonise both AKT and β-catenin to delay malignant progression 
[below] (Macdonald et al., 2014). 
In the HK1.ras/fos mouse model, the expression of p53 was sporadic and very weak in early 
stages of hyperplasia and as the epidermis expanded to form the papilloma, p53 expression 
becomes very strong and nuclear halting any further progression. Similarly, for p21 in early 
stages of hyperplasia it was almost absent from the epidermis and as the papillomas form it 





Figure 1. 7: p53 and p21 expression in HK1.ras/fos hyperplasia and papilloma.  
[A-C] Histology of normal epidermis and IHC analysis shows only sporadic low level 
expression of p53 and p21. [D-F] pre-neoplastic HK1.ras/fos epidermal hyperplasia also 
shows only cytoplasmic expression of p53 expression on IHC analysis and [E] only weak 
p21expression. [F]. In contrast [G] shows HK1.ras/fos papillomas and display [H] strong 
nuclear expression of p53 in all basal layer keratinocytes with [I] increasing expression of 




The expression of p53/p21 and different keratin analysed in this model provide a compelling 
case for the stability of the benign papillomas formed in HK1.ras1205 or HK1.ras1276/fos 
genotypes as they do not regress or progress without an additional oncogene effecter or a 
mutagen [i.e. TPA] to elicit conversion to carcinoma. This observation made this model ideal 
to study the roles of different oncogenes in the context of SCC, which was first used via 




1.7 Investigation of the roles for PTEN/PI3K/AKT pathway deregulation in 
HK1.ras fos carcinogenesis and implication of β-catenin deregulation  
 
As outlined above exclusive epidermal expression of activated rasHa and/or fos [HK1.ras; 
HK1.fos] provided stable autonomous pre-malignant papillomas ideal to study mechanisms 
driving malignant conversion and progression. Thus, subsequently this approach has 
successfully tested several oncogene combinations and loss of common tumour suppressor 
genes such as p53, p21 and importantly PTEN. Indeed, as detailed below [1.6.1], it is the data 
from earlier PTEN studies involving co-operation between HK1.fos and inactivation of PTEN 
regulation of AKT activities that identified specific roles for GSK3β inactivation in the 
formation of highly differentiated benign tumour known as keratoacanthomas [KA], which in 
turn provide the foundations to this project by identifying the importance of this 
AKT/GSK3β/β-catenin axis and of β-catenin in particular in this project.  
 
As detailed in chapter 3, whilst PTEN loss promoted papillomatogenesis with ras and fos 
oncogene promotion in carcinogenesis studies (Yao et al., 2006;2008; Macdonald et al., 2014) 
new data now confirm that increased membranous β-catenin activation in basal layers, 
downstream of the PTEN/AKT deregulation was associated with the induction of p53 and p21 
leading to a KA aetiology (Yao et al., 2008). Moreover, following p53 loss in 
HK1.fos/ras/5PTEN mice, decreased membranous and increased cytoplasmic/nuclear β-
catenin expression appears to drive early-stage malignant progression to more aggressive SCC 
(Alyamani et al., Manuscript in Preparation). Thus, the canonical β-catenin/Wnt signalling 
pathway [see section 1.8] may be a key component to induced compensatory p53-mediated 
responses that inhibit malignant conversion but drive a KA aetiology; but once p53 is lost 
nuclear β-catenin is associated with malignant progression [Chapter 3: sections 3.2 & 3.3]. 
 
Therefore, inducible β-catenin overexpression would directly investigate/validate mutations 
driving/inhibiting PTEN mediated carcinogenesis, given that PTEN functions as a tumour 
suppresser working through Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) dependent 
and independent mechanisms, in which in the dependent mechanism the PTEN facilitates the 
removal of the phosphate from phosphatidylinositol 3,4,5 trisphosphate (PIP3) in position 3 of 
the inositol ring preferably (Hopkins and Parsons, 2014). This action results in negatively 
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regulating AKT, which is also a negative regulator of GSK3-β via phosphorylation that down 
regulates β-catenin (Morin, 1999; Hopkins and Parsons, 2014) and directly links PTEN and β-
catenin signalling.  
 
This may have several implications, one involving the canonical Wnt signalling and a second 
dependent on adhesion signalling deregulations as another important function of PTEN, 
independent of PI3K mechanism, includes regulating [inhibiting] cell migration (Hopkins and 
Parsons, 2014) and a role as a scaffolding protein aiding cell-cell connectivity (Subauste et 
al., 2005) [See Chapter 8:Scatter/migration assays]. Hence the appealing co-operation 
potential with β-catenin also regulating genomic stability [hence the compensatory p53 
responses] as well as regulation of mitogen-activated protein kinase (MAPK) signalling 
pathway (Hopkins and Parsons, 2014) which links to the MAPK kinase pathway consistent 
with the co-operation between PTEN and ras fos outlined [below].  
 
Initially PTEN was an attractive TSG to investigate in this HK1 mouse model as mutations in 
the PTEN gene cause PTEN hereditary tumour syndromes (PHTS) such as Cowden disease 
(Liaw et al., 1997; Fistarol et al., 2002; Suzuki et al., 2003; Song et al., 2012). This familial 
cancer susceptibility syndrome commences with the appearance of cutaneous hyperkeratosis 
and harmatomas prior to development of internal tumours at multiple sites (Tan et al., 2012). 
This syndrome not only highlights the ability of the epidermis to resist carcinogenesis 
compared to alternate tissues [as clearly exemplified in this transgenic mouse study] but also 
demonstrates additional important roles for PTEN in keratinocyte differentiation (Tan et al., 
2012) and maintenance of the epidermal barrier (Subauste et al., 2005). Furthermore, the loss 
of PTEN through mutations in human cancers was seen almost as frequently as the loss of the 
most well-known tumour suppresser gene p53 (Parsons et al., 2004; Stiles et al., 2004; 
Downward, 2004). However, to model PTEN loss in transgenic mice was complicated by the 
fact that PTEN knockout was found to be lethal and use of the cre loxP system to induce 
expression loss throughout embryogenesis leads to a very rapid progression to SCCs in 






Therefore, in this approach an RU486-inducible cre/loxP system was employed to mutate 
PTEN and assess the consequences in the HK1 model (Berton et al., 2000; Yao et al., 
2006;2008; Macdonald et al., 2014). Here two strains of mice are employed one contains a 
keratin K14 driven cre recombinase protein fused to the progesterone ligand binging domain 
(PLBD) the other is a target strain comprised of loxP-flanked exons or stop codons. Thus, the 
cre recombinase is expressed in all keratinocytes but cre activity remains in the cytoplasm. 
After topical treatment of RU486, the cre is then translocated into the nucleus where it can 
ablate or delete the sequences flanked by lox P sites. (see Fig. 1.8).  Here epidermal specificity 
is achieved via topical administration of RU486 and the K14 promoter is used to achieve cre 
expression in the basal layer of the epidermis and hair follicles- including stem cells (Berton et 
al., 2000). Thus, the expression of K14 and the requirement for topical RU486 results in the 
ablation of exon 5 of PTEN in highly localised areas of the skin or at specific time points.  
For instance, pre-papilloma formation or post papilloma formation by RU486 treatment 
usually on the ear and back (Yao et al., 2006). In this instance the target mouse contains a 
PTEN allele modified to have loxP sites engineered to flank exons 5 (Wu et al., 2003), which 
are ablated to give the mutated form of PTEN (∆5PTEN) that fails to inhibit AKT signalling in 
this model (Yao et al., 2006; 2008). Typically, this is sufficient to ensure that RU486 
treatment is required to elicit a phenotype but as found in this study there can be a degree of 
cre leakage into the nucleus, independent of RU486 that until this project was not observed to 











Figure 1. 8: Schematic diagram illustrates the mechanism of the inducible cre/loxP 
system with RU468 treatment in bi-genic K14.creP/PTENflx/flx  mice.  
[A] Inactivation of PTEN-mediated AKT regulation is achieved by ablation of exon 5, 
the phosphatase site. The keratin K14 driven cre is used to achieve exclusive 
expression to the epidermis and hair follicles. The cre is bound to the progesterone 
ligand binging domain (PLBD) in the cytoplasm. Treatment with RU486 induced 
PLBD dimerization and translocation into the nucleus where cre acts to delete 
sequences flanked by lox P sites; in this case PTEN exon 5 [Δ5PTENflx/flx]. [B] 
K14.creP/flx-stop-flx--gal staining 5 weeks post single RU486 treatment confirms 
expression in proliferative keratinocytes and stem cells constant with K14.creP 
targeting. Note also the strands of blue cells in the epidermis [arrows], indicating the 









1.7.1 Co-operation between HK1.ras/fos and PTEN loss of AKT inhibition 
In the initial model, ∆5PTEN [PTENflx/flx] mice were mated to HK1.ras mice creating the 
∆5PTEN/K14creP/HK1.ras transgenic mice [HK1.ras.Δ5PTEN] and resulted in a rapid onset of 
papillomatogenesis, but without malignant conversion unless the mice were also treated with 
TPA promotion (Yao et al., 2006). Additionally, another study on mice was also done in 
corporation with fos activation (Yao et al., 2008). This study used a similar method with 
∆5PTEN [PTENflx/flx] and HK1.fos. The HK1.fos.∆5PTEN mice treated with RU486 exhibiting 
features of hyperplasia, hyperkeratosis and the development of tumours that became highly 
differentiated and progressed to keratoacanthomas [KA] and not to carcinomas (Yao et al., 
2008).  
This observation was later attributed to the increased activity of phosphorylated AKT [p-AKT] 
which resulted in elevated levels of GSK3β inactivation that triggered tumour suppressive 
action from p53 and p21. This p53 and p21 response thus diverted proliferating papilloma 
keratinocytes into a differentiation programme resulting in progression to KA not SCC (Yao et 
al., 2008). The p-AKT inactivated GSK3β through phosphorylation at serine 9 and 
overexpression of this process resulted in the high levels of phosphorylated GSK3β (p-
GSK3β). This triggered high level responses of p53 and p21 which resulted in a reduction in 
AKT activity that resulted in accelerating the keratinocyte differentiation and KA formation 
(Yao et al., 2008). It is theorised that, this AKT inactivation of GSKβ involved increasing 
nuclear βcatenin and this triggered the p53 and p21 responses [see below]. 
 
Furthermore, a more recent study investigated the co-operation of ∆5PTEN with both ras 
[HK1.ras] and fos [HK1.fos] oncogenes finding that RU468 treatment of HK1.ras/fos-
K14creP.Δ5PTENflx/flx skin resulted in increased hyperplasia and formation of proliferating 
cysts. Moreover, papillomatogenesis was accelerated but malignant conversion was now 
delayed, and tumours seemed to stall at a well-differentiated squamous cell carcinoma 
(wdSCC) histotype (Macdonald et al., 2014). Moreover, despite several oncogenic effectors, 
malignant conversion required additional loss of p53, which made papillomas prone to 
convert; but the appearance of p53-independent, persistent p21 expression limited early-stage 
malignant progression. This p21 expression inhibited cyclin D1 and cyclin E2 activity 
(Macdonald et al., 2014) and persistent p21 expression appeared to antagonise AKT1 to limit 
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the progression to a wdSCC state for a period of time. This status was maintained until the p21 
was lost and now increased activity of p-AKT led to more aggressive SCC (Macdonald et al., 
2014).   
This increasing AKT observation again brings into question the involvement of β-catenin, as 
high levels of p-AKT activity will lead to inactivated GSK3-β that result in stabilizing β-
catenin which may be involved in this malignant progression. Indeed, the p53 /p21 responses 
in KA formation may be due to anomalous nuclear β-catenin expression. The tumour 
supportive activity of p53 and p21 was elevated during hyperplasia, cyst and papilloma 
formation. Of relevance to this model the cyst formation was actually attributed to the 
expression of p53 and p21 that caused the alteration in the excess proliferation into increased 
differentiation which resulted in cyst formation (Macdonald et al., 2014) but the data in this 
current study suggests that β-catenin was involved also. 
Similarly, follicular cyst formation was seen before in a β-catenin related study where K14 
was used as a promoter to target the hair follicles and aimed to see the consequences of 
preventing the binding of Lef1 (∆NLef1) to β-catenin in hair follicles (HF) and epidermis 
(Niemann et al., 2002). Here in this study, the mice lost hair within 6 weeks of age and began 
to develop dermal cysts derived from the base of the hair follicles. This study conclude that 
the levels of β-catenin signalling helped determine the differentiation of keratinocytes into hair 
or interfollicular epidermis as well as irregularities within the pathway and aberrant levels of 
β-catenin signalling can lead to formation of cyst and HF tumours (Niemann et al., 2002). This 
study in addition to the previously illustrated study associated with the loss of PTEN in KA 
formation, suggest the involvement of deregulated β-catenin signalling and formation of skin 
tumours (Niemann et al., 2002; Yao et al., 2008; Macdonald et al., 2014). 
This idea was quite attractive since β-catenin signalling is strongly implicated from the 
observation of increasing AKT activity which led to the high levels of inactivated GSK3-β that 
suggest an accumulation of cytoplasmic β-catenin which probably caused the compensatory 
responses of p53 and p21 in KA; but in the triple model β-catenin accumulation in the 
cytoplasm and nucleus may have contributed to malignant conversion to wdSCC or early 
progression to aggressive SCC (Yao et al., 2008; Macdonald et al., 2014). The investigation of 




1.8 β-catenin and its role in skin cancer 
In this study one logical candidate that fits this profile for a multi-stage carcinogenesis study is 
β-catenin, which is a protein that has a dual role. It interacts with E-cadherin in cell-cell 
adhesion and is known to be a key regulator in the canonical Wnt signalling pathway (Morin, 
1999; Grigoryan et al., 2008). The deregulation of membrane adhesion and proliferation 
mediated by failure to regulate β-catenin has been implicated in many tumours including skin, 
colon, breast and prostate cancers (Morin, 1999; Grigoryan et al., 2008). However, its exact 
role in skin carcinogenesis remains poorly defined, in terms of when it becomes activated and 
its roles in membranous versus nuclear signalling. Therefore, in this study the main aim was to 
assess β-catenin overexpression in stage–specific skin carcinogenesis (Gat et al., 1998; 
Niemann et al., 2002; Kretzschmar et al., 2015). 
The β-catenin gene also known as CTNNB-1 consists of 16 exons and can be divided into 
three binding domains. The largest domain consists of ~550 amino acids known as central 
repeats or armadillo repeats and this domain is associated with binding to E-cadherin to form 
the complex needed for β-catenin to assume cell-cell adhesion function (Gao et al., 2018) 
[Fig. 1.9]. The C-terminal domain of the β-catenin gene consists of ~100 amino acids and 
possesses the binding site for canonical Wnt signalling transcriptional targets T cell 
factor[TCF] and lymphoid enhancer binding factor [LEF] [Fig. 1.9]. The N-terminal domain 
consists of ~150 amino acid and contains the phosphorylation site for binding of β-catenin 
with its down-regulator GSK3β at serine and threonine residues in exon3 [Fig. 1.9]. This is the 
key feature of maintaining normal levels of cytoplasmic β-catenin that regulate canonical Wnt 
signalling pathway and the interactions with E cadherin (Morin, 1999; Grigoryan et al., 2008). 
Thus, exon 3 has been reported to be the mutation hotspot in β-catenin and is mostly 
associated with missense mutations which have been reported in human carcinomas and in 
two-stage DMBA/TPA carcinogenesis (Grigoryan et al., 2008). This site is also exploited in 









Figure 1. 9: Important binding sites in the normal functions of the β-catenin gene 
[CTNNB-1].  
In the N-terminal domain of the gene, β-catenin binds to GSK3β to start the down regulation 
process of β-catenin to prevent cytoplasmic accumulation, whilst the biggest region of the 
gene binds to E-cadherin to form the cell-cell adhesion complex and the C-terminal of the 
gene binds to LEF/TCF in the nucleus to activate transcriptional targets of Wnt signalling.  
 
Moreover, one of the central roles of β-catenin is to act as a cell-cell adhesion protein in 
conjunction with E cadherin (Morin, 1999; Grigoryan et al., 2008). E-cadherin is a major 
player in the family of Cadherin molecules, which function as cell-cell adhesion molecules 
that are essential in regulating calcium dependent adhesion between the cells as well as 
playing roles in morphogenesis and tissue homeostasis (Takeichi, 1991; Young et al., 2003). 
E-cadherin is highly expressed in the epithelial cells and the intracellular link between E-
cadherin and the actin cytoskeleton is formed by the catenin family component (Takeichi, 
1991; Young et al., 2003). In this process, cytoplasmic β-catenin gets recruited by cytoplasmic 
E-cadherin and binds to α-catenin to form a complex that links to the actin filaments network 
creating adherent junctions between the cells [cell-cell adhesion] (Aberle et al., 1994; Jou et 
al., 1995; Pai et al., 1996). These adhesion junctions formed via β-catenin/E-cadherin 
interactions are one of the important junctions to maintain the homeostasis of epidermal 
terminal differentiation and hair follicle morphology as well (Young et al., 2003). It has been 
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shown also that knocking out either β-catenin or E-cadherin in transgenic mice resulted in 
embryonic lethality as the adhesive capacity of cells are crucial at the embryonic development 
stage (Grigoryan et al., 2008). The loss or reduction of adherent junction expression via loss 
of E-cadherin or gain of function mutation β-catenin has been associated with facilitating 
carcinogenesis which is simultaneously accompanied by β-catenin nuclear localization (Jeanes 
et al., 2008) as also shown in this study [Chapters 3 and 6]. 
 This increased nuclear localization of β-catenin in carcinomas highlights another major 
signalling role in the regulation of the canonical Wnt signalling pathway. The canonical 
pathway is activated by Wnt ligands binding to Frizzled and LRP receptors, and this results in 
inhibition of glycogen synthase kinase 3-β via phosphorylation on serine 9 (p-GSK3β) 
activity, causing β-catenin to become stabilized in the cytoplasm. Then free β-catenin travels 
into the nucleus where it binds to the transcription target genes of Wnt signalling, which are T 
cell factor (TCF) and lymphoid enhancer binding factor (LEF) (Behrens et al., 1996; 1998; 
Grigoryan et al., 2008). Given that β-catenin is known to have an essential role in hair follicle 
development, morphogenesis and differentiation via transactivation of Wnt signalling 
transcriptional targets complex of LEF/TCF (Lim and Nusse, 2013) has been associated with 
each of the stages of hair development, such as placode formation, HF renewal cycle and 
differentiation of the hair shaft. Additionally, Wnt/β-catenin activation consequently activates 
other signalling pathways associated with hair follicle maintenance such as Notch and Sonic 
hedgehog (Watt and Collins, 2008). 
Wnt/β-catenin signalling also regulates the epidermal pluripotent stem cells that reside in the 
bulge region of HFs, that are needed for maintaining normal epidermal terminal differentiation 
and hair follicle differentiation, which also links Wnt/β-catenin to the roles it plays in 
embryonic and juvenile stages of development. Embryonically Wnt/β-catenin signalling is 
highly involved in the formation of the body anterior and posterior axis, hence why null 
mutation of β-catenin induced embryonic lethality as it resulted in a failure in forming body 
axis in mouse studies (Grigoryan et al., 2008). This was also supported by influence of Wnt/ 
β-catenin on up regulating bone morphogenic protein BMP signalling (Närhi et al.,2008) 
which is essential to embryonic formation of bones. This sums up the second significant role 







Figure 1. 10: Schematic diagram of the β-catenin pathway. 
[A] β-catenin binds to α-catenin and E-cadherin in the cytoplasm to form the cell-cell adhesion 
complex at the cell membrane to maintain cellular adhesion with neighbouring cells. [B] In the 
absence of Wnt signalling receptors and suppression of AKT mediated GSK3β inactivation 
via PTEN, GSK3β forms a complex with APC and Axin that binds to and down regulates β-
catenin via phosphorylation leading to cytoplasmic degradation of the protein via the ubiquitin 
pathway and preventing cytoplasmic accumulation. [C] In presence of Wnt receptors Frizzeld 
and LRP and activation of AKT, the β-catenin destruction complex is de-activated due to 
GSK3β phosphorylation via AKT which leads to cytoplasmic accumulation of β-catenin and 
translocation into the nucleus to activate Wnt signalling target genes Lef/TCF.  
 
 
These studies highlight the importance of β-catenin being correctly regulated, which happen 
via a complex of several molecules. One of its important regulators is adenomatous polyposis 
coli (APC) via its interaction with GSK3β to form a complex that down regulates β-catenin 
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(Behrens et al., 1996; 1998; Ikeda et al., 1998) via targeting it for ubiquination. GSK3β seems 
to be the first step in the subsequent degradation by phosphorylating β-catenin within a multi 
protein complex that involves APC and Axin proteins (Behrens et al., 1996; 1998; Ikeda et 
al., 1998). This observation is highly significant as GSK3β inactivation via phosphorylation 
by AKT is thought to be an important feature in the failure to regulate β-catenin degradation 
(Grigoryan et al., 2008). AKT negatively regulates GSK3β, which results in stabilization of β-
catenin and preventing its degradation by GSK3β activity (Morin, 1999; Grigoryan et al., 
2008).  
AKT as mentioned above is regulated by PTEN which functions as a tumour suppresser 
working through Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) dependent and 
independent mechanisms, where the dependent mechanism facilitates the removal of the 
phosphate from phosphatidylinositol 3,4,5 trisphosphate (PIP3) in position 3 of the inositol 
ring preferably (Hopkins and Parsons, 2014). This action results in negative regulation of 
AKT activities, which down regulates β-catenin as outlined above (Morin, 1999; Grigoryan et 
al., 2008; Hopkins and Parsons, 2014) and provides a direct link between PTEN and β catenin 
and thus are important in the regulation to prevent carcinogenesis. 
The deregulation of β-catenin levels that result in stabilizing the protein such as gain of 
function mutation i.e. exon3 missense mutations have been associated with multiple human 
carcinomas and also frequently reported in two-stage DMBA/TPA carcinogenesis (Grigoryan 
et al., 2008). The influence of β-catenin stabilization has been associated in several types of 
cancers (Morin, 1999; Grigoryan et al., 2008). One of most common examples is colon cancer 
due to APC/β-catenin regulation as APC is found to be mutated in around 80% of colon cancer 
cases and a loss of APC expression has been associated with elevated β-catenin expression and 
facilitating tumorigenesis due to failure in forming the GSK3β/APC β catenin destruction 
complex (Morin, 1999). This APC/β-catenin interaction has proven to be also important in 
developing melanoma skin cancer, which highlights the importance of preventing β-catenin 
cytoplasmic accumulation even if the gene itself is not mutated, a failure of β-catenin regulator 
to assume it function such as GSK3β or APC could consequently lead to overexpression of β-
catenin (Morin, 1999). The importance of this is due to Wnt/β-catenin being a gateway to 
several proto-oncogenes down stream of its nuclear transcription targets LEF1/TCF including 
MYC-1, cyclinD1, Notch, Sonic hedgehog[SHH] and c-fos (Gerdes and Yuspa, 2005; Ambler 
and Watt, 2007; Grigoryan et al., 2008; Saadeddin et al., 2009; McCubrey et al., 2016). This 
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is why Wnt/β-catenin is associated with many carcinomas such as colon, prostate, ovarian, 
melanoma and non-melanoma skin cancers (Morin, 1999; Gerdes and Yuspa, 2005; 
Grigoryan et al., 2008).  
The association of non-melanoma skin cancers [SCC/BCC] derived from Wnt/β-catenin 
signalling ability to overexpress sonic hedgehog[SHH] which associated with most cases of 
BCC (Gerdes and Yuspa, 2005) and also Notch which associated with both BCC and SCC 
(Gerdes and Yuspa, 2005; Rodilla et al, 2009; Wang et al., 2011; South et al., 2014; 
Sherwood and Leigh et al., 2016).  
The other direct implication of β-catenin involvement in SCC was demonstrated in mouse 
studies. Thus, as β-catenin being a regulator of HF bulge stem cells niche, a correlation has 
been established between SCC cells driven by Ha-ras mutation to be carrying similar cellular 
characteristics of bulge stem cells which directly implicate β-catenin as contributor to SCC 
development (Malanchi, et al., 2008). Additionally, conditionally knocking out β-catenin 
resulted in either blockage or regression of DMBA/TPA tumours, which again indicate that β-
catenin expression was a necessity for the development of SCCs (Grigoryan et al., 2008). The 
majority of transgenic mice study showed that overexpression of β-catenin was associated 
with development of HF abnormalities and HF tumours. The constitutive β-catenin activation 
in mice studies was mainly associated with multiple hair follicle abnormalities. These 
abnormalities include de novo HF, formation of epidermal cyst and HF tumours such as 
pilomatricomas and trichofolliculoma (Gat et al., 1998; Huelsken et al., 2001; Grigoryan et 
al., 2008), which were also reported in humans carrying gain of function mutations of β-
catenin (Grigoryan et al., 2008). Grossly most transgenic mice with constitutive β-catenin 
activation were scruffy and had alopecia despite the increased placode formation due a failure 
to develop normal complete HF because of incorrect control of Wnt/β-catenin signalling(Gat 
et al., 1998; Närhi et al.,2008). The early constitutive activation of β-catenin in juvenile stage 
was also associated with developing enlarged extremities [feet/tail] due to Wnt/β-catenin 
activation having a central role in forming body axis (Grigoryan et al., 2008) and also β-
catenin activation resulting in up regulating bone morphogenetic protein [BMP] signalling 
(Närhi et al., 2008) hence the big feet. 
However, despite many studies conducted on gain of function β-catenin, to date none have 
directly explored constitutive activation of β-catenin in a multi-stage carcinogenesis model. 
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This is possibly because the effect of overexpression β-catenin on facilitating carcinogenesis 
and that knocking out the gene resulted in tumour regression in a multi-stage carcinogenesis 
model (Malanchi, et al., 2008). Thus, it may be that the result of constitutive activation of β-
catenin was taken for granted as it would be expected to likely lead to producing aggressive 
carcinomas. Studies in HK1 model of multi-stage carcinogenesis would support this idea yet 
indicated that possibly the effect of β-catenin on carcinogenesis was more complex and 
context dependent was observed.  
 
For instance, HK1.fos-K14creP.Δ5PTENflx/flx co-operation resulted in KA formation instead of 
SCC and this result was associated with compensatory high levels of p53/p21 (Yao et al., 
2008). This result was attributed to elevated levels of inactivated GSK3-β [p-GSK3β] due to 
Δ5PTEN activating p-AKT. Thus, β-catenin involvement was implied, as GSK3-β/APC/AXIN 
destruction complex of β-catenin could not be formed due to continuous inactivation of 
GSK3-β via AKT. Whilst this proved to be correct, in this context β-catenin overexpression 
resulted in epidermal differentiation response that inhibited malignant conversion. However, 
in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice this led to malignant conversion to SCC, likely 
facilitated by increased nuclear β-catenin following the loss of p53/p21 expression. In both 
contexts an increase in β-catenin expression resulted in different results in conjunction with 
p53/p21 expression.  
Therefore, to investigate inducible constitutive activation of β-catenin in the HK1 model an 
inducible K14.creP/loxP gene switch was employed to target Δ3β-catenin expression to the 
epidermis [Fig. 1.11]. As outlined above, epidermal specificity is achieved via topical 
administration of RU486 and the K14 promoter is used to achieve cre expression in the basal 
layer of the epidermis and hair follicles - including stem cells (Berton et al., 2000). Thus, this 
results in the ablation of exon 3 of β-catenin that contains the phosphorylation binding site for 
GSK3-β which eliminates the GSK3β/APC/Axin down regulating complex. This approach 
appears to be the first of its kind that directly investigates β-catenin roles in skin 
carcinogenesis and attempts to fill the void in literature by directly assessing β-catenin 





Figure 1. 11: The schematic diagram illustrates the mechanism of the inducible 
cre/loxP system with RU468 treatment in the ablation of exon 3 in β-catenin and the 
PCR analysis confirming Δ3β-catenin activation.  
The keratin K14.creP driven cre is used to achieve exclusive cre expression in all 
keratinocytes. To activate cre in the epidermis and hair follicles transgenic mouse skin is 
treated with RU486 and the PLBD translocates into the nucleus where cre activity deletes the 
sequence flanked by lox P sites. In this model exon 3 the binding site for β-catenin 














1.9 Aim and objectives 
Aim of the study: Can inducible β-catenin overexpression induce malignant conversion of 
benign papillomas and progression to aggressive malignant SCC in co-operation with 
oncogenic ras [HK1.ras] or fos [HK1.fos] activation and/or PTEN loss [Δ5PTEN] and what is 
the underlying molecular mechanism; or alternately can the epidermis mount a protective 
(tumour suppressive) role that inhibits carcinogenesis at each stage.  
 
Objectives: 
- To investigate endogenous β-catenin status at each specific stage in HK1.ras/fos-
K14creP.Δ5PTENflx/flx multistage carcinogenesis and investigate the interactions with 
additional relevant gene expression as the mechanism unfolds [Chapter 3].  
- To confirm whether inducible overexpression of a constitutively active β-catenin 
mutant [Δ3β-catenin] in the interfollicular epidermis of transgenic mice will induce 
stage specific progression of papillomas in co-operation with exclusive epidermal ras 
activation and achieve malignant SCC; or assess whether additional events are required 
such as inducible loss of p53/p21 TSG expression [Chapters 4/5/6]. 
 
- To assess whether inducible Δ3β-catenin can cooperate with fos and PTEN mutation 
via loss of AKT regulation and alter a keratoacanthoma aetiology and overcome a 
compensatory p53/p21 expression response that leads to carcinoma [Chapter 7]. 
 
- To mimic in vivo analysis of inducible Δ3β-catenin in vitro in co-operation with ras, 































2.1.1 PCR and DNA isolation materials  
- Taq DNA polymerase, 10X PCR buffer and 50mM Magnesium Chloride, DNTPs 
[Invitrogen] and specific oligos described in Table 2.2 
- 6x DNA loading buffer (0.25% bromophenol blue, 0.25% xylene and 30% glycerol) 
- DNA lysis buffer (50mM Tris.HCl,100mM EDTA,100mM NaCl,1% SDS, pH 8.0) 
- Proteinase K (Sigma) 
2.1.2 Immunohistochemistry [IHC] and immunofluorescence [IF] materials 
- Ethanol [VWR chemicals] 
- Xylene [Sigma] 
- Bovine serum albumin [Thermo Fisher Scientific] 
- Normal goat serum [Thermo Fisher Scientific] 
- Permafluor solution [Thermo Fisher Scientific] 
- DAB (3,3’-diaminobenzidine) staining [Dako] 
- 125 mg/kg 5-bromo-4-deoxyuridine [BrdU, Sigma] 
- acid alcohol [99ml 70% ethanol and 1ml 1M Hydrochloric acid] 
-  Haematoxylin [Sigma] 
- 10mM sodium citrate buffer (Lab Vision, Fremont, CA) 
- 3% hydrogen peroxide solution 
- PBS [Thermo Fisher Scientific] 
- Antibodies and concentration used detailed in Table 2.4 
2.1.3 Cell culture materials 
- 500mL DMEM(1X) [gibco] 4.5g/L D-Glucose. 
- 10% foetal calf serum [treated with chelex to remove Ca+2] 
- 15% keratinocyte growth media [PromoCell] 
- T75 flasks, T25 flasks, haemocytometer, 60 mm dishes 
- L-Glutamine, sodium pyruvate, penicillin/streptomycin [Sigma Aldrich] 






2.2.1 Breeding of transgenic animals and 3Rs strategy   
To investigate the effects of inducible, constitutive β-catenin activation in skin carcinogenesis, 
several epidermal-specific genotypes have been created [Table 2.1]. These transgenic 
genotypes possess a combination of activated ras [strains HK1.ras1205 & 1276] and fos 
[HK1.fos] oncogenes in addition to a mutant PTEN tumour suppresser gene.  HK1.ras and 
HK1.fos mice were maintained as heterozygotes in an outbred ICR background as one copy of 
the transgene was sufficient to produce initial epidermal hyperplasia and/or benign papillomas 
(Greenhalgh et al., 1993a-c; 1995 Greenhalgh and Roop, 1994).  
In this model, to study the requirements for malignant conversion, deregulated PTEN/AKT 
signalling was achieved using an RU-486 inducible cre/loxP system employed to induce 
specific mutation at specific times (Yao et al., 2006; 2008; Macdonald et al., 2014). This 
approach was also employed to activate β-catenin and conditionally knockout p53 via deleting 
exons 2 to exon10 (Jonkers et al., 2001). The tumour suppresser transgenes p53 [p53flx/flx] and 
PTEN [Δ5PTENflx/flx] were kept as homozygotes to elicit their phenotype, while β-catenin 
[Δ3β-catflx/wt] strains were kept mostly as heterozygotes as this was sufficient to produce the 
Δ3β-catenin phenotype. This study also used embryonic knockout of tumour suppresser gene 
p21 [p21KO] (Martín-Caballero et al., 2001), but only in preliminary experiments.  
All mice were crossed with the K14.creP regulator strain to activate cre recombinase and bi-
genic mice were topically treated with RU-468. Each cohort included at least 15-20 mice in 
repeat experiments; with 10 control mice [without K14.creP or without RU486 treatment]. All 
mice were ear tagged within 3-4 weeks of birth and were treated with RU486 [5mg/ml] [15ul 
ears/back] weekly for 4 weeks post ear tagging. All transgenic lines were bred under project 
licence project P82170325 according to the rules and regulations of the UK Home Office in 
the CRF facility of University of Glasgow.  
The breeding strategy utilized the principles of 3RS [Replacement, Reduction, and 
Refinement]. In terms of Replacement, the primary goal of the project is to establish 
transgenic mice to identify/verify causal roles for multiple, relevant mutations that drive stage-
specific tumour progression, explore the subsequent mechanism and identify putative 
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compensatory sentinel systems that have evolved to inhibit carcinogenesis. Thus, unlike cell 
culture systems, transgenic mice offer the possibility to determine the influence of factors 
critical to malignant progression such as blood supply, an intact immune system, hormonal 
and cell-mediated growth controls, together with the physical barriers that inhibit tumour cell 
growth and invasion. However, the experiments also utilised skin keratinocytes cultured from 
neonatal transgenic mice to assess transformation states in carcinogenicity and clonal growth; 
to investigate tumour invasion. These in vitro results will be compared to in vivo data to aid in 
assessment of tumour progression in parallel to monitoring malignant progression in adults.  
In terms of Reduction, the constant monitoring of the transgenic mice permits the experiments 
to be terminated as soon as significant data has been obtained, thus minimising suffering, 
whilst obtaining meaningful data. As generation of these cohorts requires breeding of multiple 
transgenic mice lines, breeding strategies are carefully structured and rigorously monitored to 
ensure that only the minimum numbers are generated. Thus, given the requirement for a 
regulator transgene and topical treatments, an individual transgenic mouse breeder can carry 
multiple target transgenes which again reduces the overall numbers of animals needed for the 
experiments. Additionally, breeders also act as untreated controls for non-specific events e.g. 
insertional mutation; whilst bi-genic progeny become the comparison controls for tri-genics, 
and since several genotypes have already been fully characterised, repeating these as 
comparison controls is unnecessary, further reducing numbers required.  
In terms of Refinement, the advantages of epidermal models in the design of these studies, 
was a distinct strength where employment of keratinocyte-specific expression vectors coupled 
to an inducible cre/lox system prevents disease during embryogenesis/development or in adult 
internal organs. Also, in most cases animals are non-phenotypic until application of RU486, 
thus compound transgenic genotypes can be maintained that lack a phenotype until treated and 
disease can be highly localised e.g., ear tip or small dorsal areas. This is a significant facet of 
the refinement category during the breeding to create the necessary genotypes, which can 
often compromise animal viability, particularly when assessing multiple genetic insults. 
Another major advantage of skin is the accessibility, which not only facilitates application to 
localise disease but also allows macroscopic observation of early neoplastic events without 
invasive procedures.  
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Moreover, in the case of increased severity of phenotypes in compound genotypes associated 
with Δ3β-catenin co-operation, a scoring system was devised and applied to such genotypes at 
the time of tail biopsy to ensure that these animals remained within the moderate category of 
the regulations for animal experimentation in the UK. Thus, the severity of phenotypes was 
divided into three degrees: Score 0, mild with only little obvious phenotype and a full size at 
tail biopsy and these individuals often required RU486 treatment to elicit β-catenin 
phenotypes; Score 1, the most typical outcome and the much rarer Score 2, where significant 
hyperplasia appeared by d16 and mice were  also a smaller size indicative of digestive 
problems following weaning possibly due to β-catenin activation in the colon (Grigoryan et 
al., 2008; Huels et al., 2015). Table 2.1 below shows the genotypes established and the 






















Table 2. 1: Compound Genotypes created in this study.    
Genotypes  Total 
number 
Serve as Chapters  
HK1.ras1205 90 Control 3/4/5/6 
HK1.fos 23 Control 7 



















K14creP.Δ3β-catwt/flx.p53flx/flx  26 Target 
genotype 
6 






































2.2.2 Analysis of mouse and tumour genotype by PCR.  
Single genotype, bi-genic and tri-genic combinations were identified using Polymerase chain 
reaction [PCR] employing DNA isolated from tail and tumour tissues. Adult/juvenile mice [~4 
weeks] were anaesthetised and tail tips [~3mm] placed in labelled tubes, frozen immediately 
and stored at -20oC. In addition, PCR genotype was re-confirmed at biopsy from frozen 
tumour or back skin samples [~2mm].  
DNA lysis buffer [50mM Tris.HCl,100mM EDTA,100mM NaCl,1% SDS, pH 8.0] containing 
20mg/ml proteinase K [Sigma] was then added [500ul] to each Eppendorf tube and the tails 
digested overnight at 55°C with a brief vortex after ~2-3 hours incubation to aid digestion. 
Samples were centrifuged to remove debris [ 13,000 rpm for 15min, RT] and an equal volume 
of ice-cold ethanol added to precipitate the DNA at the interface, which was wound onto a 
pipette tip and transferred to a new tube containing 300ul of water to be dissolved for PCR use 
or stored for sequencing.   
All PCRs were performed as 25ul reactions, consisting of PCR buffer 10x [2.5ul][ Invitrogen], 
MgCl2+ [2.5ul/2.5mM] [Invitrogen] , specific forward and reverse primers for targeted 
transgene [0.5ul/0.5mM], dNTPs[0.25ul/0.25mM], Taq 
polymerase[0.25ul/0.25mM][Invitrogen], finally DNA sample[2.5ul] and distilled water to 
make up the required volume [25ul].  
The specific oligos as well as programmes required for each transgene are illustrated below 
[Tables 2.2 and 2.3]. To visualize the PCR product results, electrophoresis was conducted [ 
~30 min 90 v] using agarose gels [1% for single bands ~400-~700 e.g. HK1.ras and K14.creP, 
up to 1.5% for better separation of smaller doublet bands e.g. β-catenin, 2% for small bands 
~150-~250 e.g. p21KO] with 5ul of 20 mg/mL ethidium bromide added to 150ml of TAE 
[Tris-acetate-EDTA] buffer cooled-down [600C] to visualize the results under UV light and 









Gene primers Expected band size 
β-catenin Forward:5'-CTG CGT GGA CAA TGG CTA CT-3' Floxed allele at ~500bp 
and wild type allele at 
~324bp  
Reverse: 5'-TCC ATC AGG TCA GCT GTA AAA A-3' 
HK1.ras Forward: 5`-GGATCCGATGACAGAATACAAGC-3`  550bp  
 Reverse: 5`-ATCGATCAGGACAGCACACTTGCA-3` 





Forward: 5`-ACTCAAGGCAGGGATGAGC-3` Floxed allele at 
~1300bp  wild type 
allele at ~1200bp  Δ5 





Forward: 5`-TCATTTGGAACGCCCACT-3 410bp 
Reverse:  5’- CCACCGTCAGTACGTGAGAT 
XJK5creP* 
  




Forward: 5`- TCT TGT GTT TCA GCC ACA GGC  
Reverse: 5`- TGT CAG GCT GGT CTG CCT CC  
 
wild type allele at 
~430bp 
P21-5- ATT TTC CAG GGA TCT GAC TC 
R1N-1A- CCA GAC TGC CTT GGG AAA AGC 
Null allele at ~150bp 
p53  Forward: 5`- CAC AAA AAC AGG TTA AAC CCA G Floxed allele at ~584bp 
wild type allele at 
~431bp 
Δ p53 band at 612bp 
Reverse: 5`- AGC ACA TAG GAG GCA GAG AC 
72 
 
Table 2. 3:PCR conditions 
Genes  denaturation  denaturation  Annealing  extension  extension  cycles 
β-catenin  950  2min 950  30sec 600  30sec 720  1min 720  10min 36 
HK1.ras  950  5min 950  30sec 560  1min 720  1min 720  10min 35 
HK1.fos  950  2min 950  30sec 620  30sec 720 
  
1min 720  10min 35 
PTEN  950  2min 950  30sec 630  1min 720  1.30
min 
720  10min 36 
K14.creP  950  5min 950  30sec 580  45sec 720  1min 720  5min 35 
XJK5cre
P*  
950  5min 950  30sec 580  45sec 720  1min 720  5min 35 
p21 950  2min 950  30sec 590  30sec 720  1min 720  3min 36 













2.2.3 BrdU labelling and biopsy procedure.  
All biopsied mice were injected with 125 mg/kg 5-bromo-4-deoxyuridine (BrdU, Sigma) 2 
hours before culling to determine cellular proliferation and mitotic index. Collected tissue 
[skin and tumour] biopsies were routinely fixed in [10% v/v] buffered formalin pH 7.4 for 
24hrs at 4oC before being sent for histological processing provided by University of Glasgow 
Vet Pathology Dept to be embedded in paraffin and stained with haematoxylin and eosin for 
microscopic analysis. At biopsy tissues were also snap frozen in liquid nitrogen and stored at -
70oC for western blot analysis, cryosectioning or DNA isolation. 
2.2.4 Section preparation for Haematoxylin and Eosin staining [H&E], 
Immunofluorescence [IF], and Immunohistochemistry [IHC].  
 
For immunofluorescence and immunohistochemistry [IF/IHC] 5-7um paraffin sections were 
incubated with several different antibodies [Table 2.4]. The paraffin sections were first 
deparaffinised [oven heating at 60°C for 30mins followed by 30mins incubation in 100% 
Xylene]. Xylene [Sigma] was removed by 5min rinse in absolute ethanol and sections 
rehydrated by rocking in phosphate buffered saline [PBS] pH 7.4 [10 mins]. Hydrated sections 
were then subjected to antigen retrieval in 10mM sodium citrate buffer [Lab Vision, Fremont, 
CA] boiled for 3 mins and allowed to cool-down for at least 30min.  
For double- labelled immunofluorescence after the antigen retrieval step, sections were 
washed in PBS [5min] then directly blocked in e.g.10% bovine serum albumin [BSA] made in 
PBS to minimize unspecific binding. Sections were stained overnight in a humidified 
atmosphere at 40C, with 100-150ul of primary antibodies at the appropriate concentration 
[Table 2.4] made in 10% blocking serum e.g. employing rabbit anti-K1[diluted at 1/100] and 
guinea-pig anti-K14 [diluted at 1/400] made in 10%BSA in PBS. In each case sections were 
counterstained for keratin K14 with a guinea pig anti-K14 antibody employed to delineate the 
epidermis or tumour. Next day, sections were washed in PBS [10 min] then incubated with a 
secondary biotinylated goat anti-guinea pig [60min] antibody made in 10% BSA in PBS [60 
min] to amplify labelling affinity for Texas red.  Sections were then subjected to final 
incubation [60min/dark box/RT] with FITC-labelled anti-rabbit IgG [Jackson Labs] to 
highlight primary antibody targeted protein [green] and Streptavidin-Texas Red [Vector Labs] 
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to highlight the K14 counterstain in follicles and intra follicular epidermis [red]. After final 
incubation slides were mounted with Permafluor solution [Thermo Fisher Scientific], 
coverslipped and stored at 40C until photographed using a Zeiss microscope and Axio vision 
3.0 imaging. For BrdU labelling, following antigen retrieval, BrdU-labelled cells were 
identified by overnight incubation [40C] with FITC-conjugated anti-BrdU. Positive cells 
[green] were counted from 3 separate areas of five different mice per cohort and the mitotic 
index expressed as BrdU-labelled cells per mm of basement membrane.  
For immunohistochemistry [IHC] analysis, a similar protocol was followed, however after the 
antigen retrieval step slides were incubated in 3% [v/v] hydrogen peroxide for 10 min to block 
endogenous peroxidase activity. Sections were then washed in PBS, dried and blocked in 10% 
serum of the secondary antibody species [10min] e.g 10% normal goat serum [NGS] made in 
PBS. Sections were stained overnight at 40C with 100-150ul of primary antibodies with 
appropriate concentration [Table 2.4] made in 10% blocking serum in a humidified 
atmosphere e.g. rabbit anti-p53 [diluted at 1/100] in NGS made in PBS. Next day, sections 
were washed in PBS [10 min] and incubated with HRP-conjugated anti-rabbit antibody 
[Vector labs] [diluted at 1/100] made in 10% bovine serum albumin [BSA] in PBS for 60 min 
at room temperature. Sections were then washed in PBS [10 mins] and followed by DAB 
[3,3’-diaminobenzidine] staining [Dako] which was prepared shortly before applying it to the 
sections. Each section was stained for 3-5min depending on the type of antibody used and 
sections were washed immediately with tap water to stop the reaction. Sections were then 
counterstained with Haematoxylin for 15-20 seconds, then washed with tap water several 
times before gently dipping [X3] in acid alcohol [99ml 70% ethanol and 1ml 1M Hydrochloric 
acid] to de-stain Haematoxylin, then briefly washed with tap water and immersed in Scott’s 
tap water for 1min to stain the nuclei blue. Sections were dehydrated by immersion in absolute 
ethanol [5 min] then, xylene [5 min] and sections were then left to dry at room temperature 
prior to mounting. Dried sections were mounted [PERTEX mounting medium] and cover-







Table 2. 4: IF and IHC Antibodies. 
Antibody  Dilution  Provider/catalogue number  
Rabbit anti-K1  1:100  Biolegend cat no:905601  
Guinea pig anti-K14  1:400  Fitzgerald cat no:20R-cp002  
Rabbit anti-K6a  1:100 Biolegend cat: 905701 
Rabbit Anti-K15 1:100 Abcam: ab52816 
Rabbit anti-β-catenin  1:50  SIGMA HPA029159/ Abcam: ab32572  
Rabbit anti-E-cadherin 1:100 Proteintech cat no: 20874 
Rabbit anti-p53  1:150  SIGMA SAB4503000/ SIGMA SAB4503015/ 
abcam:ab31333/abcam:ab131442  
Rabbit anti-P21 1:150 Proteintech cat no: 10355-1-AP 
Rabbit anti-p63 1:100 Proteintech cat no: 12143-1-AP 
Rappit anti-p73 1:100 Abcam: ab40658 
Rat anti-BrdU 1:100 Abcam: ab6326 
Donkey Anti-Rat Alexa Fluor 1:100 Abcam: ab150153 
biotinylated goat anti-guinea 
pig/Streptavidin-Texas Red  
1:100  Vector Labs  
FITC-labelled anti-rabbit IgG  1:100  Jackson Labs  




2.2.4 Method for cell culture 
Primary keratinocytes derived from new-born transgenic mouse epidermis were cultured as 
described (Hennings et al., 1980; Greenhalgh et al., 1989) and after primary keratinocyte 
genotype PCR analysis, 17 cell lines were derived from specific genotypes [see chapter8]. All 
cell lines were maintained in appropriate media as shown below [Table 2.5] supplemented 
with 10% foetal calf serum, which was previously treated with Chelex resin [mesh 100] to 
reduce Ca+2 levels from ~3.6mM to ~0.01 mM as described previously (Brennan et al., 1975). 
Briefly, 200g of chelex 100 resin was added to 500ml distilled water, and the pH adjusted to 
pH7.2-4 with HCl. The resin was filtered through a Buchner funnel and added to 500ml of 
foetal calf serum, allowed to be mixed for 1 hour and then filter-sterilised through a 22micron 
filter resulting in very low Ca+2 foetal calf serum ~ 0.01mM. 
New-born mice (24 hrs old) were injected with pentobarbital and stored in 70% ethanol as a 
sterilization step while being transferred to the lab where each mouse was placed in a 60mm 
dish. Tail tips were taken from each neonate to confirm their genotype via PCR. Their skins 
were then removed, stretched on plastic lid and then and floated on 0.25% w/v trypsin 
(Gibco/Invitrogen) in sterile serum free media overnight at 40C. The following day, after 
confirming their genotypes, each epidermis was separated from the dermis and 3-4 skins of the 
same genotype mixed together for 30min in 15ml tube in 10ml of DMEM media (Gibco) 
without Ca2+ containing 10% chelexed foetal calf serum to inhibit trypsin activity, and the 
calcium concentration adjusted to 0.05mM Ca+2 with sterile 0.3M CaCl2 [Low Ca
+2] [Table 
2.5]. Following gentle rocking [30mins] each cell solution was filtered through sterile gauze 
into 50ml tubes to remove the cornified layer and other cell debris, centrifuged [at 800 rpm] 
and the keratinocyte pellet resuspended in Low Ca+2 media.  
The cells were counted using a haemocytometer and 5 x106 cells were plated into 60 mm 
dishes containing 3 - 5ml of medium to establish primary cell lines; or 2 x 107 cells in 20ml of 
medium per T75 flasks and 5 x106 cells per T25 flasks to minimise contamination and 
cultured in Low Ca+2 media supplemented with 15% [v/v] Keratinocyte Growth Media 
(PromoCell) [clonal growth media] with medium changes every 3-4 days. By four weeks 
colonies formed in 60 mm dishes and these were carefully trypsinised and plated into T25 
flasks and cultured for another 3-8 weeks; with ad hoc sub-culture dependent upon their 
genotype and growth criteria, including levels of confluence and cellular sensitivity to 
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trypsinisation. For example, a rapidly growing primary cell line at passage 2 or 3 with 80% 
confluency and high sensitivity to trypsinisation would be split 1/5 into T75 flasks for 
different assays; while slower growing more normal cell lines with resistance to trypsinisation 
take longer time to cultivate and smaller split e.g., 1/2.  
Each cell line was sub-cultured into four T75 flasks per different assays to be conducted on the 
cell lines. Morphology assays to assess their ability to commit to terminal differentiation 
and/or resistance to calcium induced terminal differentiation indicative of malignancy, were 
conducted by culturing three T25 flasks to confluence until normal proliferative cobblestone 
keratinocytes in Low Ca2+ media were formed indicative of a basal-layer morphology; then 
increasing the calcium concentration in the other two T25 flasks to 0.075mM Ca2+ to 
photograph a flatter morphology and instigate a supra-basal morphology at 24hrs; and then 
increasing high calcium concentration by 0.125mM Ca2+in the last T25 flask to photograph 
their final differentiated morphology at 24hrs. All T25s were fixed in 10% buffered formalin 
for 15min and rinsed in water for photography. 
Clonal growth assays were also performed to test transformation and resistance to calcium 
induced terminal differentiation (Hennings et al.,1980; Greenhalgh et al.,1989). Keratinocytes 
from low passage [Sc 3-5] cell lines were plated out into 16 dishes seeded at 250 cells/60mm 
dish and incubated for 24h. Then 8 of them were maintained in low Cal 0.05mM Ca2+ whilst 
the other 8 were moved to Hi Cal 0.125mM Ca2+. These dishes were maintained for 27 days in 
the appropriate media [High or low calcium] before being fixed in formalin and stained with 
Rhodamine B to show keratinocyte growth. This assay identified which cell lines had 
malignant capabilities based on their growth profile from clonal density. 
To further assess growth, migration and transformation, a “Scatter Assay” was performed. 
Cells were plated out in T25s flasks initially placed at 300 angle and grown to confluency. For 
each cell line, six T25s were prepared and after reaching confluence three flasks were kept at a 
low calcium concentration and three challenged with high calcium concentration, where 
transformed cell lines seeded beyond the determined growth line as typically cell lines do not 
seed, unlike primary keratinocytes or highly invasive cell lines.  
For all of these tissue culture experiments two established immortalized and well characterised 
cell lines were used as comparison control. SP1 benign papilloma cell line derived from 
DMBA/TPA papillomas with activated rasHa which are transformed but not malignant in nude 
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mouse graft assays and T52 malignant keratinocytes, where SP1 cells were transfected with 
FBJ v-fos to become malignant (Strickland et al., 1988; Greenhalgh et al., 1989). 
All primary cell lines were cultured on slides for immunocytochemistry [ICC] in low and high 
calcium concentration to test the expression of different proteins in the cells. This was 
conducted by culturing six slides for each cell line, once they reach 80% confluency 2 slides 
were fixed in methanol whilst the other 4 were switched to 0.075mM Ca2+ for 2 slides to be 
fixed at 24h and last 2 at 72h in methanol in -20oC.   
The genotypes of all cultured cell lines were re-confirmed via DNA Isolation. This was carried 
out by culturing one T75 to confluency, trypsinising and transferring the cells into an 
Eppendorf tube and DNA isolated as described above. For western blot analysis, each cell line 
was analysed for the expression of different proteins and this will be discussed in the next 
section. All cell lines were frozen-down in liquid nitrogen for cryo-storage. Cell lines 

























Table 2. 5: Media formulations used for tissue culture analysis  
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Chapter 3: Analysis of endogenous β-
















Chapter 3 Results: To begin to investigate activation of β-catenin in a multi-stage 
carcinogenesis model, the tumours were recreated in HK1.fos-K14creP.Δ5PTENflx/flx KA 
formation and HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC and the data compared to analysis of 
βcatenin in archival tumours. As outlined above, epidermal specificity is achieved via topical 
administration of RU486 and the K14 promoter is used to achieve cre expression in the basal 
layer of the epidermis and hair follicles- including stem cells (Berton et al., 2000). Previously, 
this resulted in elevated levels of inactivated GSK3-β [p-GSK3β] due to Δ5PTEN activation 
of p-AKT that triggered compensatory p53/p21 expression in HK1.fos-K14creP.Δ5PTENflx/flx 
KA and formation of SCC following p53 loss in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice (Yao 
et al., 2008; Macdonald et al., 2014). Thus, β-catenin involvement was implied, but was not 
actually assessed in these earlier studies. This has been resolved in this chapter and also 
includes an investigation of E-cadherin expression. In both contexts an increase in β-catenin 
expression resulted in quite different results in conjunction with p53/p21 expression; whilst 
nuclear β-catenin and reduced E-cadherin expression were consistent with roles in driving 
malignant progression.  
 
3.1 Analysis of biopsy DNA to determine mouse genotype and confirm cre 
activity.  
Transgenic mouse genotypes were routinely identified via PCR analysis using DNA samples 
isolated from progeny tail tips and again confirmed in adult biopsy tissues. Typically, 
K14.creP, HK1.ras, HK1.fos and Δβ-catenin strains were maintained as heterozygotes in an 
outbred ICR background. This use of an outbred ICR background provides a more robust 
viability and the larger litters guarantee the chance of getting the required compound genotype 
in a minimum number of litters. For example, C57 or Balb c mice typically give 6/7 pups per 
mating, and thus do not guarantee a complete genotype when the targeted genotype is up to six 
alleles. Therefore, mating these mice with ICR compensates for their potential phenotype 
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variability; however, it must be noted that phenotype variability was found to be an advantage 
as it gave survivors in mice with severe phenotypes or a phenotypic example in mice with 
weak or subtle phenotypes.  
Furthermore, breeding was not taken beyond the F5 generation to avoid any possible 
phenotypes from in-breeding. This was confirmed by Benavides and colleagues, who 
extensively studied this phenomenon (Benavides et al., 2020); concluding that as long as the 
outbred colony maintained was refreshed via regular mating with new ICR mice [routinely 
around or before F5]. This approach gave mice with a satisfactory background and avoided 
phenotypes due to in-breeding [F. Benavides; personal communication, IECC meeting 
October, 2018].   
For instance, F3 HK1.ras.K14.creP-Δ3β-cateninflx/wt  mice were full or medium sized; 
however, to generate the more complex genotypes e.g. HK1.fos-K14creP.Δ5PTENflx/flx .Δ3β-
catflx/wt two more rounds of breeding were required to F5. This resulted in more severe 
phenotypes, where some mice exhibited abnormally small sizes, giving rise to this concern 
regarding inbreeding. However, as these studies unfolded, despite the inducible nature of the 
gene switch, this was associated with an unavoidable β-catenin mediated malnutrition in 
weaned juveniles due to internal leaky expression; yet in alternate keratin-cre driven models 
this internal expression was fatal in earlier models employing Δ3β-catenin mice (Järvinen et 
al., 2006); as confirmed in this study as no litters of K5.cre.Δ3β-catenin were obtained [not 
shown]. 
As shown in Fig 3.1 PCR analysis confirmed genotypes containing the HK1.ras and HK1.fos 
transgenes Fig 3.1 A & B, employing oligo primers specific to activated v-rasHa and FBJ/R v-
fos oncogenes [See chapter 2 Table 2.2] (Greenhalgh et al.,1993a; 1993b). Oligos specific for 
the creP component of K14creP (Berton et al., 2000) identified K14creP positivity by a band 
at 410bp [Fig. 3.1 C].  
In addition, recent attempts have been initiated to minimise a spontaneous β-catenin 
phenotype via use of a mutated cre regulator gene employing the [alleged leak-proof] XJ5-
creP* regulator transgene (Zhou et al., 2002). This XJK5creP* is similar to the K14-creP 
regulator in terms of targeted expression in basal-layer keratinocytes, follicles and stem cells 
(Zhou et al., 2002), and was designed to minimise leakage due to a mutation in the PLBD. 
Separate oligomers were designed to identify this new genotype now maintained as 
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homozygotes [Fig. 3.1D] and preliminary experiments do indeed block this spontaneous β-
catenin phenotype but in this background XJK5creP*/β-catenin are currently devoid of any 
phenotype, thus in future experiments these mice appear to require extensive, prolonged 
RU486 treatments.  
 Identification of genotypes heterozygous and homozygous for the loxP-flanked exon5 PTEN 
allele employed oligos sets 1 & 2 [Fig.3.1E] and typically homozygous Δ5PTENflx/flx   lines  
were maintained for mating with K14creP.Δ5PTENwt/flx mice to generate 
K14creP.Δ5PTENflx/flx . To confirm functional ablation of loxP-flanked exon 5 DNA isolated 
from topical RU486 treated biopsies employed PTEN oligo sets 1 & 3 to identify the truncated 
500bp Δ5PTEN band in RU486 treated K14creP groups [Fig. 3.1 F].  
However, it should be noted that this 500bp Δ5PTEN band was absent in untreated 
K14creP.Δ5PTENflx/flx genotypes and genotypes lacking K14creP [Fig. 3.1C&E-F] were also 
devoid of this band, thus there was no spontaneous loss of exon 5 either. This result [also 
appearing in p53 analysis below] was consistent with the observations that typically 
phenotypes are seldom derived from leakage of the regulator and appeared confined to β-
catenin in this model (Yao 2006;2008 Macdonald et al., 2014; Masre et al 2017, 2020).  Thus 
given this new β-catenin observation, K14.creP.Δ5PTENflx/flx   mice were reassessed for 
spontaneous  RU486 independent cre leakage into the nucleus and this was observed randomly 
when older mice were maintained  for  > 6-9 months which exhibited  occasional mild ear 
keratosis and no obvious internal problems.  
Conditional knockout of p53 [K14creP.Δp53flx/flx ] mice were also employed where exons 2 to 
exon 10 become deleted after RU486 treatment to inactivate function (Berton et al., 2000; 
Jonkers et al., 2001). Using oligo sets 1 and 2 specific for p53 intron 1 [shown Fig. 3.1G; or 3 
and 4 specific for intron 10] breeding colonies were maintained as Δp53flx/flx  homozygotes and 
the K14creP.Δp53flx/flx  genotypes were created by mating K14creP.Δp53wt/flx with Δp53flx/flx  to 
generate K14creP.Δp53flx/flx . The K14.cre activity to create the Δp53 allele was confirmed by 
the use of oligo pairs: intron 1 forward 1 & intron 10 4 reverse, giving a Δp53 band at 612 bp 
[Fig. 3.1 H]. Here the typical lack of detectable cre leakage is highlighted in lane 3 where 
untreated K14creP.p53flx/flx  skin biopsy DNA does not possess the Δp53 band. However, if 
such leakage did occur the loss of p53 in the epidermis would go undetected, as p53 null mice 
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did not develop a phenotype in the absence of additional mutations such as HK1.ras 
(Greenhalgh et al., 1996).  
To identify p21 gene knockout, specific primers 1 & 2 were employed that detect the wild 
type p21 allele [p21wt] at 430bp, and this band is absent in KO mice [Fig. 3.1I-J]. In addition 
to avoid false negatives and identify heterozygous mice, the p21koor p21het genotype was 
confirmed by employing oligos to the 5’ and 3’ non-coding sequences which gave a band at 
180 bp indicating the KO allele (Martín-Caballero et al., 2001), whilst heterozygous p21 mice 
were identified by virtue of possessing both wt bands at 430 and the KO-specific allele at 180 
bp bands [Fig. 3.1I-J].  
β-catenin transgenic mice were identified by oligo primers specific to introns 2 and 4 of the 
loxP flanked exon 3 allele, giving a wt band at 324bp and the floxed allele at 500bp (Harada 
et al., 1999). Successful Δ3β-catenin activation was confirmed using another specific set of 
oligoes giving a 200bp band in mice carrying both K14creP and Δ3β-catenin [K14creP.Δ3β-
catflx/wt] transgenes. However, given the apparent potency of β-catenin in this model, typically 
RU486-treated K14creP.Δ3β-cat mice were maintained as heterozygotes [K14creP.Δ3β-
catflx/wt ] as a novel, level of spontaneous phenotypes appeared in this model due to cre activity 
apparently independent of RU486 treatment. As cited above, this leakage was a phenomenon 
previously only observed in occasional older [> 6 month], untreated tri-genic HK1.ras/fos-
Δ5PTENflx/flx or older bi-genic HK1.ras-Δ5PTENflx/flx mice, which had each displayed a 
significant degree of neonatal ras/fos-associated hyperplasia (Greenhalgh et al 1993c) during 
development that continued into adults (Yao et al., 2006;2008; Macdonald et al., 2014). As 
described in detail below, this gene switch leakage in bi-genic K14creP.Δ3β-catflx/wt mice 
resulted in a juvenile phenotype from approx. 10 days post birth [following the first anagen]  
unless intriguingly being inhibited by loss of p53 in the p53flx/flx  progeny as well. However, 
unlike similar approaches employing constitutive keratin-driven cre (Järvinen et al., 2006), the 
K14creP.Δ3β-catflx/wt heterozygotes and homozygotes were viable, and this may explain the 





Figure 3. 1: Confirmation of genotype by PCR analysis.  
[A] HK1.ras positive mice exhibit a 550bp band [lanes 1-4]; absent in negative control DNA 
[lane 5]. [B] HK1.fos positive mice exhibit a 750bp band [lanes 2-4; lanes 1 & 5: negative 
control]. [C] K14.creP positive mice exhibit 410bp band [lanes 4-5 & 7-8]. [F] Positive 
XJK5creP* mice give a 400bp band [lanes 1-4; lane 5: negative control]. [E] A gel 
corresponding to [C], shows the PTENwt allele band at 1200bp [lanes 1-3], with 
K14creP.Δ5PTENflx/wt heterozygotes [lane 4-6] and K14creP.Δ5PTENflx/flx  homozygotes [lanes 
7-9] show the additional loxP-flanked Δ5PTEN allele at 1300bp. [F] Also corresponding to 
D/C, only RU486 treated K14creP.Δ5PTENflx/wt  mice [lanes 4-5] and K14creP.Δ5PTENflx/flx  
[lanes 7-8] show successful ablation of exon 5 [Δ5PTEN] with positive band at 500bp [G] 
Analysis of p53 mice employing intron1 oligos 1 & 2 gives a p53wt band at 431bp [lane 1], 
p53flx/flx  band at 584bp [lanes 2-5] and a doublet in p53flx/wt  heterozygosity [lane 6]. [H] To 
confirm cre activity a 612bp Δp53flx band appears in RU486-treated K14creP.p53flx/flx mice 
[lanes 1-2; 4-5], which is absent in untreated RU486 K14creP.p53flx/flx  skin [lane 3] or RU486-
treated but K14creP negative p53flx/flx  skin [lane 6]. [I] Confirmation of p21 knockout involved 
a lack of a 430bp band using oligos specific for the wt allele [lane 10] and data combined with 
[J] where oligos specific to the 5’ and 3’ non-coding sequences give DNA positive for the null 
allele at 150bp [lane 10]; whilst heterozygosity [lanes 1-5 & 11-12] is indicated by presence of 
both bands. (K) Δ3β-catenin allele analysis shows wild-type β-catenin allele at 324bp [lanes 
1-3], with mice heterozygous for the loxP-flanked exon 3 possess both wt and floxed allele 
bands at 500bp [lanes 4-6]; with homozygotes possessing the loxP-flanked exon 3 allele at 
500bp [lane 7-9]. [L] Successful ablation of exon 3 [Δ3β-catenin] in RU486-treated 
K14creP.Δ3β-catflx/wt mice is indicated in lanes 2-7 by the appearance of a lower less intense 
200bp band indicative of the heterozygous nature of Δ3β-catenin expression and the greater 
amount of non-epidermal tissue in these skin biopsy samples. Lanes 9 & 10 wt DNA; lanes 
11 & 12 non cre Δ3β-catenin alone; thus showing the leakage is K14.creP specific. 
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3.2 Analysis of endogenous β-catenin status in multistage HK1.ras/fos-
K14creP.Δ5PTENflx/flx carcinogenesis  
β-catenin expression status was analysed in tri-genic HK1.ras/fos-K14creP.Δ5PTENflx/flx 
carcinogenesis model together with the bi-genic combinations and HK1.ras/fos and 
K14cre.Δ5PTEN alone strains. As outline in the introduction these mice were ideal to assess 
possible β-catenin roles at each stage of tumour formation (Greenhalgh et al., 1993a-c; Yao et 
al., 2006; 2008; Macdonald et al., 2014) and for this study these genotypes were re-
established to provide fresh material for β-catenin analysis in addition to initial use of archival 
samples; and for use as comparison controls following RU486-mediated β-catenin activation. 
 As shown in Fig. 3.2, the new combinations of HK1.ras/fos-K14creP.Δ5PTENflx/flx mice gave 
identical results to those produced in previous studies (Greenhalgh et al., 1993 a-c; Yao et al., 
2006; 2008; Macdonald et al., 2014). HK1.ras activation (Greenhalgh et al., 1993a; 1993c) 
provided the initiation step [Fig. 3.2A] that initially results in a thickened scaly skin in 
neonates that resolves in adults [Fig. 3.2A see chapter 1 Fig. 1.5]. Histologically HK1.ras 
activation induced epidermal hyperplasia, and this persists in adult ears and is the precursor to 
an overt papilloma in the HK1.ras1205 strain [Fig. 3.2E]. (Greenhalgh et al., 1993a). Of note, 
two strains of HK1.ras mice exist, line 1205 which is highly sensitive to promotion thus the 
ear tag wounding results in papillomas in 100% of animals within 6-8 weeks, whereas line 
1276 maintains a simple hyperplasia due to induction of p53 [see below] (Masre et al., 2020). 
HK1.ras1205 papillomas are similar to HK1.ras/fos, [Fig. 3.2B see chapter 4]; and 
histologically these tumours show no sign of malignant conversion. However if the tag is lost, 
HK1.ras1205 papillomas regress whereas in HK1.ras/fos papillomas are autonomous, as the 
promotion stimulus is provided  by HK1.fos, yet together HK1.ras1276/HK1.fos results in a 
benign papilloma that does not spontaneously convert to malignancy [Fig. 3.2F] (Greenhalgh 
et al., 1993c). HK1.fos mice eventually exhibit a hyperkeratotic ear skin consistent with roles 
in keratinocytes differentiation (Greenhalgh et al., 1993b; see chapter 7) [NB: Crosses of 1205 






Figure 3. 2: HK1.ras/fos-K14creP.Δ5PTENflx/flx carcinogenesis phenotypes; 
histopathology, mK1 differentiation marker analysis and p53 expression  
Upper: Schematic diagram shows ras initiates; fos promotes; but malignant conversion 
requires PTEN  [and/or p53] loss.[A-D]: Overt HK1.ras/fos-K14creP.Δ5PTENflx/flx phenotypes: 
(A) HK1.ras1205 residual  hyperplasia; (B) HK1.ras/fos benign papilloma; (C) Highly keratotic 
HK1.fos-K14creP.Δ5PTENflx/flx keratoacanthoma [KA] and [D] malignant HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCC. [E-H] Histopathology of (E) HK1.ras1205 neonatal ear skin 
hyperplasia (F) HK1.ras/fos squamous papilloma; (G) HK1.fos-K14creP.Δ5PTENflx/flx 
keratoacanthoma: typified by extensive keratin layers and a disorganised epidermal 
differentiation; (H) Aggressive, invading HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC exhibit 
multiple mitotic figures. [I-L] IF analysis of keratin K1 vs keratin K14 expression. (I/J) 
Hyperplasia and papillomas show strong K1 expression confined to supra-basal layers with 
K14 showing expanded proliferative basal layers. (K) KAs show K1 expression in basal 
keratinocytes indicating an accelerated differentiation. (L) HK1.ras/fos-K14creP.Δ5PTENflx/flx 
SCC exhibits K1 loss indicating aggressive SCC. [M-P] IHC analysis of p53 shows 
expression increases but is lost on conversion. (M) Sporadic p53 expression in HK1.ras1205 
hyperplasia becomes strong in (N) papillomas and stronger still in (O) KAs with clear nuclear 
expression in basal keratinocytes; however (P) p53 expression is lost in HK1.ras/fos-





This phenotypic stability of benign papillomas indicated that these mice were ideal to study 
malignant conversion, and given its role in the familial cancer syndrome of Cowden’s disease 
(Hopkins et al., 2014), the failure of PTEN-mediated AKT inhibition via ablation of exon 5 
[Δ5PTEN] was the first addition to this model to study roles in papilloma formation and 
conversion to malignancy (Yao et al., 2006;2008; Macdonald et al., 2014). Initial experiments 
first introduced PTEN mutation into the HK1.ras model [HK1.ras.Δ5PTENflx/flx] which 
resulted in accelerated papillomatogenesis, as seen with earlier models (Greenhalgh et al., 
1995). Benign papillomas required TPA promotion treatment to convert to malignancy and 
this resulted in very aggressive poorly differentiated SCCs (Yao et al., 2006). Later studies 
showed that such TPA promotion was necessary to overcome a protection invoked via 
elevated levels of p53 and p21 in response to PTEN loss of AKT regulation (Macdonald et al., 
2014) and earlier studies involving HK1.fos co-operation with PTEN loss[Δ5PTEN]  
demonstrated that the KA aetiology had been dependent upon this compensatory expression of 
p53 and p21 that first inhibited proliferation as determined by BrdU labelling analysis and 
subsequent induction of keratinocyte differentiation via p21 (Toply et al., 1999) indicated by 
premature keratin K1 expression (Yao et al., 2008).  
 
Indeed, it was the co-operation between HK1.fos and Δ5PTEN that first highlighted the 
important roles for β-catenin in this model in terms of the compensatory responses deployed 
by the epidermis in order to maintain its homeostasis and inhibit tumour progression at each 
individual stage. In the co-operation of HK1.fos.K14.Δ5PTEN, novel benign keratoacanthomas 
[KA] developed [Fig. 3.2C]. This benign, regression prone tumour is typified in humans by 
the histological changes from papilloma in terms of a massive degree of hyperkeratosis 
resulting in the overt keratotic appearance of classic KA [Fig. 3.2C&G].  Here significant 
compensatory p53 and p21 expression [below] was triggered by high levels of p-AKT due to 
the lack of PTEN exon5, that in turn inactivated GSK3β (Yao et al., 2008); leading to [then 
assumed] deregulation of β-catenin [confirmed below Fig. 3.3 (Alyamani et al., manuscript in 
preparation)] This appearance of β-catenin in the basal layers of the earlier papilloma-like 
stage induced  a corresponding burst of p53 (Fig. 3.2O) which caused the massive keratosis of 
KA [Fig. 3.2C&G] (Yao et al., 2008). This was also observed in ROCK2-mediated studies in 
this model that again led to β-catenin mediated induction of p53 and inhibition of papillomas 
(Masre et al., 2020)- a noteworthy finding given the results in Chapter 5. In the tri-genic 
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HK1.ras1276/fos.Δ5PTEN genotypes, with the addition of activated rasHa, mice now showed a 
novel malignant progression, following p53 loss in late stage papillomas initially to wdSCC, 
that progressed to poorly differentiated SCC [pdSCC] following additional p21 loss and 
uniform p-AKT1 activation (Macdonald et al., 2014) which showed increasingly aggressive 
tumour phenotypes with clear sign of invasion and a highly disorganized epidermis [Fig. 
3.2D&H]. 
 
To help confirm the histotype analysis, double-labelled IF analysis was conducted for 
expression of keratin1 [mK1; green], an early stage differentiation marker expressed in supra-
basal layers and also used as a marker to indicate late-stage benign papilloma from an early 
wdSCC carcinogenesis, as it is progressively lost during conversion to SCC (Macdonald et al., 
2014). In these experiments, expression of Keratin14 [mK14; red] was routinely employed to 
delineate either the epidermis and follicles, or tumour from surrounding stroma. As shown in 
Fig 3.2 I & J, both typical hyperplasia and papillomas show a relatively normal supra-basal 
expression of K1, in a context where the basal layer expands as indicated by a wider K14+ve 
[red] basal layer due to a proliferative response to ras and/or fos activation.  
Of note, in the KAs produced by HK1.fos-K14creP.Δ5PTENflx/flx co-operation, an accelerated 
and premature differentiation pattern was indicated by strong and novel K1 expression in the 
basal layers, with mK1 expression levels often masking K14 co-expression [Fig 3.2 K]. This 
result was consistent with a premature commitment to differentiation giving the massive levels 
of keratosis associated with this tumour type (Yao et al., 2008) and the new findings on the 
responses to anomalous expression of basal-layer β-catenin [below]. However, in tri genic 
HK1.ras/fos-K14creP.Δ5PTENflx/flx SCCs, K1 expression was greatly reduced indicative of 
malignant conversion [Fig. 3.2L].  
This differentiation analysis was followed by investigation of p53 expression given its roles in 
human carcinogenesis (Mollereau and Ma, 2014). Surprisingly typically early HK1.ras and 
HK1.fos hyperplasia showed an initial weak and only sporadic expression [Fig. 3.2M] which 
was similar to normal epidermis [chapter 1 Fig 1.7]  possibly indicative of epidermal tolerance 
to excess proliferation such as in normal wound healing and the possibly danger to barrier 
maintenance from deregulated,  p53-mediated, apoptosis (Calautti et al., 2005) and therefore 
giving only sporadic expression in those basal keratinocytes  completing the cell cycle. 
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However, with time and degree of hyperplasia i.e. the greater hyperplasia in RU486-treated 
HK1.ras/fos-K14creP.Δ5PTENflx/flx , p53 expression became stronger such that on progression 
to papilloma p53 was expressed in the nuclei of most basal layer keratinocytes [Fig. 3.2 
N&O], which helped in halting any further malignant progression. This was observed in e.g. 
HK1.ras.K14.Δ5PTEN bi-genic papillomas that required TPA promotion to achieve 
malignancy, where early p53 loss was observed in aggressive papillomas making them 
susceptible to conversion via accumulation of new mutants (Yao et al., 2006). Indeed all KAs 
showed very strong p53 expression in the basal layers [Fig. 3.2 O]correlating with the massive 
increase in differentiation [Fig. 3.2K] due to GSK3-β induction of both p53 [and p21] in basal 
layers (Yao et al., 2008), while, tri-genic SCCs with additional ras activation had lost 
expression of p53 again at the papillomas stage leading to conversion to wdSCC; although 
expression of p21 [not shown] inhibited early progression which was then lost and tumours 
progressed to pdSCC [Fig. 3.2P].  
 
3.3 Analysis of β-catenin and E-cadherin expression in HK1.ras/fos-
K14creP.Δ5PTENflx/flx  carcinogenesis 
Previously, and mainly based on the levels of inactivated p-GSK3β observed in HK1.fos-
K14creP.Δ5PTENflx/flx mice (Yao et al., 2008), it was assumed that loss of GSK3β-mediated β-
catenin ubiquination resulted in the potential persistence of nuclear β-catenin and thus 
deregulation of Wnt signalling. Thus, at a specific stage in the aetiology of KA, a level of 
GSK3β inactivation may have achieved a threshold of elevated β-catenin that triggered the 
compensatory p53 expression responses that led to cessation of proliferation, and the excess 
p21 that induced the irregular differentiation and hyperkeratosis. In addition, this PTEN-
AKT/β-catenin axis was possibly involved in the malignant conversion observed in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx mice following p53 loss and to some extent alongside that 
of deregulated E-cadherin signalling, β-catenin co-operated with AKT to drive malignant 
progression following p21 loss (Macdonald et al., 2014). Therefor to finally confirm these 
ideas and provide data for endogenous β-catenin status in each of the HK1 models, 
endogenous β-catenin and E-cadherin expression were assessed at different stages of 
progression using archival and new HK1.ras/fos-K14creP.Δ5PTENflx/flx biopsies [Fig. 3.3; 
(Alyamani et al., Manuscript in Preparation)].   
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In early HK1.ras1205 or HK1.ras1276/fos hyperplasia β-catenin expression appeared to be 
increased over normal yet appeared confined to the supra-basal layers and remained strongly 
membranous [Fig 3.3A&E], in a similar fashion to that of normal epidermis. [below chapter 4 
Fig. 4.4C].  In HK1.ras papillomas this profile persisted [chapter 5 Fig. 5.14E&F] but in 
autonomous HK1.ras/fos papillomas occasional strands of basal layer β-catenin were detected 
[Fig. 3.3B&F]. Here β-catenin expression exhibited a strong membranous expression in both 
basal and supra-basal layers but now with sporadic detectable nuclear expression [Fig. 3.3F] 
that paralleled the increasing expression of nuclear p53 [Fig 3.3N]. Furthermore, HK1.fos-
K14creP.Δ5PTENflx/flx KAs showed even greater β-catenin expression levels in both basal and 
supra-basal layers again with both membranous expression as well as clear detectable nuclear 
expression [Fig. 3.3C&G]. This combination of membranous and now easily detectable β-
catenin expression correlated with strong [Δ5PTEN/AKT-mediated] p-GSK3β inactivation 
observed previously (Yao et al., 2008) associated with an increase in nuclear p53 expression 
[Fig. 3.3O] and a massive differentiation response resulting in a novel KA aetiology [Fig. 
3.2C&G]; an observation repeated in ROCK2 mice where such β-catenin -mediated p53 
expression inhibits papilloma formation (Masre et al., 2020). Moreover, whilst hyperplasia 
and papillomas gave a β-catenin profile of both membranous nuclear profile similar to KA, in 
HK1.ras/fos.K14.Δ5PTEN mice on conversion to SCC, membranous β-catenin expression was 
greatly reduced, especially in the invasive basal layers that now possessed a very strong 
cytoplasmic/nuclear β-catenin expression, particularly prominent in the more sensitive IHC 
analysis [Fig. 3.3D&H]. This may be indicative of driving malignant progression via increased 
transcription and membrane loss a compromise of focal adhesion signalling, which led to E-





Figure 3. 3: β-catenin and E-cadherin vs. p53 expression in HK1.ras/fos-
K14creP.Δ5PTENflx/flx carcinogenesis.  
[A] Early and [E] later HK1.ras hyperplasia shows membranous β-catenin expression in 
supra-basal layers with occasional strands of basal layer expression. [B & F] HK1.ras/fos 
papillomas show increasing membranous expression in basal layers but sporadic nuclear 
expression. [C & G] HK1.fos-K14creP.Δ5PTENflx/flx KA exhibit strong membranous expression 
in all layers and nuclear expression in basal keratinocytes correlating with high p53 
responses. [D & H] HK1.ras/fos-K14creP.Δ5PTENflx/flx  SCCs show strong nuclear expression 
following p53 loss, with reduced membranous expression consistent with failures in adhesion 
helping invasion. [I] Hyperplastic E-cadherin expression is membranous and supra-basal 
mimicking β-catenin. [J] E-cadherin expression in papillomas is supra-basal again similar to 
β-catenin. [K] HK1.fos-K14creP.Δ5PTENflx/flx KAs exhibit E-cadherin in basal layers, similar to 
β-catenin, associated with anomalous, accelerated differentiation. [L] HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs show reduced E-cadherin expression at the invasive front, 
suggesting a loss of cell-cell adhesion but retain some supra-basal expression consistent with 
a model of collective invasion. [M] p53 analysis shows sporadic hyperplasia expression 
becomes elevated in [N] papillomas and stronger in [O] KAs correlating with increased β-
catenin expression; however, [P] p53 expression is weak/lost in SCC correlating with reduced 
membranous/increased nuclear β-catenin and loss of E-cadherin expression in the invading 






E-cadherin is an essential part of the cell-cell adhesion complex needed for normal epidermal 
barrier functions and with β-catenin roles in the signalling functions from the plasma 
membrane to nucleus (Jeanes et al., 2008). Given these intimate interactions and the β-catenin 
results which showed alterations in membranous expression depending on the stage of tumour 
progression; E-cadherin levels were assessed in stage specific HK1.ras/fos-
K14creP.Δ5PTENflx/flx phenotypes [Fig. 3.3I-L]. In HK1.ras mice, E-cadherin expression in 
hyperplasia remained essentially similar to normal with supra-basal layer membranous 
expression [Fig. 3.3 I] consistent with focal adhesions that aid in epidermal barrier functions. 
In HK1.ras/fos papillomas, E-cadherin expression was increased but again appeared in supra-
basal basal layers with occasional strands of positive basal-layer keratinocytes possibly to aid 
the inhibition of conversion in this model via appropriate cell-cell adhesion signalling to 
increase adhesion and possible signal to induce p53 expression via β-catenin [Fig. 3.3J]. In 
HK1.fos-K14creP.Δ5PTENflx/flx KAs strong supra-basal E-cadherin expression became strongly 
expressed in the basal layers, constant with its protective roles from tumour invasion due to 
elevated, increased differentiation (Chiles et al., 2003; Jeanes et al., 2008) and thus increasing 
cell-cell adhesion [Fig 3.3 K] and preventing invasion. This expression profile correlated with 
both membranous and nuclear β-catenin expression that induced the strong compensatory 
expression of p53 [Fig 3.3C,G,K,O]. However, in aggressive HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs membranous E-cadherin expression disappeared in the invasive 
basal layers that co expressed nuclear β-catenin [Fig. 3.3D,H,L,P].  
These results reinforce β-catenin involvement in aiding malignant progression as it suggests 
that the loss of p53 and nuclear localization of β-catenin in SCCs greatly reduce the ability of 
E-cadherin to form focal adhesion junctions in the invasive front; an observation consistent 
with the collective invasion profiles observed in human SCC (Hesse et al., 2016). It also 
appears that the anomalous expression of β-catenin in the basal layers correlates with the 
resulting expression of p53 and p21, a significant observation that has relevance for the results 
in chapter 6 in facilitation of tumour invasion via failures in cell-cell signalling once the 
unique and paradoxical block of tumour formation induced in response to β-catenin 





Table 3. 1: Summary of β-catenin and E-cadherin expression in HK1.ras/fos-
K14creP.Δ5PTENflx/flx carcinogenesis 
 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 




Control hyperplasia showing membranous, supra 
basal layer β-catenin and E-cadherin expression 
correlates with a lack of basal layer p53 [similar to 
normal ICR expression] 






Control papilloma showing both membranous 
supra and basal layer β-catenin and E-cadherin 











SCC showing membranous β-catenin/E-cadherin 
expression becomes reduced in basal layers but 
cytoplasmic/nuclear β-catenin expression becomes 









KA showed increased membranous β-catenin/ E-
cadherin expression levels in both basal and supra-
basal layers with detectable nuclear/cytoplasmic β-
catenin, correlating with basal layer p53 
Conclusion: Increased cytoplasmic/nuclear β-catenin expression via loss of GSK3β-mediated β-catenin 
ubiquination, aids in driving malignant conversion in HK1.ras/fos-K14creP.Δ5PTENflx/flx SCCs 
following loss of p53. This was constant with reduced membranous β-catenin/E-cadherin basal layer 
expression indicative of reduced cell-cell adhesion. However, in benign HK1.fos-K14creP.Δ5PTENflx/flx 
KA with the absence of ras activation, increased membranous basal layer expression of β-catenin/E-
cadherin and detectable nuclear β-catenin activation triggered increased basal layer p53 expression thus 
halting malignant conversion via strengthened cell-cell adhesion unlike SCCs aetiology. These data 
indicate that β-catenin roles in carcinogenesis are context dependent and the outcome will depend other 













Chapter 4: Analysis of β-catenin 




















 β-catenin is a dual function protein, it acts to maintain the epithelial cellular barrier via 
forming a cell-cell adhesion complex with E-cadherin, Thus, failure of this function has been 
associated with facilitating tumorigenesis (Grigoryan et al., 2008; Jeanes et al., 2008). β-
catenin also acts as a nuclear transcriptional activator of canonical Wnt/β-catenin signalling 
targets LEF/TCF, which are associated with hair follicle differentiation and morphogenesis 
(Grigoryan et al., 2008). An over expression of this pathway via β-catenin gain of function 
mutation has been associated with several types of cancer such as colon, prostate, ovarian, 
melanoma and non-melanoma skin cancers (Morin, 1999; Gerdes and Yuspa, 2005; 
Grigoryan et al., 2008).  
Previous studies conducted on constitutive activation of β-catenin in skin resulted in HF 
abnormalities, hence Wnt/β-catenin roles in regulating hair follicles differentiation and 
morphogenesis. These studies reported HF abnormalities such as increased formation of HF 
placode, de novo HF, formation of epidermal cyst and HF tumours such as pilomatricoma and 
trichofolliculoma (Gat et al., 1998; Huelsken et al., 2001; Grigoryan et al., 2008). However, 
IFE tumours such as cutaneous squamous cell carcinoma were not reported in response to 
constitutive activation of β-catenin alone in skin. 
Therefore, in this analysis the aim was to investigate the phenotype similarities of inducible 
constitutive activation of β-catenin in K14creP.Δ3β-catflx/wt to previous studies and investigate 
the effect on epidermal terminal differentiation and TSGs expression in response to β-catenin 
activation. Thus, before analysing K14creP.Δ3β-catflx/wt co-operation with HK1.ras to assess 
its roles in SCC development and whether it would result in a similar or contrary effect on 
tumorigenesis in comparison to the endogenous β-catenin analysis in multistage HK1.ras/fos-







4.2 K14creP.Δ3β-catflx/wt over expression in mouse skin induced hair follicle 
abnormalities and hair follicle tumours. 
The first step taken to directly analyse the effects of constitutive β-catenin activation in the 
HK1.ras/fos-K14creP.Δ5PTENflx/flx model was to create expression of Δ3β-catenin in mouse 
epidermis by mating K14.creP with Δ3β-catenin [K14.creP.Δ3β-catflx/wt ]. As outlined in Fig. 
4.1 A, exon 3 of β-catenin is flanked by lox-P sites thus in principle following topical 
application of RU486, constitutive β-catenin activation was induced via removal of the 
APC/GSK3β binding complex to eliminate its negative regulation by cytoplasmic 
ubiquination (Harada et al., 1999; Berton et al., 2000). Routine PCR analysis confirmed 
K14creP.Δ3β-catflx/wt genotypes [Fig. 4.1B] and β-catenin transgenic mice [Δ3β-catenin] were 
identified by oligo primers [Table. 2.2] specific to intron 2 and 4 of the loxP flanked exon 3 
allele giving a wt band at 324bp and the floxed allele at 500bp (Harada et al., 1999; Berton et 
al., 2000). In addition, successful Δ3β-catenin activation was confirmed using another specific 
set of oligos giving a band at 200bp band in mice carrying both K14creP and Δ3β-catenin 
[K14creP.Δ3β-catflx/wt] transgenes [Fig. 4.1C], ideally in response to RU486 treatment but as 
discovered this was not necessarily the case for all K14.creP.Δ3β-catflx/wt mice on this outbred 




Figure 4. 1: A schematic diagram to illustrate the mechanism of RU486-inducible 
cre/loxP system in the ablation of exon 3 in β-catenin and PCR analysis confirming 
Δ3β-catenin expression.  
[A] The keratin K14creP driven cre is used to achieve exclusive cre expression in all 
keratinocytes. To activate cre in the epidermis and hair follicles transgenic mouse skin is 
treated with RU486 and the PLBD translocates into the nucleus where cre activity deletes the 
sequence flanked by lox P sites. In this model exon 3 the binding site for β-catenin 
ubiquination is removed resulting in constitutive activation. Oligo primers 1 & 2 are employed 
to identify the loxP alleles and 3 & 4 to confirm cre activity.  
[B] PCR analysis of Δ3β-catenin allele genotypes shows the wild-type β-catenin allele at 
324bp [lanes 1-3], whilst mice heterozygous for the loxP-flanked exon 3 possessed both the 
wt band and the additional floxed allele band at 500bp [lanes 4-6]; this band also appeaerd in 
mice homozygous for the loxP-flanked exon 3 allele [lane 7-9].  
[C] Successful ablation of exon 3 [Δ3β-catenin] in RU486-treated K14.creP-Δ3β-cateninflx/wt  
mice is indicated in lanes 2-7 by the appearance of a lower less intense 200bp band 
indicative of the heterozygous nature of Δ3β-catenin expression and the greater amount of 
non epidermal tissue in these skin biopsy samples. Lanes 9 & 10 wt DNA; lanes 11 & 12 non-








Typically, K14creP.Δ3β-cat mice were maintained as heterozygotes [K14creP.Δ3β-catflx/wt] 
due to a low level of spontaneous cre activity appearing in increasing numbers of juveniles as 
progressive additional transgenes were introduced. This resulted in skin phenotypes apparently 
independent of overexpression in this model. As cited above, this novel phenomenon was 
previously observed only in sub-sets of older, untreated tri-genic HK1.ras/fos-
K14creP.Δ5PTENflx/flx or bi-genic HK1.ras-Δ5PTENflx/flx mice that had undergone a more 
severe hyperplastic phase in neonatal development (Yao et al., 2006; 2008; Macdonald et al., 
2014).  
Thus, whilst most K14creP.Δ3β-catflx/wt mice still required RU486 treatment to fully elicit a 
Δ3β-catenin phenotype, frequently by 16-24d [i.e. post the initial anagen phase] juvenile mice 
often exhibited mild alopecia and a general disheveled scruffiness to the coat, and enlarged 
extremities that comprise of abnormal oversized feet, with a thickened hyperkeratotic tail and 
large ears [Fig. 4.2A-G]. In addition, and particularly following RU486 treatment, the shaven 
dorsal sites exhibited a mild keratosis within a week of initial treatment [Fig. 4.2I] and at these 
sites typically the fur remained sparse. 
It was also noted that juvenile K14creP.Δ3β-catflx/wt  mice varied in body size some being 
similar to normal ICR or smaller when compared to K14creP and Δ3β-catenin alone siblings. 
This varied appearance and the severity of these overt juvenile phenotypes were attributed to 
the randomness of early RU486-independent cre leakage as well as the differing genetic 
backgrounds of individual family trees on this outbred ICR background. Nonetheless, once 
introduced to the RU486 treatment regime, all K14.creP.Δ3β-catflx/wt  produced similar levels 
of phenotype regardless of their genetic background. 
These findings were very similar to many previous transgenic mouse studies that reported 
identical gross abnormalities involving mice where constitutive β-catenin activation was 
achieved in the epidermis (Gat et a.,1998; Van Mater et al., 2003; Celso et al.,2004; Närhi et 
al 2008). However, in all these models, effects of β-catenin overexpression focussed on hair 
follicle development and anomalies and later to effects on stem cells and useful paracrine 
effects on fibroblasts but to date none have exploit such mice in the development of classic 




Figure 4. 2: K14creP.Δ3β-catflx/wt mouse phenotypes.  
[A] RU486-treated K14creP.Δ3β-catflx/wt mice shows a general lack of correct hair growth 
resulting in a dishevelled appearance. Also note the peri-orbital hyperkeratosis and abnormal 
fibrisse; and the fact these mice are full sized in this litter. [B] Higher magnification of 
K14creP.Δ3β-catflx/wt shows a larger and thickened keratotic ear compared to [C] a normal 
ear. [D] K14creP.Δ3β-catflx/wt mice show phenotypically abnormal tails-independent of RU486-
treatment with a thickened appearance, and a greasy appearance. Also the feet of 
K14creP.Δ3β-catflx/wt mice exhibited increased hyperkeratosis on the palmoplantar surface [E] 
At higher magnification K14creP.Δ3β-catflx/wt  possess phenotypically larger feet compared to 
normal, with a swollen, oedematous nature suggesting effects on dermal physiology 
alongside that of greasy fur. [F & G] Higher magnification shows increased alopecia resulting 
in dishevelled fur in K14creP.Δ3β-catflx/wt again with larger feet against [H] normal ICR. [I] a 
typical RU486-treated K14creP.Δ3β-catflx/wt dorsal skin displays a lack of regrown fur and a 




Histologically the epidermis of RU486-treated K14creP.Δ3β-catflx/wt  mice was dominated by 
the appearance of multiple hair follicle abnormalities such as the increased formation of de 
novo hair follicle placodes; especially obvious in the ear histotype [Fig. 4.3A] but with little in 
the way of fully formed hair shafts at higher magnification [Fig. 4.3B vs. E] hence the general 
mild alopecia and dishevelled appearance of the fur.    
These hair follicle abnormalities were more apparent on back skin histotypes and were 
accompanied by formation of cysts [Fig. 4.3C], since this area normally possess more hair 
follicles than the ears and consistent with previous reports (Närhi et al., 2008) despite the 
increased numbers of placodes the actual hair regrowth following RU486 treatment was poor 
[Fig. 4.3C]. Here the treated skin shows a wrinkled nature yet on comparison to a typical 
HK1.ras or HK1.fos epidermis [above chapter 3: Fig.1.5] RU486-treated K14creP.Δ3β-catflx/wt 
exhibits only a minimal interfollicular epidermis [IFE] hyperplasia [Fig. 4.3B,C,F] often only 
slightly more hyperplastic than normal epidermis [Fig. 4.3F vs. G]. Also, despite excess basal 
layer expression of β-catenin [see below Fig. 4.4] the histotype shows a relatively ordered 
keratinocyte differentiation pattern, although at the molecular level, keratin expression was 
clearly disrupted [below Fig. 4.5].     
The lack of proper fur was explained by the apparent failure of hair follicle differentiation and 
possibly due to the formation of cysts from failed HF development and the beginnings of hair 
follicle tumours. Indeed, the diversion of failed HFs to form large cysts may be a protective 
measure to inhibit progression, as observed in HK1.ras/fos-Δ5PTENflx/flx mice  (Macdonald et 
al., 2014) and where this proliferative diversion failed to happen, benign trichofolliculomas 
formed [Fig. 4.3D]  (Gat et a., l998). Furthermore, this effect of β-catenin overexpression 
would account for the observation that prior to the first synchronised anagen, neonatal pups 
appeared relatively normal despite the potential for leakage of cre activity whilst the 




Figure 4. 3: Histological analysis of K14creP.Δ3β-catflx/wt mice.  
[A] RU486-treated K14creP.Δ3β-catflx/wt ear histology exhibits multiple hair follicle 
abnormalities, with numerous placodes; whilst [B] higher magnification also highlights the 
minimal interfollicular epidermal [IFE] hyperplasia. [C] RU486-treated K14creP.Δ3β-catflx/wt  
back skin histology also exhibits de novo hair follicles, now with overt hair follicle tumors 
[Trichofolliculoma] and formation of cysts. [D] Higher magnification of a typical early 
trichofolliculoma compared to [E] normal hair follicle morphology in ICR skin. [F] Higher 
magnification of treated K14creP.Δ3β-catflx/wt back skin again exhibits minimal IFE hyperplasia 
compared to [G] normal ICR. Scale bars: A&C: 150µm; B: 75µm; D-G: 50µm. 
 
To confirm the increase in β-catenin expression from a combination of exogenous transgene 
and endogenous gene expression, the overall levels were assessed in K14creP.Δ3β-catflx/wt  
genotypes using both IF and IHC staining [Fig. 4.4].  In both experiments strong β-catenin 
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expression was observed in supra-basal and basal layers, as well as hair follicles [Fig. 4.4A]. 
In RU486-treated K14creP.Δ3β-catflx/wt genotypes, a notable increase in nuclear expression 
was observed in basal layer and follicular keratinocytes as expected due to increased activated 
Δ3β-catenin expression from a lack of the ubiquination site following K14creP regulator 
activity [Fig. 4.4B&E]. This contrasted to the predominantly membranous and suprabasal 
expression of endogenous β-catenin in normal mice [Fig. 4.4C&F]. Constitutive high levels of 
β-catenin were also observed in both quiescent and anagen hair follicles and particularity in 
those degenerating into cysts or trichofolliculomas [Fig. 4.4A&B].  
This level of overall β-catenin expression in K14creP.Δ3β-catflx/wt mice reconfirmed the PCR 
result of Δ3β-catenin activation [Fig. 4.4A-C] and illustrated the consequences of deregulated 
β-catenin expression in terms of this spatial pattern together with increased nuclear expression, 
which highlights the importance of β-catenin/Wnt signalling in maintaining skin homeostasis 
and the epithelium of multiple organs throughout the body (Lim and Nusse, 2013). 
The increased β-catenin expression in K14creP.Δ3β-catflx/wt mice [Fig. 4.5A-C] was assessed 
using ImageJ software to quantify β-catenin levels [Fig. 4.6]. The assessment evaluated β-
catenin nuclear localization and overall increase in strands of 10 basal layer cells of 
K14creP.Δ3β-catflx/wt in 3 different skins [n1-3] and these analysed areas were identified as 
regions of interest [ROI] [Fig. 4.6A-I]. Using the colour threshold function of ImageJ software 
that identifies the localization of labelled fluorescence staining, β-catenin nuclear localization 
was detected in all ROI cells giving 100% [10cells/mm2] nuclear localization of β-catenin in 
K14creP.Δ3β-catflx/wt [n1-3] [Fig. 4.6A-J]. Additionally, the overall expression of β-catenin, 
which includes cytoplasmic and nuclear expression, was estimated to be 55% of the ROI 
areas[n1-3] [Fig. 4.6K]. These results were consistent with the lack of the ubiquination site in 
the Δ3β-catenin protein (Harada et al., 1999; Berton et al., 2000) and also consistent with cell 
adhesion roles of β-catenin/E-cadherin (Takeichi, 1991; Young et al., 2003). Therefore, this 
analysis confirmed that in K14creP.Δ3β-catflx/wt Δ3β-catenin, levels of β-catenin nuclear 
expression increased without affecting the cytoplasmic pool of β-catenin/E-cadherin, which 
seems rather strengthened [see below Fig. 4.7]. Similar quantification analysis of β-catenin 
expression in control HK1.ras[n1-3] hyperplasia [Fig. 4.6L-T] showed that β-catenin nuclear 
localization was detected only in 3% [1cell/mm2] of all ROI cells [Fig. 4.6U] and the overall 
expression of β-catenin [cytoplasmic/nuclear] estimated to occupy only 14% of ROI areas[n1-
3] [Fig. 4.6X] constant with the lack of β-catenin activation. Thus, the nuclear localization 
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assessment of β-catenin showed a 10 fold increase in the K14creP.Δ3β-catflx/wt cohort 100% 
[10cells/mm2] compared to the HK1.ras control 3% [1cell/mm2] [Fig. 4.6V], however the 
statical analysis between the two cohorts showed P>0.05[No significance] [Fig. 4.6X] which 
could be due the small number of cohorts. 
In addition to complement this analysis the β-catenin cytoplasmic partner E-cadherin was 
analysed and showed an almost identical expression profile to that of β-catenin in terms of 
both supra-basal and basal layer expression in addition to hair follicles [Fig. 4.6]. This 
suggests that cell-cell adhesion is maintained via E-cadherin/β-catenin interactions (Takeichi, 
1991; Young et al., 2003) and the potential cytoplasmic function of E-cadherin to act as a 
sponge (Huels et al., 2015) and provide further regulation of β-catenin levels was still intact 
and indeed seemed to be strengthened by Δ3β-catenin activation as observed in colon 




Figure 4. 4: Analysis of β-catenin expression in K14creP.Δ3β-catflx/wt mice.  
Upper panels: [A] Double-labelled fluorescence analysis of RU486-treated K14creP.Δ3β-
catflx/wt skin shows both membranous and nuclear expression of β-catenin [green] against K14 
[red] in basal and supra-basal layers of the IFE and in hair follicles due to Δ3β-catenin 
activation. [B] At higher magnification RU486-treated K14creP.Δ3β-catflx/wt keratinocytes show 
nuclear and membranous expression in basal layers compared to [C] the mainly supra-basal 
expression of endogenous βcatenin in normal ICR. Lower Panels: [D] IHC analysis shows 
membranous and nuclear expression of β-catenin in basal and supra-basal layers of RU486-
treated K14creP.Δ3β-catflx/wt skin as well as hair follicles. [E] Higher magnification confirms 
nuclear and membranous expression in basal layer compared to [F] supra-basal layer 


















Figure 4. 5: Quantification of increased nuclear β-catenin expression in K14creP.Δ3β-
catflx/wt hyperplasia compared to HK1.ras control hyperplasia. 
Upper panel: [A-I] Shows 3 areas (n3) of double-labelled fluorescence analysis of RU486-
treated K14creP.Δ3β-catflx/wt skin that exhibits both membranous and nuclear expression of β-
catenin [green] against K14 [red]. [A-C] shows highlighted ROI of 10 basal layer cells [A] in 
K14creP.Δ3β-catflx/wt (n1) and [B&C] Using the colour threshold function of ImageJ software 
that identifies the localization of labelled fluorescence staining, shows β-catenin (green 
threshold) to be detected in the cell nucleus of all 10 basal layer cells of ROI (10/10). 
Similarly, [D-I] shows β-catenin to be detected in the cell nucleus of all 10 basal layer cells of 
ROI (10/10) in both [D-F] K14creP.Δ3β-catflx/wt (n2) and [G-I] K14creP.Δ3β-catflx/wt (n3). [J] 
shows the quantification of nuclear β-catenin expression in all 3 analysed ROI cells in 
K14creP.Δ3β-catflx/wt (n1-3) gives 100% nuclear localization of β-catenin (10cells/mm2). [K] 
shows quantification of total β-catenin expression [cytoplasmic/nuclear] in each of ROI areas 
[n1-3] in K14creP.Δ3β-catflx/wt to represent an average of 55%. 
Lower panel: [L-T] Shows 3 areas (n3) of double-labelled fluorescence analysis of HK1.ras 
skin shows less membranous and nuclear expression of β-catenin [green] against K14 [red]. 
[L-N] shows highlighted ROI of 10 basal layer cells [L] in HK1.ras (n1) and [M&N] Using the 
colour threshold function of ImageJ software, shows β-catenin (green threshold) to be 
detected in the cell nucleus of 2 cells (arrows) out of 10 basal layer cells of ROI (2/10). 
Similarly, [O-T] shows β-catenin to be detected in the cell nucleus of 1 (arrow) out of 10 basal 
layer cells of ROI (1/10) in HK1.ras (n2), whilst [R-T] shows no detected nuclear β-catenin in 
any of the cell nucleus of 10 basal layer cells of ROI (0/10) in HK1.ras (n3). [U] shows the 
quantification of nuclear β-catenin expression in all 3 analysed ROI cells in HK1.ras (n1-3) 
gives 3% nuclear localization of β-catenin (1cell/mm2). [V] shows quantification of total β-
catenin expression [cytoplasmic/nuclear] in each of ROI areas [n1-3] in HK1.ras(n1-3) to 
represent an average of 14%. [W] Schematic diagram compares the output percentage of 
nuclear β-catenin expression in analysed K14creP.Δ3β-catflx/wt (n1-3) 100%(10cells/mm2) and 
HK1.ras (n1-3) 3%(1cell/mm2). [X] Schematic diagram shows the result of Mann-Whitney test 
ranks of the analysed values from K14creP.Δ3β-catflx/wt (n1-3) and HK1.ras (n1-3) with a 












Figure 4. 6: Analysis of E-cadherin expression in K14creP.Δ3β-catflx/wt  mice.  
[A] RU486-treated K14creP.Δ3β-catflx/wt skin shows strong membranous expression of E-
cadherin in both supra-basal and basal layer that parallels the increased β-catenin 
expression. [B] Higher magnification shows expression of E-cadherin in hair follicles prior to 
major deformation, whilst [C] shows that the mild hyperplasia exhibits basal layer E-cadherin 
expression but with fewer cells expressing nuclear E-cadherin. [D] RU486-treated normal 
control ICR epidermis mainly exhibits supra basal and non-basement membrane expression 
of E-cadherin consistent with the epidermal location of adherence and tight junctions. Scale 
bars: A: 100µm; B,C,E&F: 50µm 
 
 
These phenotypes were constant with previous studies employing constitutive activation of β-
catenin, (Gat et a.,1998; Van Mater et al., 2003; Celso et al.,2004; Närhi et al 2008; 
Grigoryan et al., 2008) and these highlight the important β-catenin roles in hair 
morphogenesis and differentiation. However, whilst later studies have studied effects on IFE 
and the stem cell niche (Watt and Collins, 2008) few investigate further the effects on IFE 
differentiation [below] and here in K14creP.Δ3β-catflx/wt  mice only a mild hyperplasia is 
observed with relatively little hyperkeratosis, which is a finding possibly consistent with β-
catenin roles in adherence and latter stages of differentiation given its supra-basal location. 
Therefore, to assess the effect of elevated β-catenin in terms of levels and incorrect spatial 
expression, the status of the early keratinocyte differentiation marker keratin K1 (Rosenthal et 
al., 1991) and the proliferation associated HF keratin K6α (Rothnagel et al., 1999) were 
analysed [Fig. 4.7: A-D; E-H]. Keratin K1 is typically expressed as keratinocytes commit to 
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differentiate and exit the basal layer [shown in Fig. 4.7D] and is thus expressed throughout the 
spinus and granular layers [Fig. 4.7C&D]. However, in the mild hyperplasia induced by 
deregulated K14creP.Δ3β-catflx/wt keratin K1 expression was completely disorganised, despite 
the apparent ordered profile observed in histological analysis [above]. At low magnification, 
K1 expression is clearly patchy and sporadic [Fig. 4.7A] whilst at high magnification, K1 
expression appears either delayed or often disappears [Fig. 4.7B].  
This suggests a lack of correct differentiation into supra-basal keratinocytes as indicated by 
the predominance of the proliferative basal layer K14 counterstain. It may be that the 
appearance of excess basal layer β-catenin may increase the numbers of anomalous adherence 
junctions as suggested by the E-cadherin staining [above] which affect epidermal rigidity and 
manifest as altered differentiation maker expression, as observed in the increased rigidity 
induced by ROCK in this model (Masre et al., 2020) In addition with respect to the increased 
p53 and p21 expression [below], whist in some contexts excess p21 appears to drive the 
commitment to the early stages of differentiation (Topley et al., 1999) other reports suggest an 
inhibitory role in the latter stages of differentiation consistent with this patchy K1 finding (Di 
Cunto et al., 1998) [Fig. 4.7B]  
Similarly, the hyperproliferation marker K6α showed expression confined to the abnormal hair 
follicles [Fig. 4.7 E & F] yet expression was completely absent in the mildly hyperplastic IFE. 
The lack of a significant hyperplastic epidermis would be consistent with this lack of K6α 
expression when compared to that of HK1.ras and to-date is a novel observation in this HK1 
model [Fig. 4.7 E & F vs H]. Again, it may be that the excess increase in adherence alters the 
hyperproliferation signals that accompany the response to wounding that typically induces 
K6α expression (Rothnagel et al., 1999). This also replicates the result of previous studies that 
investigated K6α expression with gain of function β-catenin (Van Mater et al., 2003). 
Otherwise, normal K6 expression is confined to the hair follicle in adults [Fig. 4.7 G] but 
interestingly neonatal skin also does not express K6α yet is naturally hyperplastic (Rothnagel 





Figure 4. 7: Early differentiation marker K1 and hyperproliferation marker K6 
expression in K14creP.Δ3β-catflx/wt .  
[A-D] Analysis of keratin 1(green) expression: [A] Composite images at  low magnification 
show that the mild hyperplasia in RU486-treated K14creP.Δ3β-catflx/wt  epidermis exhibits an 
altered, focal expression profile with weaker patchy expression in supra-basal layers, that at 
[B] higher magnification is sometimes absent indicating a significant change to differentiation 
in the upper supra-basal layers.[C] Supra-basal K1 expression in normal ICR is not clear due 
to the thinness of normal mouse epidermis but can be clearly seen in [D] hyperplastic 
epidermis from HK1.ras mice where K1 is smoothly expressed in supra-basal layers.  
[E-H] Analysis of keratin 6 (green) expression: [E] Composite keratin K6 images in RU486-
treated K14creP.Δ3β-catflx/wt epidermis at low and [F] higher magnification show K6 
expression remains confined to the anomalous hair follicles and K6 expression is absent from 
the hyperplastic IFE; a novel finding to date in the HK1 model. [G] Normal ICR show K6 
expression expressed in hair follicles. [H] HK1.ras hyperplasia shows strong, uniform K6 




Collectively these data show that constitutive activation of β-catenin disturbed the normal 
epidermal differentiation programme marked by abnormal K1 expression, yet the epidermis 
still managed to cope with this altered differentiation programme giving a fairly ordered 
histology as observed for K1. Also given the potency of β-catenin activation, it was a surprise 
that typically the IFE exhibited only a mild degree of hyperplasia [above]. Therefore, the 
status of tumour suppresser genes p53 and p21 were also assessed in this genotype to 
investigate their response to Δ3β-catenin activation [Fig. 4.8].  
Analysis of p53 expression found an increase in nuclear p53 expression in the basal layers of 
K14creP.Δ3β-catflx/wt  IFE and this was observed to be particularly strong in the abnormal 
follicles- possibly in attempts to inhibit further progression of the trichofolliculomas [Fig. 
4.8A-C]. Whereas normal ICR epidermis exhibits little p53 unless the keratinocyte is 
completing the cell cycle [Fig. 4.8 D; far right keratinocyte] or is progressing from hyperplasia 
to papilloma [above Chapter 3 HK1.ras/fos papilloma], given the threat to barrier function 
from apoptosis due to excess p53 expression (Calautti et al., 2005; Yao et al., 2008). 
Moreover, analysis of p21 found a significant increase in nuclear expression in both basal and 
supra-basal layers and also in the abnormal follicles [Fig. 4.8E-G]. Of note normal cells 
typically expressed little basal p21 as observed for p53, unless the cell was committing to 
differentiate [Fig. 4.8H]. However, this example exhibits weak p21 expression in the upper 
layers previously speculated to aid in cessation of differentiation and the commencement of 
cornification (Di Cunto et al., 1998). Thus, as suggested above, excess p21 in the upper layers 
of K14creP.Δ3β-catflx/wt  IFE may result in the lack of K1 expression- yet give rise to increased 
cornification and mild keratosis [Fig. 4.2I]; whilst in HK1.fos-K14creP.Δ5PTENflx/flx KAs, this 
excess of p21 in response to AKT-mediated increases of β-catenin expression also gives a 
massive keratosis coupled to and driven by the increased differentiation in co-operation with 
HK1.fos. [above chapter 3]. Furthermore, increased differentiation was also observed in 
K14.creP/ROCKer mice in response to anomalous β-catenin-mediated AKT expression (Masre 





Figure 4. 8: Analysis of p53/p21 expression in K14creP.Δ3β-catflx/wt skin.  
[A] Analysis of p53 at low and [B] higher magnification shows strong nuclear expression in 
both basal-layer and hair follicle keratinocytes. [C] High magnification compares strong 
nuclear p53 expression in mild K14creP.Δ3β-catflx/wt IFE to [D] a typical lack of p53 expression 
in normal ICR with a single positive cell [far right]. [E & F] Analysis of p21 shows stronger 
nuclear expression in basal-layer and hair follicles, whilst [G] higher magnification of 
K14creP.Δ3β-catflx/wt IFE shows strong expression in all layers compared to [H] weak 
expression in the supra basal granular layers of normal ICR IFE. Scale bars: A&E: approx. 
100µm; B&F: 50µm: C,D,G&H: 30µm 
Overall expression of p53 and p21 together with the disturbance to the ordered differentiation 
and anomalous keratin expression indicate that the epidermis is highly sensitive to the 
consequence of β-catenin activation and via its roles in canonical Wnt signalling that effect 
increased proliferation and hair follicle development together with its roles in adhesion 
signalling with E-cadherin that effects the pluripotent stem cells fate that is needed for 
epidermal homeostasis  (Grigoryan et al., 2008). 
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Table 4. 1: Summary of mouse skin phenotypes following K14creP.Δ3β-catflx/wt  over 
expression 
 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 
Normal ICR 10 β-catenin, E-
cadherin, K1, 
K6α, p53 and p21 
expressions 
-Normal supra basal layer expression of β-catenin 
and E-cadherin  
- Ordered normal differentiation indicative by 
suprabasal layer K1 and normal K6α expression 
confined to the HF  
-little or sporadic expression of p53/p21 
HK1.ras hyperplasia 90 K1, K6α, 
expressions 
-Control hyperplasia showing ordered 
differentiation despite hyperplastic epidermis.  
-Ordered suprabasal layer expression of K1 but K6α 
expression in both suprabasal and basal layer due to 





K6α, p53 and p21 
expressions 
-No IFE tumours 
-HF tumours 
-minimal IFE hyperplasia 
-Increased cytoplasmic/nuclear basal layer β-catenin 
with increased membranous basal layer β-catenin/E-
cadherin due to Δ3β-catenin 
-Altered terminal differentiation indicated by patchy 
K1 expression but with oddly normal K6α 
expression 
- nuclear basal layer expression of p53/p21 halting 
Δ3β-catenin induced proliferation 
Conclusion: constitutive β-catenin activation [Δ3β-catenin] induces HF tumors and HF 
abnormalities constant with previous studies yet lack IFE tumours presumably due to 
strengthen cell-cell adhesion [β-catenin/E-cadherin] correlating with basal layer expression of 







4.3 Summary  
The constitutive activation of β-catenin expression was achieved in this study using an 
inducible K14.creP/loxP gene switch [K14creP.Δ3β-catflx/wt ], where RU486 treatment [applied 
to ears and back skin] would result in deletion of the exon 3 sequence flanked by loxP sites. 
Exon3 is located in the N-terminus of the gene where serine and threonine residue were 
identified as the phosphorylation binding site for GSK3-β to initiate β-catenin ubiquitination 
(Behrens et al., 1996; 1998; Ikeda et al., 1998). The deletion of this exon 3 sequence [K14. 
Δ3β-catenin] mediated via cre recombinase resulted in an in-frame shortened sequence 
between exon 2 and 4 of the β-catenin gene [Δ3β-catenin] (Harada et al., 1999; Berton et al., 
2000; Grigoryan et al., 2008). Thus, preventing formation of the β-catenin destruction 
complex [GSK3-β/APC/Axin] and resulted in sustained activation of β-catenin, also known as 
gain of function mutation, in K14creP.Δ3β-catflx/wt mouse skin.  
This gave the ability to induce constitutive activation of β-catenin functions associated with 
nuclear transcription roles in Wnt signalling and cytoplasmic roles in cell-cell adhesion with 
E-cadherin. This mimics the mutation hotspots in exon3 observed in human carcinomas, and 
those also frequently reported in two-stage DMBA/TPA carcinogenesis model (Grigoryan et 
al., 2008) giving rise to the β-catenin overexpression and nuclear localization similar to the 
expression pattern observed in earlier in HK1.ras/fos-K14creP.Δ5PTENflx/flx co-operation, that 
facilitated carcinogenesis (Macdonald et al., 2014). [See chapter 3].    
Activated Δ3β-catenin expression was routinely confirmed via PCR analysis, additionally 
gross Δ3β-catenin phenotype was very apparent and easily distinguishable from a normal ICR 
mouse. Due to the potency of Δ3β-catenin phenotype, as cre leaked early and independent of 
RU486 treatment this resulted in gross appearance of Δ3β-catenin phenotypes around 16 to 24 
days of age [ear tag time], which is similar to a previous study that induced constitutive 
activation of Δ3β-catenin using a K14cre gene switch (Gat et al., 1998; Harada et al., 1999; 
Berton et al., 2000).   
These results were very similar to all previous transgenic mouse studies that reported identical 
gross abnormalities involving mice where constitutive β-catenin activation was achieved in the 
epidermis by a variety of genetic approaches, such as direct fusion of mutant stabilised β-
catenin with a keratin K14 promoter (Närhi et al 2008), some involving inducible expression 
via a tamoxifen 4HT activated switch (Van Mater et al., 2003; Celso et al.,2004). In cases 
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being driven by an earlier weaker promoter such as that involving sporadic K14.cre regulator 
gene that is expressed in approx. 10-15% of keratinocytes (Gat et al., 1998) or those requiring 
daily 4HT treatments, mice appeared full sized with little effects on development or overt 
internal problems. However, if driven by a potent keratin promoter such as K5cre, β-catenin 
overexpression proved to be lethal (Järvinen et al., 2006), and thus it appears that none were 
subsequently reported to have been used in the development of  transgenic skin carcinogenesis 
models; rather each focussed on effects on hair follicle development and later on the effects on 
stem cells but oddly, none exploit these mice in the development of classic skin carcinogenesis 
models only constitutive knockouts have been investigated (Grigoryan et al., 2008) .  
The answer to this may lie in the observation in this model that the outbred nature of the ICR 
mice juvenile K14.creP-Δ3β-cateninflx/wt   mice varied in body sizes being similar or smaller 
compared to normal ICR mice or K14.creP and Δ3β-catenin alone siblings. This varied 
appearance and severity was due to the randomness of RU486-independent cre leakage as well 
as the differing genetic backgrounds of individual family trees on this outbred ICR 
background. However, this would clearly affect viability if expressed in the internal organs – 
hence resulting in a smaller size and whilst the gross phenotype of Δ3β-catenin varied slightly 
in severity and appearance due to the randomness of early cre leakage, once mice were treated 
with RU486 all exhibited a similar degree of phenotype.  
These phenotypes of K14creP.Δ3β-catflx/wt  mice were identical with alternate studies that 
targeted β-catenin gain of function to the skin or follicles and showed alopecia, scruffiness, 
bigger ears, abnormal feet and tail as well as a variation in body sizes compared to a normal 
ICR mice (Gat et al., 1998). Although the gene switch in this study was targeting the skin via 
K14.creP, the effect of Δ3β-catenin was not exclusive to the epidermis which affected the size 
of the body and limbs as well. This can be attributed to the major roles that canonical Wnt/β-
catenin signalling plays in embryonic and juvenile stages of development. Embryonically 
Wnt/β-catenin signalling is highly involved in the formation of the body anterior and posterior 
axis, hence why null mutation of β-catenin induced embryonic lethality as it resulted in a 
failure in forming body axis in mouse studies (Grigoryan et al., 2008). Also, it should be 
noted here that presumably the cre leakage had the potential for Δ3β-catenin activation early, 
yet the effect on body extremities such as tail and feet as well as the IFE phenotypes required a 
follicular effect observed post 16 but within 24 days of age. 
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The histology showed an increase in the number of hair follicles [ear and back] with the 
expected hair follicle anomalies such as formation of de novo hair follicles and benign hair 
follicle tumours (Gat et al., 1998; Huelsken et al., 2001; Grigoryan et al., 2008), consistent 
with β-catenin mediated over expression of Wnt signalling transcriptional targets LEF1 and 
TCF which are associated with hair follicle formation, differentiation and hair follicle tumours 
(Niemann et al., 2002; Grigoryan et al., 2008).  
This finding reaffirmed β-catenin roles in not only hair follicle formation and differentiation 
but also in affecting the dermis signals to form more hair follicles which is observed in a study 
that overexpressed Lef-1 using a K14 gene switch. However, this study lacked the effect on 
the size of the limbs observed here with Δ3β-catenin, suggesting that β-catenin has roles that 
affect a plethora of other signalling mechanism and not exclusively to hair follicle 
morphogenesis. The effect of Δ3β-catenin activation on the size of the limbs could be 
attributed to findings that Wnt/β-catenin activation up regulates Bone Morphogenic Protein 
(BMP) that is required for bone, cartilage and muscle formation (Närhi, et al., 2008), hence 
the enlarged extremities. Further, the alopecia that K14creP.Δ3β-catflx/wt mice usually exhibit 
can be explained by the finding that, despite the increased formation of hair placode due to 
Δ3β-catenin activation, most of the initiated HFs fail to produce normal hair due to incorrect 
control of Wnt/β-catenin signalling (Närhi, et al., 2008) 
Although beyond the scope of this project in terms of developing a multistage β-catenin model 
for SCC, the follicle tumours observed in these Δ3β-catenin mice are variously describe as 
folliculoma, trichofolliculoma or pilomatricoma [Fig. 4.2D], which were reported in previous 
mouse studies that overexpressed β-catenin (Gat et al., 1998; Chan et al., 1999 Grigoryan et 
al., 2008 ), and have also been reported in humans as a result of gain of function mutations in 
the β-catenin gene (Grigoryan et al., 2008; Chan et al., 1999). Indeed, in parallel studies to 
this approach, β-catenin deregulation co-operated with PTEN loss [K14.Δ5PTEN.Δ3β-catenin] 
to give HF tumours that mimicked trichochilemomas observed in Cowdens disease [ see 
chapter 7].  
Furthermore, K14creP.Δ3β-catflx/wt   mice exhibited minimal interfollicular hyperplasia [IFE] 
compared to normal epidermis, and expression of differentiation markers was altered. This 
clearly indicates that Δ3β-catenin activation altered IFE homeostasis as well as hair 
morphology, which is probably due to β-catenin roles in regulating epidermal pluripotent stem 
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cells that are needed for epidermal terminal differentiation and hair follicle differentiation 
(Grigoryan et al., 2008). The early differentiation marker K1 showed an abnormal expression 
profile suggesting the commitment to differentiate was disrupted and expression of the 
hyperproliferation marker K6α was only confined to the hair follicle consistent with reduced 
IFE hyperplasia and previous studies that investigated K6 expression with gain of function β-
catenin (Van Mater et al., 2003). Additionally, the normal expression of K6 in adult mice is 
confined to the hair follicle and interestingly even in naturally hyperplastic neonatal skin 
epidermis K6α is not expressed (Rothnagel et al., 1999). Thus, it is interesting to speculate 
that here deregulated β-catenin expression may return the adult K14creP.Δ3β-catflx/wt skin to a 
more juvenile/neonatal state, consistent with increased numbers of HFs with altered terminal 
differentiation indicated by K1 and the lack of K6α expression. This speculation was 
supported by the finding of a previous study that concluded that gain of function β-catenin 
alters the dermal extra cellular matrix into a neonatal state (Collins et al., 2011), which could 
possibly explain the K1/K6α expressions and altered differentiation in K14creP.Δ3β-catflx/wt  
skin. 
This clearly indicated that Δ3β-catenin activation affected the normal epidermal differentiation 
homeostasis but still was not enough to elicit IFE tumours such as SCCs, which is evident by 
the lack of both IFE hyperplasia and K6 expression. This brings in the roles of p53/p21 that 
may be partly responsible for these findings as K14creP.Δ3β-catflx/wt  epidermis showed strong 
expression in response to Δ3β-catenin and here p53 may act to counter Wnt signalling induced 
proliferation, hence a reduced K6, and anomalous basal layer p21 acts to induce differentiation 
(Topley et al., 1999). Although this too may be context dependent and p21 may also have 
inhibitory roles in the upper layers of K14creP.Δ3β-catflx/wt  IFE resulting in increased 
cornification and mild keratosis constant with the scruffiness, scaly appearance to the skin 
phenotype of these mice.  
These data indicate that the epidermis is highly sensitive to overexpression of β-catenin, unlike 
other oncogenes such as HK1.ras or the loss of PTEN which alone do not invoke the same 
p53/p21 responses in hyperplasia and again compensatory p53/p21 appears later in KA 
formation following a threshold of GSK3β inactivation and accumulation of β-catenin (Yao et 
al., 2008).  This induction of β-catenin was also seen in ROCK mediated models and here the 
induced p53/p21 expression also inhibited papillomatogenesis (Masre et al., 2020), a result 
supporting the investigation of p53 and p21 in K14creP.Δ3β-catflx/wt   and also HK1.ras-
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K14creP.Δ3β-catflx/wt phenomenon as illustrated below [Chapter 5]. Finally, this analysis of 
K14creP.Δ3β-catflx/wt  reinforces the importance of assessing β-catenin roles in a multistage 






























Chapter 5: β-catenin overexpression in 


















5.1 Introduction  
In chapter 3, analysis of carcinogenesis in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice found that 
β-catenin expression in HK1.ras or HK1.ras/fos papillomas was mainly membranous in the 
supra-basal layer and thus similar to normal β-catenin expression. In HK1.fos-
K14creP.Δ5PTENflx/flx KA formation, β-catenin became strongly basal and also strongly 
nuclear to induce compensatory p53/p21 expression in response to AKT-mediated GSK3β 
inactivation and this basal layer β-catenin expression led to a KA outcome rather than SCC 
[above Fig 3.3; (Yao et al., 2008)]. In HK1.ras/fos–-K14creP.Δ5PTENflx/flx mice, again 
elevated levels of basal layer β-catenin were already detectable in hyperplasia and papillomas 
that also now exhibited early p53 and p21 expression. However, with the addition of activated 
HK1.ras in HK1.fos-K14creP.Δ5PTENflx/flx tumours or loss of PTEN function in HK1.fos/ras 
papillomas, as they converted to malignancy following p53 loss (Macdonald et al., 2014), 
nuclear β-catenin expression increased in the basal layers and was less membranous as 
wdSCC progressed further to become pdSCCs [above chapter 3: Fig 3.3].  
Furthermore, β-catenin expression was paralleled by initial increases in E-cadherin and 
p53/p21 expression in benign tumours including tri-genic -K14creP.Δ5PTENflx/flx, but again 
following p53 loss, in parallel with excess nuclear/reduced membranous β-catenin E-cadherin 
and thus cell-cell adhesion was progressively lost at the invasive front, which alongside p21 
loss [above] helped drive malignant progression and tumour invasion [Chapter 3: Figs. 3.2 and 
3.3]. 
Therefore, as hypothesised in the aims of Chapter 1, it was anticipated that crossing 
K14creP.Δ3β-catflx/wt  mice with HK1.ras mice would lead to a more rapid papilloma 
formation, resulting in aggressive papillomas followed by earlier malignant conversion. It was 
also thought that as Δ3β-catenin expression was independent of the deregulated 
PTEN/AKT/GSK3β signalling in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice and may also have 
circumvented the protective p53 responses observed in HK1.ras or HK1.ras/fos papillomas 
that prevent conversion [Chapter 3]. However, a contrary completely unexpected result was 





5.2 Analysis of HK1.ras-K14creP.Δ3β-catflx/wt mice show a paradoxical lack of 
papillomas 
Following the clear implication of endogenous β-catenin involvement in the various tumours 
involved in HK1.ras/fos-K14creP.Δ5PTENflx/flx carcinogenesis [above], to investigate when β-
catenin played a causal role in papilloma formation or their malignant conversion, 
K14creP.Δ3β-catflx/wt mice were bred with HK1.ras. Over many years, this HK1.ras 1205 mouse 
line has been a main feature of modelling papilloma formation (Greenhalgh et al., 
1993a;1993c; 1996) and their conversion (Wang et al., 1997; 1998; Masre et al., 2017). In 
these experiments mice develop papillomas in the wounded [tag] ear in 100 % of cases. Given 
the outbred background these can appear by 6-7 weeks and become large [7-10 mm diameter]; 
or it may take up to 8-10 weeks for papillomas to appear and these will typically remain fairly 
small [3-6 mm diameter] up 12/14 weeks.  If not tagged HK1.ras1205 do not exhibit tumours 
[typically for breeding, pups can be identified by a wrinkly skin, thus normal are culled and 
adult breeders do not have to be tagged; this achieves the refinement clause in the 3Rs].  
However, on rare occasions a subset of HK1.ras mice [< 0.1%] exhibit papillomas that 
developed on other areas of the body. These arise in specific litters and their appearance has 
been random over the past 30 years. These are designated type 2 papillomas and characterised 
by a rapid growth but are easily identified by their smooth, less keratotic appearance. Such 
type 2 papillomas maybe the equivalent of papillomas that arise early in DMBA/TPA 
promotion (Hennings et al.,1985; 1993) and these typically become malignant given the 
additional mutations elicited by DMBA treatment. In the HK1.ras model they remain benign 
but exhibit a more aggressive histological phenotype than the common [type 1] ear tag 
papillomas. As outlined above these type 1 papillomas do not progress to SCC again due to 
strong nuclear basal layer p53 expression and as β-catenin expression remains membranous 
and mainly supra-basal [chapter 3].   
These tumour growth profiles of papillomas by 8-10 weeks without conversion were 
maintained in all K14.creP/HK1.ras and all [non-cre] HK1.ras -Δ3β-catenin control progeny 
[with or with out RU486-treatment] and subsequent breeders, together with all HK1.ras alone 




Figure 5. 1: Phenotypes of HK1.ras-K14creP.Δ3β-catflx/wt mice.  
[A & B] At 8 weeks post ear-tag wounding, RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt mice 
show no sign of papilloma developing yet still exhibit the typical Δ3β-catenin phenotype of a 
scruffy hyperkeratotic skin and thickened hyperplastic ears; compared to an age-matched 
HK1.ras littermate that develop papillomas by 8-10 weeks and lack any other overt 
phenotype. [C] Shows four littermates where the two middle animals are HK1.ras-
K14creP.Δ3β-catflx/wt and have not develop papillomas, flanked by two HK1.ras mice that here 
show the range of papillomas developing either small or very large papillomas at the tagged 
ear. [D] Repeat experiments show 8 week old HK1.ras-K14creP.Δ3β-catflx/wt mice with no ear 
tumours against [E] HK1.ras littermates again showing papilloma with different sizes 8 weeks 
post ear-tag wounding. To date, only two HK1.ras-K14creP.Δ3β-catflx/wt mice developed 
papillomas. Both [F & G] have smaller papillomas at 12 weeks compared to their HK1.ras 
littermate controls, which had rapidly developed large papillomas. 
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In contrast HK1.ras-K14creP.Δ3β-catflx/wt mice showed an intriguing, almost paradoxical 
result, as almost all mice lacked papillomas or any type of tumour at 8-10 weeks [n = 58] 
produced in triple repeat experiments or as controls for p53 and p21 analysis over 3 years. In 
almost all cases HK1.ras-K14creP.Δ3β-catflx/wt mice remained tumour free for the typically 12-
14 weeks before biopsy, and where the spontaneous β-catenin phenotype was less severe, a 
cohort of RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt individuals were maintained for 22 
weeks without producing papillomas [n=5]. 
This is shown in Fig. 5.1, RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt mice showed no sign 
of papilloma formation [Fig 5.1: A-D], compared to their age-matched HK1.ras littermates 
which also show the variation in size typical of papillomas in this model [Fig 5.1C, E-G]. 
Again the HK1.ras-K14creP.Δ3β-catflx/wt mice exhibited the mild alopecia with dishevelled fur 
and possibly increased hyperkeratotic skin [Fig 5.2 below]. To date, only two HK1.ras-
K14creP.Δ3β-catflx/wt mice have developed papillomas. Both animals initially exhibited a much 
weaker spontaneous Δ3β-catenin phenotype and following RU486 treatment at 12 weeks have 
smaller papillomas compared to their HK1.ras littermate controls [Fig. 5.1F&G]. Of note in 
both cases these HK1.ras siblings had rapidly developed large papillomas at the ear tag 
suggesting that these mice had developed from a background possibly prone to development 
of the more aggressive Type 2 papillomas outlined above.  
A direct comparison of HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt is shown in 
Fig 5.2 and demonstrates that the phenotypes typical of Δ3β-catenin overexpression were 
slightly increased particular in terms of the hyperkeratosis observed and again these mice 
varied in body size associated with the time and extent of RU486-independent cre activity 
commenced during the development of these mice. HK1.ras-K14creP.Δ3β-catflx/wt phenotypes 
show increased thickened ear skin and also peri-orbital skin thickening which was also 
apparent on the thicker foot skin giving larger feet [Fig. 5.2A-C]. The most obvious change 
was the increased nature of the dishevelled fur giving a more scruffy appearance to adult skin 
[Fig.5.2C&D] with an increased back skin hyperkeratosis and alopecia in response to RU486 
treatment.  This varied depending upon the time of cre leakage but typically gave a more 
folded nature to the HK1.ras-K14creP.Δ3β-catflx/wt skin [Fig. 5.2E&G] compared to similar  
RU486-treated K14creP.Δ3β-catflx/wt  control skin that show a less severe overall phenotype 
[Fig.5.2E&G]. However, this folded skin phenotype was far less than that induced by HK1.fos 




Figure 5. 2:Comparison of HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt  
phenotypes.  
[A-G] HK1.ras-K14creP.Δ3β-catflx/wt phenotypes show an increased [A] ear hyperplasia and 
hyperkeratosis and peri-orbital skin thickening. [B & C] Again large feet were observed with 
an increased thickening to the hyperkeratotic foot skin. [D] An increase back skin 
hyperkeratosis and alopecia appeared at the RU486 treated site together with an increased in 
the overall scruffy nature of the skin, whilst [E & G] shows a variation on the intensity of the 
hyperkeratosis in HK1.ras-K14creP.Δ3β-catflx/wt mice. [H-J] RU486-treated K14creP.Δ3β-




These findings suggest that Δ3β-catenin activation in HK1.ras-K14creP.Δ3β-catflx/wt induces 
early protective epidermal responses that prevent the formation of wound-associated [Type1] 
papillomas which are observed in 100% of HK1.ras [1205] mice.  This increase in phenotype 
observed in HK1.ras-K14creP.Δ3β-catflx/wt mice over time increased further in subsets of mice 
following the increased number of crosses required to generate these complex genotypes. 
Eventually this became of concern with regard to their long-term viability. Thus a scoring 
system was devised and applied to these genotypes at the time of tail biopsy to ensure that 
these animals remained within the moderate category of the regulations for animal 
experimentation in the UK. The severity of phenotypes in HK1.ras-K14creP.Δ3β-catflx/wt mice 
was divided into three degrees: Score 0[N=10/phenotypic post RU486 treatment], mild with 
only little obvious phenotype and a full size at tail biopsy and these individuals often required 
RU486 treatment to elicit β-catenin phenotypes; Score 1[N=42/phenotypic by d16-24], the 
most typical outcome, as shown in Fig 5.1 and 5.2;  and the much rarer Score 2 
[N=6/phenotypic by d16], where significant hyperplasia appeared by d16 and mice were also a 
smaller size indicative of digestive problems following weaning possibly due to β-catenin 
activation in the colon (Grigoryan et al., 2008; Huels et al., 2015).  
The initial appearance of such score 2 mice followed the in-breeding to create the more 
complex genotypes e.g., see β-catenin co-operation with fos and PTEN in chapter 7 [but 
intriguingly not p53 loss; chapter 6] and this development necessitated significant changes to 
the Licence to perform these experiments. Thus, to comply with the revised animal licence 
limits and end points following the first appearance of such score 2 mice [late 2018]; only 
those score 2 individuals deemed of scientific importance were maintained and typically not 
more than 6-7 weeks to assess for signs of papilloma formation. Each was closely monitored 
daily and diet supplemented with baby food from d16-20, prior to weaning and to date in the 
HK1.ras-K14creP.Δ3β-catflx/wt genotype all score 2 mice produced also exhibited a blockage 
of tumour formation.  
This difference in phenotype severity was reflected in the histological analysis but in general 
typical HK1.ras-K14creP.Δ3β-catflx/wt histotypes [both ear and back] showed a common 
histotypes of the expected Δ3β-catenin-associated hair follicle abnormalities but now with an 
overlay of increased epidermal hyperplasia due HK1.ras activation [Figs 5.3-5.5; score 1 





Figure 5. 3: Histotypes of RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt skin.  
[A-D] HK1.ras-K14creP.Δ3β-catflx/wt ear skin at 8 weeks post ear tag. [A] Low magnification 
and [B] higher magnification composite images of ear [insert] histotype shows typical Δ3β-
catenin-associated hair follicle abnormalities with formation of cysts and the onset of 
trichofolliculomas [arrows] now with increased levels of IFE hyperplasia compared to 
K14creP.Δ3β-catflx/wt alone [see fig 5.4D] [C] At higher magnification increased HK1.ras-
K14creP.Δ3β-catflx/wt hyperplasia also displays a disordered differentiation with changes to the 
ordered nature of basal layer keratinocytes and a marked acanthosis; whilst [D] little effect of 
HK1.ras  activation is observed on cyst formation or HF abnormalities. [E-G] Back skin [insert] 
of same RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt mouse shows overall increased in de 
novo hair follicles with typical HF abnormalities, trichofolliculomas and cysts with again an 
increased IFE hyperplasia. [F & G] Higher magnification again shows a disturbed 
differentiation pattern of the basal layer keratinocytes. Scale bars: A&E: 150µm; B&F: 100µm; 






The increased hyperplasia in these HK1.ras-K14creP.Δ3β-catflx/wt mice [Fig. 5.3A-C; Fig 
5.4A&B]  thus accounted for the overall increased degree of thickened ear and foot skin and 
also the increased keratosis appearing at RU486-treated sites; although compared to a typical 
HK1.ras control skin, the degree of hyperplasia was less and this resulted in less of a 
papillomatous [folded ] HK1.ras-K14creP.Δ3β-catflx/wt epidermis [FIG. 5.5C]. This 
observation is likely to centre on the expression of both p53 and p21 in the HK1.ras-
K14creP.Δ3β-catflx/wt hyperplasia compared to a HK1.ras alone skin [below Fig. 5.9]. Further 
one feature of note in the increased HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia was the 
appearance of an odd basal layer which exhibited a disordered differentiation in terms of many 
more basal layer keratinocytes as well as an increased acanthosis [Fig. 5.3C&G; Fig. 5.4B; 
Fig. 5,5D] compared to that of HK1.ras [Fig. 5.5F]. The increased numbers of disorganised 
basal layer cells thus reflects the confusion of proliferative signals elicited by basal layer 
expression of Δ3β-catenin and rasHa activation and this leads to an acanthosis.  
A direct comparison of the histotypes displayed by these various overt phenotypes is shown in 
Fig 5.4 and this confirmed that these variations were associated with the degree and timing of 
phenotypes associated with Δ3β-catenin expression. For instance, the typical score 0 or score 
1 phenotypes exhibited mild increases in hyperplasia associated with HK1.ras expression and 
possessed the follicular phenotypes typical of the histotypes seen in K14creP.Δ3β-catflx/wt  
[Fig. 5.4A&B vs. D]. In contrast HK1.ras-K14creP.Δ3β-catflx/wt with a score 2 designation 
exhibited a severe set of Δ3β-catenin follicular phenotypes with clear folliculomas and cysts, 
consistent with an early expression of Δ3β-catenin during development possibly before 
juvenile mice began their first phase of anagen [Fig. 5.4C]. Moreover, in these score 2 
histotypes, whilst the IFE was disorganized it lacked the increased hyperplasia associated with 
HK1.ras but instead possessed an increased keratosis [Fig. 5.4C] suggestive of an increased 
differentiation rate as typically seen in combinations of HK1.fos-K14creP.Δ3β-catwt/flx and 
K14.Δ5PTEN.Δ3β-catenin mice [See Chapter 7]. Such increased differentiation responses 
were also suggested by KA aetiology where anomalous endogenous β-catenin expression in 
basal layer keratinocytes [Chapter 1] induced p53 to inhibit proliferation and p21 to induce 
differentiation. Therefore, in these specific score 2 mice the phenotype appears to be 
dependent upon β-catenin leakage and development of HF phenotypes and not HK1.ras – as 





Figure 5. 4: Histological variation in HK1.ras-K14creP.Δ3β-catflx/wt phenotype severity. 
[A] Typical representative of HK1.ras-K14creP.Δ3β-catflx/wt skin associated with score 0 
[N=10] exhibits mild increased HK1.ras -associated hyperplasia but only mild Δ3β-catenin-
associated follicular phenotypes. [B] Representative skin from a typical HK1.ras-
K14creP.Δ3β-catflx/wt score 1 [N=42] mouse is associated with increased hyperplasia and 
disturbed basal layer differentiation and a greater degree of typical Δ3β-catenin follicular 
phenotypes. [C] In the most sever HK1.ras-K14creP.Δ3β-catflx/wt score 2 [N=6] skin the 
histotype is associated with severe Δ3β-catenin follicular phenotypes and whilst the IFE is 
disorganised and is dominated by excessive keratosis yet exhibits a relative lack of a 
significant increase in hyperplasia. [D] Typical degree of phenotype severity [now designated 
score 1] in RU486-treated K14creP.Δ3β-catflx/wt without HK1.ras associated increase in 








Figure 5. 5: Histotypes of HK1.ras-K14creP.Δ3β-catflx/wt compared to K14creP.Δ3β-
catflx/wt and HK1.ras littermates.  
[A] shows [score 0 above] HK1.ras-K14creP.Δ3β-catflx/wt exhibiting hyperplastic epidermis and 
multiple hair follicle abnormalities, whilst [B] shows K14creP.Δ3β-catflx/wt to be lacking 
hyperplastic IFE with less hair follicle abnormalities and [C] shows HK1.ras IFE with 
papillomatous [foldy] hyperplasia and an ordered keratinocyte differentiation not seen in 
HK1.ras-K14creP.Δ3β-catflx/wt IFE. [D] At higher magnification HK1.ras-K14creP.Δ3β-catflx/wt 
hyperplasia shows a disorganised IFE basal layer differentiation and multiple follicular 
abnormalities, compared to [E] minimal IFE hyperplasia with less follicular abnormalities and 










Given these data, the next series of experiments investigated whether this lack of papilloma 
formation derived from p53 and p21 expression or an increased differentiation response. For 
instance, did HK1.ras expression affect the status of Δ3β-catenin expression in terms of levels 
and epidermal location, as in chapter 3 HK1.ras expression was associated with supra-basal β-
catenin expression [Fig. 3.8] minimal p53 and p21 and resultant papilloma development. In 
addition, given the increased keratosis observed in score 2 mice there was the idea that the 
general increase in keratosis observed in HK1.ras-K14creP.Δ3β-catflx/wt mouse skin was a 
differentiation response to rasHa and β-catenin co-operation, possibly indicated by a return to 
increased differentiation marker keratin K1 expression as seen in HK1.ras epidermis but 
which was sporadic at best in K14creP.Δ3β-catflx/wt mouse skin. This too may have inhibited 
papilloma formation with either p53 or p21 responses as seen in ROCK mice which also 
induced AKT/β-catenin in basal layer keratinocytes and an inhibition of papillomas (Masre et 
al., 2020).    
As shown in Figs 5.6 and 5.7 an increase in β-catenin expression was detected in HK1.ras-
K14creP.Δ3β-catflx/wt hyperplasia in both IF and IHC staining. As with K14creP.Δ3β-catflx/wt  
mice [above], again β-catenin showed increased expression in the proliferative basal layers 
with both membranous and nuclear β-catenin expression clearly visible [Fig. 5.6:A-E; Fig. 
5.7A]; with membranous expression particularly prominent in the expanded acanthotic layers 
[Fig. 5.6E; Fig. 5.7A] compared to the less hyperplastic K14creP.Δ3β-catflx/wt  
hyperplasias[Fig 5.6F; Fig 5.7B], while the HK1.ras  littermates exhibited supra-basal β-
catenin expression as observed previously [Fig. 5.6G; Fig. 5.7C]. Thus HK1.ras expression 











Figure 5. 6: Analysis of β-catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt compared 
to K14creP.Δ3β-catflx/wt  and HK1.ras littermates.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt mice [score 0] show overall strong expression of β-catenin 
in IFE and HFs. [B&C] Higher magnification shows nuclear localization of β-catenin in basal 
layer keratinocytes also with strong membranous expression in both the basal-layer and 
expanded [acanthotic] supra-basal layers. Similarly, [D] shows the increased phenotypes in 
score 1 animals with a greater degree of HF abnormalities that again exhibit strong β-catenin 
expression in IFE and hair follicles; whilst [E&F] higher magnification shows nuclear 
localization of β-catenin with strong membranous basal-layer expression.[G-I] Higher 
magnification comparison of β-catenin expression in [G] hyperplastic HK1.ras-K14creP.Δ3β-
catflx/wt IFE with nuclear and membranous basal-layer  expression to [H] minimal 
K14creP.Δ3β-catflx/wt  IFE hyperplasia that also exhibits nuclear and membranous basal-layer 
expression; and [I] greater HK1.ras hyperplasia exhibiting only supra-basal β-catenin 




Figure 5. 7: IHC analysis confirms similar nuclear β-catenin expression in HK1.ras-
K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt basal layers compered to HK1.ras skin.  
[A] RU-486 treated HK1.ras-K14creP.Δ3β-catflx/wt exhibits an IFE hyperplasia with strong β-
catenin expression in both supra-basal and basal layers with clear nuclear expression in 
epidermal and abnormal follicular keratinocytes. Similarly [B] K14creP.Δ3β-catflx/wt shows 
same expression in all layers but with a minimal IFE hyperplasia compared to [C] HK1.ras 
showing only suprabasal layer expression with no detectable nuclear expression of β-catenin. 
Scale bars: A-C: 100 µm 
 
Analysis of E-cadherin showed an identical expression profile to that of β-catenin in terms of 
both supra-basal and basal layer expression in the IFE in addition to hair follicles [Fig 5.8]. 
Here E-cadherin levels displayed prominent membranous expression in the suprabasal 
acanthosis again mimicking that of β-catenin [Fig. 5.8 B vs. C]. Compared to HK1.ras 
controls which again showed mainly membranous supra-basal layer expression [Fig 5.8D], 
these β-catenin/E-cadherin expression similarities suggest an increase in cell-cell adhesion 
signalling in HK1.ras-K14creP.Δ3β-catflx/wt mice, which could be aiding in the prevention of 
tumours forming (Chiles et al., 2003; Jeanes et al., 2008). Further, in both HK1.ras-
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K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt epidermis, E-cadherin expression appeared 
mainly membranous and cytoplasmic but not nuclear [Fig. 5.8B&C]. Thus, the proposed 
function to act as a cytoplasmic sponge (Huels et al., 2015) and provide further regulation of 
β-catenin levels prior to nuclear relocation was still intact and indeed seemed to be 
strengthened by Δ3β-catenin activation particularly in the more affected hair follicles. This 
result may also highlight attempts to limit cell transformation and tumour formation mediated 
by excess Δ3β-catenin expression as observed in colon carcinogenesis (Huels et al., 2015). 
 
 
Figure 5. 8: Analysis of E-cadherin expression in HK1.ras-K14creP.Δ3β-catflx/wt 
compered to K14creP.Δ3β-catflx/wt and HK1.ras controls.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt exhibits strong E-cadherin expression in supra-basal and 
basal layer epidermis together with hair follicles. [B] Higher magnification shows strong 
membranous expression similar to β-catenin expression but without obvious nuclear 
expression. [C] K14creP.Δ3β-catflx/wt is similar but with less hyperplasia whilst [D] HK1.ras 






One new feature of HK1.ras-K14creP.Δ3β-catflx/wt mice was the appearance of increased skin 
keratosis compared to the typical K14creP.Δ3β-catflx/wt  littermates [Fig. 5.1 & Fig. 5.2]. This 
was likely due to the increased levels of proliferation and the sequential differentiation of the 
resultant keratinocytes. However, the histology of this increased hyperplasia showed a novel 
disturbed basal layer differentiation [Figs 5.3C & G; 5.5D] and a greater degree of typical 
Δ3β-catenin follicular phenotypes- particularly in the rarer score 3 histotype [Fig 5.4C] that 
appeared to have a lesser degree of hyperplasia yet far more keratosis suggesting here that 
increased differentiation may be a feature of tumour inhibition too in these more severe mice. 
Therefore, to assess this novel disordered IFE differentiation seen histologically in HK1.ras-
K14creP.Δ3β-catflx/wt , again the early differentiation marker keratin K1 and the 
hyperproliferation/disease-associated keratin K6α were investigated. In Fig 5.9A-C the 
increased HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia again displayed a quite patchy, confused 
profile indicating that several sets of transit amplifying keratinocytes failed to differentiate 
correctly. Here typical of K1 expression in both HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia 
and to a less degree K14creP.Δ3β-catflx/wt   siblings, was the lack of expression in the upper 
epidermal layers, again suggesting a delay in K1 expression was mediated by responses Δ3-
βcatenin expression [Fig. 5.9B-D vs.  E]. In contrast HK1.ras littermate epidermal hyperplasia 
shows a smooth and ordered supra-basal layer expression of K1 with a thicker basal layer 
[red] due to lack of inhibitory p53 expression but with an ordered differentiation profile Fig 
5.9E due to the normal low expression of p21.   
Thus unlike HK1.ras skin, HK1.ras-K14creP.Δ3β-catflx/wt keratinocytes appear to be receiving 
very confused conflicting signals regarding proliferation and differentiation. In some patches 
of epidermis, K1 was expressed relatively normally possibly due to the co-expression of 
HK1.ras  [Fig. 5.9A&C vs. E] given its expression profile in approx. 30-50% basal layer 
keratinocytes [(Greenhalgh et al., 1993) chapter 1 HK1.βcal expression Fig. 1.3], and this may 
account in part for the patches of keratosis observed HK1.ras-K14creP.Δ3β-catflx/wt skin [Fig. 




Figure 5. 9: Analysis of early differentiation marker K1 in HK1.ras-K14creP.Δ3β-catflx/wt 
compered to K14creP.Δ3β-catflx/wt  and HK1.ras  genotypes. 
 [A-C] HK1.ras-K14creP.Δ3β-catflx/wt epidermis shows distinct variations of confused, patchy 
and in some areas loss of K1 expression in the areas of increased hyperplasia. [B] also 
shows K1 positive cysts demonstrating that IFE can also form cysts together with [C] HF 
responses to βcatenin overexpression. [D] This example of K1 expression in a K14creP.Δ3β-
catflx/wt score 0 epidermis shows a less patchy but disordered K1 expression in the final 
differentiating layers; whilst [E] HK1.ras littermate hyperplasia shows s smooth and ordered 
suprabasal layer expression of K1 with a thicker basal layer [red] due to lack of inhibitory p53 
and p21 expression. Scale bars: A: 100 µm; B-E: 75µm 
 
 
However, what was quite striking is shown in Fig 5.9A&C, where there appears to be a 
distinct lateral cut off to the patchy K1 expression (Porter et al., 2000) compared to the 
K14creP.Δ3β-catflx/wt   control [Fig 5.9D] which exhibits less hyperplasia and thus less 
expansion of the K14 staining [red]. This maybe possibly consistent with β-catenin effects on 
an individual stem cell niche (Watt and Collins, 2008) where β-catenin alters the correct 
differentiation programme decisions throughout the transit amplifying daughter keratinocytes 
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from a given individual epidermal stem cell unit [See also mK15 section below; Porter et al., 
2000). Indeed, this odd proliferation/differentiation decision appears to produce the 
proliferation dead end of K1 positive interfollicular cysts [Fig 5.9B] which would also divert 
keratinocytes away from papilloma formation.   
The relatively little hyperkeratosis observed histologically may be a finding consistent with β-
catenin roles in latter stages of differentiation given its supra-basal location involving 
increased cell-cell adherence. As suggested above in Chapter 4 incorrect differentiation in 
both K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt a lack of supra-basal 
keratinocytes indicated by the expanded K14 positive basal layer may be due to excess basal 
layer β-catenin/E-cadherin and an increased number of anomalous adherence junctions which 
affect epidermal rigidity. Thus, from a barrier viewpoint the keratins associated with 
maintaining a supra-basal layer are reduced consistent with the observed acanthosis. Possibly 
altered differentiation maker expression is due to the context of p21 expression [below] as in 
some contexts excess p21 displays an inhibitory role in differentiation and affects a 
commitment to differentiate (Di Cunto et al., 1998; Topley et al., 1999) consistent with this 
delayed and patchy K1 finding.         
Investigation of the hyperproliferation marker K6α in HK1.ras-K14creP.Δ3β-catflx/wt 
hyperplasia also showed a similar disruption of the ordered keratinocyte differentiation and 
expression was almost absent from HK1.ras-K14creP.Δ3β-catflx/wt epidermis [Fig 5.10], a 
result observed for K14creP.Δ3β-catflx/wt [Fig 5.10D above Fig 4.6] but was strongly expressed 
in HK1.ras control hyperplasia [Fig 5.10E]. Again, K6α expression appeared to be confined to 
the abnormal hair follicles yet expression was completely absent in the mildly hyperplastic 
IFE and to-date in the HK1 model this novel observation is unique to Δ3βcatenin expression. 
As speculated for K1 above, this change in K6α expression may reflect the excess increase in 
adherence junctions which in turn alters the hyperproliferation signals derived from cell-cell 
interactions that are typically disrupted in wounding. These are normally essential for the cell 
division and keratinocyte migration and thus disruption of the filament network [intermediate 
and actinomycin] would affect movement that is carried out by the underlying cytoskeletal 
network that regulate mechanical tension through adherence junctions and hemidesmosomes 
(Masre et al., 2020 Samuel et al., 2011). Hence these and other responses to HK1.ras 
activation that typically induce K6 expression (Rothnagel et al., 1999) are overcome by those 
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elicited in HK1.ras-K14creP.Δ3β-catflx/wt skin i.e. p53 and p21 [see Fig. 5.11 & Fig. 5.12] 
amongst others [e.g. p63 and p73; below chapter 6].   
These data suggest that in HK1.ras-K14creP.Δ3β-catflx/wt epidermis Δ3β-catenin combined 
with rasHa activation resulting amplification of the mild Δ3β-catenin ILE hyperplasia seen in 
K14creP.Δ3β-catflx/wt  mice and a more disrupted keratinocyte differentiation. However, this 
did not aid in the generation of tumourigenesis typically induced via HK1.ras transgene and 
data below supported the idea that this may be due to compensatory p53 and p21 expression, 
as observed in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice [Chapter 3; (Yao et al., 2006; 2008; 








Figure 5. 10: Analysis of hyperproliferation marker keratin K6 in HK1.ras-K14creP.Δ3β-
catflx/wt , K14creP.Δ3β-catflx/wt  and HK1.ras epidermis.  
[A-C] Typical RU486-treaated HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia lack K6α expression 
in the IFE and expression is confined to hair follicles. [B & C] Most cysts express K6 being 
derived from a HF origin, but not all HFs had K6 expression depending upon the degree of 
HF anomalies. [D] K14creP.Δ3β-catflx/wt skin shows K6α expression confined to many but not 
all hair follicles. [E] HK1.ras shows strong expression in the hyperplastic IFE constant with K6 
hyperproliferation and a lack of inhibitory p53 /P21 expression. Scale bars: A, D & E: approx. 






Figure 5. 11: Analysis of p53 expression in HK1.ras-K14creP.Δ3β-catflx/wt .  
[A-C] RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia shows strong p53 expression 
in basal and supra-basal layers and HFs. [B & C] Higher magnification shows elevated 
nuclear p53 expression; as does [D] K14creP.Δ3β-catflx/wt littermate skin. [E & F] HK1.ras 
hyperplasia typically lacks basal layer p53 expression until just prior to overt papilloma 
formation and with this p53 antibody appears only cytoplasmic in the supra-basal layers. 







Therefore, prompted by the paradoxical lack of tumours in the HK1.ras-K14creP.Δ3β-catflx/wt   
mice the p53 and p21 status was assessed. Analysis of p53 expression [Fig 5.11] in treated 
[and non treated score 1 skins] found an increase in nuclear p53 expression in the basal layers 
similar to that observed in K14creP.Δ3β-catflx/wt IFE [Fig. 5.11A-C vs. D]. Typically, p53 
expression appeared more intense with more uniform nuclear expression in the HK1.ras -
Δ3βcatenin IFE consistent with the response to co-expression of both activated ras and β-
catenin [Fig 5.11 A-C] compared to K14creP.Δ3β-catflx/wt IFE alone [Fig. 5.11D], whilst 
follicular expression appeared particularly intense in the more transformed HFs and in both 
cases [Fig. 5.11A-D]. This HF result was consistent with a relative lack of progression to more 
aggressive HF tumours (Misago et al., 2012) compared to other studies where β-catenin was 
overexpressed throughout embryonic development (Gat et a.,1998). NB Consistent with this 
idea all attempts to create non-inducible K5-βcat/p53 genotypes in studies geared to assess 
effects of p53 knockout failed to produce pups or pups died shortly after birth [ see below; 
Järvinen et al., 2006]   
In contrast, HK1.ras epidermis exhibited little basal layer p53 [Fig. 5.11E&F] unless a 
keratinocyte was completing the cell cycle or over time began progressing from late stage 
hyperplasia to the beginnings of papilloma, where p53 expression increased and became 
basal]. Thus, the epidermis appears relatively tolerant of ras activation as judged by the fairly 
normal differentiation responses [above; Chapter 3] and thus p53 is not invoked and this 
avoids the possibility of apoptosis and a failure of the barrier function. Indeed, it is speculated 
that the normal supra-basal expression of AKT maybe geared to block p53-mediated apoptosis 
giving time for terminal differentiation (Calautti et al., 2005; Macdonald et al., 2014). 
Thus, these HK1.ras-K14creP.Δ3β-catflx/wt vs HK1.ras data suggest that Δ3β-catenin maybe 
integral to induction of p53 [and p21] which disrupts this process giving an altered confused 
expression of differentiation markers. Further with respect to papillomas formation in 
HK1.ras-K14creP.Δ3β-catflx/wt mice this strong p53 expression in all layers would inhibit 
tumours that appear in HK1.ras alone mice, and this response is sufficiently potent to block 
both the regression prone, wound-associated type 1 and the aggressive type 2 papillomas. An 
idea supported by similar p53 responses also observed in ROCK-mediated β-catenin activation 




A similar story appears for analysis of p21 which also found a significant increase in nuclear 
expression in both HK1.ras-K14creP.Δ3β-catflx/wt basal and supra-basal layers and also in the 
abnormal follicles [Fig. 5.12A-C] as observed in K14creP.Δ3β-catflx/wt  IFE but again absent in 
HK1.ras epidermis [Fig. 5.12D vs. E&F]. Of note p21 expression in HK1.ras mice again 
appeared less than that of p53 and typically expressed little basal p21 unless the cell was 
committing to differentiate.  
Thus, as previously speculated for K14creP.Δ3β-catflx/wt  epidermis [Chapter 4] again in 
HK1.ras-K14creP.Δ3β-catflx/wt mice excess p21 in the basal layers may increase the 
commitment to differentiate and, with ras-induced hyperplasia, give rise to the increased 
cornification and keratosis observed [Fig 5.2] (Topley et al., 1999); but excess expression in 
the upper layers may inhibit the latter stages of differentiation that results in the apparent lack 
of K1 expression (Di Cunto et al., 1998).  
In terms of papilloma formation, p21 again aids p53 in the inhibition of tumours and appears 
quite potent even at this early stage. Indeed based on HK1.ras/fos-K14creP.Δ5PTENflx/flx 
tumours this potent TSG effect remains as following p53 loss, p21 expression persists in 
wdSCC and limits further progression possibly via maintaining this inhibitory differentiation 
profile in basal layers, along side the increased adherence junctions, until lost quite late in 
carcinogenesis when membranous β-catenin was also diminished [chapter 3 Fig 3.3] and 
becomes nuclear alongside uniform AKT expression [not shown; paper in prep] giving 













Figure 5. 12: p21 expression in HK1.ras-K14creP.Δ3β-catflx/wt skin.  
[A-C] At low and higher magnification, p21 expression mirrors that of p53 with strong nuclear 
expression in basal layer and suprabasal layers together with the hair follicle while [D] 
K14creP.Δ3β-catflx/wt skin also shows slightly less intense expression of p21. [E & F] HK1.ras 
hyperplasia expresses low p21 levels until at the later papilloma stage. Scale bars: A, D & E: 















Table 5. 1: Summary of HK1.ras-K14creP.Δ3β-catflx/wt phenotypes. 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 
HK1.ras hyperplasia 90 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-Control hyperplasia exhibiting suprabasal layer 
membranous β-catenin/E-cadherin expression 
-ordered terminal differentiation indicated by 
suprabasal layer K1 and expressing K6α in both supra 
and basal layer due to HK1.ras activation stress 
signals  
-weak basal layer p53/p21 
K14creP.Δ3β-catflx/wt  74 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-No IFE tumours 
-HF tumours 
-minimal IFE hyperplasia 
-Increased cytoplasmic/nuclear basal layer β-catenin 
with increased membranous basal layer β-catenin/E-
cadherin due to Δ3β-catenin 
-Altered terminal differentiation indicated by K1 
expression but with normal K6α expression 
- Nuclear basal layer expression of p53/p21 halting 






K6α, p53 and 
p21 
expressions 
-No IFE tumours  
-More HF tumours vs. K14creP.Δ3β-catflx/wt  
-Mild hyperplasia due to HK1.ras 
-Increased cytoplasmic/nuclear basal layer β-catenin 
with increased membranous basal layer β-catenin/E-
cadherin due to Δ3β-catenin expression 
-More Aberrant confused terminal differentiation vs. 
K14creP.Δ3β-catflx/wt  indicated by patchy K1 
expression but still maintain fairly normal K6 
expression 
- Nuclear basal layer expression of p53/p21 halting 
Δ3β-catenin-induced proliferation 
Conclusion: constitutive β-catenin activation [Δ3β-catenin] with ras activation increases the severity 
of β-catenin associated HF abnormalities yet still blocks IFE tumour development due to 
compensatory early elevated levels of TSGs [p53/p21] which consequently resulted in the confused 
terminal differentiation whilst maintaining strengthened basal layer cell-cell adhesion [β-catenin/E-




5.3 Analysis of the rare HK1.ras-K14creP.Δ3β-catflx/wt papillomas 
On only two occasions over this study period did HK1.ras-K14creP.Δ3β-catflx/wt mice develop 
papillomas. In almost every case it appears that logically the p53 and p21 responses outline 
above blocked formation of both mild type 1 papillomas and the aggressive type 2. Thus, to 
address this point and compare the mechanism to HK1.ras alone, the backgrounds of these two 
individuals [ Fig 5.1F&G; Fig 5.13A&B] were examined more closely to assess for clues to 
this papilloma aetiology. Firstly, it was noted that in each case [separated by 10 months] these 
two HK1.ras-K14creP.Δ3β-catflx/wt  mice were almost full-sized when subjected to the tail 
biopsy and thus had been designated score 0. This indicated that in these mice the spontaneous 
cre did not leak early in the development. Furthermore, they still showed the typical Δ3β-
catenin phenotypes post RU486 treatment [Fig 5.1F&G; insert Fig 5.13A & B]. 
However, with hindsight, a close examination of their records showed that RU486 treatment 
had commenced following PCR conformation, as these were likely originally assumed to be 
Δ3β-catenin or K14cre negative given their score 0 and full size. Thus, in the probable absence 
of major cre leakage and normal development, RU486 treatment to activate Δ3β-catenin likely 
occurred 10 -14 days post ear tagging, and it may be that the wound promotion of this period 
allowed for a commitment to a papilloma outcome. Thus, a later RU486 treatment when the 
p53 and p21 may have committed would also account for these papillomas formed in 
HK1.ras-K14creP.Δ3β-catflx/wt taking more than 10 weeks to appear and being much smaller 
[3-4 mm diameter]. In each case papillomas were about a third the size of their littermate 
papillomas in HK1.ras control that were larger [7-10 mm diameter] and began to appear as 
early as 6 weeks post tagging [Fig. 5.1F&G; Fig. 5.13A&B].  
It thus appeared that these mice may have been the kind envisaged in the original aims and 
hypothesis [chapter 1]. Therefore, it was possible that despite their smaller size these RU486–
treated HK1.ras-K14creP.Δ3β-catflx/wt papillomas may possess signs of further progression. 
However, histological analysis did not show any significant indication of invasiveness in 
theses HK1.ras-K14creP.Δ3β-catflx/wt papillomas aside from the size difference [Fig. 5.13], a 




Figure 5. 13: Histological analysis of HK1.ras-K14creP.Δ3β-catflx/wt papilloma against 
HK1.ras littermate papilloma.  
[A] Insert shows overt smaller papilloma from HK1.ras-K14creP.Δ3β-catflx/wt exhibits a typical 
benign papilloma histotype and lacking any sign of invasiveness despite Δ3β-catenin 
activation. Indeed this has a less aggressive papilloma histotype compared to [B] a HK1.ras  
benign papilloma which is approx. 3 fold larger in size  but still lacks invasiveness. Scale bars 
A&B: 250µm 
Consistent with the appearance of Δ3β-catenin phenotypes following RU486 treatment 
analysis of β-catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt papillomas again showed 
the typical strong membranous expression in both supra-basal and basal-layers with strong 
nuclear expression [Fig. 5.14A-D]. HK1.ras littermate controls showed typical membranous 
β-catenin expression mainly in the supra-basal layers with only sporadic expression 




Figure 5. 14: Analysis of β-catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras papillomas.  
[A] Composite micrograph at low and [B] medium magnification shows strong uniform β-
catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt papillomas. [C & D] At higher 
magnification HK1.ras-K14creP.Δ3β-catflx/wt mice highlight strong nuclear and membranous β-
catenin expression in papilloma basal layers. [E & F] HK1.ras papilloma shows mainly 
membranous expression in supra-basal layers and weak β-catenin in basal layers. Scale 
bars: A: approx.150µm; B:100µm C-F: 50µm  
In addition, this result suggests that Δ3β-catenin activation and nuclear localization in 
HK1.ras-K14creP.Δ3β-catflx/wt papillomas induced the responses that appeared in K14.cre-
Δ3β-catenin mice and aided in limiting tumour progression, contrary to previous results seen 
in tri-genic HK1.ras/fos-K14creP.Δ5PTENflx/flx where nuclear localization of endogenous β-
catenin aided the progression of papilloma into carcinoma following p53 loss hence p53 /p21 
analysis below. Similarly, whilst in the main E-cadherin expression in both these sets of 
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HK1.ras-K14creP.Δ3β-catflx/wt papillomas generally paralleled that of β-catenin expression, it 
was noticed that in several instances strands of papilloma basal layers appeared to express less 
intense membranous E-cadherin [Fig. 5.15A&B; arrows]. This was not simply a squint cut of 
the tumour tissue as most of the remaining section did exhibit strong membranous basal layer 
E-cadherin. An example of squint cut appeared in HK1.ras controls [Fig. 5.15 C; arrows] 
where an island of folded papilloma has been cut above the basal layers and shows apparent E-
cadherin expression in all layers absent it the remaining section or the repeat experiments [Fig. 
5.15D]. 
 
Figure 5. 15: Analysis of E-cadherin expression in HK1.ras-K14creP.Δ3β-catflx/wt verses 
HK1.ras papilloma. 
[A & B] Both sets of HK1.ras-K14creP.Δ3β-catflx/wt papillomas mainly show strong 
membranous expression of E-cadherin in both supra-basal and basal layers with little nuclear 
expression. However, in each case strands of papilloma appear where E-cadherin appears 
confined to the suprabasal layers [arrows]. [C & D] HK1.ras papilloma shows only supra-
basal layer E-cadherin expression, except for an island of squint cut [arrows C] where the 
folds of papilloma go into the image and the section was cut above the basal layer. Scale 




These E-cadherin data suggest that there may have been a delay in the responses to β-catenin 
deregulation in these normal sized score 0 mice, this may have given less numbers of 
adherence junctions in the early basal layers of a wounded, tagged ear that allowed papillomas 
to start and this is reflected here by the remaining strands of supra-basal E-cadherin in some 
parts of the HK1.ras-K14creP.Δ3β-catflx/wt papillomas.  
Some of the clearest indications that the dominance of Δ3β-catenin expression was less in 
these two mice came from the analysis of differentiation markers K1 and K6α [Fig. 5.16 & 
Fig. 5.17]. In both individuals, K1 showed normal expression in HK1.ras-K14creP.Δ3β-
catflx/wt papilloma giving an intense, strong expression in the supra-basal layers similar to the 
typical expression in control HK1.ras papilloma [Fig. 5.16A&B vs. E&F]. However, it was 
noted that the transition from basal to suprabasal keratinocytes appeared disordered and 
ragged compared to the equivalent HK1.ras littermate papilloma [Fig. 5.16B vs. E&F]. This 
suggests that eventually Δ3β-catenin expression in the HK1.ras-K14creP.Δ3β-catflx/wt 
papilloma epidermis again disrupts the ordered nature of keratinocyte differentiation, possibly 
due to the conflicting proliferative signals from β-catenin/Wnt deregulation vs. basal  E-
cadherin and excess p53 and/or the pro differentiation roles for deregulated p21 expression 
[outlined above] (Di Cunto et al., 1998; Topley et al., 1999).  
Additionally, hyperproliferation marker K6α was now expressed strongly in HK1.ras-
K14creP.Δ3β-catflx/wt papillomas [Fig 5.17A & B] but again supporting a diminished yet 
increasing influence this K6 expression was patchy and these papillomas seem to be lacking 
the basal layer expression typically expressed in HK1.ras papilloma [Fig 5.17C & D]. Taken 
together, these results indicate that HK1.ras-K14creP.Δ3β-catflx/wt papillomas were similar to 
typical HK1.ras  papillomas possibly with some nuanced changes in the nature of the tumour 
due to Δ3β-catenin expression e.g. the patchy K6 expression could be due to excess p53/p21 
reducing the overall proliferation leading to smaller tumour sizes or roles of alternate TSGs 
such as p63 or p73 [below chapter6]; whilst this lesser E-cadherin expression would suggest 
lesser adhesions and thus less cell-cell rigidity to facilitate tumour formation.  
Returning to the theme that these papillomas appeared in full size mice, suggesting a lack of 
spontaneous cre leakage, coupled to a short delay in RU486 treatment it was speculated that 
p53 and p21 expression may have been delayed also and this aided the commitment to form 
papillomas. Unfortunately, this cannot be fully addressed as by the time of biopsy the 
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accompanying hyperplastic portion of these ears exhibit strong p53 /p21 expression similar to  
that expressed in HK1.ras-K14creP.Δ3β-catflx/wt papillomas and also observed in HK1.ras  
control papillomas [Fig. 5.18 & 5.19], which adds another factor that confirms the benign 
nature of these tumours.  
 
Figure 5. 16: Analysis of K1 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras  
littermate papillomas. 
 [A & B] Again both HK1.ras-K14creP.Δ3β-catflx/wt papillomas show strong and relatively 
normal K1 expression in supra-basal layers with a more expended basal layer in [B] and 
possibly a more ragged basal/supra-basal interaction compared to [C & D] the typical 
HK1.ras littermate papillomas with their ordered differentiation and smooth basal/supra-basal 





Figure 5. 17: Analysis of K6α expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras 
papillomas.  
Both [A] and to a lesser extent [B] HK1.ras-K14creP.Δ3β-catflx/wt papillomas show strong if 
patchy K6α expression in supra-basal layers but still oddly lacking in basal layers particularly 
in [B] with a more expanded basal layer. [C & D] Typical HK1.ras littermate papillomas shows 
strong expression in both supra-basal and basal layers; although D exhibits less basal layer 
K6α which can indicate a more aggressive papilloma consistent with the age and size of this 
specific littermate papilloma or occasional batch to batch differences in the polyclonal 







Figure 5. 18: Analysis of p53 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras  
littermate papillomas.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt papilloma exhibits the typical p53 expression observed in 
benign tumours with [B & C] an all over strong and nuclear expression of p53 in basal layer 
keratinocytes at higher magnification. [D-F] HK1.ras papillomas exhibit an identical p53 





Figure 5. 19: Analysis of p21 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras  
littermate papillomas.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt papilloma exhibits p21 expression in all layers with [B & C] 
exhibiting a uniform cytoplasmic expression together with nuclear p21 expression in basal 
layer keratinocytes. [D-F] HK1.ras papillomas exhibit a similar p21 expression profile but with 
less numbers of nuclear positive basal keratinocytes, typical of these papillomas.  Scale bars: 
A & D: 100 µm; B, C, E & F: 50µm. 
 
Collectively, the results generated from the HK1.ras-K14creP.Δ3β-catflx/wt cohort indicate that 
Δ3β-catenin activation in the epidermis induces protective responses against tumourigenesis 
highlighted by early expression of tumour suppresser genes [p53/p21] and confused 
differentiation with seemingly strengthened cell-cell adhesion. Additionally, the only two 
papillomas formed in HK1.ras-K14creP.Δ3β-catflx/wt mice were benign and smaller than 
typical HK1.ras with no signs of invasiveness, indicating that Δ3β-catenin activation still 
resulted in protective responses against tumorigenesis at the benign tumour stage in these bi-
genic mice compared to tri-genic HK1.ras/fos-K14creP.Δ5PTENflx/flx mice; until p53 and later 
p21 were lost.  
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Thus, the findings of this cohort indicated that the most logical step to follow up the results of 
the HK1.ras-K14creP.Δ3β-catflx/wt cohort was to induce conditional p53 knockout followed by 
p21 knockout in an attempt to provide a better understanding of the protective mechanism 
observed with Δ3β-catenin activation against tumourigenesis. 
 
Table 5. 2: Summary of rare HK1.ras-K14creP.Δ3β-catflx/wt papillomas phentypes 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 
HK1.ras papilloma 90 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-Control papilloma size 7-10 mm diameter 
-Exhibiting membranous β-catenin/E-cadherin 
expression mainly in the supra-basal layers with only 
sporadic nuclear/cytoplasmic β-catenin expression in 
basal layers  
-ordered terminal differentiation indicated by suprabasal 
layer K1 and expression in K6α in both supra and basal 
layers due to HK1.ras activation stress signal  







K6α, p53 and 
p21 
expressions 
-papillomma size 3-4 mm diameter  
-Exhibiting Increased cytoplasmic/nuclear basal layer β-
catenin with increased membranous basal layer β-
catenin/E-cadherin due to Δ3β-catenin 
-Ordered terminal differentiation indicated by 
suprabasal layer K1 and expressing K6α mainly in 
suprabasal layer 
- Nuclear basal layer expression of p53/p21 halting 
malignant conversion 
Conclusion: in the rare occasions when Δ3β-catenin activation was delayed [i.e. no cre leak], 2 
individual HK1.ras-K14creP.Δ3β-catflx/wt  mice developed small papillomas vs. typical 100% of HK1.ras 
mice presumably due to delay in compensatory TSGs expression [p53/p21] to Δ3β-catenin that blocked 
papillomatogenesis in most cases; however here, that affect only began post RU486 treatment which 
restricted papilloma further development in terms of size via elevated TSGs expressions and strengthen 







A literature search of previous studies showed the importance of β-catenin to the epidermis 
and specifically the regulation of hair follicle formation (Gat et al., 1998; Chan et al., 1999 
Van Mater et al., 2003 Grigoryan et al., 2008). However, these transgenic mouse studies lack 
the understanding of β-catenin activation roles in SCCs. Despise its clear relevance observed 
in human SCC in conjunction with notch pathway deregulation (Doglioni et al., 2003; Koch et 
al., 2007; Krishnamurthy et al., 2018), to date it is odd that no mouse studies have been 
successfully established that employ these activated β-catenin transgenic mice to model β-
catenin over expression in carcinogenesis. Perhaps the outcome of activating β-catenin in 
carcinogenesis was taken for granted as it would only facilitate tumour invasiveness and 
metastasis due the involvement of Wnt/β-catenin gain of function in the advancement of 
several types of carcinomas (Morin, 1999; Grigoryan et al., 2008). Indeed, only one study 
reports the essential roles for β-catenin as knockouts employed in classical two-stage 
DMBA/TPA chemical carcinogenesis experiments revealed a lack of tumours showing the 
integral requirement for β-catenin expression for tumorigenesis (Malanchi et al., 2008). 
Additionally, that result observed in HK1.ras/fos-K14creP.Δ5PTENflx/flx mouse model clearly 
implicated endogenous β-catenin roles on tumorigenesis [See chapter 3].  
As shown in the results section, in repeat experiments over 12-14 month period, almost all 
HK1.ras-K14creP.Δ3β-catflx/wt mice lacked papilloma formation yet still exhibited the 
K14creP.Δ3β-catflx/wt phenotypes, but with increased levels of severity in terms of increased 
scruffiness, enlarged extremities, effect on body size and increased hyperkeratosis in back 
skin. This was also consistent histologically as the hair follicle abnormalities such as 
formation of more cysts and hair follicle tumours were clearly more severe with increased 
interfollicular hyperplasia accompanied by abnormal and confused differentiation compared to 
both K14creP.Δ3β-catflx/wt and HK1.ras alone.  
 
The induced interfollicular hyperplasia in HK1.ras-K14creP.Δ3β-catflx/wt could be attributed to 
HK1.ras  activation as ras activation affects a plethora of other signalling pathways such as 
MAPK which consequently activate c-fos and PI3K which consequently activate p-AKT 
resulting in activating Wnt/β-catenin via de-activating GSK3- β. However, the IFE hyperplasia 
invoked in HK1.ras-K14creP.Δ3β-catflx/wt was clearly less than the typical HK1.ras 
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hyperplasia due to the early elevated expressions of p53/p21, that is normally not induced in 
HK1.ras hyperplasia. 
This affect was then prompted via Δ3β-catenin, which given its established role in 
carcinogenesis was expected to induce possibly accelerated papillomatogenesis as seen in 
HK1.ras-K14creP.Δ5PTENflx/flx (Yao et al., 2006) or even SCCs as observed in HK1.ras/fos-
K14creP.Δ5PTENflx/flx (Macdonald et al., 2014). However, HK1.ras-K14creP.Δ3β-catflx/wt 
showed only more aggressive phenotype of Δ3β-catenin with only a minimal affect in term of 
tumorigenesis, which indicates that Δ3β-catenin triggered an epidermal protective response 
against tumorigenesis. This is an unpreceded result as 100% of HK1.ras mice [n=80] produce 
benign papillomas within 6-8 weeks post ear tag (Greenhalgh et al., 1993); where as HK1.ras-
K14creP.Δ3β-catflx/wt remained tumour free for up to 16 weeks when the β-catenin phenotypes 
necessitated the animals to be culled.  
This intriguing result does not fit the current dogma in the literature (Morin, 1999; Grigoryan 
et al., 2008) as conditionally knocking out β-catenin resulted in either blockage or regression 
of DMBA/TPA tumours, which again indicate that β-catenin expression was a necessity for 
the development of SCCs (Malanchi et al., 2008; Grigoryan et al., 2008), and this is 
consistent with  the result observed in HK1.ras/fos.Δ5PTEN, where nuclear localization of β-
catenin facilitates tumorigenesis and invasiveness [see chapter 3] However, instead these  data 
suggest that β-catenin overexpression in co-operation with ras activation induced early, 
protective responses against tumour formation possibly similar to the responses observed in 
HK1.fos-K14creP.Δ5PTENflx/flx which resulted in the formation of benign KA (Yao et al., 
2008) and a lack of malignant conversion in HK1.ras.Δ5PTEN mice (Yao et al., 2006).  
To explore these possibilities, initially β-catenin and E-cadherin levels were assessed first to 
observe possible changes in cell-cell adhesions in HK1.ras-K14creP.Δ3β-catflx/wt mice. β-
catenin and E-cadherin showed identical expression with increased membranous expression 
and nuclear expression of β-catenin in basal layers as expected due to Δ3β-catenin activation. 
This suggests an increase in cell-cell adhesion signalling which possibly resulted in preventing 
formation of papillomas in a similar if later effect as seen in HK1.fos-K14creP.Δ5PTENflx/flx 
KA (Yao et al., 2008) [see Chapter 3]. This also indicated that the cytoplasmic pool of β-
catenin was not overtaken by Wnt signalling as seen in HK1.ras/fos-K14creP.Δ5PTENflx/flx and 
rather showed increased expression in the basal layer with nuclear localization of β-catenin as 
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well. Here again in HK1.ras-K14creP.Δ3β-catflx/wt ,  cytoplasmic E-cadherin/β-catenin 
interaction was acting as a sponge and providing further regulation of β-catenin levels (Huels 
et al., 2015), that indeed seemed to be strengthened by Δ3β-catenin activation as observed in 
colon carcinogenesis (Huels et al., 2015) . 
The early differentiation marker K1 showed a confused and patchy expression indicating that 
HK1.ras-K14creP.Δ3β-catflx/wt co-operation disturbed the epidermal terminal differentiation. 
This patchy K1 expression could be attributed to excess expression of p21 in the upper IFE 
layers which may inhibit the latter stages of differentiation (Di Cunto et al., 1998), however 
basal layer expression of p21 with p53 accelerated epidermal terminal differentiation as seen 
in HK1.fos-K14creP.Δ5PTENflx/flx KA (Topley et al., 1999; Yao et al., 2008)[see Chapter 3] 
and a recent study in ROCK-mediated β-catenin activation (Masre et al., 2020). 
The disturbed epidermal differentiation could also be attributed to β-catenin roles in regulating 
epidermal pluripotent stem cells that are needed for epidermal terminal differentiation and hair 
follicle differentiation (Watt and Collins, 2008). As increased Wnt/β-catenin signalling affect 
the correct control of the stem cell niche, leading to continuously altering the differentiation 
programme fate resulting in possibly confused transit amplifying cells evident by the 
formation of K1 positive interfollicular proliferative dead end cysts which would also divert 
keratinocytes away from papilloma formation.  
However, despite this aberrant expression of K1, the hyperproliferation marker K6α was 
completely absent from the epidermis, whereas usually it is strongly expressed in HK1.ras 
hyperplastic controls. One possible mechanism for this aberrant expression is a study that 
concluded the ability of constitutive activation of β-catenin to remodel the developed mouse 
dermis into a neonatal state (Collins et al., 2011). In neonates the epidermis is naturally 
hyperplastic but lacks k6 expression and remains confine to HF (Rothnagel et al.,1999), 
similar to Δ3β-catenin activation phenotype. 
Constitutive β-catenin activation [Δ3β-catenin] induces formation of new hair follicles 
observed in K14creP.Δ3β-catflx/wt  and HK1.ras-K14creP.Δ3β-catflx/wt , which normally only 
takes place in the embryonic and neonatal stage of life, (Närhi et al., 2008; Grigoryan et al., 
2008) this affect leads to inducing new dermal proliferation similar to neonatal mice which 
deregulate the epidermal-dermis interaction needed to maintain interfollicular terminal 
differentiation (Watt and Collins, 2008). Although, Δ3β-catenin activation increased HF 
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placode formation, most of them fail to develop normal hair (Närhi et al., et al.,2008), hence 
why these mice suffer from alopecia. This perhaps could be attributed to elevated expression 
of p53/p21 in HFs which are normally involved in regulating HF differentiation (Song and 
Lambert, 1999; Botchkarev et al., 2001) as increased p53/p21 induces apoptosis to halt the 
excess HF proliferation leading to a general regression in HF development, which might be 
contributing to the lack of IFE tumours but not HF tumours. 
Further these changes in K6α expression may also derive from the increase in adhesion 
junctions which in turn alters the hyperproliferation signals derived from cell-cell interactions 
that are typically disrupted in wounding. These are normally essential for cell division and 
keratinocyte migration and thus disruption of the filament network [intermediate and 
actinomycin] would affect movement that is carried out by the underlying cytoskeletal 
network that regulates mechanical tension through adhesion junctions and hemidesmosomes 
(Masre et al., 2020; Samuel 2011). Hence these data suggest that β-catenin overcomes the K6 
responses typical of ras activation via increased E-cadherin, except in the possible aetiology of 
the two outlying papillomas where E-cadherin may have been less or delayed in their basal 
layers (Takeichi, 1991; Young et al., 2003) 
This also brings the status of p53/p21 expression into question, because the increased cell-cell 
adhesions are also associated with elevated p53/p21 expression (Wu et al., 1997). The 
expression of p53/p21 confirmed this hypothesis showing strong expression was triggered via 
Δ3β-catenin as seen in K14creP.Δ3β-catflx/wt mice thus overexpression would inhibit papilloma 
formation. Also, this result is constant with the elevation seen in KA due to endogenous β-
catenin activation via inactivated GSK3-β/p-AKT activation. Again in HK1.ras-K14creP.Δ3β-
catflx/wt p53/p21 expression could possibly explain the absence of the hyperproliferation marker 
K6 from the IFE and the confused K1 expression seen in HK1.ras-K14creP.Δ3β-catflx/wt mice, 
suggesting a disfunction in epidermal homeostasis due to ras and β-catenin cooperated 
activation. In contrast HK1.ras hyperplasia showed only weak p53/p21 expression until overt 
papilloma formation with normal K1 expression and strong K6 expression, in addition to β-
catenin/E-cadherin showing similar membranous expression mainly in supra basal layer and to 
a lesser extent in basal layer. This indicates that the lack of basal layer p53/p21 in HK1.ras 
hyperplasia correlates with the reduced cell-cell adhesion [β-catenin/E-cadherin] which results 
in facilitating papilloma formation, unlike the early increased basal layer p53/p21 expression 
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in HK1.ras-K14creP.Δ3β-catflx/wt corelating with increased cell-cell adhesion and halting 
tumour progression but also disturbing terminal differentiation as observed by K1 expression. 
All of these data suggest that K14creP.Δ3β-catflx/wt in co-operation with HK1.ras triggered 
early p53/p21 protective responses due to HK1.ras and Wnt signalling induced proliferation. 
This resulted in a confused and abnormal epidermal differentiation,  as basal layer expression 
of p53/p21 halted the induced proliferation resulting in reduced IFE hyperplasia compared to 
HK1.ras, whilst the increased expression of p21 in the upper layers of the IFE distributed the 
terminal epidermal differentiation signalling evident by patchy expression of K1 but also 
resulted in strengthening cell-cell adhesion signalling due to β-catenin/E-cadherin elevated 
expression correlating with p53/p21 expression and preventing tumour development. 
For the two outlier mice HK1.ras-K14creP.Δ3β-catflx/wt  that developed benign papillomas, 
these papillomas grossly and histologically looked smaller and less aggressive compared to 
typical HK1.ras1205 papillomas , which still contrary to the widely assumed notion that 
overexpression of β-catenin/Wnt signalling leads to more aggressive tumours and possibly 
malignant progression. This suggests that even in the rare event when the papilloma was 
formed in HK1.ras-K14creP.Δ3β-catflx/wt strains, the papilloma could not progress to more 
aggressive tumour and possibly with more time would regress, which challenges the findings 
represented earlier in HK1.ras/fos-K14creP.Δ5PTENflx/flx strains where nuclear localization of 
endogenous β-catenin seemed to be facilitating malignant progression. The mice also looked 
bigger and less phenotypic than the majority of HK1.ras-K14creP.Δ3β-catflx/wt that did not 
develop the tumours. This indicates that probably the cre switch did not leak early [neonatal or 
juvenile] and only was activated post Ru-486 treatment, which gave HK1.ras 1205 enough 
time to develop the distant papilloma before Δ3β-catenin activation. 
 
 
The analysis of these HK1.ras-K14creP.Δ3β-catflx/wt tumours, although showed increased 
nuclear β-catenin localization, it still maintained a strong membranous expression in the basal 
layer. This expression was also mainly mimicked by E-cadherin, which indicate that cell-cell 
adhesion was still intact despite β-catenin nuclear localization, similar to the expression profile 
in HK1.ras/fos-K14creP.Δ5PTENflx/flx [see Chapter 3] and this would help prevent malignant 
progression. This suggests that even with delayed activation of Δ3β-catenin after initiation of 
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papillomatogenesis, unlike tri-genic HK1.ras/fos.Δ5PTEN, here nuclear localization of β-
catenin did not facilitate invasion but as outlined above it could be argued in these two 
examples that it might hindered the tumourigenesis progression. However, its delay due to 
lack of cre leakage and in RU486 treatment, may have facilitated the commitment to 
papilloma formation as indicated by the differentiation marker K1 and K6 expression data 
being similar to HK1.ras expression and the speculation that p53 and p21 would be delayed 
and if expressed would be suprabasal also resulting in data similar to typical ras 
papillomatogenesis.  
Lending further support to this idea it was noted that some strands of papilloma basal layers 
appeared to possess less membranous E-cadherin.  This E-cadherin expression, therefore again 
suggest that a delay in the responses to β-catenin deregulation in these normal sized score 0 
mice may have given less numbers of adherence junctions in the early basal layers of a 
wounded tagged ear, which allowed papillomas to start and is reflected here in the remaining 
strands of supra-basal E-cadherin in the HK1.ras-K14creP.Δ3β-catflx/wt papillomas. This idea 
will be tested in future studies involving recently imported E-cadherin floxed mice.  
The early differentiation marker K1 showed normal expression confined to the suprabasal 
layer as is always observed in HK1.ras 1205 benign papillomas. However, the 
hyperproliferation marker K6 showed strong expression as well but interestingly was lacking 
in the basal layer, A finding that seems to be exclusive to HK1.ras-K14creP.Δ3β-catflx/wt 
papilloma and is not seen in HK1.ras controls. This indicates that these tumours are benign but 
could Not be the same type of papilloma in HK1.ras1205 control as eventually Δ3β-catenin 
expression induces the responses to inhibit papilloma growth [indicated by patchy K6 
expression]. This is also similar to HK1.fos-K14creP.Δ5PTENflx/flx co-operation where 
papilloma were expected to be formed as observed previously in HK1.ras/fos-
K14creP.Δ5PTENflx/flx co-operation, however endogenous localization of β-catenin was 
delayed as it was a consequence of activating AKT resulting in diverting papillomatogenesis 
into KA aetiology. 
The tumour suppresser genes[TSG] p53/p21 were both strongly expressed confirming the 
benign nature of these tumours and also correlating with strong cell-cell adhesion observed in 
the basal layer. This correlation between TSGs expression and cell-cell adhesion seems to be 
the key to the protective responses induced in response to β-catenin nuclear localization. Thus 
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in the next chapter a cohort of conditional knockout of p53 in HK1.ras-K14creP.Δ3β-catflx/wt 





















Chapter 6: Conditional loss of p53 in β-






















6.1 Introduction   
The intriguing finding that in HK1.ras-K14creP.Δ3β-catflx/wt cohorts responses to β-catenin 
activation appeared to block papilloma formation required further investigation to provide a 
better understanding in this genotype. The tumour suppresser genes p53 and p21 seemed to 
play a major role in these findings, highlighted by their immediate and strong expression 
triggered via Δ3β-catenin activation in both HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-
catflx/wt  mice. This induction of p53 and p21expression appeared to only affect the IFE 
phenotypes produced by rasHa activation, as the follicular component remained unaffected; 
and indeed a sub-population of HK1.ras-K14creP.Δ3β-catflx/wt mice [those designated score 2] 
possessed a significant increase in the degree of follicular abnormalities, yet their IFE 
possessed only mild hyperplasia.  
That this inhibition of papilloma formation was not due to a technical feature such as 
inhibition of the HK1 promoter via Δ3β-catenin expression was excluded given that the 
neonatal HK1.ras-K14creP.Δ3β-catflx/wt pups exhibited the standard wrinkled skin; juveniles 
exhibited an increased keratosis; and in adults, this increased keratosis compared to 
K14creP.Δ3β-catflx/wt cohorts was induced by HK1.ras-specific expression in the IFE 
hyperplasia.  
That this inhibition appeared to centre on p53 and p21 expression was also supported by 
previous findings at each stage of carcinogenesis in the HK1 model. Firstly in HK1.ras/ROCK 
co-operation (Masre et al., 2020), endogenous β-catenin expression also appeared in the basal 
layers, mediated by ROCK2-induced AKT inactivation of GSK3β, to induced p53 and p21 
resulting in a block on papilloma formation. Secondly at the benign stages, the potency of this 
p53/p21 response to the dangers of anomalous β-catenin expression was clearly displayed in 
HK1.fos-K14creP.Δ5PTENflx/flx mice, where this time PTEN-mediated AKT expression 
initially co-operated with HK1.fos to elicit early papillomas but again the build-up of p-
GSK3β inactivation and an increasing degree of nuclear β-catenin [Chapter 3; Fig. 3.3]  
triggered a massive p53/p21 expression response diverting papilloma progression into massive 
differentiation, tumour keratosis and a KA outcome (Yao et al., 2008). Of note, this result is 
consistent with the significant differentiation and keratosis observed in the direct 
investigations of HK1.fos/K14.Δ3β-cathet.Δ5PTENflx/flx in Chapter 7. This differentiation may 
prevent tumour formation driven by β-catenin (Clevers and Nussse, 2012), given that the 
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regression phase of human KA aetiology was associated with β-catenin/Wnt down regulation 
(Zito et al., 2014). 
At the malignant conversion stage, these links between ras/β-catenin and p53/p21 are again 
observed as here the addition of activated ras to HK1.fos-K14creP.Δ5PTENflx/flx 
tumourigenesis resulted in the immediate expression of p53/p21 in HK1.ras/fos-
K14creP.Δ5PTENflx/flx  hyperplasia (Macdonald et al.,  2014), but as p53 became lost in 
papillomas this was paralleled by increased basal layer β-catenin leading to malignant 
conversion [Chapter 3; Fig. 3.3]. Moreover, later following p21 loss, nuclear β-catenin 
expression increased but became less membranous and this potential loss of cell-cell 
adherence coupled to increased Wnt deregulation via nuclear β-catenin expression probably 
contributes to the malignant progression of HK1.ras/fos-K14creP.Δ5PTENflx/flx wdSCCs to 
pdSCCs (Alyamani et al., manuscript in preparation).  
Thus, all these data suggest that as p53 and p21 are common features of cutaneous SCC 
inhibition (Brash et al., 1991; Topley et al., 1999; Macdonald et al., 2014), their expression 
maybe targeted to specific responses mediated by Ras and/or β-catenin signalling 
deregulation. Similar p53/p21 responses to pGSK3β/β-catenin expression have been 
documented in K-Ras colon carcinogenesis; where following APC loss and failure of the 
pGSK3β complex to ubiquitinate and remove β-catenin (Behrens et al., 1996; 1998; Ikeda et 
al., 1998), coupled to potential failures of E-cadherin to act as a sink (Huels et al., 2015) the 
increased nuclear β-catenin again induced transcriptionally active p53 (Damalas et al., 2001; 
Ghosh and Altieri, 2005; Clevers and Nussse, 2012). Thus, it appears that in both models an 
elevated p53 attempts to provide protection against additional mutations, and an increased 
p21-associated differentiation response [below (Topley et al.,1999)] avoids excessive p53-
induced apoptosis to maintain the paramount barrier function of skin (Calautti et al., 2005; 
Yao et al., 2008; Macdonald et al., 2014) also important in the function of colon epithelia.  
Therefore, introducing p53 conditional knockout into HK1.ras-K14creP.Δ3β-catflx/wt mice to 
generate the HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx genotype was the most sensible approach 
to understand p53 roles in this mechanism to both confirm the protective response and assess 
if p53 loss influenced papilloma formation and then co-operated with Δ3β-catenin to induce 
malignant conversion, as seen in HK1.ras/fos-K14creP.Δ5PTENflx/flx flx mice. This was a 
logical step, as previously classic DMBA/TPA chemical carcinogenesis studies employing 
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generic p53 knockout mice showed a significant increase in SCCs derived from DMBA-
induced ras activation and TPA-mediated fos promotion (Kemp et al., 1993); whilst in reverse 
β-catenin KO inhibited two-stage DMBA/TPA carcinogenesis (Malanchi, et al., 2008; 
Grigoryan et al., 2008).   
It should be pointed out that another less logical and to date a completely paradoxical result 
was seen via employment of generic p53 knockout mice in this HK1 model (Donehower et al., 
1992). Here in HK1.ras; HK1.fos and HK1.TGFα mice loss of p53 function e.g.  
HK1.gene.p53fl/flxx co-operation, resulted in a lack of tumours similar to that observed in 
HK1.ras-K14creP.Δ3β-catflx/wt mice; despite the loss of p53 protection. Whereas all wild type 
and heterozygous p53 progeny exhibited the standard papillomatogenesis of their parents 
(Greenhalgh et al., 1996). These data demonstrate the complexity of these signalling systems 
and here in this current study, generation of the control/breeder HK1.ras-K14.p53flx/flx 
genotypes showed that constitutive inducible p53 loss again provided the reverse paradoxical 
outcome expected of p53 roles; namely the inhibition of papilloma formation similar to the 
reverse outcome and lack of papillomas expected of rasHa/β-catenin co-operation in HK1.ras-
K14creP.Δ3β-catflx/wt mice. 
Thus, development of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx cohorts served to answer these 
paradoxical results observed in this study and in earlier HK1.ras/fos mouse models. One of 
which was to understand the lack of papillomas in HK1.ras-K14creP.Δ3β-catflx/wt mice and 
how conditional loss of p53 [and/or p21] could change these results. The other purpose was to 
understand β-catenin roles in the paradoxical result reported previously in HK1.ras-
K14.p53flx/flx co-operation and assess whether introduction of Δ3β-catenin activation in 
HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  cohorts would overcome the paradoxical block of 
HK1.ras/p53flx tumour formation? For instance, was β-catenin signalling the key to the block 
of rasHa tumours in these early HK1.ras-K14.p53flx/flx co-operation studies e.g., via increased 
p21. Hence was compensatory p53 [or p21] the key to blocking HK1.ras-K14creP.Δ3β-catflx/wt 
papillomas? Once again, the results raised more questions than answers but demonstrated the 





6.2 Conditional loss of p53 paradoxically reduces the severity of Δ3β-catenin 
phenotypes without IFE tumour development.  
The same K14.creP/loxP gene switch system was used to induce conditional p53 knockout 
[Fig. 6.1A] via deletion of p53 exons 2 to exon 10 [K14creP.p53flx/flx] (Jonkers et al., 2001). 
Topical application of RU486 thus gives the non-functional Δp53 allele [Fig. 6.1B&C]. These 
mice have been established in house for several years for studies on the paradoxical inhibition 
of HK1.ras papillomas by complete generic p53 knockout (Greenhalgh et al., 1996); but 
without any obvious phenotype. Indeed, consistent with this observation, typically little cre 
leakage activity was observed in untreated K14cre.p53flx/flx  skin [Fig. 6.1C; lane 3] and no 
read through was observed in K14creP-negative Δ3β-cat/p53flx/flx  skin [lane 6]; a result that 
was considered another possibility for the production of untreated phenotypes in this model 
but unlikely since no phenotypes were ever observed in [cre negative] Δ3β-catflx/flx  or new 
Δ3β-catflx/flx/p53flx/flx  breeders. However, in both RU486-treated and untreated K14creP.Δ3β-
catflx/wt.p53flx/flx  skin, the Δp53flx band at 612bp was typically strong in RU486-treated skin 
[lanes 1 & 2] but also now appeared in untreated K14creP.Δ3β-catflx/wt .p53flx/flx  skin [score 0; 




Figure 6. 1: Confirmation of p53 knockout.  
[A] Schematic diagram of the RU468-inducible cre/loxP system employs the same keratin 
K14 promoter-driven cre regulator to achieve ablation of p53 exons 2-10 in epidermis and 
hair follicles. [B] PCR analysis employing primers specific for the loxP modified intron 1 of the 
Δp53flx allele shows the p53wt band at 431bp [lane 1]; the p53flx/flx allele band at 584bp [lanes 
2-5] and a doublet indicates p53flx/wt heterozygosity [lane 6]. [C] To confirm K14creP activity 
employing an intron 1 forward and intron 10 reverse primer identifies a Δp53flx-specific band 
at 612bp in RU486-treated K14creP.Δ3β-catflx/wt.p53flx/flx mice [lanes1-2; 4-5] which is absent 
in untreated K14creP.p53flx/flx RU486 control skin [lane 3] and K14creP-negative Δ3β-









The first interesting observation was immediately seen in the litters that generated 
K14creP.Δ3β-catflx/wt.p53flx/flx mice [Fig.6.2]. The appearance of overt phenotypes typically 
appeared in K14creP.Δ3β-catflx/wt mice between 16-24d due to cre leakage [above Chapter 4]. 
Whilst the breeding to create these compound transgenic mice had given typical score 1 
phenotypes at the juvenile stage of K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt.p53flx/wt 
mice, in the first litters to give potential K14creP.Δ3β-catflx/wt.p53flx/flx it was noticed that there 
were more score 0 mice than previously observed which lacked the typical Δ3β-catenin skin 
phenotypes. In addition, whilst their size still varied there was a trend towards larger, more 
normal individuals [Fig. 6.2].  
A comparison of typical 23/24day old littermates at the time of tail biopsy clearly shows this 
delay in the appearance of Δ3β-catenin phenotypes [Fig. 6.2A]. A comparison of phenotypes 
in K14creP.Δ3β-catflx/wt.p53flx/flx vs.  K14creP.Δ3β-catflx/wt.p53flx/wt siblings showed a generally 
noticeable reduction in hyperkeratosis of back skin and dishevelled fur, as well as the overall 
severity of typical K14creP.Δ3β-catflx/wt  phenotypes [larger size, smaller feet, normal tails 
etc]. This inhibition of Δ3β-catenin phenotypes persisted in older adults even following 
treatment with RU486 [Fig. 6.2B], where K14creP.Δ3β-catflx/wt.p53flx/flx individuals maintained 
this score 0 phenotype compared to the Score 1 phenotype of a K14creP.Δ3β-catflx/wt.p53flx/wt  
heterozygotes. In some instances, this score 0 skin phenotype and larger size was maintained 
for over 8-10 weeks with only very minor patchy hyperkeratosis compared to increased levels 
of increasing hyperkeratosis in RU486-treated [score 1] K14creP.Δ3β-catflx/wt.p53flx/wt siblings 
[Fig. 6.2C vs. D].  
This indicated that a p53-mediated response appears critical to the induction of the typical 
Δ3β-catenin phenotypes seen in K14creP.Δ3β-catflx/wt genotypes, yet control K14cre.p53flx/flx 
mice appeared completely normal in terms of their development and hair cycles; a result 
consistent with the relative lack of p53 in a normal epidermis until hyperplasia approaches the 
papilloma development stage [above; Chapter 3].   
In the K14creP.Δ3β-catflx/wt.p53flx/flx cohorts it may be that conditional loss of p53 reduced the 
severity of Δ3β-catenin phenotypes due to the lack of major apoptotic responses mediated by 
p53 that likely led to the internal problems and embryonic lethality observed in other models 
of β-catenin deregulation (Järvinen et al.,2006; Grigoryan et al., 2008). However, this lack of 
p53 function and despite β-catenin overexpression, failed to elicit IFE tumours. Furthermore, 
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in another interesting development p53 expression appears integral to the production of the HF 
anomalies as this histological analysis also showed that p53 loss blocks HF tumour formation.  
 
Figure 6. 2: Comparison of K14creP.Δ3β-catflx/wt.p53flx/flx and K14creP.Δ3β-
catflx/wt.p53flx/wt phenotypes.  
[A] Left to right: Typical lack of overt phenotypes in two 24d old juvenile K14creP.Δ3β-
catflx/wt.p53flx/flx mice compared to a K14creP.Δ3β-catflx/wt.p53flx/wt sibling. Note K14creP.Δ3β-
catflx/wt.p53flx/flx mice appear slightly larger and lack the scruffy dishevelled fur or peri-orbital 
keratosis and large feet seen in the heterozygous p53 K14creP.Δ3β-catflx/wt.p53flx/wt mouse. 
[B-D] A comparison of RU486-treated adults highlights the difference in hyperkeratosis 
between the two genotypes over time, where [B] at 4-5 weeks K14creP.Δ3β-catflx/wt.p53flx/flx 
littermates still possess a mild score 0 phenotype with little keratosis compared to the uniform 
keratosis and wrinkled skin of the K14creP.Δ3β-catflx/wt.p53flx/wt mouse. [C] At 8-10 weeks two 
separate K14creP.Δ3β-catflx/wt.p53flx/flx mice exhibit minor hyperkeratosis compared to [D] the 





Histological analysis confirmed these gross observations in K14creP.Δ3β-catflx/wt.p53flx/flx mice 
compared to heterozygous K14creP.Δ3β-catflx/wt.p53flx/wt littermates [Fig. 6.3 & Fig. 6.4]. At 3 
weeks of age, both the ear and back histology of K14creP.Δ3β-catflx/wt.p53flx/flx mice exhibited 
very weak histotypes associated with Δ3β-catenin overexpression [Fig. 6.3A&B]. Little IFE 
effects, other than a minimal hyperplasia were observable in the ear epidermis; example 
shown was one of the few to exhibit sporadic HF abnormalities [Fig. 6.3A]. In the 3-week old 
back skin at the end of the first anagen, few hair follicle abnormalities were present as all 
follicles appeared to be normal and there was a complete absence of cysts associated with 
Δ3β-catenin [Fig. 6.3B]. In comparison, the p53 heterozygous K14creP.Δ3β-catflx/wt.p53flx/wt 
littermates already possessed typical Δ3β-catenin-associated abnormalities such as formation 
of multiple de novo hair follicle and cysts with minimal IFE hyperplasia [Fig. 6.3C&D]. 
These juvenile mice data clearly suggest that p53 was required to elicit the responses to 
deregulated β-catenin signalling in both IFE and more importantly the development not 
repression of HF anomalies and the analysis of RU486-treated K14creP.Δ3β-catflx/wt.p53flx/flx  
adults at 8 weeks of age also strengthen this idea. As shown in Fig. 6.4, over time RU486 
treatment of adult K14creP.Δ3β-catflx/wt.p53flx/flx  skin began to exhibit more Δ3β-catenin 
associated abnormalities [Fig. 6.4A&B], yet these were still very mild phenotypes compared 
to the increasing severity of phenotypes observed in heterozygous K14.Δ3β-cathet.p53hetskin 
[Fig. 6.4C&D]. Again, this histological analysis emphasised the roles of p53 in affecting the 
level of severity of Δ3β-catenin, as even when these histotypes appeared they were mild and 
moreover in back skin K14creP.Δ3β-catflx/wt.p53flx/flx mice lacked cysts and HF abnormalities 
were limited to follicular hyperplasia rather than progression to overt folliculoma as observed 








Figure 6. 3: Histological analysis of 3-week-old juvenile K14creP.Δ3β-catflx/wt .p53flx/flx 
skin compared to a Δp53 heterozygous K14creP.Δ3β-catflx/wt .p53flx/wt littermate.  
[A & B] K14creP.Δ3β-catflx/wt .p53flx/flx skin appears relatively normal. [A] Ear skin displays 
minimal IFE in this example with only sporadic HF abnormalities. [B] Back skin displays the 
final stages of the first anagen with many anagen 7 follicles yet each appears fairly normal 
and the skin lacks formation of multiple hair follicle abnormalities, folliculomas or cysts and 
the IFE displays only sporadic hyperplasia. [C & D] Δp53 heterozygous K14creP.Δ3β-catflx/wt 
.p53flx/wt littermates already exhibits the typical Δ3β-catenin phenotypes multiple hair follicle 
abnormalities and cysts in both [C] ear and [D] back and mild IFE hyperplasia. Scale bars: A, 
& C: 150 µm; C & D: 100 µm 
 
The reasons for this effect are unclear, but these results show that p53 was necessary to 
develop the phenotypes associated with Δ3β-catenin deregulation. It may be that p53 functions 
were required downstream to effect these changes or more logically as this is such a 
fundamental molecule that regulates many processes of proliferation, differentiation and 
apoptosis, it is likely that additional compensatory systems respond to this lack of p53. Indeed, 
this may be why few effects of p53 loss are observed in RU486-treated K14creP.p53flx/flx mice 





Figure 6. 4: Histological analysis of 8-week-old RU486-treated K14creP.Δ3β-
catflx/wt.p53flx/flx and heterozygous K14creP.Δ3β-catflx/wt.p53flx/wt littermate skin compared 
to K14creP.p53flx/flx controls.  
[A & B] With time and RU486 treatment by 8 weeks a K14creP.Δ3β-catflx/wt.p53flx/flx skin now 
displays mild Δ3β-catenin histotypes typical of a mouse with a score 0 designation. [A] Ear 
skin displays mild IFE hyperplasia and the sporadic HF abnormalities increased [B] Back skin 
also displays mild hyperplasia with increased numbers of hair follicle abnormalities but less 
progression to folliculoma nor any cyst production. [C & D] Δp53 heterozygous K14creP.Δ3β-
catflx/wt.p53flx/wt littermate exhibits a much more increased set of Δ3β-catenin phenotypes with 
multiple hair follicle abnormalities and cysts in both [C] ear and [D] back and increasing IFE 
hyperplasia consistent with the increased appearance of keratosis and thickened skin [Fig. 
6.2B & D]. [E & F] RU486-treated K14creP.p53flx/flx controls appear normal with only 
occasional displays of subtle epidermal hyperplasia in [E] the tagged ear. Scale bars: A-F: 





This appears to be an important finding and identifies p53 status as a direct effector of β-
catenin. Indeed, this appears to be a novel finding, given few other approaches have employed 
this strategy to investigate the consequences of β-catenin overexpression. In addition, the 
context of p53 loss appears to be important also, as whatever compensates for p53 loss to 
block effects of β-catenin activation in K14creP.Δ3β-catflx/wt.p53flx/flx genotypes fails to act in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx papillomas following p53 loss, which convert to 
malignancy given the increased signalling deregulation, loss of p53 guardian functions and in 
this context, nuclear β-catenin helps drive progression. Equally, in reverse where β-catenin 
loss inhibited chemical carcinogenesis (Malanchi, et al., 2008), at some stage p53 was also 
lost and again any putative backup TSG effects were quickly circumvented due to the 
numerous other DMBA/TPA-induced mutations leading to SCC (Malanchi, et al., 2008). 
Thus, these ideas will be tested next via creation of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
genotypes to further assess the effect of this interaction between Δ3β-catenin and p53flx on 
tumorigenesis. 
 
6.3 Conditional loss of p53 does not affect the lack of papillomatogenesis in  
most HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  genotypes. 
 
Following the interesting novel and reverse effects of p53 loss on reduction not expansion of 
the early Δ3β-catenin phenotypes, HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx genotypes were 
generated. These mice were assessed for their ability to form papillomas and if so, would these 
tumours convert to carcinomas due to the loss of p53 protection, which was suspected to be 
the main cause in halting papilloma formation in HK1.ras-K14creP.Δ3β-catflx/wt cohorts [above 
Chapter 4] and co-operated with β-catenin overexpression in the malignant conversion of 
HK1.ras/fos-K14creP.Δ5PTENflx/flx papillomas.  
As cited above, K14cre.p53flx/flx mice have been established in house for several years for 
studies of a similar paradoxical inhibition of HK1.ras papillomas induced by p53 loss 
(Greenhalgh et al., 1996). Thus, these experiments assessed whether the responses that 
reduced β-catenin overexpression phenotypes following p53 loss were also able to inhibit 
papillomas observed in HK1.ras-K14.p53flx/flx mice and HK1.ras-K14creP.Δ3β-catflx/wt cohorts; 
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or did the reverse happen, was β-catenin overexpression in HK1.ras-K14creP.Δ3β-catflx/wt 
.p53flx/flx  cohorts able to overcome the paradoxical mechanism of tumour inhibition observed 
in HK1.ras-K14.p53flx/flx  mice following p53 loss?  
These are difficult questions that highlight the complexity of these signalling systems and that 
in different contexts result may differ – however it was the former idea that proved to be the 
case and led to investigations of alternate p53 family members, p63 and p73 together with 
assessment of p21 knockout [see below]. 
As shown in Fig.6.5, except for two instances [see section 6.4 below], most HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice [N=22] again exhibited a complete lack of papillomas 
despite the loss of p53, similar to HK1.ras-K14creP.Δ3β-catflx/wt [Fig. 6.5A-C]. Once again, 
their size varied but tended to be larger and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice 
grossly showed a noticeable reduction in severity of Δ3β-catenin skin phenotypes, similar to 
observations illustrated in K14creP.Δ3β-catflx/wt.p53flx/flx mice [above]. Whilst neonatal 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice exhibited the wrinkled HK1.ras-associated skin 
phenotype [not shown], juvenile and early adults exhibited only mild spontaneous Δ3β-catenin 
associated phenotypes typically seen in HK1.ras-K14creP.Δ3β-catflx/wt cohorts [Fig.6.5 D vs. 
E, F vs G]. 
Histological analysis was conducted on RU486-treated 4-week and 10-week old HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx skin biopsies to observe changes in Δ3β-catenin-associated IFE 
hyperplasia compared to HK1.ras-K14creP.Δ3β-catflx/wt skin [above Chapter 5]. At 4 weeks, 
following a single application of RU486, the histology of a juvenile HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx skin showed only very mild Δ3β-catenin phenotypes with minimal IFE 
hyperplasia in both ear [Fig. 6.6A&B] and back specimens [Fig. 6.6E&F] together with 
significantly reduced problems with HF anomalies. In comparison, equivalent heterozygous 
HK1.ras-K14.Δ3β-cathet/p53het littermates exhibited the identical histotypes of HK1.ras-
K14creP.Δ3β-catflx/wt skin [not shown]; designated with a score 1 [above, chapter 5].  
It was also noted that at higher magnification there was an increased disorder to the basal 
layer, yet there appeared to be few cysts [Fig. 6.6B, D&F]. This example also shows less 
hyperplasia than expected [see below Fig. 6.7A&B] consistent with the lack of keratosis 
[insert] and there is a distinct degree of disordered differentiation in upper epidermal layers 
[Fig. 6.6B, F&G]. This again suggests that supra-basal keratinocyte differentiation is disrupted 
175 
 
possibly due to increased supra-basal p21 [below Fig.6.12] affecting the final stages of 
differentiation as observed in HK1.ras-K14creP.Δ3β-catflx/wt [above chapter 5 Fig. 5.9C] and 
K1 analysis in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin [below Fig.6.10B&C].  
 
 
Figure 6. 5: HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx genotypes lack papilloma formation. 
[A & B] At 8 weeks post ear-tag wounding, RU486-treated HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx tagged ears show a lack of papillomas similar to [C] RU486-treated HK1.ras-
K14creP.Δ3β-catflx/wt and each exhibits only a mild keratosis. [D] HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx again show a reduced keratosis with less scruffiness to the fur compared to [E] 
treated HK1.ras-K14creP.Δ3β-catflx/wt and comparison of [F] HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx [G] with age-matched HK1.ras-K14creP.Δ3β-catflx/wt control at 8 weeks again 





With time and further RU486 treatments, by 10 weeks HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
skins exhibited phenotypes more typically associated with Δ3β-catenin expression as they 
showed more hair follicle abnormalities with a slightly increased HK1.ras-associated IFE, 
although again few cysts appeared. [Fig. 6.6C&D; G&H]. Indeed, consistent with a repression 
of Δ3β-catenin-associated phenotypes by p53 inactivation, HF abnormalities appeared less 
compared to HK1.ras-K14creP.Δ3β-catflx/wt skins, with little cyst formation [Fig. 6.7A vs. C]. 
However, again a disordered differentiation was noted in basal layer HK1.ras-K14creP.Δ3β-
catflx/wt .p53flx/flx  keratinocytes similar to the disordered differentiation of HK1.ras-
K14creP.Δ3β-catflx/wt expressing a wt p53 [Fig. 6.7B vs. D] or heterozygous p53 HK1.ras-








Figure 6. 6: Histological analysis of HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  skin biopsies 
at 4 and 10 weeks.  
[A & B] At 4 weeks HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx ear skin [insert] shows minimal IFE 
hyperplasia and only minor effects of Δ3β-catenin on HF morphology. [C & D] At 10 weeks, 
RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin now shows a more typical Δ3β-
catenin phenotype highlighted in [D] at higher magnification by multiple hair follicle 
abnormalities and again an increased disorder to the basal layer with hyper-chromatic 
nuclear keratinocytes. [E & F] A 4 week old HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx back skin 
also shows minimal IFE hyperplasia and minor HF effects. [G] By 10 weeks, HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx back skin shows the typical Δ3β-catenin effects of multiple hair 
follicle abnormalities, but with little cyst formation. [H] This example also shows less 
hyperplasia than expected [see Fig.6.7 A & B] consistent with the lack of keratosis [insert] 
and exhibits a distinct degree of disordered differentiation in upper epidermal layers. Scale 






Figure 6. 7: Histological comparison of RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt 
.p53flx/flx  skin to HK1.ras-K14creP.Δ3β-catflx/wt , HK1.ras-K14creP.p53flx/flx and HK1.ras 
epidermis.  
[A & B] At 10 weeks and RU486 treatment HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx exhibits 
multiple hair follicle abnormalities but few cysts with a more IFE hyperplasia [compared to 
Fig.6.3 #2 G & H] and again this disordered differentiation of prominent nuclei in basal layer 
keratinocytes. [C & D] HK1.ras-K14creP.Δ3β-catflx/wt displays increased IFE hyperplasia and 
more hair follicle abnormalities including formation of multiple cysts, whilst [D] displays a 
disordered differentiation but lacks the prominent nuclei. [E & F] RU486-treated HK1.ras-
K14creP.p53flx/flx skin shows increased hyperplasia with an ordered differentiation; but [F] 
occasional patches of disturbed basal layer keratinocytes suggested attempts to undergo 
apoptosis due to p53 loss. [G & H] HK1.ras epidermis exhibits a more papillomatous 
hyperplasia with ordered differentiation. Scale bars: A,C,E&G:100µm; B,D,F&H: 50µm  
 
In comparison to this HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  histotype both  RU486-treated 
HK1.ras-K14creP.p53flx/flx  and HK1.ras controls possessed a larger degree of IFE hyperplasia 
with increased papillomatogenesis and a smooth ordered differentiation [Fig.6.7 E-F]; 
although occasional patches of disturbed basal layer keratinocytes appeared in RU486-treated 
HK1.ras.p53fxl/flx epidermis compared to HK1.ras alone [Fig.6.7F vs. H];  suggesting an 
anomalous premature differentiation or attempts to undergo apoptosis in response to loss of 
p53 functions in screening DNA for repair. Indeed, it was speculated that the normal supra-
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basal expression of AKT maybe geared to block p53-mediated apoptosis giving time for 
terminal differentiation (Calautti et al., 2005; Macdonald et al., 2014); thus, the loss of p53 in 
this context may allow for premature AKT expression in basal layers adding to the 
proliferation and the beginnings of a disordered differentiation or p53 independent apoptosis 
to counter basal AKT. 
This analysis clearly illustrated an effect of p53 loss on the time of appearance and severity of 
Δ3β-catenin phenotypes, as little to no effect was observed on HK1.ras-K14creP.Δ3β-catflx/wt 
.p53flx/flx  tumorigenesis, as seen in HK1.ras-K14creP.Δ3β-catflx/wt [above] and the paradoxical 
block of papillomas in HK1.ras-K14creP.p53flx/flx mice. Therefore, to confirm this histological 
analysis and show that the mechanism remained the same, these biopsies were assessed by the 
standard analysis of β-catenin/E-cadherin status; assessment of keratinocyte differentiation via 
K1/K6 marker expression and analysis of p21 expression to determine whether this remained 
or increased in basal layers due to p53 loss and thus helped inhibit papilloma formation.  
Analysis of β-catenin levels in 4-week-old HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice 
showed the expected increased expression in basal layers, again with both membranous and 
elevated nuclear β-catenin [Fig. 6.8A&B] that was virtually identical to β-catenin levels and a 
greater degree of hyperplasia observed in HK1.ras-K14creP.Δ3β-catflx/wt controls [Fig. 
6.8C&D]. In comparison both HK1.ras-K14creP.p53flx/flx and HK1.ras control hyperplasia 
exhibited mainly suprabasal layer expression [Fig.6.8 E & F; G&H]. Thus, p53 loss did not 
appear to affect the epidermal location or levels of Δ3β-catenin expression in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice. Moreover this HK1.ras-K14creP.p53flx/flx result maybe 
important as it also suggests that the responses to p53 loss in HK1.ras-K14creP.p53flx/flx mice 
are independent of β-catenin expression at this stage and this inhibitory compensatory 
mechanism to p53 loss maybe generic, hence a lack of early papillomas in both contexts. 
Analysis of E-cadherin also showed an increase in basal layer expression in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice again mimicking that of β-catenin and also similar to 
HK1.ras-K14creP.Δ3β-catflx/wt expression of E-cadherin, whilst both HK1.ras-
K14creP.p53flx/flx and HK1.ras control hyperplasia exhibited a mainly suprabasal layer 






Figure 6. 8: Analysis of β-catenin expression in RU486-treated HK1.ras-K14creP.Δ3β-
catflx/wt .p53flx/flx  compared to HK1.ras-K14creP.Δ3β-catflx/wt controls.  
[A & B] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis displays an overall strong uniform 
expression of β-catenin in IFE and hair follicles; where at higher magnification [B] shows 
nuclear localization of β-catenin with strong membranous and nuclear expression in basal-
layer keratinocytes. [C & D] HK1.ras-K14creP.Δ3β-catflx/wt displays an identical β-catenin 
expression profile where [D] at higher magnification again shows nuclear localization of β-
catenin with strong membranous basal-layer expression in IFE and hair follicles. [E & F] 
HK1.ras.p53flx/fx exhibits increased papillomatous hyperplasia and mainly suprabasal-layer 
expression of β-catenin similar to [G & H] supra-basal expression of β-catenin in HK1.ras 





Figure 6. 9: Analysis of E-cadherin expression in RU486-treated HK1.ras-K14creP.Δ3β-
catflx/wt .p53flx/flx  and HK1.ras-K14creP.Δ3β-catflx/wt epidermis. 
 [A & B] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis displays strong uniform E-cadherin 
expression in the IFE and hair follicles that parallels β-catenin. [B] Higher magnification 
shows strong membranous E-cadherin expression in both supra-basal and basal layers with 
little detectable nuclear localization. [C & D] HK1.ras-K14creP.Δ3β-catflx/wtdisplays an identical 
profile. [E & F] HK1.ras-K14creP.p53flx/flx exhibits only supra-basal E-cadherin expression 
identical to [G & H] supra basal expression in HK1.ras hyperplasia. Scale bars: A,C,E&G: 
75µm; B,D,F&H: 50µm 
 
These data indicate that despite the loss of p53 expression in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx, an increased cell-cell adhesion was still maintained in basal layers by E-
cadherin expression [Fig. 6.9A&B] and identical to that observed in HK1.ras-K14creP.Δ3β-
catflx/wt epidermis [Fig. 6.9C&D]. In contrast, HK1.ras-K14creP.p53flx/flx and HK1.ras control 
hyperplasia lacked this early expression which suggests the possibility of a mechanism of cell 
adhesion responses aiding tumour inhibition alongside altered differentiation or elevated p21. 
Furthermore E-cadherin expression appeared mainly membranous and cytoplasmic but not 
nuclear [Fig. 6.9A&B]. Thus, the proposed function to act as a sponge and provide additional 
regulation of β-catenin (Huels et al., 2015) remained intact in the cytoplasm [Fig. 6.9C&D; as 
seen previously for HK1.ras-K14creP.Δ3β-catflx/wt epidermis [see Chapter 5 Fig.5.8] but was 
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not present in the nucleus. Hence retention of nuclear β-catenin levels in basal keratinocytes 
also means that nuclear translocation of β-catenin was not affected by p53 loss, thus ruling out 
another possibility for the inhibition of Δ3β-catenin phenotypes.  
In respect to differentiation, to explore the possibility of an increased differentiation response, 
the early differentiation marker keratin K1 and the hyperproliferation/disease-associated 
keratin K6α were investigated to assess whether a similar novel lack of K1 and K6α also 
appeared in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice [Fig. 6.10 & Fig. 6.11]. The 
disordered HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx histotype was very similar to HK1.ras-
K14creP.Δ3β-catflx/wt hyperplasia and consistent with this observation K1 showed a very weak 
expression profile in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin [Fig. 6.10A-C]. Indeed, this 
was much more pronounced as K1 expression almost disappeared from the epidermis, whilst 
HK1.ras-K14creP.Δ3β-catflx/wt showed patchy, confused expression [Fig. 6.10 D]. As observed 
previously in HK1.ras-K14creP.Δ3β-catflx/wt mice, this patchy K1 expression disappeared quite 
abruptly in some parts of the epidermis suggesting all daughter cells form a specific epidermal 
stem cell unit underwent this changed differentiation pattern. If so then the loss of p53 
compounded this result in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  histotypes [Fig. 6.10A-C vs. 
D] as not only was K1 virtually absent but also when actually present K1 expression appeared 
to be confined to the upper layers of the hyperplastic epidermis [Fig.6.10 B & C]. In contrast, 
RU486-treated HK1.ras-K14creP.p53flx/flx and HK1.ras control hyperplasia again exhibited a 
normal expression of K1 confined to the suprabasal layer with a smooth transition of basal 
keratinocytes to the supra basal layer [Fig. 6.10E&F] possibly due to the indifference of 
HK1.ras epidermis to a lack of p53 expression responses and the normal low expression of 




Figure 6. 10: Analysis of differentiation marker keratin K1 in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx  epidermis.  
[A-C] K1 expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx is very weak sporadic and 
absent in many areas. [B & C] K1 appears confined to the upper layers consistent with a 
delay in expression. [D] HK1.ras-K14creP.Δ3β-catflx/wt skin displays expression of K1 in 
specific patches. [E] Treated HK1.ras-K14creP.p53flx/flx epidermis displays an ordered K1 
profile despite the occasional disturbed differentiation observed in their histology. [F] HK1.ras 
shows smooth, ordered expression of K1 confined to the suprabasal layer. Scale bars: A&D: 
100µm; B,C,E&F: 50µm 
 
This expression of K1 in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis clearly indicated 
that the terminal differentiation programme was highly disturbed following the loss of p53 and 
more so than previously observed in HK1.ras-K14creP.Δ3β-catflx/wt skin. Thus, this feature of 
K1 expression  appears to be a significant marker of the altered differentiation caused by 
deregulated β-catenin expression and exacerbated by p53 loss-although exactly why is unclear 
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but may relate to the increased numbers of adherence junctions due to excess E-cadherin and 
the resultant increase in rigidity feeds back to alter the commitment to begin K1 expression in 
the early stages of differentiation as keratinocyte migrate from the different epidermal stem 
cell niches (Watt and Collins, 2008). Alternately, this effect on K1 maybe due to 
compensatory p21 expression [below] that appeared particularly strong in the upper layers of 
the epidermis following p53 loss.    
Furthermore, it may be that these effects of β-catenin involve decisions by individual stem 
cells in the given niches as speculated above for HK1.ras-K14creP.Δ3β-catflx/wt IFE (Watt and 
Collins, 2008). These are further altered following p53 loss in the IFE epidermis, and p53 loss 
also affected the typical HF anomalies HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx HFs. Here 
overall, the response to p53 loss was potent enough to diminish the intensity of the HF 
anomalies including a lack of K1+ve abnormal follicles [Fig. 6.10A-C vs. D] and their apparent 
ability to de –differentiate into a cyst appears to be absent also, suggesting that this too is 
mediated by p53 in attempts to avoid potential tumour progression in p53wt cells.  
It may be that the resultant danger and potential proliferation of keratinocytes with increased 
susceptibility to genetic mutations due to loss of the p53 repair surveillance, subsequently 
affects the pluripotent HF stem cell niche. For instance, as this induced a more potent response 
to p53 loss one feature may result in causing specific stem cell populations to exit that niche in 
order to prevent production of proliferating cells gaining the mutations leading to follicular 
tumours. This protection thus manifests as a lesser degree of HF abnormalities and may also 
account for the reduced expression of the K15 stem cell marker in the IFE [see below]. 
Consequently, this idea possibly indicates that a loss of K15+ve IFE stem cell targets for 
HK1.ras activation would thus account for the lack of papillomas and was investigated below.   
If so, then this kind of inhibition of such potential mutant keratinocyte populations as a backup 
to p53 loss may also help account for the general total lack of hyperproliferation marker 
keratin K6α expression observed once again in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice 
[Fig.6.11]. Analysis of a variety of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx samples showed 
K6α expression was confined to the hair follicles [Fig.6.11A-C] as seen in HK1.ras-
K14creP.Δ3β-catflx/wt mice [Fig. 6.11D & E]. In contrast HK1.ras-K14creP.p53flx/flx and 
HK1.ras control hyperplasia both exhibited strong K6α expression in the IFE constant with 
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increased proliferation and a lack of p53 [HK1.ras.p53flx/flx] or lack p53 induction [HK1.ras] 
[Fig. 6.11 F & G].  
 
 
Figure 6. 11: Analysis of hyperproliferation marker K6α expression in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx epidermis.  
[A-C] Separate examples of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx show K6α expression is 
absent in most epidermal areas with [B] expression in occasional patches of IFE otherwise 
K6 α is confined to the HFs and [C] some appear quite normal. Similarly, [D & E] HK1.ras-
K14creP.Δ3β-catflx/wt shows even less K6α expression in both IFE and only few HFs. [F] 
HK1.ras-K14creP.p53flx/flx and [G] HK1.ras both show strong K6α expression in IFE. Scale 
bars: A-F 150µm; G: 100µm 
 
To-date this novel K6α observation remains unique to the Δ3β-catenin model and as 
speculated for K1 above, this change in K6α expression may reflect the alterations in 
adherence junction physiology that are normally essential for cell division and keratinocyte 
migration. These keratin data suggest that from a barrier viewpoint the keratins associated 
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with maintaining a supra-basal layer or in response to wounding are consistently reduced. In 
both cases  this may be possibly due to p21 expression; as in some contexts excess p21 
displays an inhibitory role in differentiation and affects a commitment to differentiate (Di 
Cunto et al., 1998;Topley et al., 1999) consistent with this delayed and patchy K1 finding; 
whilst p21 roles in cell cycle regulation would be consistent with reductions in K6α 
expression and a diminished level of hyperplasia in HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx   
IFE and the hair follicle’s reduced Δ3βcatenin phenotypes.  
Therefore p21 levels were assessed which again showed strong nuclear expression in all IFE 
layers together with hair follicles in RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
epidermis [Fig. 6.12 A]. The example shown at 8 weeks represents one of the most phenotypic 
examples and is included as this also clearly demonstrated the very strong levels of p21 in the 
upper layers of the hyperplastic HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   IFE compared to an 
age matched HK1.ras-K14creP.Δ3β-catflx/wt mouse also displaying a designated score 1 
phenotype Fig. 6.12 A vs B]. In contrast HK1.ras-K14creP.p53flx/flx and HK1.ras control 
hyperplasia both lack such a compensatory p21 expression response consistent with their 
increased hyperplasia [Fig. 6.12D&E] and a general observation that p21 expression trailed 
that of p53 expression in papillomatogenesis [above; chapter 1: Fig.6]; becoming more 
effective at later stages in the inhibition of malignant progression as an antagonist to AKT and 
nuclear β-catenin (Macdonald et al., 2014). Thus, p21 expression in HK1.ras mice remained 
low unless the cell was committing to differentiate [Fig. 6.12 E].  
Thus, as previously speculated for HK1.ras-Δ3βcatenin mice, increased compensatory basal 
layer p21 may inhibit the latter stages of differentiation and result in an apparent lack of K1 
expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx (Di Cunto et al., 1998), with its roles in 
cell cycle reducing the proliferation hence reduced hyperplasia reflected by K6α, and in terms 
of papilloma formation, increased p21 would again inhibit tumours. Given that this effect of 
p21 expression appears immediately following p53 loss it appears quite a potent event at this 
early stage context alongside the apparent increase in adherence junctions mediated by 
elevated E-cadherin. This p21 expression and the lack of papillomas forming in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice indicated that elevated p21 levels maybe a key mechanism 
in halting early-stage tumorigenesis. However preliminary data suggests that p21ko may not 
be the key to tumour inhibition, as newly established HK1.ras-K14creP.Δ3β-catflx/wt.p21KO 
[n=5] were also devoid of tumour development [below Fig. 6.29]. Furthermore, all these data 
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highlight the complexity of these signalling systems and that in different contexts results may 
differ; and this was exemplified by the appearance of tumours in two HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice.  
 
Figure 6. 12: Analysis of p21 expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
epidermis compared to HK1.ras-K14creP.Δ3β-catflx/wt epidermis and treated HK1.ras-
K14creP.p53flx/flx skin.  
[A] Typically treated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis shows strong expression 
of p21 in all layers and HFs with a particular increase observable in the suprabasal layers. [B] 
HK1.ras-K14creP.Δ3β-catflx/wt also shows strong expression in all layers and hair follicles but 
with less supra-basal expression. [C] Typical HK1.ras-K14creP.p53flx/flx epidermis lacks p21 
compensatory expression to p53 loss similar to [D] weak expression almost absent from the 






Table 6. 1: Summary of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  phenotypes and 




[N] Analysed for 






K6α, p53 and 
p21 
expressions 
-Control hyperplasia exhibiting membranous β-catenin/E-
cadherin expression in supra-basal layers 
-ordered terminal differentiation indicated by supra-basal layer 
K1 and K6 expression in both supra- and basal layers due to 
HK1.ras activation  






K6α, and p21 
expressions 
-Control hyperplasia exhibiting suprabasal layer membranous β-
catenin/E-cadherin 
-ordered terminal differentiation indicated by suprabasal layer 
K1 and K6α expression in both supra and basal layers due to 
HK1.ras activation  








K6α, p53 and 
p21 
expressions 
-No IFE tumours  
-More HF tumours and more cyts vs. K14creP.Δ3β-catflx/wt  
-Mild hyperplasia due to HK1.ras 
-Increased cytoplasmic/nuclear basal layer β-catenin with 
increased membranous basal layer β-catenin/E-cadherin due to 
Δ3β-catenin 
-More Aberrant confused terminal differentiation vs 
K14creP.Δ3β-catflx/wt  indicated by patchy K1 expression but 
still maintain fairly normal K6α expression 









K6α, and p21 
expressions 
-No IFE tumours  
-less HF tumours, less cysts and more normal looking HFs vs. 
HK1.ras-K14creP.Δ3β-catflx/wt genotyopes 
-Mild hyperplasia due to HK1.ras 
-Increased cytoplasmic/nuclear basal layer β-catenin with 
increased membranous basal layer β-catenin/E-cadherin due to 
Δ3β-catenin 
- Very disturbed terminal differentiation indicated by the almost 
complete absence of K1/ K6α expression exhibit for the normal 
expression of K6 in HF 
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- Nuclear basal layer expression of p21 halting Δ3β-catenin 
induced proliferation 
Conclusion: inducible loss of p53 with constitutive β-catenin activation [Δ3β-catenin] in 
conjunction with ras activation paradoxically block IFE tumours; a result similar to HK1.ras-
K14creP.Δ3β-catflx/wt yet with notable reduction in appearance and severity of Δ3β-catenin 
associated phenotypes. These data indicate that p53 expression played an integral role in 
inducing Δ3β-catenin phenotypes but not terms of blocking papillomatogenesis at this stage in 





6.4 Conditional loss of p53 elicits rare HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  
papillomas and co-operated with β-catenin to produce SCC  
Previous studies have shown another completely paradoxical inhibition of HK1.ras tumours 
occurred following generic p53 knockout (Donehower et al., 1992; Greenhalgh et al., 1996) 
and hints at the potent responses available to the epidermis that help prevent tumours forming 
and are logical in a tissue most exposed to environmental carcinogens such as UV-B. Thus, 
employing the same cre/loxP system to target p53 loss to the epidermis, it was originally 
envisaged that constitutive inducible HK1.ras-K14creP.p53flx/flx would co-operate with Δ3β-
catenin whereby β-catenin activation elicited papillomas that were prone to conversion due to 
p53 loss, as suggested in HK1ras/fos.Δ5PTEN experiments [Chapter 3]. However, to date only 
two HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   individuals developed papillomas [Fig. 6.13A-C] 
and despite a similar timeline in their appearance, unlike the two papillomas formed in 
HK1.ras-K14creP.Δ3β-catflx/wt mice which remained small and benign [Fig.6.13: D & E]; by 8 
weeks post tag, the HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours had change their 
appearance to one more typical of conversion to wdSCC. Despite their relatively small size, 
both tumours adopted a redder colouring and an oval shape with a depressed centre [Fig.6.13: 
B & C]. These are all characteristics of SCC in this model [Chapters 1 & 3].   
Again, of note, these two HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx individuals were of a full size 
at the time of tail tip biopsy, with little evidence of the internal β-catenin phenotypes, and they 
remained relatively phenotype free even following treatment with RU486 [Fig. 6.13 F]. Their 
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skin also showed very weak hyperkeratosis consistent with the continued Δp53-mediated 
inhibition of Δ3β-catenin phenotypes compared to that of wt p53 HK1.ras-K14creP.Δ3β-
catflx/wt parents [Fig. 6.13F vs. G] or older p53 heterozygous HK1.ras-K14.Δ3β-cathet/p53flx/wt 
littermates [above]. These data indicated that the tumour inhibitory responses to Δ3β-catenin 
activation appeared during development, in response to the time and degree of the cre leakage 
levels and the overall phenotypes in skin appear to depend upon the functions of p53; or 
responses to p53 loss.  
The observation that papillomas appeared in full sized mice was identical to that observed in 
HK1.ras-K14creP.Δ3β-catflx/wt [above] where full sized, score 0 mice were the only mice to go 
on to develop papilloma, as illustrated earlier in Chapter 5; although these exhibited a greater 
degree of keratosis when treated with RU486 [Fig. 6.13G].  In these instances of papilloma 
formation, the normal size of these mice, which appears independent of p53, appears to be 
required in both HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  
mice, otherwise the early responses to Δ3β-catenin activation inhibit papilloma, and now these 
results suggest that effects appear to be either independent of p53 too; or responses to loss of 
p53 give a similar effect to Δ3β-catenin overexpression [see below; p73 and 63 analysis]. 
However, a significant effect of p53 loss appeared later, as once allowed, the papillomas that 
formed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice converted to malignant SCC [Figs 6.14 









Figure 6. 13: Comparison of papillomas in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx to 
HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras papillomas suggests malignant conversion.  
 
[A-C] shows the only two examples of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice that 
developed tumours where at higher magnification [B] shows an aggressive, ovoid tumour a 
shape which   suggests papilloma conversion and [C] smaller doughnut-shaped tumour with a 
depressed centre again typical of a papilloma converting to wdSCC. [D & E] For comparison 
[left] rare HK1.ras-K14creP.Δ3β-catflx/wt papillomas remain small and [right] HK1.ras 
littermates exhibit bigger but still benign papillomas. [F] Shows that both HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice that developed tumours were full sized and lack the 
hyperkeratosis seen in [G] their age-matched HK1.ras-K14creP.Δ3β-catflx/wt equivalents. 
 
In a change to the papilloma formation observed in HK1.ras-K14creP.Δ3β-catflx/wt mice, the 
histological analysis of the larger HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumour confirmed 
that this papilloma had become malignant [Fig. 6.14 & Fig. 6.15]. That this malignant 
conversion relied on acquisition of additional mutations due to loss of the p53 genomic 
guardian roles was suggested by the fact that this tumour possessed benign papilloma 
histotypes [Fig. 6.14A&B] together with a rapid progression to more aggressive SCC [Fig. 
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6.15 C & D] and also to areas of highly invasive pdSCC [Fig. 6.15E; confirmed by K1 
expression].   
 
Figure 6. 14: Histological analysis of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours 
confirms papilloma conversion to aggressive SCC.  
[A & B] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumour [insert] shows a component of benign 
papilloma tissue evidenced by [B] at higher magnification, the ordered differentiation, lack of a 
disrupted basal layer and appearance of keratin pearls. [C-E] Alternate sections show 
malignant conversion to give [C] a mix of wdSCC and SCC; [D] more uniform aggressive 
SCC and progression to [E] poorly differentiated SCC as evidenced by the presence of highly 
invasive cells from a very disordered basal layer basal layer and the failure to differentiate 
correctly. scale bars: A C & D:100µ; B: 75µm; E: 150µm.  
 
 
A comparison of histotypes between HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  tumours and the 
small papillomas in HK1.ras-K14creP.Δ3β-catflx/wt and typical larger HK1.ras papillomas [Fig. 
6.15] showed that in these age matched tumours, already p53 loss in HK1.ras-K14creP.Δ3β-
catflx/wt .p53flx/flx  tumours possessed many areas of malignancy and the papilloma appeared 
more aggressive compared to the small size or invasiveness of HK1.ras-K14creP.Δ3β-catflx/wt 




Figure 6. 15: Histological analysis of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumour 
against HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras benign papillomas.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx displays a mix of wdSCC [left] and invasive SCC 
[right] and [B] shows benign papilloma with an ordered basal layer except in one part that 
looks like the beginnings of carcinoma in situ [ arrow]. [C] The smaller [insert] HK1.ras-
K14creP.Δ3β-catflx/wt tumour shows uniform benign papilloma with many keratin pearls 
similarly [D] a typically larger [insert] HK1.ras papilloma also shows a uniform benign 
papilloma. Scale bars: A & B:100µm; C & D: 150µm  
Analysis of β-catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours also 
suggested that the earlier benign papilloma histotypes were more aggressive, as papilloma 
histotypes already showed strong nuclear β-catenin expression but with reduced membranous 
expression in basal layers [Fig. 6.16A&B] consistent with a greater degree of papilloma 
progression due to p53 loss as indicated by their histotype [above Fig. 6.15B]. This pattern of 
expression was even present in parts of the ear hyperplasia prior to tumour formation, as it was 
already showing nuclear localization of β-catenin in all basal layer cells but with very weak 
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membranous expression [Fig. 6.16B]. Indeed, this effect was clearly demonstrated in areas of 
malignant progression [Fig. 6.16C-G] as wdSCC progressed through to SCC and further to 
pdSCC, as at each stage even stronger nuclear expression appeared with a complete loss of 
membranous β-catenin expression by the time the aggressive SCC and pdSCC stage was 
reached [Fig. 6.16D-G].   
In contrast the rare HK1.ras-K14creP.Δ3β-catflx/wt papillomas exhibited strong nuclear 
expression as well, but still maintained strong membranous β-catenin expression in basal 
layers [Fig. 6.16H], whilst HK1.ras papillomas exhibited membranous expression in mainly 
supra-basal layers with only sporadic nuclear expression [Fig. 6.16H]. This result therefore is 
in agreement with the original hypothesis, where endogenous β-catenin expression in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC was theorised to facilitate conversion and tumour 
progression after the loss of p53 expression [See chapter 3].  
With respect to E-cadherin, as outlined above, in general its expression had mirrored that of β-
catenin [above section 6.3, Fig. 6.17A B] and despite p53 loss in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice, an increased cell-cell adhesion was still maintained in basal layers by E-
cadherin expression [Fig. 6.17A&B] similar to HK1.ras-K14creP.Δ3β-catflx/wt epidermis and 
the resultant papilloma inhibition. However, in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
papillomas, E-cadherin expression appeared more like that of a typical HK1.ras hyperplasia, 
in being mainly expressed in the supra-basal layers [Fig. 6.17A vs. G]. This again repeated a 
similar observation for HK1.ras-K14creP.Δ3β-catflx/wt papillomas [Fig. 6.17A vs. H; above 
chapter 5]. This lack of basal layer expression appeared for both β-catenin and E-cadherin in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  mice destined to produce papillomas [a direct 
comparison is shown in Fig. 6.18A vs. B]. Thus, this suggests that if there was an absence of 
the responses to β-catenin deregulation in these normal sized mice due to p53 loss, the reduced 
numbers of adherence junctions may have allowed papillomas to form; and this is reflected by 
the supra-basal E-cadherin expression in most HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  





Figure 6. 16: Analysis of β-catenin expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
papilloma. 
[A & B] Early HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx ear hyperplasia displays elevated nuclear 
β-catenin expression in basal layer keratinocytes there is a clear reduction in membranous 
expression. [C-F] β-catenin expression increases as HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
tumours convert to malignancy and undergo further malignant progression [C] wdSCC/SCC 
shows mostly nuclear but some membranous expression in the invasive basal layers which 
becomes progressively less in [D] SCC and [E] pdSCC at low and [F & G] higher 
magnification shows weak to no membranous β-catenin expression. [H] HK1.ras-
K14creP.Δ3β-catflx/wt papilloma exhibits both nuclear and membranous expression; whilst [I] 
HK1.ras papillomas exhibit only membranous, supra-basal expression. Scale bars: A, C, F, G 








Figure 6. 17: Analysis of E-cadherin expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
papilloma and malignant histotypes.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours with an early pre-papilloma histotype shows 
an ear skin where membranous E-cadherin expression in the basal layers is weak to none. 
[B-F] Expression of E-cadherin in progression of HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  
tumours from wdSCC through SCC and on pdSCC. [B] Initially wdSCC/SCCs exhibit strong 
E-cadherin expression in a halo of immediate supra-basal membranous expression, but with 
less membranous expression in the invasive cells of the basal layer. [C] Similarly, aggressive 
SCC exhibits an increase set of invasive basal layer cells that express little membranous E-
cadherin. [D] Low magnification specimen of SCC and pdSCC shows a clear loss of 
membranous E-cadherin expression in the pdSCC [right; red of invasive basal layers]; 
highlighted at higher magnification in [E] SCC and [F] the edge of SCC and pdSCC. [G] E-
cadherin expression in benign HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx papilloma exhibits little to 
no membranous expression in basal layers compared to [H] HK1.ras-K14creP.Δ3β-catflx/wt 
papilloma that mainly exhibits membranous suprabasal expression but possesses strands of 
E-cadherin negative basal layers. [I] HK1.ras papilloma exhibits membranous supra-basal 







Moreover, with respect to tumour progression following p53 loss, there appears to be a very 
clear correlation between strong nuclear β-catenin expression and an increasing reduction of 
E-cadherin in the invasive basal layers that supports the collective model of tumour invasion 
(Hesse et al., 2016) via a loss of cell-cell adhesion mediated by adherence junctions [Fig. 6.17 
and Fig. 6.18]. Analysis of E-cadherin as HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx progressed 
from wdSCC through SCC and on to become pdSCC showed that initial membranous 
expression in basal layers correlated with that of nuclear β-catenin and resulted in a halo effect 
[Fig. 6.17B]. With time this strong membranous E-cadherin continued in supra-basal cells 
with less membranous expression in the invasive cells of the basal layers [Fig. 6.17C; Fig. 
6.18C vs. D; E vs. F]. On malignant progression to a more uniform SCC histology, the 
increasing numbers of aggressive invasive basal layer cells gradually expressed less 
membranous E-cadherin, but the supra-basal expression remained [Fig. 6.17C&E]. On further 
progression to pdSCC [Fig. 6.17D&F] almost complete loss of E-cadherin expression was 
observed in the pdSCC component [Fig. 6.17D right hand side].  
In contrast, as reported in Chapter 5 [Fig. 5.15] whilst the earlier HK1.ras-K14creP.Δ3β-
catflx/wt hyperplasia possessed strands of weaker basal layer E-cadherin expression, in its 
papilloma mainly membranous basal layer E-cadherin expression was observed, hence the 
lack of tumour progression [Fig. 6.17H]. HK1.ras control papillomas exhibited typical supa-
basal and membranous E-cadherin expression [Fig. 6.17I] and a lack of progression in this 
case was due to the suprabasal expression of β-catenin [Fig. 6.16I] coupled to compensatory 
p53 and p21 expression. Additionally, a direct comparison of the expression of β-catenin/E-
cadherin in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx papillomas showed the correlation between 
increased nuclear β-catenin localization with this reduced membranous expression of E-
cadherin in basal layers but the retention in suprabasal cells as tumours became invasive.  
In pre-papilloma ear skin [Fig. 6.18A vs. B], the beginnings of elevated nuclear β-catenin in 
basal layer keratinocytes appeared less membranous, and thus less E-cadherin expression 
appeared in the basal layers resulting in less cell-cell adhesion to form adherence junctions 
giving the susceptibility to form papillomas. Further, the appearance of the halo effect [Fig. 
6.18C&D] at higher magnification shows the intensity of nuclear β-catenin expression directly 
correlates with the weakened E-cadherin expression in the invasive cells and a band of strong 
E-cadherin immediately behind this invasive front. These data are constant with HK1.ras/fos-
K14creP.Δ5PTENflx/flx β-catenin/E-cadherin interactions [see Chapter 3] and the literature 
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concerning expression of β-catenin/E-cadherin in the invasive modes driving SCC carcinoma 
(Grigoryan et al., 2008; Clevers and Nussse, 2012; Hesse et al., 2016).  
 
Figure 6. 18: Comparison of β-catenin and E-cadherin expression in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx papilloma and malignant histotypes.  
[A] β-catenin and [B] E-cadherin expression in early pre-papilloma histotype shows ear skin 
where elevated nuclear β-catenin expression appears in basal layer keratinocytes with 
reduced membranous expression, whereas membranous E-cadherin expression in the basal 
layers is weak to none. [C] β-catenin and [D] E-cadherin expression in [C] malignant 
wdSCC/SCC shows strong nuclear β-catenin expression with some residual membranous 
expression in the wdSCC component that disappears in the SCC part. [D] The serial section 
of E-cadherin expression parallels this result with an increasing level of low E-cadherin 
expression as the invasive layers increase. At higher magnification [E] β-catenin and [F] E-
cadherin expression demonstrate that clear nuclear localization of β-catenin correlates with 




Analysis of the early differentiation marker K1 showed a gradually disappearing expression 
profile as HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx papillomas progressed from wdSCC through 
to SCC [Fig. 6.19A&B]. The example shown is the serial section from Fig. 6.16D and Fig. 
6.17 D that also possessed areas of hyperplasia. Thus, unlike a typical HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx epidermis [above], in this individual the hyperplasia was K1+ve; although 
expression was more reduced following p53 loss [i.e., yellow/red not green/red] compared to 
K1 expression in the earlier HK1.ras-K14creP.Δ3β-catflx/wt individuals that also went on to 
develop papillomas [Fig. 6.19C & D]. This result suggests as with their histology [Fig. 6.15B-
arrow] the hyperplasia in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx -specific epidermis was more 
transformed hence production of larger papillomas once treated with RU486 to eliminate p53 
and activate Δ3β-catenin expression consistent with the susceptibility to become malignant 
and the potential to progress to aggressive K1-ve  SCC. 
On the other hand, the hyperproliferation marker K6α again showed an overall patchy 
expression profile in serial sections that was similar to expression in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx skin that lacked papilloma and in this p53 null context, K6α expression did not 
appear until overt papilloma/wdSCC formed [Fig. 6.20A]. Indeed although SCC/pdSCC 
exhibited strong levels of K6α tumours, the actual invasive layers were K6α negative [Fig. 
6.20B] similar to the HK1.ras-K14creP.Δ3β-catflx/wt individuals but not HK1.ras papillomas 
[Fig. 6.20C vs. D]. This again links to their β-catenin/E-cadherin profiles [above] where 
abnormal presence of adherence junctions in the basal layers send incorrect signals for the 
ordered differentiation and lead to a lack of K6α expression. Here, in this example the reduced 
responses to either β-catenin or p53 loss allowed a certain level of K6α expression [Fig. 6.20 
A] consistent with a more aggressive hyperplasia [Fig. 6.15B] and this suggested this 
combination of p53 loss and β-catenin/E-cadherin profiles created a more aggressive 
papilloma [with weaker K1 expression; [Fig. 6.19A&B] prone to become malignant given the 
uniform levels of K6α observed in the SCC [Fig. 6.20B]. If so, these data also suggest that the 
aetiology of this carcinoma prone HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx papilloma was 
already different at the earliest stage in this p53 null contact compared to earlier HK1.ras-
K14creP.Δ3β-catflx/wt individuals that developed papillomas. This idea and conclusion was also 
suggested by the keratin K15 analysis which again found a lack of this stem cell marker in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx vs. HK1.ras-K14creP.Δ3β-catflx/wt papillomas [see 




Figure 6. 19: Analysis of K1 expression in converting HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx  papilloma.  
[A & B] K1 expression in a HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx papilloma with areas 
converting to wdSCC shows a fairly uniform not patchy expression but levels overall are 
reduced expression in the K1 positive hyperplasia [i.e., yellow/red not green/red]. In the 
progression to wdSCC/SCC areas K1 expression is reduced further and becomes lost in 
aggressive SCC. [C & D] Low and high magnification of HK1.ras-K14creP.Δ3β-catflx/wt 
papilloma shows a relatively normal [green/red] K1 expression profile in supra-basal layers; 
whilst [E & F] exhibit the ordered differentiation and smooth basal/supra-basal interactions of 






Figure 6. 20: Analysis of K6α expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
papilloma and carcinoma.  
[A] K6α expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx hyperplasia/papilloma now shows 
patchy expression in areas converting to wdSCC/SCC that become uniform in [B] 
SCC/pdSCC tumours; although the invasive layers are K6α negative alongside that of nuclear 
β-catenin and the halo of suprabasal E-cadherin. [C] HK1.ras-K14creP.Δ3β-catflx/wt papillomas 
exhibit strong K6α expression in suprabasal layer but again lacking in basal layers sim ilar to 
[B]; whilst [D] shows HK1.ras papillomas express K6α in both supra-basal and basal layers 
Scale bars: A- D: 150µm   
 
Thus, expression of both K1 and K6α in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx hyperplasia 
suggest that this papilloma-prone p53 null epidermis was closer to the phenotype of a typical 
HK1.ras skin. This was also suggested by the two papilloma forming HK1.ras-K14creP.Δ3β-
catflx/wt individuals, where a similar normalised expression of K1 and K6α was observed due to 
late expression of Δ3β-catenin. These data also suggest that if the inhibitory responses to β-
catenin and/or p53 loss are similarly overcome, circumvented or simply not deployed [as 
202 
 
suspected] for HK1.ras epidermis [Chapter 1; Fig. 1.7]; once a papilloma formed in these 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice it quickly converted to malignancy due to p53 
loss and lack of p21 contributed to progression.  
Furthermore, based on the odd patchy K6α expression and the K15 expression [below] it 
suggests that there is a separate type of papilloma forming from HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx hyperplasias with a greater propensity to convert to malignancy e.g., a type 2 
vs type 1 papilloma (Hennings et al., 1993; Greenhalgh et al., 1989). If so, unlike HK1.ras-
K14creP.Δ3β-catflx/wt papillomas or HK1.ras/fos- Δ5PTENflx/flx genotypes, the resultant 
wdSCCs rapidly progressed to SCC and pdSCC histotypes within the same tumour. This not 
only highlights the instability of the genome following p53 loss, but also suggest a failure in 
other genes such as p21 that were present in HK1.ras/fos- Δ5PTENflx/flx   skin to offset 
expression of nuclear β-catenin [Chapter 1 Fig. 8; Chapter 3: Figs. 3.3] and activated AKT 
(Macdonald et al., 2014) and inhibit further malignant progression.  
This proved to be the case as analysis of p21expression levels in these two individual 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   found that tumour suppresser gene p21 expression 
was already absent at the papilloma stage [Fig. 6.21 A & B]. This was also indicative of the 
rapid conversion to malignancy and the lack of protection so that WDCSS rapidly progressed 
to SCC and pdSCC [Fig. 6.21C&D]. Again in contrast, HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras benign papillomas strongly expressed p21 indicative of the benign nature of the 
tumour [Fig. 6.21 E  & F].  
Thus, at these early stages, as in HK1.ras epidermal hyperplasia, p21 was not significantly 
deployed [Chapter 1 Fig. 7], a lack of p21 in these papilloma prone HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx individuals thus now allowed papilloma formation as in HK1.ras-
K14creP.Δ3β-catflx/wt and HK1.ras skin. However, these roles for p21 did not fully account for 
the inhibition of the β-catenin phenotypes observed in the majority of HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx   mice and again observed in these two papillomas prone individuals. 
Therefore, experiment proceeded to investigate the p53 family members p63 and p73, together 






Figure 6. 21: Analysis of p21 expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
papilloma and carcinoma.  
[A] At low and [B] higher magnification an area of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
hyperplasia/papilloma shows little to no p21 expression. Similarly [C & D] HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx wdSCC/SCC have no detectable p21 expression in any layers 
compared to strong expression in [E] HK1.ras-K14creP.Δ3β-catflx/wt and [F] HK1.ras 










Table 6. 2: Summary of rare HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  papillomas 
phenotypes and conversion to SCCs  
 
Genotype analysed [N] Analysed for 
expression of 
Data summary 
HK1.ras papilloma 90 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-Control papilloma size 7-10 mm diameter 
-Exhibiting membranous β-catenin/E-cadherin expression 
mainly in the supra-basal layers with only sporadic 
nuclear/cytoplasmic β-catenin expression in basal layers 
-ordered terminal differentiation indicated by suprabasal 
layer K1 and expressing K6α in both supra and basal 
layers due to HK1.ras activation stress signal 







K6α, p53 and 
p21 
expressions 
-papilloma size 3-4 mm diameter 
-Exhibiting increased cytoplasmic/nuclear β-catenin in 
basal layers with increased membranous basal layer β-
catenin/E-cadherin due to Δ3β-catenin 
-Ordered terminal differentiation indicated by suprabasal 
layer K1 and expressing K6α mainly in supra basal layer 




catflx/wt .p53 [SCCs] 
2 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-SCCs 10mm diameter 
-Exhibit loss of membranous basal layer β-catenin/E-
cadherin expression with increased cytoplasmic/nuclear 
basal layer β-catenin 
-Reduced levels of K1 indicating conversion to 
carcinoma and strong expressing of K6α 
- loss of basal layer p21 expression as another indicator 
of conversion to malignancy 
Conclusion: Delayed phenotypes from β-catenin activation due to inducible loss of p53 in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx resulted in accelerated papillomatogenesis and conversion to SCC. 
Malignant conversion correlated with reduced basal layer focal adhesion [β-catenin/E-cadherin] and 
cytoplasmic/nuclear β-catenin driving malignant progression following additional loss of p21. These 
data indicate that p53 loss at a later stages of papilloma development facilitate conversion to SCC, 




6.5 Analysis of p63 and p73 status in HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mouse skin and tumours 
 
The HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx cohorts both 
resulted in a lack of papillomas forming in the vast majority of mice except for four outliers.  
One set developed papillomas in HK1.ras-K14creP.Δ3β-catflx/wt mice, but in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx papillomas rapidly converted to wdSCC and progressed to 
pdSCC in the same tumour consistent with their genomic instability following p53 loss. Thus, 
these few mice produced results more consistent with the literature and as originally theorised 
co-operation between ras and β-catenin activation and loss of p53 TSG function would result 
in malignant SCCs as observed in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice. 
For the majority of mice however initially the results had suggested that this paradoxical lack 
of tumours in HK1.ras-K14creP.Δ3β-catflx/wt mice was attributed to early, increased levels of 
p53 and p21, triggered via RU486-independent Δ3β-catenin expression. This maybe true in 
that context, but subsequently the p53 knockout data suggested that p53 loss in itself was not 
the cause of this tumour inhibition, but with the background knowledge that p53 loss in 
HK1.ras mice also inhibit papillomas, the possibility remains that the same inhibitory factors 
play roles in papilloma inhibition in both models. Indeed for HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx cohorts results suggests that papilloma inhibition was attributed in part to 
increased levels of p21 expression.  
These findings highlighted two necessities, one of which would involve investigating p21 
knockout in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt to 
understand the roles of p21 in these results, and experiments are on-going. However, very 
preliminary data suggests that p21 loss alone may not be the key to tumour inhibition either, as 
newly established HK1.ras-K14creP.Δ3β-catflx/wt.p21KO adults were also devoid of tumours at 
12 weeks [see below; Fig. 6.29]. Moreover, all juvenile K14creP.Δ3β-catflx/wt.p21KO or 
HK1.ras-K14creP.Δ3β-catflx/wt .p21KO  mice became score 1 [or 2]  by day 20; and none 
exhibited the delay in of Δβ-catenin phenotypes that appeared in all K14creP.Δ3β-catflx/wt 
.p53flx/flx  and HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  mice, including those individuals that 
exhibited tumours.  
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This suggests that this intriguing phenotype was specific to p53 hence, it was fortuitous that 
the second investigation of alternate p53 family members, p63 and p73, had begun to try to 
decipher the intriguing observation that in terms of differentiation, p53 loss induced responses 
that blocked these Δ3β-catenin phenotypes, and which possibly could also account [or not] for 
the inhibition of papilloma formation by these p53 family members.  
A brief review of their extensive literature shows that both p63 and p73 have important, highly 
complex functions in epidermal physiology (Koster and Roop, 2007; Crum and McKeon, 
2010; Su et al. 2013; Botchkarev and Flores, 2014). Unlike p53 itself which does not appear 
to be closely involved in development given p53 null mice develop properly (Donehower et 
al., 1992; Greenhalgh et al., 1996), both p63 and p73 have important roles in development 
and maintenance of the epidermis (Koster and Roop, 2007; Crum and McKeon, 2010; 
Botchkarev and Flores, 2014). Here for both p63 and p73 genes there are two distinct isoform 
families that have separate roles of transcription repression [ΔN] or transcription activation 
[TA]. One form lacks an amino terminus transactivating domain ΔNp63/ΔNp73 and represses 
target genes whilst the other isoforms TAp63/TAp73 activate target gene expression and the 
sets of genes regulated do not overlap to a great extent (Koster and Roop, 2007; Crum and 
McKeon, 2010; Su et al. 2013; Botchkarev and Flores, 2014). 
 
Thus, both p63 and p73 play important roles in maintaining homeostasis of epidermal 
proliferation and differentiation and most is known regarding p63 function. In the epidermis 
the dominant isoform is ΔNp63 which plays a vital role in development of the epidermis as 
shown in knockout mice. Here loss of p63 resulted in the failure of the epidermis to stratify 
and disrupted the formation of hair follicles and the development of limbs (Mills et al., 1999; 
Koster et al., 2004; Koster and Roop, 2007). These studies suggest that a role for the ΔNp63 
isoform is to maintain the basal layer proliferation, and a major role for ΔNp63 in the 
developing embryonic epidermis is geared to inhibit premature differentiation via repression 
of genes associated with differentiation including p21 and PTEN (Westfall et al. 2003; Moll 
and Slade, 2004; Nguyen et al., 2006; Leonard et al., 2011; Botchkarev and Flores, 2014), 
hence any compensatory expression of p53 backup may account for the lack of an apparent 
effect of p21KO in juvenile K14creP.Δ3β-catflx/wt.p21KO or HK1.ras-K14creP.Δ3β-





Of more significance to this Δ3β-catenin model, ΔNp63 inhibits stratification via repression of 
Notch and the induction of keratin K1 as cells commit to leave the basal layer (Koster and 
Roop, 2007; Botchkarev and Flores, 2014). This has implications for the patchy K1 observed 
in these mice and given that Notch repression results in elevated β-catenin (Powell et al., 
2006; Leigh et al., 2014; 2016), these studies begin to link the results and observations in this 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx model to the responses mediated by p53 to Δ3β-catenin 
overexpression and now to the functions of p63 and p73 family members.   
 
In respect to carcinogenesis, roles for p63 and p73 are also unclear, indeed this is such a 
complex network that much controversy exists to determine whether these genes function as 
classic TSG or possess oncogenic functions in their own right (Liefer et al., 2000; Moll and 
Slade, 2004; Mills, 2006; Koster and Roop, 2007; Koster et al., 2007; Botchkarev and Flores, 
2014). In human SCC the ΔNp63 isoform is highly expressed indicating that by this stage it 
may act as an oncogene. Consistent with this idea and its roles in maintaining proliferation and 
inhibiting differentiation [above], the ΔNp63 isoform was down-regulated in response to UV-
B, thus allowing for expression of p53 to repair mutations (Liefer et al., 2000). However, in 
transgenic mice, one study suggested a lack of a TSG role for ΔNp63 as their p63+/- mice did 
not develop spontaneous tumours even following chemical carcinogenesis (Keyes et al., 2006; 
Mills, 2006); whilst a separate study showed that p63+/- mice did develop tumours suggesting 
TSG role (Flores et al., 2005). Adding further complexity to this system transgenic mice that 
overexpress the alternate TAp63 isoform did increase the numbers of DMBA/TPA SCCs, 
indicating that some p63 isoforms function as oncogenes in the appropriate context (Koster et 
al., 2006). Further specific TAp63 knockout mice develop highly metastatic SCCs similar to 
high grade metastatic human SCC that loose expression of TAp63 suggesting that that TAp63 
is a suppressor of metastasis and again highlighting that the context of the tumour is important 
to suppression or progression (Su et al., 2010).  
 
 
For p73 few studies have actually been reported, but again given the different functions 
assigned to different isoforms it is likely that the repressive ΔNp73 and transcriptionally active 
TAp73 isoforms exert completely differing functions. For instance, some studies suggest that 
the TAp73 isoform exhibits pro-apoptotic activity giving suppressor properties (Rocco et al., 
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2006) and is activated to induce apoptosis following DNA damage (Irwin et al., 2003). It may 
be that ΔNp63 acts in an oncogenic role to inhibit TAp73-mediated apoptosis and show the 
complex interactions within this p53 family (DeYoung and Ellisen, 2007). Furthermore, whilst 
p73 is silenced in a number of tumour types through methylation, and transgenic mice 
heterozygous for p53 and p73 develop cutaneous SCC indicating TSG roles for p73 (Flores et 
al., 2005), in human cutaneous SCCs p73 remains strongly expressed indicating an oncogenic 
function (Moll and Slade, 2004). However, a major problem for these and this current study, is 
that the available p63 and 73 antibodies do not distinguish between the ΔN- or TA- isoforms.  
Therefore, against this highly complex background of close interactions between the p63 and 
p73 isoforms in both p53-dependent and p53-independent contexts the skins and 
papillomas/SCCs from HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx were analysed for p63 and p73 status.  
 
Analysis of p63 expression [Fig.6.22] in typical RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt 
skin found that strong expression was exhibited by all the anomalous hair follicles [Fig. 
6.22A&B]; suggesting that its normal roles in HF here may have been subverted by Δ3β-
catenin, given that p63 knockout results in disruption of hair follicles (Mills et al., 1999; 
Koster et al., 2004; Koster and Roop 2007). Further in the hyperplastic IFE, p63 expression 
was not only sporadic but also any nuclear expression appeared in strands of basal layer 
keratinocytes and these were clumped together and separated by larger strands of negative 
keratinocytes [ Fig.6.22A]. This suggests that these positive strands represent a niche of p63- 
regulated stem cells or perhaps a better term is the one coined by Botchkarev and Flores, 
2014, namely Keratinocyte Precursor Cells [KPCs] as these could be the precursors of transit 
amplifying keratinocytes or the precursor’s of cells about to commit to differentiate.  
 
This result would be consistent with a major role for ΔNp63 in the developing epidermis that 
inhibits premature differentiation via repression of genes associated with differentiation such 
as Notch (Koster and Roop, 2007; Crum and McKeon, 2010; Leonard et al., 2011; Botchkarev 
and Flores, 2014), and the resulting inhibition of Notch would in turn lead to increased β-
catenin expression (Proweller et al 2006). This idea thus indirectly links p63 to β-catenin 
whilst the expression of p63 in specific strands may account for the patchy K1 expression 
observed [see below]. Alternately the TAp63 isoform keeps KPC/stem cells in a quiescent 
state to avoid depletion and this provides the cells for wounding and helps suppress 
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tumorigenesis from mutated stem cells (Su et al. 2009; 2013; Romano et al. 2012). This idea 
may help account for the inhibition of papillomas as Δ3β-catenin is expressed in stem cells 
from the K14 promoter [chapter 1: Fig. 8] which also shows strands of [blue] KPC cells in the 
basal layer.  
 
In HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis the loss of p53 appears to increase the 
expression of p63 which is now elevated in hair follicles and increased in IFE [Fig. 6.22C&D]. 
Thus, again consistent with roles for p63 in normal HF development this increased expression 
of p63 may contribute to the overall lesser degree of HF anomalies observed in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx skin. Further, the increased p63 expression in the IFE not only 
appears in more strands of basal layer keratinocyte nuclei but also here p63 appears in the 
upper layers of the reduced ras associated hyperplasia and also appears in strands/block of 
expression.  
 
These results again support the idea that p63 is induced in response to p53 loss, and in this 
context given its roles in inhibiting differentiation into the suprabasal layers it may account for 
the lesser degree of hyperplasia and keratosis observed in these mice [Fig.6.22 C & D]. 
Moreover, the appearance of p63 in blocks of IFE epidermis [Fig. 6.22 D] could now account 
for both the lack of K1 expression and its abrupt disappearance in blocks of HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx IFE. This result also suggests that p63 may influence K6α 
expression in attempts to maintain order following disruption by Δ3β-catenin expression, as 
p63 mice are highly susceptible to spontaneous wounds from blistering (Mills et al., 1999; 
Westfall et al. 2003). 
 
Interestingly, neither HK1.ras nor HK1.ras-K14creP.p53flx/flx hyperplasia exhibited p63 
expression [Fig. 6.22E&F]. This indicates this p63 response appears specific to Δ3β-catenin 
expression and that ras activation appears to actually repress p63-hence the relatively normal 
differentiation observed and the general degree of increased hyperplasia. This result [as with 
p73 below] suggests that the inhibitory responses to p53 loss that inhibit HK.ras.p53flx/flx  
papilloma formation are separate to those  observed in these Δ3β-catenin models, and further 





Figure 6. 22: Analysis of p63 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx epidermis.  
[A] Low and [B] higher magnification of composite images shows that a typical RU486-treated 
HK1.ras-K14creP.Δ3β-catflx/wt exhibits strong follicular expression of p63 in the anomalous 
HFs. In the hyperplastic IFE p63 expression appears only sporadic, with nuclear expression 
appearing in strands of basal layer nuclei but clumped together [arrows] more prominent at 
higher magnification. [C & D] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx exhibits increased p63 
expression in most basal layer keratinocytes and in the lesser transformed HFs at higher 
magnification. In addition, p63 appears in the upper layers of the reduced ras associated 
hyperplasia and also appears in strands/block of expression. [E] HK1.ras and [F] HK1.ras-
K14creP.Δp53flx/flx hyperplasia both exhibit weak, if any expression of p63 in the IFE and little 




Analysis of p73 suggested that it plays an even greater role to both help combat co-expression 
of HK1.ras and Δ3βcatenin and moreover compensate for p53 loss particularly in the 
inhibition of the early Δ3β-catenin phenotypes of juvenile HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice [Fig. 6.23]. In comparison to HK1.ras-K14creP.Δ3β-catflx/wt skin, p73 
expression was similar and strongly expressed in the transformed HFs yet in the hyperplastic 
IFE, p73 expression appeared more closely associated with keratinocytes emerging from the 
HFs [Fig.6.23 A & B; arrows]. This again is consistent with p73 roles in general epidermal 
development and the localisation to keratinocytes emerging from HFs is very interesting as it 
may reflect roles for the TAp73 isoform in regulating HF bulge stem cell decisions to enter 
anagen as its ablation stops follicle formation (Rufini et al., 2012). Thus, here it would help 
combat the deregulated Δ3β-catenin expression in juvenile epidermis as the first hair cycle 
begins. Also, this TAp73 depletion accelerates cellular aging and this links to a return to the 
theme that Δ3β-catenin expression may return an epidermis to an earlier neonatal/juvenile 
state (Collins et al., 2011) as explored further in vitro [see Chapter 8]. 
However, the most striking increase in p73 expression appeared in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx skin [Fig.6.23 C & D]. Here significant levels of increased p73 expression 
appeared in most basal layer keratinocyte nuclei and now p73 was very strongly expressed in 
the HFs. Closer examination of the IFE shows that again p73 also appears in the suprabasal 
layers and few strands/block of negative expression are observed [Fig.6.23 D]. In contrast 
HK1.ras and HK1.ras-K14creP.p53flx/flx hyperplasia lacked such compensatory p73 expression 
[Fig. 6.23E&F]. It also again supports the idea that inhibitory responses to p53 loss that inhibit 
HK.ras-K14creP.p53flx/flx papilloma formation are separate to those observed in these Δ3β-





Figure 6. 23: Analysis of p73 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx epidermis.  
[A] Low and [B] higher magnification of RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt skin 
shows strong p73 expression transformed HFs and also appears in the hyperplastic IFE but 
in occasional strands close to the HFs [arrows]. [C & D] HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx exhibits greater levels of p73 expression in most basal layer keratinocytes and 
also in the lesser transformed HFs. p73 expression appear in the suprabasal layers and also 
appears in most keratinocytes with few strands/blocks of negative expression. [E] HK1.ras 
and [F] HK1.ras-K14creP.p53flx/flx hyperplasia both exhibit weak, if any expression of p73 in 
the IFE or normal HFs. Scale bars: A, & C:100 µm; B & D-F: 75 µm.  







These results show that p73 isoform expression was far more effective in blocking Δ3β-
catenin phenotypes in juvenile skin following p53 loss than p63 isoforms. This is consistent 
with the roles often assigned to p73 in terms of pro-apoptotic TSG functions alongside those 
of p53 (Rocco et al., 2006; DeYoung and Ellisen, 2007). It is also consistent with the idea that 
β-catenin expression had to become basal before the p53 family members reacted to its 
anomalous expression; i.e. this p73 response was again β-catenin specific and the absence of 
basal layer β-catenin in HK1.ras or HK1.ras-K14creP.p53flx/flx hyperplasia resulted in a lack of 
compensatory p73 [and p63] expression. If so, this has significant implications for 
papillomatogenesis inhibition and may account for p73 appearance in human SCCs (Moll and 
Slade, 2004; DeYoung and Ellisen, 2007) following Notch repression by ΔNp63 (Koster and 
Roop, 2007; Botchkarev and Flores, 2014) thus resulting in β-catenin overexpression and 
invasive E-cadherin negative keratinocytes as observed in this current model [below]. 
This may be the case, given the results in the rare HK1.ras-K14creP.Δ3β-catflx/wt papillomas 
and the progression to SCC in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice for p63 and p73 
expression as shown in Fig.6.24 and Fig.6.25. Analysis of p63 in HK1.ras-K14creP.Δ3β-
catflx/wt papillomas showed weak basal layer expression [Fig. 6.24A&B]. Given that this was 
also paralleled by both p53 and p21 [above Chapter 5] hence any potential oncogenic 
properties of say the ΔNp63 isoform in conjunction with β-catenin[above] were successfully 
combatted by compensatory p53 and p21 expression [ Chapter 5]. However, following p53 
loss in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours, p63 expression appeared to become 
stronger and more uniform [Fig. 6.24C&D] as tumour progressed and this does indeed suggest 
an oncogenic property of  the ΔNp63 isoform in that it is known to down regulate p21 (Koster 
and Roop, 2007; Botchkarev and Flores, 2014) and this maybe the reason that HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx tumours were devoid of p21 expression and this contributed to 
their rapid progression to SCC. This idea would also be supported by the findings that 
HK1.ras papillomas now showed similar but weaker p63 expression [Fig. 6.24E&F] than both 
sets of Δ3β-catenin papillomas, suggesting that p53 and p21 reacted to ras activation, but in 




Figure 6. 24: Analysis of p63 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx tumours.  
[A & B] HK1.ras-K14creP.Δ3β-catflx/wt papillomas show weak expression of p63 in basal 
layers. [C & D] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours a mix of papilloma and 
wdSCC now show stronger expression of p63 than A or B consistent with their malignant 
progression and potential oncogenic roles of any ΔNp63 isoform expression. [E & F] HK1.ras 
papilloma now also shows elevated expression of p63. Scale bars: A, C & E: approx. 100 µm; 
B: 50µm; D&F: 75µm 
  
Analysis of p73 in HK1.ras-K14creP.Δ3β-catflx/wt papillomas displayed strong expression in 
the proliferative basal layers [Fig. 6.25A&B] supporting its anti-tumour roles alongside that of 
p53, which may also inhibit ΔNp63 functions to prevent conversion as seen in Fig.6.24. 
However, whilst HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours showed a more intense p73 
expression profile in the papilloma/wdSCC tumour in response to p53 loss [Fig. 6.25C&D] it 
may be that the TSG functions are now uncoupled by ΔNp63 functions and p21 loss. As 
outlined above this observation may reflect p73 appearance in human SCCs (Moll and Slade, 
2004; DeYoung and Ellisen, 2007) following Notch and p21 repression by ΔNp63 (Nguyen et 
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al., 2006; Koster and Roop, 2007; Botchkarev and Flores, 2014) and results in fully 
deregulated β-catenin overexpression. Thus, despite p73 expression, the resulting lack of p21 
[and possibly PTEN] (Botchkarev and Flores, 2014), coupled to nuclear βcatenin and the E-
cadherin profile of halos of negative keratinocytes all combine to facilitate invasion as 
observed in this HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours context. For HK1.ras 
papillomas the relatively small and sporadic increase in p73 [Fig. 6.25E&F] again probably 
reflects the fact that HK1.ras papillomas carry little basal layer β-catenin even following p53 
loss, unlike the equivalent HK1.ras/fos-K14creP.Δ5PTENflx/flx tumours [Chapter 3].  
 
Figure 6. 25: Analysis of p73 expression in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx tumours.  
[A & B] HK1.ras-K14creP.Δ3β-catflx/wt papillomas show strong   uniform p73 expression in all 
basal layers. [C & D] In HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumors both papilloma and 
wdSCC show even stronger p73 expression consistent with responses attempting to 
compensate for both p53 and p21 loss. [E & F] HK1.ras papilloma shows only sporadic 
expression of p73 in strands of basal layer keratinocytes. Scale bars: A, & C: 100 µm; B, D & 




6.6 Analysis of keratin K15 in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx skin show stem cell changes and an alternate 
tumour aetiology. 
 
Taken collectively the above observations clearly link Δ3β-catenin overexpression in the 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx model to the responses mediated by p53/p21 and now 
to the functions of p63 and p73 family members. Studies also show that major roles for p63 
and p73 focus on regulation of stem cell activities, and the interesting findings that p63 and 
p73 were expressed in strands or blocks of basal cell keratinocytes suggested that these 
positive strands represent a niche of p63/73 regualted IFE stem cells. Indeed, supporting this 
idea, the putative non-oncogenic TAp63 isoform keeps KPC/stem cells in a quiescent state to 
both avoid their depletion and suppress tumorigenesis from a continual supply of mutated cells 
(Su et al. 2009b; 2013; Romano et al., 2012); whilst the TAp73 isoform appears to control HF 
bulge stem cells (Rufini et al. 2012) and these are clearly affected by anomalous changes in β-
catenin and E-cadherin expression (Gregorian, et al., 2008; Jeanes et al., 2008). Given the 
emerging complexity of numerous stem cell niches within the epidermis (Watt and Collins, 
2008) perhaps a better definition of these cells is keratinocyte precursor cells [KPC], as 
defined in the review by Botchkarev and Flores, 2014, as this broader definition can include 
the precursors of transit amplifying keratinocytes about to commit to differentiate.  
 
The idea that anomalous β-catenin may alter specific KPC populations in the epidermal stem 
cell unit also came from the K1 data, which showed not only weaker and patchy expression 
[now consistent with p63 expression] but also the blocks of p63 would be consistent with the 
abrupt lateral edges to both K1 and on occasion K6 expression made by specific stem cell 
units in the IFE. This feature of K1 expression appears to be a significant marker of the altered 
differentiation caused by deregulated β-catenin expression and the increased numbers of 
adherence junctions due to excess E-cadherin. As suggested above [Chapters 4 and 5], the 
resultant increase in rigidity may feedback to alter the commitment to the early stages of 
differentiation as keratinocyte migrate from the different epidermal stem cell niches (Watt and 
Collins, 2008). In addition, effects from compensatory p21 expression that appeared 
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particularly strong in the upper layers of the epidermis particularly following p53 loss [Fig. 
6.12] are also known to help regulate stem cell decisions to proliferate and differentiate 
(Topley et al., 1999).  
Hence one possibility to explain the differences in papilloma formation in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt vs. HK1.ras may centre on 
the lack of p53/p63/p73 and p21 responses in HK1.ras hyperplasia given its lack of expression 
in HF bulge region keratinocytes [Chapter 1: Fig.3B]. Here, this provides the KPC population 
targets for papilloma formation (Li et al., 2013); whilst in reverse the responses to Δ3β-catenin 
activation in p53wt or p53flx possibly protect the KPC populations via maintaining their 
quiescence [see mitotic index analysis below] and at this very early stage there is a lack of 
potential papilloma forming cells due to protection form combinations of p53 and p21 backed 
up when necessary, by p63 and p73 and resultant anomalous differentiation.  
To begin to address this idea, expression of keratin K15 was assessed in HK1.ras-
K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  genotypes [Fig. 6.26 and Fig. 
6.27] as it has been regarded as a stem cell marker (Bose et al., 2013); and its promoter is 
regularly employed to target gene expression/KO to bulge region stem cells (Liu et al., 2003) 
to model the effect of HF stem cell mutation in development of SCCs (Chen et al., 2020). 
Keratin K15 is also normally expressed in the basal layer of IFE (Bose et al., 2013), thus, this 
role as a stem cell marker appears inconsistent with its expression in the proliferative basal 
layers. However, much evidence supports K15 as a marker of stem/KPC cells at some point, 
as K15 is strongly expressed in bulge region keratinocytes (Lyle et al., 1998) and bulge cells 
that express a K15-promoter driven reporter gene reconstituted the entire epidermis with 
positive cells (Liu et al 2003; Morris et al., 2004). Also, K15 positive cells are also positive 
for the Lgr5 epithelial stem cell marker (Jaks et al., 2008); but unfortunately, in this Δ3β-
catenin study, preliminary experiments that assessed Lgr5 [and Lgr6] gave very unclear results 
as the antibodies employed are suspected to cross react with alternate proteins in the 
epidermis.  
 
It may be that the basal layer K15 expression observed in human tumours may reflect the 
KPCs with their proliferative potential within the transit amplifying cells given that in human 
skin cancer, K15 expression actually increases in BCCs (Jih et al., 1999; Abbas and Bhawan, 
2011) in a role thought to echo its stem cell role that helps maintain an epithelial lineage and 
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not progress to undergo metastasis or EMT[epithelial-mesenchymal transition] (Bose et al., 
2013). In SCCs, K15 expression appears and is then lost (Abbas and Bhawann, 2011) 
consistent with their de-differentiation and loss of K1 (Porter et al., 2000) and regulator 
control [p21/p53p63/p73 above].  
 
Of interest to this study and consistent with β-catenin deregulation, was the fact that K15 was 
strongly expressed in human HF tumours (Jih et al., 1999). Also, in DMBA/TPA chemical 
carcinogenesis studies an initial burst of K15 expression would be consistent with 
amplification of a mutant stem cell population [that escape the p63/p73 control] and was later 
lost on progression to overt papilloma (Troy et al., 2011). However, Morris and co-workers 
showed that in labelling studies using the same RU486 gene switch and the K15 promoter 
crossed to the Rosa 26 β-gal reporter gene [Krt1-15CrePR1;R26R] the continued presence of 
keratinocytes derived from K15 positive stem cells persisted for many months (Li et al., 
2013). This was again consistent with initiating DMBA mutations of K15 positive HF stem 
cells that gradually loose this marker as they distance themselves from the stem cell niche; but 
perhaps gain a cancer stem cell phenotype in the K15/β-gal positive papilloma cells destined 
to become SCC. Intriguingly, the fact that not all papilloma cells expressed this reporter shows 
their heterogenicity (Li et al., 2013), a result consistent with one of the ideas from above, that 
rare papillomas in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
genotypes derive from different cells than that of typical HK1.ras papillomas.  
 
In both HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mouse skin, 
K15 analysis showed strong expression, mainly confined to the anomalous hair follicles [Fig. 
6.26]. Closer inspection also showed that K15 was more strongly and more uniformly 
expressed in the more transformed HFs of HK1.ras-K14creP.Δ3β-catflx/wt skin [Fig. 6.26A] vs. 
the lesser Δ3β-catenin HF phenotypes of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx [Fig. 6.26B]. 
This result would be consistent with the high K15 levels observed in human folliculoma (Jih 
et al., 1999) and also differences in K15 expression may reflect the expression of higher 
follicle levels of p21, p63 and especially p73 recorded following p53 loss [above]. 
The lack of K15 expression in IFE of HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx was somewhat unexpected, given the roles of β-catenin in 
maintaining hair follicle stem cell proliferations and their differentiation which are essentials 
for epidermal homeostasis (Watt and Collins, 2008; Närhi et al., 2008; Grigoryan et al., 
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2008). Therefore, overexpression of β-catenin was assumed to exhibit a more positive 
influence on the migration of K15-positive stem cells out of the HF and into the IFE basal 
layer- as suggested by the p73 expression profile which was associated with follicles in 
HK1.ras-K14creP.Δ3β-catflx/wt hyperplasia [above Fig. 6.23A&B]. However, instead Δ3β-
catenin expression has clearly had the opposite effect and interfered with the normal stem cell 
niches in a different manor. This too would reflect roles of p21, p63 and p73 in regulating 
these niche populations and attempts by p63 and p73 to keep the stem cells quiet and thus this 
K15 expression profile reflects these responses.  
Further this lack of IFE K15 expression may show a lack of appropriate stem/KPC target cells 
for HK1.ras activation hence the lack of papillomas as the greater HK1.ras hyperplasia 
showed strong expression in IFE basal keratinocytes [Fig. 6.26C], as did the HK1.ras/p53flx/flx  
epidermis again suggesting the blockage of papillomas was different in these two models [Fig. 
6.26A&B vs. C&D] and combined that the eventual papilloma aetiology may derive from 
different keratinocyte populations, as observed in DMBA/TPA papillomas (Li et al., 2013).  
In respect to carcinogenesis, K15 expression showed a basal layer expression in both HK1.ras-
K14creP.Δ3β-catflx/wt papillomas and in the papilloma histotypes of HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx tumours [Fig. 6.27A,B&D], whilst the SCC lacked K15 expression as did  
typical HK1.ras papillomas [Fig. 6.27C,E&F]. A closer inspection shows that the strong K15 
expression was strictly confined to specific strands of basal layer HK1.ras-K14creP.Δ3β-
catflx/wt papilloma keratinocytes, but the benign papilloma histotype in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice exhibited strong basal layer expression in some areas but it was beginning 
to fade in others. Also, expression appeared multi-layered as in HK1.ras hyperplasias [Fig. 
6.26C] and not confined to the basal layer keratinocytes suggesting the beginnings of 
conversion [Fig.6.27A, B vs. D]. In the serial sections that comprised hyperplasia papilloma 
and SCC histotypes K15 was already lost and was also not present in the hyperplasia 
suggesting it may never have been induced and any residual minimal K15 expression was 
erratic and appeared in several layers [Fig.6.27C]. At this stage, [12wks] HK1.ras papillomas 








Figure 6. 26: Analysis of keratin K15 expression in HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin.  
[A & B] K15 expression in [A] HK1.ras-K14creP.Δ3β-catflx/wt and [B] an older patch of RU486-
treated keratotic HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin is strong but confined to the hair 
follicle. [C] HK1.ras and [D] HK1.ras-K14creP.p53flx/flx hyperplasia show strong expression in 









Figure 6. 27: Analysis of keratin K15 expression in rare HK1.ras-K14creP.Δ3β-catflx/wt 
and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours.  
[A & B] The two RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt papillomas show strong K15 
expression in specific strands of basal layer keratinocytes where K15 is also confined to 
basal layers. [C] The HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx lacks K15 expression in the mix of 
hyperplastic, papilloma and SCC histotypes; and this minimal expression appears erratic and 
supra-basal. [D] At higher magnification, benign papilloma histotype of the HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx tumour exhibits strong basal layer expression similar to [A & B]; 
but this is beginning to fade and of note the expression is wider and not confined to the basal 
layer keratinocytes. [E & F] By this time [12wks] HK1.ras papillomas are larger and 
completely lack the K15 expression observed in earlier hyperplasia. Scale bars: A, & B: 150 
µm; C & D: 75 µm. 
  
These K15 expression data again suggest that the reduced leakage and later Δ3β-catenin 
expression again allowed for K15 to be expressed in the HK1.ras-K14creP.Δ3β-catflx/wt 
papilloma keratinocytes as observed in chemical carcinogenesis and a general lack of the early 
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inhibitory p63/p73 or p21 responses as observed in HK1.ras alone hyperplasia given that β-
catenin expression remained supra-basal. However, following p53 loss in HK1.ras-
K14creP.Δ3β-catflx/wt .p53flx/flx  mice this leads to unstable areas when coupled to nuclear and 
membranous β-catenin expression [above], where either K15 is missing or in the papilloma 
stage, the sporadic low K15 expression is multi-layered as seen in HK1.ras hyperplasia. Thus, 
as seen in human SCC (Abbas and Bhawan, 2011) and late-stage chemical papillomas (Troy et 
al., 2011), K15 expression becomes reduced and lost. 
Furthermore, the different K15 expression profiles between papillomas developed with Δ3β-
catenin activation compared to typical HK1.ras papillomas, again indicate that in HK1.ras-
K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   mice their papillomas carry 
different characteristics and thus may derived from different KPC/stem cell niches particularly 
since the HK1.ras transgene is not expressed in HFs. These results are therefore consistent 
with the findings by Morris and co-workers who showed that in cell labelling studies using the 
K15-promoter crossed to the Rosa 26 β-gal reporter mouse (Li et al., 2013) whilst many 
papilloma cells derived from K15-positive precursors, many papilloma keratinocytes were β-
gal negative, a result consistent with multiple mutations in many KPC types derived from 
DMBA initiation indicating the overall potential heterogeneity of papillomas as observed here 
[Fig. 6.27A,B vs. D] and their different progression potential [Fig. 6.27C].     
Finally, following these findings of compensatory p53 family responses and the excess 
expression of p21 coupled to these changes in the K15 KPC/stem cell marker, the effect of 
early Δ3β-catenin, βcatenin was also assessed in keratinocyte proliferation employing the 
standard BrdU labelling analysis [Fig.6.28].  This was used to assess whether reduced 
proliferation in the tumour free HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice reflected the p63/p73 and p21 responses and this contributed to and was 
the possible reason for the reduced hyperplasia observed or even the overall lack of tumours.  
This proved to be the case as in early untreated and RU486-treated HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice [n1] [Fig. 6.28A&B], the result showed a lower mitotic index of 10.20 [+/- 
2.5] compared to HK1.ras-K14creP.Δ3β-catflx/wt mice [n1] [Fig. 6.29C] at 19.6 [+/- 1.1]  or 
HK1.ras [n1] mice [Fig. 6.28D] with an index of 20.2 [+/- 5.5] comparable to previous studies 
(Yao et al., 2006; 2008; Macdonald et al., 2014 ). Although this experiment was conducted 
qualitatively due to technical error in mice BrdU injection, these proliferation results were 
consistent with the reduced hyperplasia observed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
following p53 loss when compared to HK1.ras-K14creP.Δ3β-catflx/wt or HK1.ras IFE 
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hyperplasia. For HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis this result probably reflects 
the increased expression of p21, p63 and p73 in the context of Δ3β-catenin overexpression and 
all targeted to protect the epidermis following the additional loss of p53 mediated cell cycle 
control. 
 
Figure 6. 28: BrdU labelling analysis of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin 
indicates a lower mitotic index compared to HK1.ras-K14creP.Δ3β-catflx/wt skin. 
Quantitation of BrdU labelling from the four genotypes is based on counts averaged from 8 
fields to give a mitotic index of: [A & B] HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx (n1): 10.20 [+/- 
2.5] cell per mm basement membrane. [B] HK1.ras-K14creP.Δ3β-catflx/wt (n1): 19.6 [+/- 1.1] cell 
per mm basement membrane; [D] HK1.ras (n1): 20.2 [+/- 5.5] cell per mm basement 
membrane and [E] normal epidermis (n1): 3.70 cell per mm basement membrane. Scale 
bars: A-D: 75 µm; E: 50 µm. 
  
When coupled to the K15 data, it also suggests that Δ3β-catenin alters the stem cell niches 
such that there may be reduced numbers of KPC targets for papilloma formation; an idea 
supported by the lack of these responses in all four mice that to date develop papillomas and 
those two that were prone to convert. This also applies to the similar lack of p53/p63/p73 and 
p21 responses observed in HK1.ras hyperplasia given its lack of expression in HF bulge 
region keratinocytes [Chapter 1: Fig.3B]. Hence, this change in potential KPC population 
targets for papilloma formation (Li et al., 2013) highlights that papillomas formed come from 
different cell types including those arising in Δ3β-catenin activation in p53wt or p53flx contexts 
as these have to overcome the p21/p53 and/or p63/p73 responses that normally protect theses 
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KPC populations that do not appear at this stage in HK1.ras mice but appear later to prevent 
their progression to SCC. 
6.7 Preliminary analysis of p21 knockout in HK1.ras-K14creP.Δ3β-catflx/wt 
mice  
The data from HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   
cohorts analysis clearly implicated p21 roles in multiple aspects such as inducing commitment 
to differentiation, halting tumor development and possibly maintaining KPC. Thus to directly 
assess these roles on-going experiments directly induced p21 loss via embryonic knockout 
(Martín-Caballero et al., 2001) to create the K14creP.Δ3β-catflx/wt.p21KO and HK1.ras-
K14creP.Δ3β-catflx/wt.p21KO genotypes.  
The preliminary data again demonstrated a lack of tumour formation in all HK1.ras-
K14creP.Δ3β-catflx/wt.p21KO mice at 12 weeks of age [Fig.6.29: A & B] similar to that 
observed in  HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  and HK1.ras-K14creP.Δ3β-catflx/wt  mice 
[Fig. 6.29C&D]. However, all litters of K14creP.Δ3β-catflx/wt.p21KO or HK1.ras-
K14creP.Δ3β-catflx/wt.p21KO mice became score 1 [or 2] and by day 20, showed the typical 
Δβ-catenin phenotypes in all adult mice [Fig.6.29: E & H] including the associated keratosis 
and scruffiness observed in HK1.ras-K14creP.Δ3β-catflx/wt littermates [Fig. 6.29G&J]. To date 
none of these K14creP.Δ3β-catflx/wt.p21KO or HK1.ras-K14creP.Δ3β-catflx/wt.p21KO 
individuals exhibited a delay in the onset of Δβ-catenin phenotypes that appeared in all 
K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice [Fig. 6.29F&I].  
These preliminary data clearly indicate that blocking tumour development was not dependent 
on p21 protection in at least the early stages of tumour development. Instead possibly the 
importance of p21 expression comes in once a tumour is formed, or even once it has converted 
to early malignancy, as losing p21 expression at that stage was associated with rapid 
progression to more invasive carcinomas as seen above in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx SCC and HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC (Macdonald et al., 2014).  
These data also indicate that delay in the onset of Δβ-catenin phenotypes depended upon p53 
responses as HK1.ras-K14creP.Δ3β-catflx/wt.p21KO and HK1.ras-K14creP.Δ3β-catflx/wt 
phenotypically look indistinguishable from each other. However, these are initial observations 
and more analysis needs to be conducted on these mice to establish the similarly and 
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differences in protein expression to the loss of p21 in HK1.ras-K14creP.Δ3β-catflx/wt .p21KO 
,HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx . 
 
Figure 6. 29: HK1.ras-K14creP.Δ3β-catflx/wt.p21KO genotypes lack papilloma formation.  
[A & B] At 8 weeks post ear-tag wounding shows RU486-treated tagged HK1.ras-
K14creP.Δ3β-catflx/wt.p21KO lack any sign of tumour development as observed in [C] RU486-
treated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx . [D] HK1.ras-K14creP.Δ3β-catflx/wt tagged ear at 
8 weeks post ear-tag wounding also lacks tumour development. [E-G] shows typical keratosis 
of Δ3β-catenin in [G] HK1.ras-K14creP.Δ3β-catflx/wt.p21KO compared to greatly reduced 
keratosis in [F] HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx , and the typical Δ3β-catenin keratosis 
in [G] HK1.ras-K14creP.Δ3β-catflx/wt. [H-J] A contrast between the differences in keratosis in 
[H] HK1.ras-K14creP.Δ3β-catflx/wt .p21KO , [I] HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  and [J] 





Table 6. 3: Summary of p63, p73 and keratin K15 status in HK1.ras-K14creP.Δ3β-catflx/wt 
and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mouse phenotypes 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 
HK1.ras hyperplasia 90 p63,p73,K15, 
BRDU 
labeling 
-No basal layer p63/p73 expression 
-Expressing K15 in both basal and supra-basal 
layers 






22 p63, p73,K15 -No basal layer p63/p73 expression 
-Expressing K15 in both basal and supra-basal 
layers 
 HK1.ras-K14creP.Δ3β-




-Sporadic p63/p73 expression in basal layer with 
HF expression 
-K15 expression confined to HF 









-Increased basal layer expression of p63/p73 with 
HF expression 
-K15 expression confined to HF 
- Mitotic index: 10.20 [+/- 2.5] cell per mm 
basement membrane 
 
Conclusion: β-catenin activation triggered compensatory p63/p73 TSG expression in efforts to possibly 
regulate incorrect control of the stem cell niche and consequently the IFE terminal differentiation 
especially with p53 loss, as stem cell marker K15 was not present in the IFE, contrary to the control 
hyperplasia due to elevated p63/p73. This elevation coupled to p53/p21 or p21 consequently resulted in 









Table 6. 4: Summary of p63 and p73 status in HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx   tumours. 
Genotype analysed  [N] Analysed for 
expression of  
Data summary 
HK1.ras papilloma 90 p63, p73, K15 -Basal layer expression of p63 and sporadic, 
basal layer expression of 73  




2 p63, p73, K15  -Weak basal p63 expression and increased 
p73 basal layer expression 
-Basal layer K15 expression 
 
HK1.ras-K14creP.Δ3β-
catflx/wt .p53flx/flx  SCCs 
2 p63, p73, K15 -Increased basal layer expression of both 
p63/p73  
-Basal layer K15 expression 
 
Conclusion: elevated expression of p63/p73 in HK1.ras-K14creP.Δ3β-catflx/wt p53flx/flx SCCs is consistent 
















6.8.  SUMMARY    
 
The previous chapters illustrated the impact of constitutive β-catenin activation [K14creP.Δ3β-
catflx/wt] on epidermal homeostasis and regulation of hair follicle formation as well as different 
body organs such as extremities [feet and tail]. All the K14creP.Δ3β-catflx/wt  data were 
generally in agreement with the literature (Närhi et al., 2008; Grigoryan et al., 2008) in terms 
of HF anomalies, yet even in score 2 skin there was a relatively weak degree of hyperplasia as 
also seen previously (Gat et al., 1998; Celso et al., 2003) and in that context this was now 
shown to be due to early elevated levels of p53/p21 TSGs expression that inhibited Δ3β-
catenin induced proliferation and altered the keratinocyte differentiation programme [Chapter 
4]. 
In Chapter 5, HK1.ras-K14creP.Δ3β-catflx/wt mice demonstrated a paradoxical block of 
papillomatogenesis except in two cases of full-sized mice where papillomas appeared and 
maintained a benign histotype when biopsied. Thus, indicating that in a model more consistent 
with what was expected for β-catenin and ras co-operation, here again expression of p53/p21 
was so strongly present in HK1.ras-K14creP.Δ3β-catflx/wt papillomas, that Δ3-βcatenin was 
unable to induce conversion; a result consistent with findings in HK1.ras/fos papillomas where 
β-catenin expression remained supra-basal. This expression of p53 and p21 was also assumed 
to result in the blockage of tumour forming in vast majority of mice, as in these cohorts the 
leakage of Δ3β-catenin resulted in pronounced p53 and p21 expression in the IFE thus 
preventing papillomas forming.  
The influence of Δ3β-catenin-mediated compensatory p53/p21 expression on the fate of 
papillomas forming was clearly apparent when IFE hyperplasia invoked high levels of 
p53/p21 that were not observed in HK1.ras controls, which eventually develop benign 
papillomas in 100% of mice. This indicted that in this context of HK1.ras-K14creP.Δ3β-
catflx/wt mice, such compensatory p53/p21 expression halted the proliferation needed for 
papilloma development and whilst the disordered differentiation indicated by aberrant K1/K6α 
expression also suggested a contribution to tumour inhibition in this context of wtp53/p21.  
Thus, to validate this theory, a logical approach induced conditional p53 knockout first in 
K14creP.Δ3β-catflx/wt  genotypes and then in HK1.ras-K14creP.Δ3β-catflx/wt to understand p53 
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roles in these contexts. However, the results indicated that in this new context HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx genotype not only was p53 loss unable to induce papillomas 
[except on two occasions discussed below], but also the juvenile skin data of K14creP.Δ3β-
catflx/wt.p53flx/flx mice demonstrated that the Δ3β-catenin phenotypes were directly dependent 
upon wild type p53 function. Both K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx   mice grossly lacked typical Δ3β-catenin hyperkeratosis and with minimal 
effect on body size and extremities. Histologically K14creP.Δ3β-catflx/wt.p53flx/flx, at 3 weeks 
[~24d], mice appeared fairly normal and exhibited few to none Δ3β-catenin phenotypes; 
whilst at 8 weeks showed a mild level of Δ3β-catenin phenotype with a lack of hair follicle 
tumours such as folliculoma frequently seen in K14creP.Δ3β-catflx/wt mice (Gat et al., 1998; 
Celso et al., 2003). This clearly implicated p53 roles in both the appearance and the intensity 
of Δ3β-catenin phenotypes as well as in the follicular tumours associated with Δ3β-catenin 
overexpression and prevented the internal problems that have dogged this project in terms of 
animal viability.  
The reasons for this unique and potent block of Δ3β-catenin phenotypes by p53 loss are again 
very unclear but this does appear to be a very important finding and as discussed below the 
p63 and p73 data suggest that it may be expression responses to p53 loss that also altered 
keratinocyte proliferation/differentiation that possibly had major effects on the stem cell /KPC 
populations that reduced or countered the effects of deregulated β-catenin to some extent and 
thus the numbers of pluripotent targets for ras activation and β-catenin overexpression. 
There are strong links between p53 and β-catenin and during embryonic development p53 has 
been found to normally regulate embryonic stem cell proliferation via the β-catenin dependent 
canonical Wnt signalling among other pathways (Lee et al., 2010). This canonical Wnt 
signalling also regulates embryonic epidermal stem cell proliferation required for hair follicle 
morphogenesis and epidermal differentiation (Grigoryan et al., 2008). Thus it may be that 
deregulated overexpression of Δ3β-catenin during juvenile development which results in de 
novo hair follicle placodes and hair follicle tumours as well as effects on general body size and 
limbs, requires a competent p53 system to sense the problems caused, as observed in 
K14creP.Δ3β-catflx/wt cohorts (Gat et al., 1998; Van Mater et al., 2003;Grigoryan et al., 2008) 
[see Chapter4] and these responses in K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx  are lacking.  
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Indeed, from this it can be speculated, that in developing juvenile K14creP.Δ3β-catflx/wt  
genotypes [and the internal problems], it is the overexpression of p53 in response to Δ3β-
catenin that plays an unavoidable role in the induction of phenotypes. Here, in this context, a 
feedback loop maybe established where elevated p53 activates the canonical Wnt signalling 
receptors to alter the stem cell niches which induce anomalous 
proliferation/differentiation/cysts/and HF anomalies via adding heterozygous endogenous β-
catenin expression to that of Δ3β-catenin activation resulting in typical Δ3β-catenin 
phenotypes (Gat et al., 1998; Niemann et al., 2002Van Mater et al., 2003; Grigoryan et al., 
2008; Lee et al., 2010; Kretzschmar et al., 2015). Thus, it appears that p53 was necessary for 
Δ3β-catenin by activating Wnt receptors to proliferate embryonic stem cells,  
If this scenario of elevated p53 expression in K14creP.Δ3β-catflx/wt induced the excess HF 
proliferation (Song and Lambert, 1999; Botchkarev et al., 2001) and p53 loss led to general 
regression in HF development, it would explain to some extent why these mice had more 
alopecia and scruffiness, whilst K14creP.Δ3β-catflx/wt.p53flx/flx had less p53-mediated responses 
available resulting in a more normal looking hair follicle and bigger body size as seen in 
histology and gross phenotype analysis. The other aspect of this scenario may be more logical, 
on considering the actual general responses mounted by the epidermis to loss of potent 
protection which could be the cause for the striking reduction in the appearance and the 
intensity of Δ3β-catenin phenotype following p53 loss in K14creP.Δ3β-catflx/wt.p53flx/flx that 
might be influenced by roles of p63/p73 and the changes in the KPC indicated by K15 
expression. As discussed below in terms of the continued lack of tumours following p53 loss, 
the induction of p63 and p73 expression responses would alter overall IFE and HF 
keratinocyte proliferation/differentiation with major effects on the stem cell /KPC populations 
as indicated by K15 expression.  
The p63 and p73 gene share many similarities in epidermal function, perhaps more so than 
p53 which is simply involved with maintaining cell cycle and inducing apoptosis or 
responding to anomalous situations as outlined above. p63 and p73 have important generic 
roles that maintain correct epidermal stem cell/PCK niches ready for proliferation or later for 
the commitment or inhibition of the commitment to terminal differentiation; and also hair 
follicle morphogenesis (Moll and Slade 2004; Koster et al., 2007; Botchkarev et al., 2014).  
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For instance, p63 loss induces a failure of the epidermis to stratify and also disrupted the 
formation of hair follicles and the development of limbs (Mills et al., 1999; Koster et al., 
2004; Koster and Roop 2007) which echoes the phenotypes induced by β-catenin 
deregulation. The ΔNp63 isoform is essential in maintaining basal layer proliferation and 
inhibiting premature differentiation via repression of genes such as p21 and PTEN (Westfall et 
al. 2003; Moll and Slade 2004; Nguyen et al., 2006; Leonard et al., 2011; Botchkarev and 
Flores, 2014) thus again linking to the normal suprabasal expression of β-catenin. For p73, 
pro-apoptotic roles inducing apoptosis following DNA damage (Irwin et al., 2003; Rocco et 
al., 2006) also associate with elevated expression in human SCC (Moll and Slade, 2004), and 
has also been detected in preliminary analysis of HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC [not 
shown]. 
Thus, in wild type p53 contexts the generally strong p63/p73 expression in hair follicles 
appearing in K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice 
may attempt to antagonise Δ3β-catenin, constant with p63/p73 roles in maintaining hair 
follicle stem cells and differentiation (Moll and Slade 2004; Koster et al., 2007; Botchkarev et 
al., 2014).  However, with conditional loss of p53 in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
mice an increase in basal layer expression of p63/p73 was noted in comparison to sporadic 
basal layer expression in HK1.ras-K14creP.Δ3β-catflx/wt with wild type p53. This indicated that 
p63/p73 elevated expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx skin was possibly 
compensating for the lack of p53 expression to regulate epidermal homeostasis. The intense 
increase of p73 in basal layer clearly compensated for lack of p53 as this basal expression was 
not seen in p53 positive basal layers of HK1.ras-K14creP.Δ3β-catflx/wt mice which is constant 
with pro-apoptotic roles of p73 alongside those of p53 (Rocco et al., 2006; DeYoung and 
Ellisen, 2007).  
This directly links to the idea that anomalous β-catenin alter specific KPCs populations in the 
epidermal stem cell unit, as the weaker and patchy K1 expression would be consistent with 
blocks of p63 expression that repress differentiation and also the abrupt lateral edges to both 
K1 and on occasion K6 expression made by specific stem cell units in the IFE (Porter et al., 
2000). This feature of K1 expression appears to be a significant marker of the altered 
differentiation caused by deregulated β-catenin expression and the increased numbers of 
adherence junctions due to excess E-cadherin –which too may play a role in the reduced 
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response to β-catenin now mediated by p63 and p73 compensatory roles in HF and IFE 
physiology. 
Therefore, following the analysis of p63/p73 and given the intense expression they exhibit in 
hair follicles of Δ3β-catenin activated genotypes and the role they might play in regulating the 
stem cell niche, keratin K15 was analysed as a stem cell marker. K15 is normally expressed in 
the bulge region of hair follicles and is considered to be a stem cell marker, which is also 
normally expressed in basal layer of IFE (Bose et al., 2013). Given the stem cell proliferation 
presumably induced via Δ3β-catenin activation, it was expected that K15 would exhibit strong 
expression in the IFE epidermis. However, K15 exhibited mainly strong expression confined 
to the hair follicle and was absent from the epidermis in K14creP.Δ3β-catflx/wt.p53flx/flx and 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx.  
These results suggest that possibly the danger from excess stem cell/PCK cell proliferation 
induced via Δ3β-catenin triggered p63/p73 expression which resulted in the lack of K15 
expression in the IFE. This too is consistent with the responses to Δ3β-catenin activation in 
p53wt or p53flx backgrounds, which are possibly geared to protect the KPC populations via 
maintaining their quiescence yet allowing for their availability e.g., upon wounding that 
involve communication between the β-catenin/wnt and the p53/63/p73 signalling cascades to 
mobilise the correct cells and is clearly deregulated in terms of K6α expression.  
This scenario is also paralleled by the actual additional responses to p53 that are of greater 
significance to the continued lack of tumours in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx, which 
also led to a similar effect on the otherwise well-known anti-tumorigenic roles of p53 giving 
the paradoxical block of papillomatogenesis in HK1.ras-K14.p53flx/flx observed over the past 
25 years [discussed below; (Greenhalgh et al., 1996)]. Following the interesting observation 
in K14creP.Δ3β-catflx/wt.p53flx/flx, ras activation was added to K14creP.Δ3β-catflx/wt.p53flx/flx to 
answer two questions. One of which is to understand p53 protective roles in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx by directly knocking-out the gene [p53flx]. The other purpose of 
this cohort was to investigate Δ3β-catenin in HK1.ras-K14creP.p53flx/flx co-operation which 
paradoxically resulted in lack of tumours in a previous study and was also repeated in this 
cohort as control genotype showing identical result. Therefore, HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx cohort potentially served as an important tool to understand β-catenin/p53 
interaction in relation to tumour development with HK1.ras activation and the HK1-ras- 
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K14creP.Δ3β-catflx/wt.p53flx/flx cohorts showed another striking result as the majority of mice 
were tumour free, except for two mice that developed accelerated aggressive SCC within 8 
weeks. Thus, compensatory mechanisms are elicited. 
This result thus challenges the current dogma in the literature where β-catenin nuclear 
localization and p53 loss facilitate tumour invasion and metastasis (Polakis 2000; Gunther et 
al., 2003; Yao et al., 2008). This also shows that the context and timing of these co-operating 
mutations is important given that in HK1.ras/fos-K14creP.Δ5PTENflx/flx [see Chapter 3], the 
overt papillomas expressed little membranous or nuclear β-catenin in basal layers until p53 
was lost when endogenous β-catenin nuclear localization and p53 loss facilitated the 
progression of papillomas into SCCs.  
The other interpretation of these data in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx cohort, taking 
into account the reported findings of HK1.ras-K14creP.p53flx/flx mice was that possibly the 
tumorigenesis paradoxically required the expression of p53, due to the lack of papilloma 
development in both genotypes. This echoes the theory outline above that p53 created a feed 
back loop to elicit β-catenin phenotypes. This suggestion can be supported by the observation 
in HK1.ras-K14creP.p53flx/flx cohorts that if RU486 treatment was delayed by 2 or 3 weeks by 
10-12 weeks papillomas would result and by 16 -20 weeks could progress to aggressive SCC 
in some cases, however this approach could not be achieved in HK1.ras-K14creP.Δ3β-catflx/wt 
.p53flx/flx cohorts due to uncontrollable early cre leakage with Δ3β-catenin but may have 
happened on two occasions [see below]. 
Collectively, both indications bring up the old discussion regarding p53 fundamental roles in 
carcinogenesis, as in HK1.ras-K14creP.Δ3β-catflx/wt and similarly HK1.fos-
K14creP.Δ5PTENflx/flx co-operation, p53 expression was essential in halting tumour 
development, which is constant with p53 role as tumour suppresser gene. However, in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and similarly in HK1.ras-K14creP.p53flx/flx mice the 
responses to p53 loss maybe equally or more potent in the inhibition of tumour development. 
This indicates that despite the wide spectrum of studies conducted on p53 roles, it is not yet 
entirely understood how HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.p53flx/flx 
cohorts could lack tumour development and thus further analysis was conducted on possible 
contributors to this paradoxical result via investigations of p63, p73,p21 and K15 [below].  
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As with K14creP.Δ3β-catflx/wt.p53flx/flx mice, investigation of HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx phenotypes showed clear reduction in the severity of phenotypes compared to 
HK1.ras-K14creP.Δ3β-catflx/wt . The histological analysis of HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx showed a minimal effect of Δ3β-catenin in terms of de novo hair follicle and 
formation of cysts, which seems to be gradually increasing with age until it reaches typical 
degree of phenotype in some cases e.g., post 10 weeks of age. Another observation was that in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx unlike K14creP.Δ3β-catflx/wt.p53flx/flx, hair follicle 
tumours such as trichofolliculoma which appeared only in some cases and after a significant 
delay of more than 8 weeks compared to HK1.ras-K14creP.Δ3β-catflx/wt or K14creP.Δ3β-
catflx/wt , where they developed hair follicle tumours sooner. The IFE hyperplasia was also 
slightly less than that of HK1.ras-K14creP.Δ3β-catflx/wt but it still had the similar disordered 
differentiation, and both were clearly less than HK1.ras-K14creP.p53flx/flx or HK1.ras typical 
ordered differentiation.  
Here analysis of β-catenin/E-cadherin expression in tumour free HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx, showed increased membranous expression in both supra and basal layer with 
nuclear localization of β-catenin. This indicated that an increase in cell-cell adhesion 
signalling helped prevent papillomas similar to HK1.ras-K14creP.Δ3β-catflx/wt findings. This 
also indicated that increased cell-cell adhesion in HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx was 
not dependent on p53 expression, as suggested by HK1.ras-K14creP.Δ3β-catflx/wt data; yet in 
the context of HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology compensatory p53 and p21 
appeared to be associated with  increased cell-cell adhesions [β-catenin/E-cadherin 
expression], thus this may depend upon p21, hence following p21 loss in HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs  E-cadherin is reduced at the invasive front.  
However, despite the loss of p53 which is essential in maintaining the homeostasis of cellular 
adhesion (Wu et al., 1997), in the HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx context, the 
cytoplasmic pool of β-catenin/E-cadherin interactions to maintain cell-cell adhesion seems 
unaffected. Thus, the proposed function of E-cadherin to act as a sponge to provide additional 
regulation of β-catenin (Huels et al., 2015) remained intact similar to the observations in 
HK1.ras-K14creP.Δ3β-catflx/wt [Chapter 5].  
By default, these data also show that the responses to p53 loss which inhibited 
papillomatogenesis in HK1.ras-K14creP.p53flx/flx mice were also independent of β-catenin 
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expression; as Δ3β-catenin was unable to overcome the paradoxical inhibition of papillomas. 
Thus, this suggests that the inhibitory compensatory mechanism to p53 loss maybe generic, 
hence a lack of early papillomas in both contexts. Thus, future experiments such as genomic 
and proteomic profiling of these different contexts that are designed to identify the component 
pathways could be of significant value for future therapeutics.  
The early differentiation marker K1 showed weak expression almost disappearing from the 
epidermis in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx as seen in HK1.ras-K14creP.Δ3β-catflx/wt 
and the odd confused patchy expression was amplified by the loss of p53 in HK1.ras-Δ3β-
cathet/p53flx/flx.  This was odd given that p53 loss greatly disturbed terminal differentiation in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx but papillomas did not develop and the 
hyperproliferation marker K6α was also not expressed in the epidermis. It may be that this 
further reduction in K1 expression in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis could 
be due to basal layer p63 expression that inhibits the commitment to terminally differentiate 
and maintain a population of proliferative keratinocytes. As above, blocks of p63 would give 
the abrupt lateral edges to both K1 made by specific stem cell units in the IFE (Porter et al., 
2000). This feature of K1 expression also appears to be a significant marker of the altered 
differentiation caused by deregulated β-catenin expression and the increased numbers of 
adherence junctions due to excess E-cadherin.  
This latter point would also contribute to the inhibition of tumours in these mice. Here it might 
be that basal layer p53 in HK1.ras-K14creP.Δ3β-catflx/wt were attempting to regulate the Δ3β-
catenin effect on epidermal differentiation by promoting differentiation signals with p21 as 
seen with the accelerated differentiation in HK1.ras/fos-K14creP.Δ5PTENflx/flx KA due to 
endogenous β-catenin overexpression. Alongside p63 and p73 the lack of basal p53 in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  and lack of K1 expression despite the increased basal 
layer p21 which maybe   promoting epidermal differentiation in response to loss of stress 
signal p53-mediated responses and the suggestion above that p21 may be more important to E-
cadherin and adherence junction formation in KAs.  
The lack of K1 yet elevated p21 was also constant with the proposed function of p21 in the 
upper layers of the IFE epidermis (Topley et al., 1999; Devagn et al., 2006) as increased 
expression here could induce inhibitory differentiation signals as seen in both HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt . Similarly, the lack of K6α 
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expression could be attributed to high levels of basal layer p21 expression similar to HK1.ras-
K14creP.Δ3β-catflx/wt . Another hypothesised mechanism for the lack of tumour was that p53 
loss might have led to a lack in regulating stem cell proliferation due to Δ3β-catenin 
activation, which in return invoked compensatory responses of other TSGs to halt this 
oncogenic proliferation, hence analysis of p63/p73 together with assessing K15 as stem cell 
marker and the mitotic index in both HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  and HK1.ras-
K14creP.Δ3β-catflx/wt . 
Conditional loss of p53 in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx gave an increase in basal 
layer expression of p63/p73 indicating again that they may have been expressed to compensate 
for p53 loss in the inhibition of tumours. The intense increase of p73 in basal layers clearly 
supports this idea as this basal expression was not seen in p53 positive basal layers of 
HK1.ras-K14creP.Δ3β-catflx/wt and is constant with TSG roles of p73 (Rocco et al., 2006; 
DeYoung and Ellisen, 2007). This also might indicate that p73 response was more effective in 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx to block typical Δ3β-catenin where alternatively p53 
failed to reduce Δ3β-catenin effectively in HK1.ras-K14creP.Δ3β-catflx/wt .  
This suggest that possibly the excess stem cell proliferation induced via Δ3β-catenin triggered 
early compensatory TSGs [p53/p21/p63/p73] expression resulted in the lack of K15 
expression in the IFE. This also might explain the aberrant K1/K6 expression seen in HK1.ras-
K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx as TSGs expression halted the 
tumour development but at the same time possibly depleted the stem cell niche required for 
normal terminal differentiation.  
This is consistent with the responses to Δ3β-catenin activation in p53wt  or p53flx possibly to 
protect the KPC populations via maintaining their  quiescence and at this very early stage 
there is a lack of potential papilloma forming cells due to protection form combinations of p53 
and p21 backed up when necessary by p63 and p73 and resultant anomalous differentiation. 
This was also reflected in BrdU-labelling analysis, where a low mitotic index suggested 
possibly a loss of stem cell targets as the cause for the lack of tumours forming in both tumour 
free HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt as evident by 
the lack of K15 in the IFE due to the KPC populations being protected by TSGs. 
With respect to the two tumours that developed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx these 
now began to make more logical sense for the outcome of p52 loss and β-catenin co-operation 
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with activated rasHa. Firstly, they appeared, suggesting that again full sized mice which lacked 
developmental phenotypes would produce papillomas as observed in HK1.ras-K14creP.Δ3β-
catflx/wt mice if the skin was allowed to develop normally. Moreover, consistent with p53 loss 
in these HK1.ras- K14creP.Δ3β-catflx/wt.p53flx/flx mice both tumours converted to carcinoma the 
histological analysis confirmed progression to aggressive SCC. This histotype was confirmed 
by early differentiation marker K1 expression disappearing, consistent with progression of the 
papilloma to carcinoma. The hyperproliferation marker K6α also showed weak expression in 
the converted pdSCC and also strong expression in the benign part; but both lacked basal layer 
expression This suggested that perhaps early progression to HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx carcinoma was not the same as that in HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC 
due to Δ3β-catenin effects.  
However, HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx showed p53 loss correlated with reduced 
membranous expression of β-catenin /E-cadherin and increased nuclear localization of β-
catenin. This was becoming more constant with endogenous β-catenin expression analysis in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx [see Chapter 3] that showed similar correlation and both 
examples were also constant with the literature dogma (Polakis 2000; Gunther et al., 2003; 
Yao et al., 2008; Jeanes et al., 2008). Thus as HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx tumours 
progressed from wdSCC through SCC and finally pdSCC. this correlated with increasing 
nuclear localization of β-catenin and loss of membranous β-catenin/E-cadherin expression at 
the invasive front.  
This mechanism appeared distinct from papillomatogenesis in HK1.ras-K14creP.Δ3β-catflx/wt 
mice, which showed increased nuclear β-catenin but with stable strong membranous β-
catenin/E-cadherin expression similar to the expression profile of endogenous β-catenin in 
HK1.fos-K14creP.Δ5PTENflx/flx KA [Chapter3]. Thus, indicating that as long as the 
cytoplasmic pool of β-catenin/E-cadherin is functioning correctly, nuclear localization of β-
catenin can not induce conversion to carcinoma without p53 loss; whilst invasive progression 
requires p21 loss and loss of E-cadherin at the invasive front.  
Furthermore, in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and similarly in HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs both lost p21 expression, unlike benign papillomas in HK1.ras-
K14creP.Δ3β-catflx/wt or the tumour free HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx where high levels of p21 appeared in their hyperplasia. This 
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indicates that p21 protective responses might be as effective to counter AKT/β-catenin in later 
stages of tumour progression as well as earlier; given loss of p21 appears in both HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx progression and following conversion in HK1.ras/fos-
K14creP.Δ5PTENflx/flx mice (Macdonald et al., 2014). 
Moreover, additional anti-tumour assistance and possibly progression may have come from 
high levels of p63/p73 in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx SCCs consistent with 
previous reports (Moll and Slade 2004; Koster et al., 2007; Botchkarev et al., 2014) as seen in 
analysis of HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC [not shown]. On one hand the release of 
p63 [i.e. ΔNp63] in the context of aggressive p53-null papillomas, may exert an oncogenic 
property that successfully countered p21-mediated responses and which also circumvented 
elevated p73 TSG responses. Whereas, in rare HK1.ras-K14creP.Δ3β-catflx/wt benign 
papillomas the weaker p63 [ΔNp63] expression was probably suppressed by p53/p21 
expression and elevated p73 to maintaining the benign nature of this papilloma. This again 
indicated that once tumour development escaped the early protective responses to Δ3β-
catenin/p53 loss where cre did not leak, the progression and conversion to carcinoma of these 
tumours was highly dependent on p53 response. 
Additionally, K15 expression was analysed in papillomas developed in HK1.ras-
K14creP.Δ3β-catflx/wt and the SCCs developed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx where 
in both cases basal layer expression was observed in tumours, which was not seen in 
HK1.ras1205 control papillomas. This expression of K15 therefore seems to be exclusive to 
tumours developed in genotypes carrying Δ3β-catenin which could be a key marker in 
understanding the development of tumours in these genotypes. This idea is supported by 
reports that K15-positive cells derived from hair follicle stem cells contribute to papilloma 
development (Li et al., 2013). Thus, tumours developed in HK1.ras-K14creP.Δ3β-catflx/wt and 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice may derive from such excess stem cell 
proliferation initially mediated by ΔNp63 expression that escaped the early p73 TSGs 
responses due to cre leakage of Δ3β-catenin.  
Given the implications of p21 roles in halting tumour development and the observation that it 
loss in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx SCC facilitated conversion, on-going 
experiments investigated p21 knockout (Martín-Caballero et al., 2001) in HK1.ras-
K14creP.Δ3β-catflx/wt.p21KO  genotypes. The preliminary data indicate that p21 loss does not 
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facilitate tumour formation in conjunction with Δ3β-catenin and HK1.ras as these mice 
remained tumour free 12 weeks. This again indicated that p21 roles on in antagonising tumour 
development appear at later stages rather than early prevention of tumorigenesis. The other 
major finding demonstrated that K14creP.Δ3β-catflx/wt.p21KO and HK1.ras-K14creP.Δ3β-
catflx/wt.p21KO and look indistinguishable from HK1.ras-K14creP.Δ3β-catflx/wt in terms of 
juvenile Δ3β-catenin phenotypes. This result indicating that the delayed onset of Δ3β-catenin 
was directly associated with p53 loss.   
Collectively, these data suggest that Δ3β-catenin activation invoked several epidermal 
protective responses and halting tumour development and was not exclusively dependent on 
p53 expression, however p53 seems to play two major roles in these cohorts. One of which 
was influencing the severity of Δ3β-catenin phenotype, as Δ3β-catenin/p53flx co-operation 
which results in reducing the severity of the presented phenotype. The other role of p53 was 
controlling the fate of tumours converting to carcinomas, as seen in the rare examples when 
they developed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx SCCs or HK1.ras-K14creP.Δ3β-
catflx/wt benign papillomas. However, these are only the preliminary findings and much work 
remains to identify and validate whether p63 and p73 are indeed the key facets that block 
papillomatogenesis in both HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and possibly HK1.ras-
K14creP.Δ3β-catflx/wt . Although, this finding clearly suggests p21 as an easy answer for 
blocking of tumours, early data of HK1.ras-K14creP.Δ3β-catflx/wt.p21KO suggest that p21 is 
not responsible for either blocking of tumour or repression of Δ3β-catenin phenotypes which 
appears p53-specific.  
These data also suggest that early activation of Δ3β-catenin elicits multiple protective 
responses with or without p53; resulting in blocking of tumorigenesis. However, in the rare 
cases where Δ3β-catenin was not prematurely activated by a leaking cre within 20-24d of age 
it appeared that HK1.ras associated papillomas were given enough time to develop. Thus, 
producing a very different tumour outcome in the context of HK1.ras-K14creP.Δ3β-catflx/wt 
where wt p53 maintained a papilloma vs. Δ3β-catenin/rasHa in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx where loss of p53 expression more logically governed the fate of papilloma 

















7.1 Introduction  
As investigated above, analysis of HK1.ras or HK1.ras/fos papillomas showed that β-catenin 
expression was supra-basal and membranous, similar to normal β-catenin expression. In 
HK1.fos-K14creP.Δ5PTENflx/flx KA formation, loss of PTEN regulation and a specific level of 
AKT-mediated GSK3β inactivation allowed β-catenin expression to become strongly basal 
and also strongly nuclear and this triggered compensatory p53/p21 expression. This 
compensatory p53/p21 expression diverted the papillomatogenesis expected from HK1.fos-
K14creP.Δ5PTENflx/flx co-operation into one of massive differentiation, which gave the 
keratoacanthoma aetiology [see chapter 3 (Yao et al., 2008)]. Endogenous β-catenin levels in 
HK1.fos-K14creP.Δ5PTENflx/flx KA showed increased expression in basal layers, with nuclear 
localization correlating with the trigger of p53/p21. Meanwhile, together with E-cadherin 
expression, this strong membranous β-catenin expression would aid in cell-cell adhesion 
which led to a KA outcome rather than invasive SCC [above Chapter 3; (Yao et al., 2008)]. 
This analysis confirmed β-catenin involvement in the formation of HK1.fos-
K14creP.Δ5PTENflx/flx KA as a consequence of Δ5PTEN loss/AKT activation and associated 
GSK3-β inactivation (Alyamani et al., manuscript in preparation). 
In HK1.ras/fos-K14creP.Δ5PTENflx/flx mice, basal layer β-catenin expression was already 
detectable in hyperplasia and papillomas that also exhibited p53 and p21 expression. However, 
as the tumours converted to malignancy following p53 loss (Macdonald et al., 2014), nuclear 
β-catenin expression increased in basal keratinocytes that expressed less membranous β-
catenin [above; Chapter 3 Fig. 3.3]. This was paralleled by initial increases in E-cadherin, but 
again following p53 loss, as the profile of excess nuclear/reduced membranous β-catenin 
expression became widespread, E-cadherin was progressively lost at the invasive front and 
thus cell-cell adhesion was reduced and this aided tumour invasion [Chapter 3 Fig. 3.3]. 
Therefore, as hypothesised in the aims, it was expected that crossing K14creP.Δ3β-catflx/wt  
mice with HK1.fos mice would lead to more rapid papilloma formation, with β-catenin acting 
as an initiator and fos as a promoter; since the fos transcription factor in AP1 is a target of Wnt 
signalling (Toualbi et al., 2007; Saadeddin et al., 2009). It was also thought that as Δ3β-
catenin expression was now independent of deregulated PTEN/AKT/GSK3β signalling, it may 
circumvent the protective p53 responses observed in HK1.fos-K14creP.Δ5PTENflx/flx mice and 
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thus in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice this could result in SCC not KA 
formation.  
Instead, an unexpected block of either KA or papilloma was observed in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice, and in this case it appears that increased 
differentiation was a major inhibitory event. Indeed, the levels of differentiation not only 
resulted in a significant keratosis but the folding observed in Δ3β-catenin skin now became 
not just folds but the accelerated keratinocyte differentiation which led to an almost scale –like 
appearance that overtly resembled a pangolin skin – the only scaled mammal; hence the 
reference to a pangolin phenotype thorough this chapter. However, there was clear co-
operation between Δ5PTEN mutation and Δ3β-catenin overexpression in the development of 
follicular tumours in both these and K14.Δ5PTEN.Δ3β-catenin mice. Further, in preliminary 
experiments, again an effect of p53 loss was observed in the IFE of these mice that protected 
against the effects of Δ3β-catenin. 
 
7.2 HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt co-operation resulted in 
massive keratinocyte differentiation and formation of a unique folded skin 
phenotype. 
These experiments were originally designed to assess β-catenin activation in the HK1.ras/fos 
model based on the co-operative effects of PTEN/p-AKT/p-GSK3β signalling observed in 
previous studies that confirmed β-catenin’s role in Chapter 3 and also investigate the effects of 
p53 loss given the malignant conversion of rare p53 null tumours in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx   vs. HK1.ras-K14creP.Δ3β-catflx/wt mice with wild type p53. Thus, to directly 
test whether activated Δ3β-catenin will facilitate tumorigenesis or induce similar protective 
responses as seen in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
[See chapters 4 & 5] cohorts of HK1.fos-K14creP.Δ5PTENflx/flx .Δ3β-catflx/wt were established.   
This approach also investigated Δ3β-catenin co-operation with HK1.fos alone and HK1.ras1276 
/fos to mimic previous studies outlined in chapter 3 (Yao et al., 2008; Macdonald et al., 2014) 
using Δ3β-catenin activation instated of Δ5PTEN/AKT.  Here the use of HK1.ras1276 mice was 
necessary given that the sensitivity of HK1.ras1205 mice to HK1.fos promotion would result in 
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phenotypes too severe for UK experimentation and HK1.ras1276  are used in PTEN 
experiments also.  
 
The first notable results in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice and also observed 
in HK1.fos-K14creP.Δ3β-catwt/flx and HK1.ras/fos-K14creP.Δ3β-catflx/wt was the complete lack 
of tumour development [Fig. 7.1]. This was again consistent with protection protective 
responses induced via Δ3β-catenin activation as seen previously in HK1.ras-K14creP.Δ3β-
catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx . Indeed, in all the mice produced for these 
genotypes and regardless of size none of the mice produced any tumours to date unlike the non 
β-catenin controls which repeated their previous KA or SCC aetiology [Fig. 7.1A-C vs. D&E]. 
However, all these genotypes shared a novel phenotype resulting in the formation of an 
overlapping scaly skin, resembling the scales of a pangolin. The most severe from appeared in 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice [Fig. 7.1F-H] and this was not observed in 
any previous genotypes even those of the score 2 [see Chapter 5] in HK1.ras-K14creP.Δ3β-
catflx/wt or K14creP.Δ3β-catflx/wt mice [Fig. 7.1I&J].   
Thus the appearance of this skin phenotype in all genotypes associated with HK1.fos-
K14creP.Δ5PTENflx/flx co-operation suggest that these epidermal responses were a result of the 
combine roles for fos  (Fisher et al., 1991; Greenhalgh et al., 1993b; Basset-Seguin et al., 
1994;  Angel et al., 2001) expression in normal keratinocyte differentiation and that of β-
catenin (Karim et al., 2004), consistent with fos being a downstream transcription factor target 
of Wnt signalling (Toualbi et al., 2007; Saadeddin et al., 2009) and the fos roles in the 







Figure 7. 1: Analysis of skin phenotypes in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt , 
HK1.ras/fos-K14creP.Δ3β-catflx/wt  and HK1.fos-K14creP.Δ3β-catflx/wt.  
[A-C] RU486-treated mice lack any tumor development 10-12 weeks post ear tag in: [A] 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt; [B] HK1.ras/fos-K14creP.Δ3β-catflx/wt and [C 
]HK1.fos-K14creP.Δ3β-catflx/wt mice; compared to [D] benign KA in HK1.fos-
K14creP.Δ5PTENflx/flx and [E] SCC in HK1.ras/fos-K14creP.Δ5PTENflx/flx cohorts. [F] Adult 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mouse exhibits a significant increase in Δ3β-
catenin skin where the disheveled scruffy appearance has been replaced by a thickened 
folded skin devoid of hair. The folds overlap giving a unique phenotype resembling the shape 
of scales on a pangolin skin. [G & H] At higher magnification this overlapping fold is clearly 
visible when compared to [I] the typical hyperkeratosis in HK1.ras-K14creP.Δ3β-catflx/wt and [J] 








The histological analysis of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt is shown in Fig. 7.2 
and the variations in the histotypes are contrasted to those of HK1.fos-K14creP.Δ3β-catwt/flx 
and HK1.ras/fos-K14creP.Δ3β-catflx/wt in Fig. 7.3 and Fig. 7.4. Analysis of HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt adult ear skin [Fig 7.2] at 10 weeks post tagging showed a 
very different, unique histotype of more disturbed and abnormal IFE differentiation, with a 
severe case of increased hair follicle tumours again with a very different histology [Fig. 7.2 A-
C]. Here, in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt RU486 treatment induced a novel 
Δ3β-catenin/Δ5PTEN-associated histotype of excess keratosis with areas missing an IFE or 
strands of mild hyperplasia with a massive degree of acanthosis associated with a dominance 
of spinus layer keratinocytes weakly stained in the epidermis [Fig. 7.2 B&C]. In addition the 
numbers and severity of HF anomalies and cysts increased, moreover these HF tumours no 
longer possessed a trichofolliculomas appearance but now the HF tumour histotype produced a 
separate tumour type that closely resembles HF trichilemmomas produced in Cowden’s 
disease (Liaw et al 1997; Fistarol et al., 2002; Suzuki et al., 2003) suggesting a direct co-
operation between β-catenin overexpression and PTEN mutation in their aetiology consistent 
with the fact that both induced HF anomalies in transgenic mice (Grigoryan et al., 2008;  
Suzuki et al., 2003); an idea currently being pursued in separate studies. 
RU486-treated adult HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin also exhibited the same 
disturbed IFE and now with an even more pronounced cyst formation that merged into the IFE 
to contribute to the folded keratosis effect and areas devoid of an IFE [Fig. 7.2 E-G]. Again, 
the very different HF trichilemmomas -like tumour histotype is quite clear whilst the histology 
of their upper regions suggests a derivation from the HF outer root sheath. In the IFE of 
K14.Δ5PTENflx/flx   mice a similar effect of blooms of keratosis was observed (Yao et al., 
2006;2008) consistent with a role for PTEN in the latter stages of epidermal differentiation 
that lead to the characteristic mild keratosis of Cowden patients (Liaw et al 1997; Fistarol et 
al., 2002) and which led to keratinisation and a KA aetiology (Yao et al., 2006; 2008). These 
too are again consistent with interactions with fos (Fisher et al., 1991; Greenhalgh et al., 
1993b; Basset-Seguin et al., 1994; Angel et al., 2001) and may underlie the degree of 
acanthosis observed with additional Δ3β-catenin and the reappearance of K1 [below]; which 
together suggests that an accelerated differentiation is another compensatory element to inhibit 




Figure 7. 2: Histological analysis of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin and 
HF tumours. 
 [A-C] RU486-treated HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt tagged ear [insert] exhibits a 
severe Δ3β-catenin/Δ5PTEN-associated increase in phenotype on the RU486 treated dorsal 
surface with both excess keratosis; strands of mild vs. increased hyperplasia and quite 
different HF anomalies and increased numbers of cysts. [B] At higher magnification the IFE 
exhibits a highly disturbed epidermal differentiation, with [C] a massive degree of acanthosis 
also unique to this cohort. In addition, the numbers of hair follicle tumours and cysts formation 
are increased and [D] shows a separate HF tumour histotype that resembles HF 
trichilemmomas produced in Cowden’s disease. [E-G] RU486-treated adult HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin [insert] also exhibits a highly disturbed epidermis 
accompanied by [E] a more pronounced predominance of cyst formation that [F] appear to 
break through into the IFE and contribute to the folded keratosis effects. At low and [G] higher 
magnification again the different HF trichilemmomas tumour histotype is clear and their upper 
regions suggest a derivation from the HF outer root sheath. Scale bars: A & E:150µm; B,C & 






The ear and back histology of this increased pangolin-like skin phenotype was examined 
across the three genotypes HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt , HK1.ras/fos-
K14creP.Δ3β-catflx/wt  and HK1.fos-K14creP.Δ3β-catwt/flx to investigate the degree of severity 
in regards to genotype and the formation of trichilemmomas  vs. folliculaomas [Fig. 7.3 and 
Fig. 7.4]. A comparison of the ear histology of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt  
[Fig. 7.3A&B] to that of HK1.ras/fos-K14creP.Δ3β-catflx/wt  [Fig. 7.3C&D] and HK1.fos-K14. 
Δ3β-catenin [Fig. 7.3E&F] showed that while these genotypes exhibited a similar degree of 
IFE severity, with slightly decreased hyperplasia in HK1.fos Δ3β-catenin genotypes; the IFE 
was essentially complete and lacked the acanthosis observed in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt  histotypes [Fig. 7.3B]. In these examples, an important 
observation was that whilst the pangolin-like state remained fairly constant in the IFE, the HF 
histotypes in HK1.ras/fos-K14creP.Δ5PTENflx/flx and HK1.fos-K14creP.Δ5PTENflx/flx skins 
were essentially similar to that of the earlier HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-
catflx/wt  ears [Fig. 7.3G&H], although by this time at 10 weeks post tagging they were quite 
aggressive yet  the HF anomalies, remained of a folliculoma nature, consistent with the lack of 
both deregulated PTEN and β-catenin [Fig. 7.3C-F] (Gat et al., 1998; Rankin et al., 
1992Niemann et al., 2002; Kretzschmar et al., 2015; Suzuki et al., 2003).  
Another important observation was again recorded on comparison of the IFE in the various 
histopathologies of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt , HK1.ras/fos-K14creP.Δ3β-
catflx/wt  and HK1.fos-K14creP.Δ3β-catwt/flx back skin [Fig.7.4]. In the more severe histology 
of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin, in many areas the IFE was absent or 
completely acanthotic; i.e. the epidermis was comprised of differentiated spinus keratinocytes 
giving a pale staining to the epidermis termed acanthiosis [Fig. 7.4A; Fig. 7.4B arrows] (Candi 
et al., 2005; Mehic et al., 2005; Gerdes et al., 2006). This was also accompanied by many of 
the cysts breaking through giving areas lacking a complete IFE; and particularly prominent in 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin. This acanthosis, associated with a dominance 
of spinus layer keratinocytes, also appeared in the more hyperplastic HK1.ras/fos-
K14creP.Δ3β-catflx/wt IFE [Fig. 7.4C; Fig. 7.4D arrow] and more rarely in HK1.fos-
K14creP.Δ3β-catwt/flxskin where the IFE was less hyperplasia and exhibited folliculoma, but 
the banding leading to scale-like formation can still be seen with a trough between the ridges 
[Fig. 7.4E&F]. In comparison, the score 0 examples of HK1.ras-K14creP.Δ3β-catflx/wt and 
K14creP.Δ3β-catflx/wt back skin phenotypes exhibited the typical Δ3β-catenin phenotypes but 
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with few cysts and fewer hair follicle tumours and more hyperplasia HK1.ras-K14creP.Δ3β-
catflx/wt IFE [Fig. 7.4G&H]. 
 
Figure 7. 3: Comparison of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt ear histotypes to 
HK1.ras/fos-K14creP.Δ3β-catflx/wt  and HK1.fos-K14creP.Δ3β-catflx/wt mice.   
[A & B] Severe Δ3β-catenin phenotypes appear in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
at 10 weeks with the highly disturbed IFE and trichilemmomas that mimic HF tumours of 
Cowden disease.[C & D] At the same 12week time point, HK1.ras/fos-K14creP.Δ3β-catflx/wt  
mice display the increased IFE hyperplasia of ras and fos co-operation but the IFE lacks the 
acanthosis, is complete and there are less cysts. Also, all the follicle tumours are again 
folliculomas and present a completely different histotype. [E & F] At this time point, HK1.fos-
K14creP.Δ3β-catflx/wt are the least phenotypic but still exhibit highly disturbed epidermal 
differentiation, with hair follicle tumours and cyst formation appearing similar to [G] HK1.ras-
K14creP.Δ3β-catflx/wt exhibiting moderate (used in Fig. 5.4A) and [H] K14creP.Δ3β-catflx/wt 
tagged ears exhibiting only mild levels of Δ3β-catenin phenotypes in this score 0 mouse 




Figure 7. 4: Histological variation of the “pangolin” phenotype in back skin 
demonstrates areas of IFE acanthosis.  
[A & B] HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt shows histology typical of the most sever 
phenotype associated with a highly disturbed epidermis accompanied by predominance of 
cyst formation that [B] seem to be overtaking the IFE in many areas; giving rise to a lack of 
IFE or acanthosis [arrows].[C & D] HK1.ras/fos-K14creP.Δ3β-catflx/wt  show a similar feature 
but with HF folliculomas and more IFE hyperplasia, here again the cysts break through to 
give strands of acanthosis associated with a dominance of spinus layer keratinocytes [arrow]. 
[E & F] HK1.fos-K14creP.Δ3β-catflx/wt IFE has less hyperplasia, folliculomas and at low 
magnification the banding leading to scale-like formation is shown with a trough between. [G] 
HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.3F) and [H] K14creP.Δ3β-catflx/wt back skin (used 
in Fig. 4.3C) exhibits only moderate and mild levels of phenotype with more IFE hyperplasia 
in [G] HK1.ras-K14creP.Δ3β-catflx/wt compared to [H] K14creP.Δ3β-catflx/wt  back skin. Scale 
bars: A, C, E, G & H:150µm; D & F:100µm; B: 75µm. 
 
 
Although not shown, as they are part of a separate study, the formation of trichilemmomas vs. 
folliculomas was also observed in the HFs of K14creP.Δ5PTEN.Δ3β-cat histotypes. Thus, the 
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histological analysis suggests that Δ3β-catenin and HK1.fos co-operation amplified the Δ3β-
catenin phenotypes, giving a highly disturb IFE differentiation with many areas of acanthosis. 
This indicated that a significant degree of differentiation was associated with overexpression 
of both Δ3β-catenin (Gat et al., 1998; Niemann et al., 2002; Kretzschmar et al., 2015 ; Rankin 
et al., 1992; Yao et al., 2008; Macdonald et al., 2014) and fos activation (Fisher et al., 
1991;Basset-Seguin et al., 1994; Angel et al., 2001) as observed in previous studies 
(Greenhalgh et al., 1993b Yao et al., 2008; Macdonald et al., 2014) that associate fos with the 
decisions of keratinocytes to commit to terminal differentiation (Candi et al., 2005; Mehic et 
al., 2005;  Gerdes et al., 2006).  
In addition, increased formation of cysts and trichilemmomas vs folliculomas is a novel 
tumour phenotype associated with overexpression of both Δ3β-catenin and Δ5PTEN. This 
would again be consistent with roles for β-catenin in HF development (Gat et al., 1998; 
Huelsken et al., 2001; Niemann et al., 2002) in co-operation with PTEN mutation and AKT 
activation (Suzuki et al., 2003) and possibly with the high levels of E-cadherin associated with 
the development of these specific HF tumours [below (Young et al., 2003)]. It may be that the 
lipo-phosphatase PTEN scaffolding functions at the membrane independent of 
phosphatase/AKT regulation (Kotelevets et al., 2001; Tamura et al., 1998; Subauste et al., 
2005) that aid in cell-cell adhesion (Kotelevets et al., 2001; Young et al., 2003) remain intact 
and these help with resistance to tumour formation. Indeed, these lipo-phosphatase roles may 
even increase as part of efforts to increase the Δ5PTEN phosphatase function that feeds back 
to its promoter from increased AKT; although this idea will require further investigation in 
new K14.Δ5PTEN.Δ3β-catenin studies.     
As expected for the model, analysis of β-catenin in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
showed increased expression in both suprabasal and basal layers, with both membranous and 
nuclear β-catenin appearing in basal layer cells [Fig. 7.5A-D]. However, it was noted that in 
certain areas, the proliferative keratin K14 was absent [Fig. 7.5B; arrow]; and it is interesting 
to speculate whether K14 was replace by K15 (Bose et al., 2013), given that these areas 
expressed strong levels of membranous β-catenin and E-cadherin [below]. Thus, this strong 
cell-cell binding [also consistent with PTEN scaffolding roles above] and the increased 
differentiation, suggested by K1 expression [below] would all contribute to the tumour 
inhibition observed.  
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β-catenin expression in HK1.ras/fos-K14creP.Δ3β-catflx/wt and HK1.fos-K14creP.Δ3β-catwt/flx 
skin [not shown] was identical to the expression observed in HK1.ras-K14creP.Δ3β-catflx/wt 
and K14creP.Δ3β-catflx/wt  [Fig. 7.5E&F]. Furthermore, this early β-catenin expression in 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin was also similar to nuclear and membranous 
expression of β-catenin in HK1.fos-K14creP.Δ5PTENflx/flx KA [Chapter 3], whilst HK1.fos 
hyperplasia showed only supra-basal membranous expression similar to that of HK1.ras. This 
suggests that early activation of Δ3β-catenin in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
genotypes or the triggered activation in HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology led to an 










Figure 7. 5: Analysis of β-catenin expression in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt IFE.  
[A] IFE shows strong β-catenin expression in all layers and the trichilemmomas-like HF 
tumours. [B] At higher magnification IFE shows an area of β-catenin positivity accompanied 
by a lack of K14 expression [arrow]. [C & D] Other sections higher magnification show strong 
membranous expression in both suprabasal and basal layers with nuclear expression in most 
basal layers cells. For comparison [E] HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.6E) and 
[F] K14creP.Δ3β-catflx/wt (used in Fig. 5.6F) display an all over strong expression of Δ3β-











The analysis of E-cadherin levels in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt also 
demonstrated an increase in IFE basal layer expression [Fig. 7.6A&B] and it was noticed that 
E-cadherin expression was particularly strongly in the trichilemmomas -like HF tumours; and 
also in the surrounding cysts [Fig. 7.6C&D]. In several IFE strands that mimicked β-catenin 
expression [above], areas again lacked K14 expression, being green only; whilst the areas that 
lacked hyperplasia or were acanthotic were strongly positive for E-cadherin. Again, this 
intense E-cadherin expression profile was exclusive to these animals as HK1.ras/fos-
K14creP.Δ3β-catflx/wt and HK1.fos-K14creP.Δ3β-catwt/flx skin [not shown] exhibited a HF 
expression similar to HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt [Fig. 7.6E&F] 
and an IFE of similar intensity also. 
 
These E-cadherin results exhibited by HK1.fos-K14creP.Δ5PTENflx/flx .Δ3β-catflx/wt 
trichilemmomas and cysts is another novel tumour feature suggesting a significant degree of 
co-operation between Δ3β-catenin and Δ5PTEN in HF development (Gat et al., 1998; 
Huelsken et al., 2001; Niemann et al.,2002)and the resulting HF tumour type (Suzuki et al., 
2003). Further, the excess numbers of HF-derived cysts suggests a response to this HF 
progression was a diversion of anomalous HF formation into cysts (Young et al., 2003) as 
observed in HK1.ras/fos-K14cre.Δ5PTEN mice (Macdonald et al ., 2014). In the IFE of all 
three fos/Δ3β-catenin genotypes, this increased E-cadherin might also contribute to the 
inhibition of papillomas as suggested in previous studies (Kotelevets et al., 2001) alongside 
the differentiation responses elicited by HK1.fos [below; (Candi et al., 2005; Mehic et al., 






Figure 7. 6: Analysis of E-cadherin expression in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt IFE and tumours.  
[A & B] HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt exhibits very strong expression in supra 
and basal layers of the IFE together with even stronger expression in the trichilemmomas -
like HF tumours; [C] At higher magnification E-cadherin also appears around the cysts whilst 
[D] shows areas of minimal hyperplasia still expressing basal layer E-cadherin; yet some 
areas lack K14 expression [green]. [E] HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.8B) and 
[F] K14creP.Δ3β-catflx/wt (used in Fig. 5.8C) exhibit elevated supra and basal layers E-cadherin 
expression together with hair follicles, but the absence of K14 and the IFE remains 
hyperplastic. Scale bars: A: 100µm; B-D: 75µm; E & F: 50µm. 
 
The analysis of early differentiation marker K1 expression also supported the idea that an 
accelerated or premature differentiation response was occurring in the pangolin-like skins of 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice. Unlike the non-fos/PTEN models [above] 
wherever strands of hyperplastic IFE were actually present, in this instance K1 was also 
expressed [Fig. 7.7A-C].  However, as seen in Fig. 7.7 B and C, not only was K1 expressed 
but the expression was ragged, suggesting confusion to the progression of basal into spinous 
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keratinocytes; which indicated an accelerated differentiation, consistent with the degree of 
novel acanthosis observed in their histopathology [above; Fig. 7.2B&C; Fig. 7.4].  
Supporting this idea, strands of K1 expression appeared in basal layer keratinocytes, 
suggesting a premature commitment of basal layer keratinocytes to terminal differentiation, a 
result also suggested in KA aetiology (Macdonald et al., 2014) and possibly amplified by 
increased early HK1.fos expression due to the premature basal K1 expression (Fisher at 
al.,1991; Greenhalgh et al., 1993b; Basset-Seguin et al., 1994). Meanwhile closer 
examination of the IFE shows that K1 expression was not uniform with weaker areas 
appearing [Fig. 7.2C], a result confirming the disturbed differentiation and consistent with the 
degree of acanthosis observed or possibly premature fos-mediated cornification (Candi et al., 
2005 ). Furthermore, in addition to the highly disturbed IFE hyperplasia and K1 expression 
was also noted in the cysts [Fig. 7.7A], suggesting that a response to help inhibit progression 
to trichilemmomas in the aberrant HFs which expressed K1 in their upper regions may pave 
the way for cyst formation (Kotelevets et al.,2001; Niemann et al.,2002;  Suzuki et al., 2003) in 
addition to that mediated by excess E-cadherin expression [above]. 
This K1 expression in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt was quite different to the 
aberrant, laterally confined patchy expression of K1 in HK1.ras-K14creP.Δ3β-catflx/wt or the 
less altered expression in K14creP.Δ3β-catflx/wt where strands of positive K1 expression appear 
but again with many patches where K1 is thin or lost [Fig. 7.7D&E]. In contrast K1 expression 
in HK1.fos hyperplasia exhibits the relatively normal supra-basal K1 profile [Fig. 7.7F] whilst 
HK1.fos-K14creP.Δ5PTENflx/flx KA shows the very strong K1 expression masking the K14 
counterstain [Fig. 7.7G] with a very thin basal layer, which again indicates a far more 
accelerated and premature differentiation pattern due to elevated p53/p21 expression 





Figure 7. 7: Analysis of keratin K1 in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE and 
HF tumours.  
[A] Low magnification of a typical skin shows aberrant K1 expression in areas of highly 
disturbed IFE hyperplasia and K1 expression was also noted in the cysts, suggesting that the 
aberrant HFs which also expressed K1 in the upper regions, paved the way for cyst 
formation. [B] At higher magnification strands of IFE hyperplasia show a ragged K1 
expression at the junction between basal and supra-basal layers. Also strands of basal layer 
keratinocytes are positive for K1 expression [arrow]. [C] Closer examination of this site shows 
K1 expression is not uniform with weaker areas appearing, a result possibly consistent with 
the degree of acanthosis observed or possibly early fos-mediated cornification. [D] For 
comparison a typical HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.9A) epidermis shows 
patchy expression of K1 with only occasional HFs being weakly positive for K1; whilst [E] this 
K14creP.Δ3β-catflx/wt (used in Fig. 5.9D) example shows a strand of positive K1 expression 
but again with many patches where K1 is thin or lost. [F] HK1.fos hyperplasia exhibits a 
relatively normal K1 profile with expression confined to supra-basal layers; whilst [G] shows 
very strong K1 expression in HK1.fos-K14creP.Δ5PTENflx/flx KA (used in Fig. 3.2K) that masks 
the K14 counterstain; whilst the very thin basal layer in this example indicates an accelerated 
or premature differentiation. Scale bars: A,D & G: 100µm; E: 75µm; B: 60µm; C: 50µm;  F: 
30µm. 
 
Analysis of the hyperproliferation marker K6α in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
showed that in strands of IFE hyperplasia expression was barely detectable and when present 
257 
 
it was only patchy. [Fig. 7.8A]. K6α was mainly expressed in hair follicles, trichilemmomas 
and also around the edges of the cysts, which may indicate that these cysts maybe those of a 
proliferative histotype as seen in the epidermis of younger HK1.ras/fos.K14.Δ5PTEN mice 
(Macdonald et al., 2014). Overall, K6α expression seemed diminished compared to the 
follicular expression seen in HK1.ras-K14creP.Δ3β-catflx/wt and K14creP.Δ3β-catflx/wt or the 
strong IFE expression in HK1.fos hyperplasia Fig. 7.8A-D], similar to that of HK1.ras [above] 
and previously observed in the aetiology HK1.fos-K14creP.Δ5PTENflx/flx KAs (Yao at al., 
2008). This lesser expression may also indicate an effect of an accelerated differentiation and 
possibly diversion of proliferation into cysts formation appearing to be a major anti-
tumorigenic mechanism in this HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt genotype.  
To-date in the HK1 model this observation is only the second instance where K6α expression 
was weak and again suggests that this result is unique to Δ3βcatenin expression. As speculated 
for K1 above [and in earlier chapters], this change in K6α expression may also reflect the 
increased E-cadherin expression, which in turn alters the hyperproliferation signals derived 
from cell-cell interactions that are typically disrupted in wounding. Hence, these and other 
responses to HK1.fos activation that induce K6 expression (Rothnagel et al., 1999) are 
overcome by those elicited in both HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt skin models. i.e. p53 and p21 [below] and others e.g. p63 and p73 
[above] that have yet to be analysed.  
Another possible mechanism returns to the idea that constitutive activation of β-catenin returns 
the adult mouse skin to one resembling a neonatal state (Collins et al., 2011). Here the 
epidermis is naturally hyperplastic but lacks K6α expression, which remains confined to the 
developing HFs. Thus in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin, so many new HFs 
are being created due to the effects of Δ3β-catenin expression that are then further 
compromised by K14.Δ5PTEN expression and fail to differentiate properly; hence reduced 




Figure 7. 8: Analysis of keratin K6α in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE and 
HF tumours.  
[A] Typical HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin shows little K6α expression in the 
IFE and also weaker expression in the trichilemmomas and abnormal HFs. In addition, K6α 
expression was also noted in outer regions of the cysts, suggesting that cyst formation results 
in proliferative cysts; hence the generally larger size in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt skin and their propensity to emerge into the IFE. For comparison [B] HK1.ras-
K14creP.Δ3β-catflx/wt (used in Fig. 5.10C) and [C] K14creP.Δ3β-catflx/wt (used in Fig. 5.10D) 
IFE also lack K6α expression, except in a few strands but strongly express K6α in the 
folliculoma of [B]. [D] Strong K6α in expression appears in all layers of older HK1.fos 





The K1/K6 observations suggested that accelerated differentiation in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice played a role in the formation of the pangolin-like skin 
phenotype. Therefore, as outlined above in previous chapters, this may involve roles for p53 to 
halt proliferation and p21 expression to instigate differentiation in co-operation with roles for 
fos. This is an attractive idea given that fos-mediated photo-carcinogenesis associates with both 
AKT activation and GSK3 inactivation, hence another direct link to β-catenin activity 
(Gonzales and Bowden, 2002).  Further linking fos and β-catenin, UV-B-mediated p53 mutation 
and subsequent PTEN inhibition [and thus increased p-AKT/p-GSK3β/nuclear β-catenin], 
induces AP-1 expression and an initial protective differentiation response (Wang et al., 2005).  
In addition, p21 expression would add to the commitment to differentiation (Di cunto et al., 
1998; Topley et al., 1999) whilst the increased AKT expression may also contribute to 
differentiation given its normal supra-basal roles in antagonising p53 to prevent apoptosis 
giving time to committee to differentiation (Calautti et al., 2005; Macdonald et al., 2014). 
Both these findings being consistent with the return of K1 in the patchy IFE; whilst p21 roles 
in cell-cycle regulation would be consistent with reductions in K6α expression. 
This proved to be the case when p53/p21 status was assessed HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE [Fig. 7.9 and Fig. 7.10]. For both p53 and p21, strong 
expression appeared in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin particularly in the 
anomalous hair follicles, overt trichilemmomas and cysts; and of note also appeared in the 
strands of sporadic IFE hyperplasia [p53: Fig. 7.9A arrows; p21: Fig. 7.10A]. Indeed, both p53 
and p21 expression appeared more intense in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin 
compared to that of HK1.ras-K14creP.Δ3β-catflx/wt or K14creP.Δ3β-catflx/wt  [Fig. 7.9B&C; Fig. 
7.10B&C]; whilst HK1.fos-K14creP.Δ5PTENflx/flx bi-genic mice expressed p53/p21 in all IFE 
layers and follicles [not shown], but similar to HK1.ras-K14creP.Δ3β-catflx/wt ; and HK1.fos 
hyperplasia displayed only supra-basal and mainly cytoplasmic p53/p21 expression until overt 





Figure 7. 9: Analysis of p53 expression in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE 
and HF tumours.  
[A] Strong expression of p53 appears in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin 
mainly in hair follicles, the trichilemmomas, and cysts and also in many strands of sporadic 
IFE hyperplasia [arrows]. [B] HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.11B) and [C] 
K14creP.Δ3β-catflx/wt (used in Fig. 5.11D) also express p53 in all IFE layers and follicles, whilst 
[D] HK1.fos hyperplasia shows only supra-basal cytoplasmic expression until an overt 
papilloma forms. Scale bars: A:150µm; B & D: 60µm; C: 50µm. 
 
Thus, these results confirm p53/p21 involvement in the formation of the pangolin-like 
phenotype, again protecting against tumour/KA formation in the IFE due to anomalous β-
catenin expression at this early, initiating stage. Indeed, as above in HK1.ras-K14creP.Δ3β-
catflx/wt skin this excess p53/p21 expression possibly explains the confused manor of the 
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returned K1 expression seen in the sporadic IFE and the continued the absence of 
hyperproliferation marker K6 from the IFE Fig. 7.7B&C; Fig. 7.8A] suggesting a dysfunction 
in epidermal homeostasis due to combinations of fos, PTEN and β-catenin co-operation.  
 
Figure 7. 10: Analysis of p21 expression in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
IFE and HF tumours.  
[A] HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin displays strong p21 expression appears 
mainly in the trichilemmomas and cysts; but some expression appears in IFE hyperplasia. For 
comparison [B] HK1.ras-K14creP.Δ3β-catflx/wt (used in Fig. 5.12B) and [C] K14creP.Δ3β-
catflx/wt (used in Fig. 5.12D) express p21 in all IFE layers and follicles, whereas [D] HK1.fos 





These data also suggest that the β-catenin trigger of p53 and p21 which resulted in the 
keratosis observed in earlier HK1.fos-K14creP.Δ5PTENflx/flx mice and their resultant KA 
outcome (Macdonald et al., 2014) again gave the massive differentiation programme observed 
here. However, in this new HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt model, this defence 
was deployed at the immediate stage of leakage as Δ3β-catenin was now constitutive and 
independent of deregulated PTEN/AKT/GSK3β, to prevent tumour forming rather than KAs 
converting to SCC. In this juvenile IFE, Δ3β-catenin then co-operated with the differentiation 
signals regulated by fos expression in the epidermis, particularly in the decisions to commit to 
differentiation that account for the return of keratin K1 expression (Fisher et al., 1991; 
Greenhalgh et al., 1993b; Basset-Seguin et al., 1994; Angel et al., 2003; Candi et al., 2005; 
Mehic et al., 2005; Gerdes et al., 2006; Yao et al., 2008; Macdonald et al., 2014). Thus, 
elevated K1 expression appears to be a marker of the altered differentiation caused by 
deregulated β-catenin expression and the increased adherence junctions due to excess E-
cadherin in combination with fos activation.  
That a stronger p53/p21 expression appeared in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
skin [p53: Fig. 7.9A; p21: Fig. 7.10A] compared to HK1.ras-K14creP.Δ3β-catflx/wt expression 
[p53: Fig. 7.9B; p21: Fig. 7.10B] also supports the idea that the novel co-operation between 
anomalous β-catenin and mutant PTEN expression gave rise to the trichilemmomas and that 
p53/p21 expression may have contributed to the increased numbers of cysts in an attempt to 
minimise anomalous HF progression into these trichilemmomas. This would be consistent 
with a model of constitutive Δ3β-catenin activation inducing formation of new [if anomalous 
hair follicles] in K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt mice coupled to 
PTEN mutation in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt diverting the tumour outcome 
to trichilemmomas not folliculoma, as HF hyperplasia was also observed in previous 
constitutive [not inducible] Δ5PTEN studies (Suzuki et al., 2003).  
Overall, these experiments again found an inhibited tumour formation where the IFE 
expression analysis data suggest that in this case it was the increased differentiation that 
appears a major inhibitory event. This idea of Δ3β-catenin enhanced fos-mediated 
differentiation responses is consistent with the differentiation signals regulated by fos 
expression in the epidermis particularly those in the decisions to commit to differentiation 
(Fisher et al., 1991; Greenhalgh et al 1993b;  Basset-Seguin et al., 1994; Angel et al., 2001; 
Mehic et al., 2005; Gerdes et al., 2006 ); whilst the roles for fos in cornification (Candi et al., 
263 
 
2005) may contribute to the early accelerated differentiation that gave rise to the IFE 
acanthosis and the significant keratosis so that each epidermal fold became the overt scales of 
the pangolin-like skin. It remained to be seen whether this response to the combinations of 
fos/PTEN and β-catenin co-operation were dependent on p53, p21 or both.  
7.3 Loss of p53 in HK1.fos-K14creP.Δ3β-catflx/wt mice blocks Δ3β-catenin 
phenotypes  
As outlined above, the responses to Δ3β-catenin activation in HK1.fos-K14creP.Δ3β-catwt/flx 
mice appeared to completely block tumour formation, as previously observed in HK1.ras-
K14creP.Δ3β-catflx/wt cohorts, even with up to three potent mutations as in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt cohorts. Further, here there was a distinct and novel 
increase in the differentiation responses that led to a pangolin-like skin. Alongside roles for 
excessive E-cadherin co-operation with Δ3β-catenin that led to the return of [a confused] K1 
expression profile in basal layers was the increased expression of p53 and p21 in the resultant 
sporadic IFE and their strong expression in the HFs. Previous studies showed compensatory 
p53/p21 was also observed in HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology (Yao et al., 2008) 
and this suggests that again in juvenile mice with a leaky K14cre gene switch, elevated 
p53/p21 [amongst others eg p63/p73/K15] were quickly deployed to counter anomalous β-
catenin expression.  
Consistent with Δ3β-catenin enhancement of HK1.fos interference with normal c-fos functions 
in proliferation, stem cell decisions and differentiation  (Angel et al., 2001; Mehic et al., 2005; 
Gerdes et al., 2006) logically, increased p53 inhibits proliferation and provides protection 
against additional mutations; whilst increased p21-associated differentiation responses (Topley 
et al.,1999) avoids potential p53-induced apoptosis to maintain the paramount barrier function 
of skin (Calautti et al.,2005; Yao et al., 2008; Macdonald et al., 2014) and also aids in 
proliferation control to inhibit tumourigenesis. 
However, it remained to be seen whether the combinations of fos/PTEN and β-catenin co-
operation would now give rise to tumours if p53 was lost and whether this resulted in KA or 
malignancy. Generating the HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx genotype not only tested 
whether this could elicit tumours, but also addressed whether these excess differentiation 
responses to fos [PTEN] and β-catenin co-operation were dependent on specific p53-mediated 
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responses to β-catenin activation, as observed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx 
models.  
Yet several questions remained, i.e. if the strong differentiation responses observed in 
HK1.fos-K14creP.Δ3β-catwt/flxmice were again blocked by p53 loss, it may indicate that this 
was a general response to β-catenin deregulation and not just specific to HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx models. This block may depend upon wild type p53 expression 
functions or alternately may depend upon specific responses e.g. whether p63/73 expression in 
response to p53 loss again altered specific KPC populations [via K15 expression/Lgr 5 & 6] 
that also successfully nullified anomalous β-catenin/HK1.fos co-operation.  
Therefore, to begin to examine the role of p53 in tumour inhibition and the appearance of the 
pangolin-like skin phenotype, a conditional p53 knockout was bred in HK1.fos-
K14creP.Δ5PTENflx/flx and the preliminary data from initial HK1.fos-K14creP.Δ3β-catflx/wt -
p53flx/flx cohorts are shown in [Fig. 7.11]. These experiments showed both a continued lack of 
tumours and again a block of the pangolin-like skin presented in HK1.fos.K14.Δ5PTEN. 
Indeed, even by 10 weeks all [n=7] HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx mice showed only 
mild hyper keratosis, if any; and a relatively normal fur [Fig. 7.11 A-C]. By this stage, the 
tagged ears also had little keratosis [Fig. 7.11 B] with a phenotype similar to HK1.fos and 
earlier HK1.fos-K14creP.p53flx/flx studies, which often possessed very minimal hyperkeratosis 
at only 10 weeks post tagging (Greenhalgh et al., 1993b;1996).  
Close inspection of HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx  back skin displayed less keratosis 
than RU486-treated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  mice which usually exhibited 
patches of keratosis after 4-5 weeks RU486 treatment [above; Chapter 5]; although not the 
pangolin like skin that emerged again in repeat parallel experiments giving typical HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice [Fig. 7.11D-F]. This suggests that similar to 
previously illustrated HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice, p53 loss in HK1.fos-
K14creP.Δ3β-catflx/wt.p53flx/flx was more potent and completely blocked the severity of Δ3β-




Figure 7. 11: Comparison of skin phenotypes in HK1.fos-K14creP.Δ3β-catflx/wt -p53flx/flx  
and HK1.fos-K14creP.Δ5PTENflx/flx .Δ3β-catflx/wt mice.  
[A] Two typical examples of RU486-treated HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx  at 10 weeks 
show only mild hyper keratosis, if any; and little in the way of a scruffy fur. [B] At this stage 
the tagged ear also has little keratosis which was similar to HK1.fos-K14creP.p53flx/flx or 
HK1.fos controls with no tumour development at this time. [C] Another HK1.fos-K14creP.Δ3β-
catflx/wt.p53flx/flx  back skin at higher magnification again lacks any keratosis; even less than a 
typical HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  and certainly far less than the pangolin-like 






The observation from HK1.fos-K14creP.Δ5PTENflx/flx and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt mice demonstrated that early activation of Δ3β-catenin in juvenile skin had a more 
severe effect on differentiation to prevent tumourigenesis compared to similar HK1.ras models 
and this again appeared to rely on compensatory p53 and p21 expression. However, it appears 
that a major discovery again centres on these HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx data, 
which demonstrate that these inhibitory responses appear to be directly dependent upon the 
presence of p53 and its loss which again completely blocked even the hyper-response 
mediated by the Δ3β-catenin enhanced HK1.fos-mediated differentiation. Moreover, unlike 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx models where some degree of keratosis was observed, 
p53 loss in HK1.fos-K14creP.Δ5PTENflx/flx completely reduced the appearance of Δ3β-catenin 
phenotypes over a longer period of time; yet without facilitating tumourigenesis as to date no 
KAs have been observed let alone SCC.  
The reasons are very unclear. In HK1.fos models this appears to be a potent response, affecting 
migration from the stem cell niches and reducing the numbers of KPC cells that potentially 
give rise to tumours, and that affect overall IFE and HF differentiation. Although yet to be 
analysed, it may be that strong compensatory p63 and p73 expression moved the proliferative 
keratinocytes out of their stem cell niche and quickly through the KPC niches and transit 
amplifying stages and this rapid transit somehow avoided the differentiation responses. 
Alternatively, the lack of p53 failed to trigger the alarms in this context thus allowing for 
normal proliferation. However, further experimentation will be required to increase animal 
numbers to assess if any individual can bi-pass this tumour inhibition, assess histopathology 
and differentiation markers and determine whether p63/p73/K15 observations also appear in 
HK1.fos.K14.Δ5PTEN.p53flx/flx   models and if this is specific to p53 via creation of 
HK1.fos.K14.Δ5PTEN.p21KO mice.  It will be important to discover what is causing 








Table 7. 1: Summary of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lack of tumours and 
unique skin phenotype 
 
Genotype analysed  [N] 
 
Analysed for 
expression of  
Data summary 
HK1.fos hyperplasia 23 β-catenin, E-
cadherin, K1, 
K6α, p53 and 
p21 
expressions 
-Control hyperplasia exhibiting suprabasal 
expression of β-catenin/E-cadherin 
-ordered terminal differentiation indicated by 
suprabasal layer K1 but expressing K6α in 
both supra and basal layers due to HK1.fos 
activation 









K6α, p53 and 
p21 
expressions 
-No IFE tumours  
-Sever increase in HF tumours and greater 
cyst formation vs HK1.ras-K14creP.Δ3β-
catflx/wt results in a pangolin like-skin 
phenotype 
-Predominance of IFE cysts formation 
-Highly disorganized epidermis 
-Increased cytoplasmic/nuclear basal layer β-
catenin with increased membranous basal 
layer β-catenin/E-cadherin due to Δ3β-catenin 
-Accelerated terminal differentiation of IFE 
keratinocytes indicated by premature basal 
layer K1 also appearing in IFE cysts 
indicating confused keratinocytes that express 
K6α as well indicating completely disrupted 
terminal differentiation 
- Nuclear expression of p53/p21in basal 
layers and in IFE cysts possibly halting Δ3β-
catenin/fos-induced proliferation and inducing 










catflx/wt -p53flx/flx  
6 ND -Complete blockage of IFE tumours and 




Conclusion: β-catenin activation co-operation with HK1.fos results in increased 
differentiation responses that block IFE tumour formation accompanied by a severe 
skin phenotype amplified by PTEN loss or HK1.ras co-operation. However, this skin 
phenotype was absent in HK1.fos-K14creP.Δ3β-catflx/wtp53flx/flx with inducible p53 loss, 



















The observation from HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice suggest that early 
activation of Δ3β-catenin in these juveniles had a more severe effect on differentiation to 
prevent tumorigenesis. Overall, these experiments found an inhibited tumor formation again 
involving p53 and p21 expression, but the K1 and K6 expression analysis in the IFE suggest it 
was the increased differentiation that appears to be the most significant event. These data 
showed that Δ3β-catenin interference of normal roles in differentiation (Gat et al., 1998; 
Niemann et al., 2002; Grigoryan et al., 2008; Kretzschmar et al., 2015) enhanced the 
HK1.fos-mediated interference of differentiation normally regulated by sporadic c-fos 
expression in basal layers (Fisher et al., 1991; Greenhalgh et al., 1993b; Basset-Seguin et al., 
1994; Angel et al., 2001) and the HF stem cell decisions to form IFE, sebocytes or HF cells 
(Gerdes et al., 2006) coupled to major roles in regulation of keratinocyte cornification in 
supra-basal layers (Candi et al., 2006). This role in cornification may be quite important given 
the supra-basal roles for both fos and β-catenin and that fos/β-catenin-mediated co-operation 
enhance not only an accelerated differentiation but also the significant premature cornification 
that led to early keratosis, so that each proliferative fold gave rise to a scale-like structure 
hence the reference to a pangolin-like skin. 
 
Thus, for the first time these HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice identified a 
direct link between fos and β-catenin activation in regulation of keratinocyte differentiation, 
consistent with photo-carcinogenesis studies that associates both instant and delayed c-fos 
responses to UV-B exposure in the epidermis with AKT activation and GSK3 inactivation 
(Gonzales and Bowden, 2002). This too strengthens links to co-operation between failure of 
PTEN-mediated AKT regulation and the axis of GSK3β/β-catenin and fos. Indeed, the often-
neglected lipo-phosphatase functions of PTEN at the cell membrane that act as a scaffolding 
protein in the assembly of adherence junctions and cell-matrix interactions (Tamura et al., 
1998; Subauste et al., 2005), could also contribute to the increased levels of E-cadherin 
observed that would also add to the degree of keratosis.  
Another important discovery in these experiments was the finding that mutant PTEN co-
operation with Δ3-βcatenin deregulation gave a novel HF histotype that closely resembles the 
trichilemmomas, a hair follicle tumour histotype produced in Cowden’s disease, a familial 
(Liaw et al 1997; Fistarol et al., 2002; Suzuki et al., 2003) cancer predisposition syndrome 
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(Liaw et al., 1997) associated with cutaneous hyperkeratosis (Fistarol et al., 2002). This again 
is a logical finding consistent with the fact that deregulation of both these proteins induces HF 
anomalies in transgenic mice (Gat et al., 1998; Niemann et al., 2002; Grigoryan et al., 2008; 
Kretzschmar et al., 2015; Suzuki et al., 2003); and this discovery is currently being actively 
pursued in separate studies. 
It appears that another major finding centres on the role of p53 in this complex model as its 
loss fails to elicit tumours yet appears necessary for either the appearance of or the inhibition 
of this intense differentiation response. These HK1.fos-K14creP.Δ3β-catflx/wt.p53flx/flx data 
again demonstrated that these inhibitory responses appear to be directly dependent upon the 
presence of p53 as its loss completely blocked the Δ3β-catenin enhanced HK1.fos-mediated 
differentiation; unlike the HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx model where some degree of 
keratosis was eventually observed. However, the fact that this occurred in two separate models 
suggests that these strong differentiation responses that depend upon p53 one way or another 
are a general response to β-catenin deregulation, and not just specific to HK1.ras- or HK1.fos-
K14creP.Δ3β-catflx/wt.p53flx/flx  models; an idea consistent with the finding of a similar response 
to endogenous β-catenin deregulation following inducible activation of ROCK2 signalling to 
the AKT/GSK3β/β-catenin axis in this K14.creP model that also altered the differentiation 
response (Masre et al., 2020).  
This differentiation response was also observed previously in the synergy between HK1.fos-
K14creP.Δ5PTENflx/flx that resulted in KA instead of SCC. Here again, Δ5PTEN-derived 
increases in p-AKT activation inactivated GSK3-β triggering compensatory p53/p21(Yao et 
al., 2008), which has now been confirmed to be also associated with elevated 
membranous/nuclear β-catenin and the corresponding increased E-cadherin [see chapter 3 Fig. 
3.3C&G; Alyamani et al., manuscript in preparation]. This KAs analysis demonstrated that the 
protective responses to endogenous β-catenin activation played a major role in KA aetiology, 
but only once a threshold level of GSK3 β-catenin inactivation was achieved (Yao et al., 2008) 
to deliver the necessary levels of nuclear β-catenin [Fig. 3.3C&G]. The fact that this was 
dependent upon p53 was revealed by progression to SCC in HK1.ras/fos-
K14creP.Δ5PTENflx/flx mice following p53 loss [Fig. 3.3D&H] where now the membranous β-
catenin component was lost, leaving the nuclear component to drive invasion alongside loss of 
E-cadherin at the invasive front. Whereas in the HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
mice, strong membranous expression of β-catenin was maintained together with strong levels 
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of E-cadherin, as observed in KA [Fig.3.3 vs Fig. 7.5 & Fig. 7.6] and again suggesting that the 
differentiation response to deregulated β-catenin involves a general differentiation response 
mediated by p53.  
The analysis of endogenous β-catenin expression in both HK1.fos-K14creP.Δ5PTENflx/flx KA 
and HK1.ras/fos-K14creP.Δ5PTENflx/flx SCC showed that depending on the context of different 
oncogene expression together with specific TSGs responses and the time when nuclear β-
catenin localization was induced governed the fate of tumour progression and conversion. It 
was these latter observations on tumour inhibition and the KA vs. SCC outcome in different 
contexts that led to questioning whether direct, earlier Δ3β-catenin activation in co-operation 
with HK1.fos-K14creP.Δ5PTENflx/flx [and similarly HK1.ras/fos ] would lead to malignant 
progression, or still give protective responses in the shape of a KA outcome and now in the 
light of the tumour inhibitory data seen in HK1.ras-K14creP.Δ3β-catflx/wt mice, would there be 
a similar out come in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice? In the final analysis in 
terms of IFE tumourigenesis co-operation in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt , 
HK1.ras/fos.Δ3β-catenin and HK1.fos-K14creP.Δ5PTENflx/flx all resulted in a lack of tumours 
which reinforce the fact that early Δ3β-catenin activation resulted in triggering epidermal 
protective responses even in the presence of several potent oncogenes: fos, Δ3β-catenin or loss 
of PTEN-mediated AKT inhibition. 
 
However, in this case, the hallmark of each HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt , 
HK1.ras/fos.Δ3β-catenin and HK1.fos-K14creP.Δ5PTENflx/flx co-operation was the appearance 
of a novel skin phenotype of overlapping and highly keratotic bands or scales with a 
concentric geometric harlequin pattern. This pattern supposes that the proliferation induced 
resulted in a folded skin which then differentiated into hardened scales resembling a pangolin 
skin [the only scaled mammal]. As this gross phenotype was observed in all three genotypes, it 
suggests that the underlying mechanism for the development of this novel pangolin like-skin 
phenotype was specifically associated with epidermal responses to β-catenin and fos 
dysfunctional interactions on normal skin homeostasis. This would be consistent with 
disruption of β-catenin roles in regulating epidermal pluripotent stem cells that are needed for 
epidermal terminal differentiation and hair follicle differentiation (Gat et al., 1998; Niemann 
et al., 2002; Grigoryan et al., 2008;  Kretzschmar et al., 2015) coupled to those of c-fos that 
also plays roles in the commitment to terminal differentiation (Fisher et al., 1991; Greenhalgh 
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et al., 1993b; Basset-Seguin et al., 1994;  Angel et al., 2001; Candi et al., 2006) and the HF 
stem cell decisions to form IFE, sebocytes or HF cells (Gerdes et al., 2006). 
 
Further, the histology of the HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice in particular 
demonstrate a very abnormal epidermis dominated by the formation of numerous novel HF 
tumours and cysts. This epidermal response is indicative of the potency of these genotypes to 
generate this type of protective response from the epidermis, in this case diversion of 
excessive proliferation into either differentiation and massive keratosis or formation of dead-
end cysts. Either mechanism would prevent further tumour formation. This novel skin 
phenotype becomes more severe with additional Δ5PTEN mutation due to AKT-associated 
activation that promotes cellular proliferation and tumourigenesis (Downward, 2004; Segrelles 
et al., 2006; Yao et al., 2008; Macdonald et al., 2014), which also disturbs epidermal terminal 
differentiation (Callutti et al., 2005). Indeed, it was speculated above that given in normal 
epidermis AKT expression is supra-basal (Masre et al., 2020), it may be geared to block p53-
mediated apoptosis giving time for terminal differentiation (Callutti et al., 2005; Yao et al., 
2008; Macdonald et al.,2014). Thus, the loss of PTEN may allow for premature AKT 
expression in basal layers adding to the proliferation and the beginnings of a disordered 
differentiation and induction of p53/p21 apoptosis to counter p-AKT activation. 
 
However, hair follicles tumours previously associated with Δ3β-catenin such as folliculoma 
and pilomatricoma (Gat et al., 1998; Niemann et al., 2002; Kretzschmar et al., 2015) have 
now significantly changed in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice when compared 
to those produced in HK1.fos-K14creP.Δ3β-catwt/flx which were similar to HK1.ras-
K14creP.Δ3β-catflx/wt mice previously analysed. Thus in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt mice, mutant PTEN co-operation with Δ3-βcatenin deregulation gave a novel increased 
numbers of HF and with a tumour histotype that appears to be trichilemmoma, a hair follicle 
tumour histotype also produced in Cowden’s disease, (Liaw et al., 1997; Fistarol et al., 2002; 
Suzuki et al., 2003). This again is a logical finding consistent with the fact that deregulation of 
both these proteins induces HF anomalies in transgenic mice (Gat et al., 1998; Niemann et al., 
2002; Kretzschmar et al., 2015; Suzuki et al., 2003); whilst the increased cyst formation [also 
in HK1.fos-K14creP.Δ5PTENflx/flx co-operation] maybe another underlying reason for the 
protective response against tumourigenesis. Previously excessive cyst formation was also 
prompted by the activation of other oncogenes such as ras and fos in conjunction with 
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Δ5PTEN (Macdonald et al., 2014). Thus, as formation of cysts has been reported previously in 
separate studies in association with over expression of β-catenin (Gat et al., 1998; Niemann et 
al., 2002; Kretzschmar et al., 2015) and also fos (Yao et al., 2008; Macdonald et al., 2014) 
this indicates that cyst formation is a common intertwined phenotype as a result of β-
catenin/fos and PTEN co-operation. 
 
E-cadherin levels also increased in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE basal 
layers and it was noticed that E-cadherin expression was particularly strongly in the 
trichilemmoma-like HF tumours. This mimicked β-catenin expression, and this intense E-
cadherin expression profile was exclusive to these HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
animals as neither HK1.fos-K14creP.Δ3β-catwt/flxskin nor HK1.ras-K14creP.Δ3β-catflx/wt 
possessed this intense E-cadherin profile. Thus, increased E-cadherin exhibited by HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt trichilemmomas and cysts is another novel tumour feature 
and suggests co-operation between β-catenin and PTEN in HF development (Gat et al., 1998; 
Huelsken et al., 2001; Niemann et al.,2002) and the resulting HF tumour type (Suzuki et al., 
2003).  
 
Moreover, the excess numbers of HF-derived cysts again suggest this is a common response to 
divert anomalous HF formation away from tumour formation and into the dead end of cyst 
formation (Young et al., 2003) as observed in HK1.ras/fosΔ5PTEN mice (Macdonald et al., 
2014). Nonetheless in the IFE of all three fos/Δ3β-catenin genotypes, increased E-cadherin 
would contribute to the inhibition of papillomas as suggested in previous studies (Kotelevets et 
al., 2001) alongside the differentiation responses elicited by HK1.fos [below; (Candi et al., 
2005; Mehic et al., 2005) that also diverted progression to KA (Macdonald et al., 2014). Thus, 
whilst β-catenin expression was strongly nuclear and membranous in the basal layer which 
was also confirmed via E-cadherin analysis indicative of strengthened cell-cell adhesions. This 
also correlated with strong p53/p21 expression, similar to that seen previously in HK1.fos-
K14creP.Δ5PTENflx/flx KA (Macdonald et al., 2014); and in analysis of HK1.ras-K14creP.Δ3β-
catflx/wt or K14creP.Δ3β-catflx/wt skin [see Chapters 3 & 5]  
Thus, in all of these genotypes, the membranous β-catenin component, and increased E-
cadherin strengthened cell-cell adhesion and with the increased p53/p21 to divert excess KPC 
proliferation into differentiation, which together combined to block tumour formation. In 
support of this idea histological analysis of the early differentiation marker K1 showed patches 
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of accelerated differentiation marked by basal layer K1 expression which also appeared 
around the cysts; whilst the hyperproliferation marker K6 showed only patchy IFE expression 
at best. As K1 possessed the AP1 binding sites that allow for fos regulation as keratinocytes 
commit to differentiate [and that are missing in the HK1 vector, hence its basal layer 
expression [Chapter 1] it now explains why K1 expression appeared in the IFE basal layers 
and accelerate differentiation. Indeed, K1 expression in the sporadic HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE was quite different to the aberrant, laterally confined 
patchy expression in HK1.ras-K14creP.Δ3β-catflx/wt which was often fairly thin. This again 
indicates a far more accelerated and premature differentiation pattern due to elevated p53/p21 
expression responding to excess β-catenin/E-cadherin, and the odd ragged nature to K1 
expression in the many patches of acanthosis possibly reflects the role of fos [and PTEN] in 
cornification (Candi et al., 2006) that are now subverted by HK1.fos/Δ3β-catenin expression.   
 
Another possible mechanism returns to the idea that constitutive activation of β-catenin returns 
the adult mouse skin to one resembling more of a neonatal state (Collins et al., 2011) a theme 
explored further in the in vitro experimentation Scatter Assay [ below]. In neonatal skin for the 
first 5-6 days the epidermis is naturally hyperplastic but e.g., lacks K6α expression and p-AKT 
is uniformly expressed in the suprabasal layer (Masre et al., 2020). Also, at day 4-6 HK 
development begins, thus in leaky HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin so many 
new HFs are being created in juveniles due to the effects of Δ3β-catenin expression that are 
then further compromised by K14.Δ5PTEN expression and fail to differentiate properly; hence 
reduced K6α and rapid degeneration into increased numbers of cysts by adulthood.    
Analysis of the hyperproliferation marker K6α supports this return to a juvenile state (Collins 
et al., 2011) as in strands of IFE HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt hyperplasia K6α 
expression was barely detectable; and whilst K6α was expressed in hair follicles and 
trichilemmomas, overall K6α expression seemed diminished compared to the follicular 
expression seen in HK1.ras-K14creP.Δ3β-catflx/wt folliculomas suggesting a less developed, 
primitive less differentiated HF. This reduced expression may again induce the response to 
divert odd anomalous HF cell proliferation into cyst formation, and not just in the KHFs but 
also in the IFE as K1 was also noted to be expressed in some cysts. This K1/K6α analysis 
indicated that these cysts originated from both IFE and HFs and that expression had fallen off 
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possibly due to the greatly disturbed terminal differentiation by HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt co-operation.  
To-date in the HK1 model this lack of K6α expression is only the second instance where it was 
weak even in HFs and suggests that this is unique to Δ3βcatenin expression and may also 
reflect the excess increased E-cadherin expression observed in HK1.fos-K14creP.Δ5PTENflx/flx 
.Δ3β-catflx/wt skin, which in turn alters the hyperproliferation signals derived from cell-cell 
interactions which are overcome by i.e. p53 and p21 [below] and possibly others e.g. p63 and 
p73 [above] that have yet to be analysed. 
 
Collectively, despite the difference in phenotype between HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt and earlier HK1.ras-K14creP.Δ3β-catflx/wt mice, the essence of the defensive 
mechanism seems to carry similar pattern to that observed in previous HK1.fos-
K14creP.Δ5PTENflx/flx KA aetiology but appearing earlier, during epidermal development; 
hence the more severe epidermal response in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt . In 
HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology, β-catenin activation led to a triggering of 
p53/p21 responses resulting in accelerated differentiation halting any possible malignant 
progression. Whereas in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt or HK1.fos-
K14creP.Δ5PTENflx/flx epidermis the timing of β-catenin activation seems to be the key 
condition that governed the appearance of massive keratosis. Here, in this context the data 
suggested that p53-mediated proliferation and increased p21-mediated differentiation aided 
the developing pangolin like-skin preventing further progression via cyst production. This was 
similar to the conclusions made in HK1.ras-K14creP.Δ3β-catflx/wt analysis, where p53/p21 
responses to Δ3β-catenin appeared to be the main reasons for blocking tumours formation 
[outlined above; chapters 4 & 5], although perhaps not via the massive differentiation 
responses observed here and those from KA aetiology (Macdonald et al., 2014).   
 
However, the situation became more complicated when conditional p53 loss was introduced to 
create the HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx genotype and began to confirm this theory in 
terms of p53 protection at least. This resulted in an inhibition of these leaky Δ3β-catenin phenotypes 
and whilst full sized non leaky mice failed to display the initial phenotypes and thus this unique 
paradoxical result was missed, despite p53 loss and ras and β-catenin activation, only two mice 
gave tumours; but these did convert to malignancy consistent with the original hypothesis as 
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observed in HK1.ras/fos-Δ4PTEN mice. It remained to be seen whether this response to the 
combinations of fos/PTEN and β-catenin co-operation were dependent on p53 or p21 or both 
given their clear implication in developing the pangolin like-skin phenotype as anti-
tumorigenesis response.  
HK1.fos-K14creP.Δ3β-catflx/wt -p53flx/flx again confirmed the essential requirement for p53 to 
elicit these Δ3β-catenin phenotypes and highlighted the fact that this co-operation completely 
blocked the appearance of a pangolin like-skin phenotype. Indeed unlike HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx where some degree of keratosis was observed, p53 loss in 
HK1.fos-K14creP.Δ3β-catflx/wt -p53flx/flx mice completely blocked Δ3β-catenin phenotypes over 
longer periods of time; yet without facilitating tumorigenesis, as to date no KAs have been 
observed, even in full sized mice.  
The reasons for this intriguing result are unclear. It may be that p53 functions are essential to 
trigger this overall response as observed in KA aetiology and were lacking in SCC, or 
alternatively compensatory p63 and p73 expression observed above, may alter the KPC niches 
to maintain a proliferative cell barrier that in this case negates the fos and p21 induction of an 
excessive commitment to terminal differentiation. However, further experimentation will be 
required to increase animal numbers to assess if any individual can bi-pass this tumour 
inhibition, assess histopathology and differentiation markers and determine whether 
p63/p73/K15 observations also appear in HK1.fos.K14.Δ5PTEN.p53flx/flx  models.  
The total disappearance of these phenotypes suggest that it is a p53-mediated response to 
HK1.fos-K14creP.Δ5PTENflx/flx that plays a major role in generating the pangolin like skin, but 
possibly not necessary for the blockage of tumours. This again returns to the central p53 
paradox: that p53 loss blocks HK1.ras or HK1.fos papilloma formation (Greenhalgh et al., 
1996) and this cannot be overcome by β-catenin activation in ras or fos models. In one context 
this appears to be due to inhibitory responses to β-catenin deregulation that depended on the 
presence of wt p53 [ but possibly not p21]; another involves responses to p53 loss, possibly 
mediated by p63 and 73 that alter the stem cell niche to prevent tumour development and 
possibly return differentiation to that of a HK1.fos.K14.Δ5PTEN.p53flx/flx   skin.  
These potent responses to p53 loss may be quite general appearing in ras/β-catenin/p53; fos β-
catenin/p53; ras/p53 and fos/p53 models to inhibit early benign tumour [papilloma/KA] 
aetiology and it remains to be seen if this response to p53 loss can inhibit PTEN/β-catenin co-
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operation in development of HF tumours also. Thus, an epidermis in being most exposed to 
environmental carcinogens has many options to prevent benign tumour formation; which may 
become lost in aggressive papillomas leading to conversion as observed in Chapter 3. This 
latter point and these results above show the importance of both context and temporal 
expression of oncogenic tumour promotion events vs. endogenous TSGs responses will govern 
the final outcome in this very complex mechanism. In the final analysis it will be important to 
exploit these findings to discover exactly what is achieving this tumour inhibition and find 
















Chapter 8: In vitro analysis of primary 
transgenic keratinocytes and cell lines 











8.1 Establishment of keratinocyte lines and resistance to calcium-induced 
terminal differentiation 
 
As outlined above, the co-operation between Δ3β-catenin, HK1.ras, HK1.fos and K14.Δ5 
PTEN expression in vivo resulted in a novel lack of carcinogenesis either with or without p53; 
and a novel co-operation between K14creP.Δ3β-catflx/wt and K14.Δ5 PTEN expression 
resulting in tumours that mimicked human trichilemmomas produced in Cowden’s disease 
patients. These results were novel, unexpected and demonstrated the power of the epidermis to 
resist early-stage tumour formation by a variety of responses and show the importance of 
regulated β-catenin to epidermal homeostasis in adults and developing juvenile epidermis. 
Further, these data show that only the analysis of β-catenin in the original HK1.fos-
K14creP.Δ5PTENflx/flx KA and HK1.ras/fos-K14.Δ5 PTEN SCC models [plus four instances in 
Δ3β-catenin mice] appear to be consistent with the original hypothesis: that β-catenin would 
co-operate with ras and fos to either convert papillomas to malignancy and/or increase 
invasiveness following p53 [and p21] loss and reduced E-cadherin.  
 
Therefore, to begin to explore these discoveries further and to directly manipulate cells in vitro 
in normal and transgenic keratinocytes, classic keratinocyte culture assays were performed 
employing cell lines derived from primary neonatal keratinocytes cultured in vitro (Hennings 
et al., 1980) with modifications that prevent spontaneous transformation (Greenhalgh et al., 
1989). These experiments assessed effects of transgene expression on differentiation signals 
and assessed: the ability of early passage cell lines [<10] to grow clonally as an indication of 
transformation; to compare cell motility as an indication of invasive potential; and seeding 
ability to test the idea that Δ3β-catenin expression had somehow returned an adult epidermis 
to a more juvenile state, as reported in previous studies (Collins et al., 2011). 
 
In total culturing and maintaining primary keratinocytes from mouse epidermis for 3-4 months 
successfully established seventeen cell lines of low passage (SC3-10) keratinocytes [Table. 
8.1] for assessment of calcium-induced differentiation in response to a staggered increased in 
calcium [0.05- 0.075-0.15 Ca2+ mM] and a test of transformation via standard carcinogenicity 
assays involving abilities to grow from single cells in low calcium media 
[immortalised/benign] or High calcium media [transformed and malignant]. It was envisaged 
that these lines would also be assessed by westerns that explored differentiation marker 
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expression [K1, K6α, K10, K14, K15] and repeat the same analysis on cells grown on 
coverslips in Low KGM low cal or Hi cal via IF and IHC. Similarly p53,p21 p63 p73 and 
Lgr5 & 6  were also planned to be investigated, together with PTEN/AKT1/β-catenin and E-
cadherin to investigate cell migration in classic scratch assays. However, these experiments 
remain to be completed.  







Normal ICR [wt 1 ; ICR1] 
Δ3β-catenin [ B1, B2 B3] 
2 
3 
Normal phenotype: no resistance to Ca2+-
mediated terminal differentiation; no clonal 
growth 
K14creP.Δ3β-catflx/wt   
KB 1 & 2 
2   Immortalized cell line; some resistance to Ca2+- 
induced terminal differentiation sporadic clonal 
growth only in Low Ca2+ KGM 
HK1.ras-K14creP.Δ3β-
catflx/wt  
KRB 1 & 2  
2 Transformed cell line; resistance to Ca2+- 
induced terminal differentiation with clonal 
growth in Low & High Ca2+ 
HK1.ras/fos.K14creP.Δ3β
-catflx/wt  
KRFB1 and KRFB2  
2  Transformed cell lines; rapid growth and 
resistance to Ca2+- induced terminal 




KFB 1 & 2  
2 Immortalized cell line; differentiated squames 
in Low Ca2+; some resistance to terminal 
differentiation. Clonal growth in Low  Ca2+ & 
slow High Ca2+ 
HK1.fos-
K14creP.Δ5PTENflx/flx 
.Δ3β-catflx/wt   
KFPB1; KFPB2; KFPB3 
3 Transformed cell lines; rapid growth and 
resistance to Ca2+- induced terminal 




KPB 1 & 2  
2  Immortalized cell line; some resistance to 
calcium induced terminal differentiation Clonal 
growth in Low & High Ca2+ 
ras.fos [transformed 
control] T52 
2 Transformed cell line and resistance to calcium 
induced terminal differentiation with Clonal 




Primary keratinocytes from all possible combinations of K14creP.Δ3β-catflx/wt  with 
HK1.ras/fos-K14creP.Δ5PTENflx/flx were established (Greenhalgh et al., 1989), including 
normal ICR controls, and lines were established for each genotype and their phenotype 
assessed as summarised in Table. 8.1. All cells were initially established in low 0.05mM Ca2+ 
media supplemented with 10% [chelated] FCS and 20% KGM and 20% fibroblast conditioned 
media, designed to prevent spontaneous keratinocyte transformation which is revealed by a 
sudden ability to easily sub-culture and maintain (Greenhalgh et al., 1989). Subsequently for 
transformed transgenic lines, most were cultured in 0.05mM Ca2+ media supplemented with 
10% chelexed FCS and 10% KGM. All cell lines were induced to differentiate by increasing 
the calcium concentration to 0.075mM for the first 24h to instigate a supra-basal morphology 
and then high calcium concentration of 0.125mM Ca2+ for a further 24hrs to complete 
differentiation resulting in morphology of squamous and cross-linked keratinocytes, which is 
the case in normal cell lines [Fig. 8.1] (Hennings et al., 1980; Greenhalgh et al., 1989).  
 
In Low Cal  [0.05mM Ca2+] media, HK1.ras-K14creP.Δ3β-catflx/wt lines rapidly achieved a 
packed monolayer within 4-5 days of plating in 60mm dishes, indicative of a lack of contact 
inhibition as the cells appear much smaller [Fig. 8.1A]. This suggests a fully transformed cell 
line, however in echoes of the in vivo observation that certain responses inhibited tumours in 
HK1.ras-K14creP.Δ3β-catflx/wt mice, after 24hrs in 0.075mM Ca2+ media surprisingly these 
cells adopted a morphology typical of spinus keratinocytes; thus mimicking transition to the 
supra basal layer as in vivo. However, these keratinocytes continued to grow in Hi calcium, 
unlike benign papilloma lines such as SP1 or 308 keratinocytes (Strickland et al., 1988; 
Greenhalgh and Yuspa, 1988). HK1.ras-K14creP.Δ3β-catflx/wt keratinocytes also became more 
tightly packed 
after 24 hours in 0.125mM Ca2+ media and showed no further signs of differentiation such as 
stratification or cornification into squamous cell [Fig. 8.1A]; a phenotype also exhibited by the 
T52 SSC line positive control [not shown (Greenhalgh and Yuspa, 1988)].  
 
Similarly, HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lines also exhibit a transformed 
morphology at confluence; but now with numerous squames and other indications of 
anomalous early differentiation in proliferative Low Cal media, such as larger spinus and 
granular cells. Thus, this was consistent with the in vivo observations that differentiation was 
accelerated in this genotype [Fig. 8.1B]. However, indicating a greater degree of 
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transformation, after 24hr in 0.075mM Ca2+ media these keratinocytes appeared indifferent to 
terminal differentiation and still retain a degree of the proliferative cobblestone morphology in 
Low Cal. Nonetheless, in Hi Cal 0.125mM Ca2+ media, HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt  keratinocytes showed an increased degree of terminal differentiation compared to 
HK1.ras-K14creP.Δ3β-catflx/wt cells; such as attempted stratification and formation of granular 
cells [Fig. 8.1B], again consistent with the increased differentiation observed in vivo.  
 
In contrast, K14creP.Δ3β-catflx/wt lines showed a near normal basal layer morphology in Low 
Cal 0.05mM Ca2+ media, with normal sized cells that committed to differentiate in 0.075mM 
Ca2+ media but got no further and exhibit a similar spinus layer morphology in Hi Cal media 
rather than stratification and cornification [Fig. 8.1C]; a result again consistent with the lack of 
hyperplasia observed in vivo and only sporadic K1 expression. For comparison, normal 
keratinocytes showed the typical cobblestone morphology in proliferative 0.05mM Ca2+ media 
and almost complete stratification and cell loss in response to calcium induced terminal 
differentiation in both 0.075mM Ca2+ and 0.125mM Ca2+ media; thus showing their sensitivity 
to media conditions and the continued use of media supplemented with 20% fibroblast 
conditioned media to maintain their growth (Greenhalgh et al., 1989). 
 
Collectively, these data suggests that in vitro, β-catenin activation induced cellular 
transformation and proliferation in a manner more consistent with accepted dogma (Morin, 
1999; Polakis, 1999; Doglioni et al., 2003; Grigoryan et al., 2008; Krishnamurthy and 
Kurzrock, 2018); and also demonstrate the differences in phenotypes in vitro compared to in 








Figure 8. 1: Assessment of cell line growth in Low calcium media and response to 
calcium-induced terminal differentiation.  
Cells were seeded at 5x 106 cells per dish in 0.05mM Ca2+ and three days later cells were 
switched to 0.075mM Ca2+ for 24hours to initiate differentiation and then to 0.125mM Ca2+ for 
a further 24 hours to complete the latter stages of differentiation and formation of 
cornified squames.  
[A] In low Cal media HK1.ras-K14creP.Δ3β-catflx/wt line KRB1 exhibits a packed monolayer 
indicative of a lack of contact inhibition as the cells appear much smaller with many floating 
cells. At 24hr in 0.075mM Ca2+ media surprisingly these cells adopted a morphology typical of 
spinus keratinocytes; thus mimicking transition to the supra basal layer; but cells continue to 
grow and became packed tighter after 24 hours in 0.125mM Ca2+ media and show no further 
signs of differentiation such as stratification or cornification into squamous cells  
[B] HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt line KFPB1 exhibits a transformed morphology 
at confluence; with numerous squames and other indications of anomalous differentiation in 
proliferative Low Cal media. At 24hr in 0.075mM Ca2+ media these keratinocytes still retain a 
degree of Low Cal morphology consistent with their transformed nature. In 0.125mM Ca2+ 
media, these cells show a degree of terminal differentiation such as attempted stratification 
and formation of granular cells. [C] K14creP.Δ3β-catflx/wt line KB1 shows a near normal basal 
layer morphology in Low Cal 0.05mM Ca2+ media with normal sized cells that commit to 
differentiate in 0.075mM Ca2+ media but go no further and exhibit this spinus layer 
morphology in Hi Cal 0.125mM Ca2+media rather than stratification and cornification. 
[D] Normal ICR1 keratinocytes show the typical cobblestone morphology in 0.05mM Ca2+ and 
almost complete stratification and cell loss in response calcium induced terminal 
differentiation in both 0.075mM Ca2+ and 0.125mM Ca2+ media; thus showing their sensitivity 
to media conditions. Scale Bar: 20µm. 
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8.2 Analysis of cell lines growth from clonal density and correlation with a 
transformed or immortalised phenotype 
Clonal growth assays were conducted on all cell lines to assess their ability to grow from 
single cells which for primaries cultured in Low Cal 0.05mm Ca2+ KGM media represents 
immortalisation and early-stage transformation no longer requiring communication with other 
cells; whilst culture and growth in Hi cal 0.125mm Ca2+ media is a stringent test of their 
transformation status. In repeat experiments, 12 dishes per cohort of low passage [Sc 3-5] cell 
lines were plated at approx. 250 cells per 60mm dish in 0.05mm Low Ca2+ [6 Dishes] and 24 
hours later a cohort was switched to Hi Cal media 0.125mm Ca2+ [6 Dishes]. Cells were 
maintained for 30 days and then formalin fixed and stained with Rhodamine B, a keratinocyte 
specific stain. Although all cell lines were assessed, the salient results from representative 
lines are given in [Fig. 8.2].  
Both HK1.ras-K14creP.Δ3β-catflx/wt and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt grew well 
at clonal density in both Low and Hi Cal media indicating a highly transformed state. Indeed 
by 28 days even in Hi Cal media cohorts of HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lines 
KFPB1 [shown], KFPB2 and KFPB3 were fully confluent; whilst HK1.ras-K14creP.Δ3β-
catflx/wt lines KRB1 [shown] and KRB2 were still growing from colonies; although the Low 
Cal cohorts were fully confluent by this time [Fig. 8.2A vs. B]. HK1.ras.fos.K14creP.Δ3β-
catflx/wt lines KRFB1 and KRFB2 also exhibited this more fully transformed growth producing 
confluent dishes in both Hi and Low Cal media, as did the ras/fos T52 SCC line (Greenhalgh 
and Yuspa, 1988); whereas HK1.fos-K14creP.Δ3β-catwt/flx lines KFB1 and KFB2 were more 
similar to HK1.ras-K14creP.Δ3β-catflx/wt line KRB1 with confluence reached by day 28, but 
only producing colonies in Hi Cal media [not shown].  
K14creP.Δ3β-catflx/wt  lines KB1 [and KB2 not shown] grew from clonal density only in Low 
Cal [0.05mM Ca2+] media [Fig. 8.2C], which suggests that this line is immortalized but not 
fully transformed to malignancy; although grafting or sub-cutaneous injection would be 
needed to confirm this and to confirm their benign nature based on previous studies would 
produce either a hyperplastic skin or benign papilloma when grafted onto nude mice, but no 
sub-cutaneous tumours (Greenhalgh and Yuspa, 1988; Greenhalgh et al., 1989). In contrast all 
lines without K14.creP or HK1.ras and fos showed no growth at all even from clonal density 




Figure 8. 2: Assessment of cell line clonal growth in Low calcium [proliferative] or Hi 
calcium [differentiation] media.  
[A] HK1.ras-K14creP.Δ3β-catflx/wt line KRB [passage 4] and [B] HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt [passage 5] showed growth from clonal density in both low 
calcium (0.05mM Ca2+) and high calcium (0.12mM Ca2+) concentrations, which indicates 
these lines are fully transformed and malignant. [C] K14creP.Δ3β-catflx/wt line KB1 [passage 3] 
grows in low calcium concentration (0.05mM Ca2+) only, which suggest this line is 
transformed but benign. [D] Δ3β-catenin line B1 [passage 3] without K14creP displays normal 






8.3 Analysis of cell line ability to seed from a confluent monolayer indicative 
of a juvenile phenotype 
The above experiments assessed effects of transgene expression on differentiation and clonal 
growth as an indication of transformation. In a third series of experiments, transgenic cell lines 
were assessed not just for their motility as an indication of invasive potential; i.e. the rate cells 
grow past a specific point after they reached confluence as in standard scratch assays; but also 
to assess their ability to seed from a confluent monolayer. This simple experiment was 
primarily designed to test whether the fully transformed cell lines exhibited a loss of adhesion 
by being able to seed and scatter to form outlying colonies and thus mimic individual rather 
than collective modes of tumour invasion (Hesse et al., 2016) and experiments were planned 
to assess expression of β-catenin and E-cadherin at the monolayer edge but remain to be 
performed. This experiment also tested the idea that Δ3β-catenin expression returns adult 
keratinocytes to a more juvenile state, as reported in previous studies (Collins et al., 2011) and 
as suggested by K6α and p63/K15 expression in vivo.  
 
Typically, non-transformed but immortalised keratinocyte lines established by this method 
(Greenhalgh et al., 1989) cease to be able to seed such satellite colonies by passage 3-5; 
unlike their normal primary counterparts where satellite colonies are common- as an indication 
of the presence of numerous stem–like/PCK cells in keratinocyte monolayers derived from 
new born vs. adult mouse skin, which are far more complicated to culture (Morris et al.,2004; 
and references therein).  
  
A Scatter Assay involved simply initial culturing of lines in T25s flasks plated at 300 angle, 
and grown to confluence. Three/Four days later these T25s were laid flat and carefully treated 
with appropriate calcium concentrations [Low and High] to observe their ability to migrate 
past a determined growth line and also seed the free areas and then produce colonies [Fig. 
8.3]. For each cell line six T25s were prepared and after reaching confluence three flasks were 
kept in low calcium concentrations and three challenged with high calcium to induce 
differentiation. Two weeks later, cells were fixed stained and their ability to form colonies 
assessed blind by 3 individual and the average number of colonies per flask from repeat 




The most transformed HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt line showed the highest SF 
scores in both low (5/5) and high (4/5) calcium media, suggesting that this line was quite 
malignant with a high probability of invasive capabilities [Fig. 8.3A]. This result was 
consistent with the loss of E-cadherin at the invasive front of HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs together with nuclear β-catenin but was inconsistent with the 
strong E-cadherin observed in vivo in these cohorts. Similarly transformed HK1.ras-
K14creP.Δ3β-catflx/wt line KRB1 showed a high scatter factor score in low (4/5) calcium 
concentration; but less so in Hi Cal with a lower score (2/5) in high calcium concentration 
[Fig. 8.3B] indicating that this line may be malignant but still possessed sufficient focal 
adhesions to invade collectively rather than individually during malignant progression. Ideally 
growth on coverslips and assessment of E-cadherin and β-catenin via IF /IHC would help 
answer this question. 
K14creP.Δ3β-catflx/wt line KB1 also had a SF score of 2/5 in Low Cal but no seeding was 
observed in high calcium medium [Fig. 8.3C]. This indicates Δ3β-catenin activation alone 
may achieve a return to the juvenile phenotype ability to seed colonies but the line may remain 
benign given the lack of seeding in Hi Cal media, with possibly minimal reduction of focal 
adhesion. The normal appearing Δ3β-catenin line B-1 [Fig. 8.3D], along with wild type line 
ICR1 [not shown], scored a scatter factor of 0/5 in both calcium concentrations, confirming 
that typically immortalised normal mouse lines lose the capacity to seed, unlike primary 
keratinocytes; unless spontaneously transformed (Greenhalgh et al., 1989). 
These data therefore suggest that all Δ3β-catenin lines are able to seed/scatter in a manner 
similar to neonatal primary keratinocytes and support the idea that β-catenin overexpression 
may return the epidermis to a more juvenile state as suggested in previous studies (Watt and 
Collins, 2008; Collins et al., 2011) an idea also suggested by epidermal lineage studies 
(Kretzschmar et al., 2015). This ability was especially pronounced in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt lines and may indicate a 
reduction in cell-cell adhesion signalling causing these to mimic invasion consistent with a 
malignant phenotype. This observation is also constant with endogenous β-catenin activation 
in vivo where loss of focal adhesion with E-cadherin facilitated malignant progression in tri-
genic HK1.ras/fos-K14creP.Δ5PTENflx/flx mice [see Chapter 3]. These data also highlight that 
in vitro β-catenin activation [Δ3β-catenin] apparently results in a decrease in cell-cell adhesion 
in certain combinations which facilitate cell invasion, unlike in vivo were the epidermis is able 
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to respond to Δ3β-catenin activation via an increase in cell-cell adhesion as demonstrated by 
E-cadherin analysis [see Chapters 4, 5 & 7].  
 
 
Figure 8. 3: Scatter Assay: assessment of cell line ability to migrate and seed colonies. 
Cells were seeded at 5x106 cells per 25cm flask in 0.05mM Ca2+ and flasks grown at an angle 
of 300 for three days until confluent. Flasks were carefully re-fed and cultured horizontally with 
one set switched to 0.075mM Ca2+ for 24hours to initiate differentiation and then to 0.125mM 
Ca2+ for 10 days. Cells were fixed in formalin and stained with Rhodamine B. The ability to 
seed was given a scatter factor of 1-5; independently scored blind by 3 individuals and 
averaged from counts of 3 flasks per cohort in repeat experiments.    
[A] Transformed HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt line KFPB1 showed the highest 
SF score in both low (5/5) and high (4/5) calcium media and scattered the farthest [brackets] 
also the main bulk of these cells migrated the farthest. [B] Transformed HK1.ras-
K14creP.Δ3β-catflx/wt line KRB1 also showed a high scatter factor score in low (4/5) calcium 
concentration; but less so in Hi Cal with a lower score (2/5). [C] K14creP.Δ3β-catflx/wt line KB1 
showed a scatter score of 2/5 in Low Cal with no seeding observed in high calcium medium. 
Also, the colonies were close to the confluent migrating front. [D] Normal appearing 
transgenic line B-1 [non-crePΔ3β-catenin] scored a scatter factor of 0/5 in both calcium 
concentrations, [as did ICR1 and wt-1] confirming that typically immortalised normal mouse 






8.4 SUMMARY  
Classic keratinocyte culture assays were performed employing cell lines derived from primary 
neonatal keratinocytes cultured in vitro to assess effects of transgene expression on 
differentiation and transformation and provide cells for western/IF/IHC analysis. The first 
series of experiments assessed differentiation responses to calcium-induced terminal 
differentiation via a challenge with 0.125mM Ca2+ [High calcium] medium. The second tested 
the ability to grow clonally again as an indication of immortalisation and partial 
transformation. Finally, a third series of experiments tested the seeding ability and cell 
motility, not only as an indication of invasive potential but also to test the idea that Δ3β-
catenin expression maintains a neonatal/juvenile phenotype, as suggested in previous studies 
that investigated β-catenin expression in keratinocytes and the ECM (Collins et al., 2011) and 
also β-catenin effects on the emerging variety of KPC/stem cell niches (Watt and Collins, 
2008; Kretzschmar et al 2015).  
In classic calcium induced terminal differentiation assays (Hennings et al., 1980; Greenhalgh 
et al., 1989; Morgan et al., 1992) all compound lines such as HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt displayed resistance to 
Calcium-induced differentiation, as expected given their rapid growth and carrying multiple 
oncogenes activation in addition to Δ3β-catenin. These data are more consistent with what was 
originally hypothesised as these cells exhibited classic patterns of transformed keratinocytes, 
which indicate that Δ3β-catenin activation in vitro induced transformation via overexpression 
of the canonical Wnt signalling pathway resulting in increased proliferation and a delay or 
resistance to normal epidermal differentiation which was  also constant with the literature 
dogma that β-catenin gain of function would facilitate tumorigenesis (Morin, 1999; Polakis, 
1999; Doglioni et al., 2003; Grigoryan et al., 2008; Krishnamurthy and Kurzrock, 2018).  
 
Nonetheless, whilst these results contrasted with the in vivo observations most likely due to 
disruption of tissue homeostasis and thus monolayers in vitro lack the responses available in 
vivo to counter β-catenin deregulation there were subtle differences between these lines that 
echo in vivo results. For instance, HK1.ras-K14creP.Δ3β-catflx/wt lines adopted a morphology 
typical of spinus keratinocytes in 0.075mM Ca2+; thus mimicking an accelerated transition to 
the supra basal layer as suggested in vivo. However consistent with a lack of correct K1 
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expression in vivo these cells continued to grow in Hi calcium consistent with a fully 
transformed malignant line, as finally observed in the rare SCC tumours of HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice. Often in vitro p53 is also lost/mutated as cells become 
immortalised and transformed  e.g. the spontaneous human HaCaT keratinocyte cell line 
(Boelsma et al., 1999), and the transformed SP1 benign papilloma cell line being derived from 
DMBA/TPA papillomas with activated rasHa which are transformed but not malignant in nude 
mouse graft assays and T52 malignant keratinocyte cell line where SP1 cells were transfected 
with FBJ v-fos to become malignant (Strickland et al., 1988; Greenhalgh and Yuspa, 1988). 
Hence, p53 has been found to normally regulate embryonic stem cell proliferation by 
activating β-catenin dependent, canonical Wnt signalling amongst other pathways (Lee et al., 
2010). 
 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lines also exhibit a transformed morphology at 
confluence, but possessed numerous squames and many floating cells suggesting attempts to 
differentiate in low Cal. However, these keratinocytes resisted forming spinus cells in 
0.075mM Ca2+ and required full Hi Cal to commence differentiation; but then these did 
differentiate to some extent consistent with the excess keratosis observed in vivo and the return 
of K1. These lines thus echo the odd differentiation evoked by fos/PTEN/βcatenin co-
operation and it may be that the excess of floating cells continually observed in low Cal media 
and the granular/squames in Hi Cal reflect attempts to de-differentiated into cysts and die.    
 
Furthermore, whist K14creP.Δ3β-catflx/wt exhibited a normal cobblestone basal layer 
morphology in Low Cal 0.05mM Ca2+ media and committed to differentiate in 0.075mM Ca2+ 
media this differentiation appeared to stall at this spinus morphology stage and exhibit a 
similar spinus layer morphology in Hi Cal media rather than stratification and cornification. 
This result echoes the sporadic K1 expression and may reflect the minimal interfollicular 
hyperplasia compared to a HK1.ras as the supra-basal roles of β-catenin in regulating terminal 
differentiation are altered by Δ3β-catenin (Grigoryan et al., 2008). Thus, in planned 
western/IF and IHC analysis, early differentiation marker K1 maybe abnormally expressed in 
Low Cal whilst expression of the hyperproliferation marker K6α maybe reduced again as in 
previous studies that showed altered K6 expression with a gain-of-function β-catenin (Van 
Mater et al., 2003).  
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The second series of experiments conducted on these cells tested their ability to grow from 
clonal density in both low and high calcium concentrations, which is a classic carcinogenicity 
assay (Hennings et al., 1980; Greenhalgh et al., 1989; Morgan et al., 1992). Clonal growth 
assays for cells cultured in Low Cal 0.05mm Ca2+ KGM media represents immortalisation and 
early-stage transformation, with cells being somewhat self sufficient no longer requiring 
communication with other cells; whilst culture and growth in Hi Cal 0.125mm Ca2+ media is a 
stringent test of their transformation status. In addition, this assay also tests for stem-like or 
KPC phenotypes that have been maintained or reactivated by β-catenin overexpression as 
suggested in previous studies (Watt and Collins, 2008) and epidermal lineage studies 
(Kretzschmar et al., 2015).   
 
Most of the β-catenin overexpressing cell lines were able to grow from clonal density in Low 
Cal media but only HK1.ras-K14creP.Δ3β-catflx/wt and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-
catflx/wt lines were able to grow from clonal density in Hi Cal media which indicated their fully 
transformed nature. Cells able to grow in low calcium such as K14creP.Δ3β-catflx/wt alone are 
usually benign in nature when grafted onto nude mice and those able to grow in high calcium 
are often malignant in this assay (Strickland et al., 1998; Greenhalgh and Yuspa, 1998; 
Greenhalgh et al., 1989; 1990; Morgan et al., 1992). Since these data now show growth in 
high calcium concentrations in cell lines carrying Δ3β-catenin in co-operation with 
ras/fos/Δ5PTEN, suggesting that K14creP.Δ3β-catflx/wt  alone achieves a benign hit and in co-
operation with other oncogenes, deregulated β-catenin results in a malignant phenotype that 
fits the current dogma of β-catenin oncogenicity (Morin, 1999; Polakis, 1999; Doglioni et al., 
2003; Grigoryan et al., 2008; Krishnamurthy and Kurzrock, 2018) but miss the nuances of the 
in vivo findings.  
 
Some of the most fascinating in vitro data came from the simple scatter assays that were 
originally envisaged to test whether the fully transformed cell lines mimicked an individual or 
collective mode of tumour invasion via migrating as an invasive front or via seeding.    
These experiments also tested the idea that Δ3β-catenin expression returned adult 
keratinocytes to a more juvenile state, as reported in previous studies (Collins et al., 2011) as 
suggested by K6α and p63/K15 expression data in vivo. Typically, normal immortalised 
keratinocyte lines established by this method (Greenhalgh et al., 1989) cease to be able to 
seed such satellite colonies by passage 3-5; unlike their normal primary counterparts where 
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satellite colonies are common given the presence of more numerous stem–like/KPC 
populations derived from newborn vs. adult mice, (Morris et al., 2004). 
 
These experiments showed that all Δ3β-catenin lines were able to seed/scatter especially in 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt cohorts. This 
indicated a reduction in cell-cell adhesion signalling giving the cells this ability to invade as a 
series of individuals consistent with a malignant phenotype and progression to aggressive 
possibly metastatic nature. Although yet to be analysed these observations would be consistent 
with endogenous β-catenin activation becoming less membranous, as observed in vivo, 
together with reduced E-cadherin at the invasive front, which would result in a loss of focal 
adhesions to facilitate the invasion observed in HK1.ras/fos-K14creP.Δ5PTENflx/flx tri-genic 
mice. This also brings in the necessity of future analysis for these cell lines via western blot 
for expression of different proteins [p53, p21, K1,AKT,etc] as initial western analysis to date 
has only confirmed the cre-mediated expression of Δ3β-catenin. 
Nonetheless, the ability of these lines to seed coupled to the seeding displayed by 
K14creP.Δ3β-catflx/wt cells but not normal non-cre Δ3β-catenin β-1 cells nor ICR-1 or Wt-1 
lines does indeed suggest that here deregulated β-catenin expression may return K14creP.Δ3β-
catflx/wt cells to a more juvenile/neonatal state now able to seed distant colonies as observed in 
all primary keratinocyte cell cultures. This result was consistent with the lack of K6 
expression observed in this model and previous studies that concluded that gain-of-function β-
catenin affects the dermal extra cellular matrix and appeared to return the skin to neonatal 
state (Collins et al., 2011). This idea was also suggested by epidermal lineage studies 
(Kretzschmar et al., 2015) and this ability was especially pronounced in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt lines which would also 
be consistent with a de differentiation into a highly proliferative state as observed in neonatal 
epidermis-an idea supported by hyperproliferation marker K6α being barely detectable as in 
neonatal mice (Rothnagel et al., 1999; Masre et al., 2020).  
Collectively these data suggest that all Δ3β-catenin lines are able to seed/scatter in a manner 
similar to neonatal primary keratinocytes to support the idea that β-catenin overexpression 
returns the epidermis to a more juvenile state (Watt and Collins 2008; Collins et al., 2011 
Kretzschmar et al., 2015) They also show the major differences between in vitro and in vivo 
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findings that indicate the in vitro analysis lacks the biological spectrum needed to generate 
results observed in vivo. However, clonal growth and seeding in Low Cal would be consistent 
with Δ3β-catenin mediated influences on stem cells or a return to a more stem-like PCK 
phenotype; whilst growth in Hi Cal demonstrate that at least in vitro these combinations with 
β-catenin definitely fulfilled all criteria requited for a malignant phenotype in these classic 
transformation assays; consistent with the HK1.ras/fos/PTEN model of Chapter 3 and the 




































The β-catenin protein is known to have two main functions. In the cytoplasm, β-catenin bind 
to E-cadherin to form the cell-cell adhesion complex that is needed for calcium dependent 
adhesion between the cells that aids roles in morphogenesis and tissue homeostasis (Takeichi, 
1991; Young et al., 2003), thus impairment of this function has been associated with 
facilitating tumourigenesis most likely in terms of cell invasion (Jeanes et al., 2008). The 
other major function of β-catenin is in the nucleus as a transcriptional activator of canonical 
Wnt/β-catenin signalling nuclear targets [LEF/TCF] and again increased nuclear expression of 
β-catenin has been associated with facilitating cancer invasion and metastasis (Morin, 1999; 
Grigoryan et al., 2008). Given that β-catenin controls these two critical cellular functions, 
gain-of-function mutations in β-catenin i.e., particularly those in exon 3 that prevent down 
regulation, have been associated with diverse types of cancers such as colon, prostate, ovarian, 
melanoma and non-melanoma skin cancers (Morin, 1999; Gerdes and Yuspa, 2005; 
Grigoryan et al., 2008).  
 
In this study these roles for β-catenin overexpression were investigated in a transgenic mouse 
model of multistage skin carcinogenesis to assess the causal roles and determine when β-
catenin became active. These models were envisaged to mimic the development of non-
melanoma skin cancers specifically SCC given the more clinically aggressive nature and 
potential for metastasis, as BCC were mostly associated with de-regulation of Wnt signalling 
at earlier stages e.g., sonic hedgehog [SHH] (Clifford and DiGiovanni, 2010; Huang and 
Balmain, 2014). The implication of β-catenin in developing SCC in human is driven from the 
fact that Wnt/β-catenin nuclear overexpression was a known phenomena in humans SCC 
aetiology (Malanchi, et al., 2008) and that mutations often resulted in constitutive 
overexpression via either direct β-catenin gene mutation in exon 3 or in genes that regulate β-
catenin levels such as APC and GSK3β (Grigoryan et al., 2008). Further in reverse, the 
importance of β-catenin in carcinogenesis was supported by findings in two-stage chemical 
carcinogenesis studies, where similar endogenous β-catenin gain of function was reported in 
DMBA/TPA induced SCCs (Malanchi, et al., 2008; Grigoryan et al., 2008) whilst functional 
inactivation resulted in tumour inhibition (Malanchi, et al., 2008; Grigoryan et al., 2008).  
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These studies indicated that β-catenin was a necessity for developing SCC and additional 
studies also suggested that β-catenin overexpression contributes directly to the development of 
cancer stem cells to incorrectly control of β-catenin regulation in the HF bulge region; a 
logical conclusion given this is the location of a major stem cell niche in the skin (Malanchi, et 
al., 2008). However, despite the clear relevance of β-catenin in the development of SCC, 
surprisingly to date, it appears that no study has directly explored constitutive activation of β-
catenin in the classic multi-stage carcinogenesis model to unravel the exact mechanism of the 
roles of β-catenin in SCC. This maybe due to the fact that most studies of β-catenin [both 
overexpression and functional knockout] in mouse skin were associated with the HF 
anomalies and HF tumours derived from the Wnt/β-catenin roles in regulating HF 
differentiation and morphogenesis via activation of LEF/TCF; but it may also be due to 
unreported findings such as those in this current study that effect viability (Järvinen et al., 
2006). 
 
To begin to address this, inducible constitutive β-catenin overexpression was targeted to the 
skin employing a Cre/loxP system and co-operation assessed with activated ras and fos 
oncogenes and loss of TGS PTEN, p53 and p21. This approach derived from previous studies 
which showed that the HK1 mouse model of carcinogenesis in this model, loss of PTEN, and 
overexpression of AKT-mediated GSK3-β inactivation was found to trigger compensatory 
p53/p21 expression in KA formation in HK1.fos-K14creP.Δ5PTENflx/flx mice; whilst in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx mice, p53 loss resulted in malignant at conversion and p21 
loss resulted in malignant progression, all associated with AKT/GSK3 and thus implicating β-
catenin. As shown in Chapter 3 this proved to be the case as now formal investigation of 
endogenous β-catenin demonstrated that overexpression in the proliferative basal layers 
appeared in papillomas and KAs whilst invasive SCCs demonstrated strong nuclear β-catenin 
expression associated with a lack of membranous expression that supported a role alongside 
loss of E-cadherin in tumour invasion. This result was consistent with the literature, as was the 
initial series of experiments reported in Chapter 4 that targeted constitutive β-catenin 
expression to the epidermis, as K14creP.Δ3β-catflx/wt mice showed all the hallmarks of HF 
anomalies, altered bone development, and general keratosis observed in the classic earlier 
studies- but with a lack of IFE tumours showing the necessity of additional initiating and 
promoting events.   
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However, these logical results appeared to be highly context dependant and dependent upon 
the cell type [stem/KPC/transit amplifying] or timing of β-catenin deregulation. This was 
clearly seen in Chapter 5 and the intriguing results of inducible β-catenin[Δ3β-catenin] in co-
operation with HK1.ras, where the vast majority of mice lacked tumours development 
probably due to compensatory p53/p21 expression in this context. Moreover, and adding 
further complexity, this lack of tumour development was also repeated in HK1.ras-
K14creP.Δ3β-catflx/wt co-operation experiments with inducible conditional loss of p53, where 
most mice still resulted in a lack of tumorigenesis [see Chapter 6]. Another important finding 
was that the epidermal responses to β-catenin deregulation appeared to be dependent upon p53 
expression [but apparently not p21]. Yet in the rare instances of papilloma formation which 
overcame this paradoxical tumour block in HK1.ras-K14creP.Δ3β-catflx/wt genotypes the 
tumours remained papilloma whereas in HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx mice once 
started the papillomas rapidly converted to tumours with histotypes of papilloma, wdSCC, 
SCC and pdSCC within the same tumour; consistent with loss of the p53 guardian roles and 
increasing mutations and again nuclear β-catenin with loss of E-cadherin at the invasive front. 
All findings more consistent with the literature on progression and invasion.   
The induction of HK1.fos and Δ5PTEN with Δ3β-catenin also resulted in a lack of tumours but 
with more aggressive skin keratosis due to mainly differentiation responses to the activation of 
these oncogenic hits [See Chapter 7]. These experiments demonstrated direct co-operation 
between fos and β-catenin deregulation, and the excess differentiation observed is consistent 
with their roles in the commitment to differentiate and their roles in the decision-making of 
stem cells in their various niches.  Another important finding was observed in 
K14.Δ5PTEN.Δ3β-catenin mice which demonstrated a change in HF tumours from folliculoma 
to trichilemmomas observed in Cowden’s Disease; also consistent with their roles in HF 
development and this model may be useful to explore further this HF tumour type. 
In vitro, activation of Δ3β-catenin with ras/fos/and PTEN loss again showed classic signs of 
immortalisation and transformation to a malignant phenotype, similar to known β-catenin roles 
in carcinogenesis reported in the literature but cultured cell cannot deploy the same responses 
as intact tissue. This chapter discusses the most possible reasoning for the intriguing and 




9.1 Endogenous β-catenin overexpression in multistage HK1.ras/fos-
K14creP.Δ5PTENflx/flx carcinogenesis fits current dogma. 
The HK1model of carcinogenesis was ideal to study possible β-catenin roles at each stage of 
tumour formation (Greenhalgh et al., 1993a-c; Yao et al., 2006; 2008; Macdonald et al., 
2014) given the stage-specific stability of the induced phenotypes where benign papillomas do 
not spontaneously convert (Greenhalgh et al., 1993c) without an additional oncogenic activity 
such as activation of AKT via inducible PTEN loss or TPA promotion (Yao et al., 2006; 2008; 
Macdonald et al., 2014). β-catenin was implicated in this model following results that 
highlighted inactivated GSK3-β via AKT mediated by PTEN loss triggered elevated levels of 
p53 and p21 diverting papilloma formation into massive accelerated differentiation giving the 
classic benign KA aetiology (Yao et al., 2008). These compensatory responses deployed by 
the epidermis to maintain its homeostasis and inhibit tumour progression are a theme running 
through all the findings in these experiments.  
The assumed overexpression of β-catenin was then confirmed in this study (Alyamani et al., in 
prep) and the β-catenin expression profile showed that KAs maintained elevated levels of 
nuclear β-catenin whilst still maintaining membranous β-catenin/E-cadherin expression 
correlated with elevated levels of basal p53/p21 that accelerated commitment to differentiation 
evident by basal K1 expression (Yao et al., 2008). Thus, indicating that in this context 
responses to β-catenin overexpression can have inhibitory roles on tumorigenesis via invoking 
compensatory TSGs [p53/p21] expression. This highlights the sensitivity of the epidermis to 
alterations in β-catenin levels as a similar observation was repeated in ROCK2 mice where 
again such β-catenin -mediated p53 expression inhibited papilloma formation (Masre et al., 
2020).  
However, in HK1.ras/fos-K14creP.Δ5PTENflx/flx co-operation SCCs were formed, and again β-
catenin overexpression was hypothesised due to AKT associated GSK3-β inactivation. Here 
with added HK1.ras activation, the expression profile was different than that of KA, where β-
catenin exhibited mostly an increase in nuclear localization with greatly reduced membranous 
β-catenin/E-cadherin expressions [cell-cell adhesion] following the loss of p53/p21 expression 
in these SCCs. Thus, in this context, this expression profile reinforced β-catenin involvement 
in aiding malignant progression as it suggests that the loss of p53 and nuclear localization of 
β-catenin in SCCs greatly reduce E-cadherin ability to form focal adhesion junctions in the 
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invasive front; an observation consistent with the collective invasion profiles observed in 
human SCC (Hesse et al., 2016).  
This analysis of endogenous β-catenin suggested that overexpression of β-catenin in different 
contexts or at different times may yield different outcomes as in early stages of tumour 
development as in HK1.fos-K14creP.Δ5PTENflx/flx KA, the response to β-catenin nuclear 
localization elicit protective responses by TGSs[p53/p21],that halt tumour progression, 
However when these TSGs response fails to halt tumour progression as in HK1.ras/fos-
K14creP.Δ5PTENflx/flx  SCCs at later stages of tumour progression, β-catenin seems to drive 
and facilitate malignant progression. These findings made it clear that β-catenin roles in SCC 
required a better understanding which was tested by inducing constitutive activation of β-
catenin using a an inducible K14.creP/loxP gene switch [K14.creΔ3β-catenin] similar to the 
induction of PTEN loss in this model. 
 
9.2 Constitutive activation of β-catenin in mouse skin which paradoxically 
blocks HK1.ras mediated IFE tumour development but not HF tumours. 
The constitutive activation of β-catenin over expression was achieved using an inducible 
K14.creP/loxP gene switch [K14.creΔ3β-catenin], where RU486 treatment would result in 
deleting exon 3 sequence flanked by loxP site; preventing formation of the β-catenin 
destruction complex [GSK3-β/APC/Axin] and sustained activation of β-catenin. This 
approach thus mimics the mutation hotspots in exon3 observed in human carcinomas, which 
are also frequently reported in two-stage DMBA/TPA carcinogenesis (Malanchi, et al., 2008; 
Grigoryan et al., 2008). 
Unfortunately, due to cre expression independent of RU486 treatment, which to date is a 
phenomenon seen in K14creP.Δ3β-catflx/wt mice and rarely appeared previously in this model, 
due to the potency of Δ3β-catenin expression in epithelial cells this resulted in the gross 
appearance of Δ3β-catenin phenotypes around 16 to 24 days of age post the first anagen and 
also appears to promote internal problems leading to smaller mice (Huels et al., 2015). 
However, of note, if these mice were driven by a non-inducible keratin promoter, such as 
K5.cre available in the lab, β-catenin overexpression proved to be lethal in this study and in 
others (Järvinen et al., 2006).  
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Thus, it may be that this lack of viability may underlie the lack of these mice in development 
of a transgenic skin carcinogenesis models; rather each focussed on effects on hair follicle 
development and later to effects on stem cells but oddly, none exploit these mice in the 
development of classic skin carcinogenesis models only constitutive knockouts have been 
investigated (Malanchi, et al., 2008; Grigoryan et al., 2008). Aside from these unavoidable 
features K14creP.Δ3β-catflx/wt mice displayed identical phenotypes to previous studies that 
targeted β-catenin overexpression to the skin or follicles in terms of alopecia, scruffiness, 
bigger ears, abnormal feet and tail as well as a variation in body sizes compared to a normal 
ICR mouse (Gat et al., 1998).  
The increased numbers of de novo hair follicles and formation of benign hair follicle tumours 
[trichofolliculoma and pilomatricoma] (Gat et al., 1998; Huelsken et al., 2001; Grigoryan et 
al., 2008) are consistent with β-catenin mediated over expression of Wnt signalling 
transcriptional targets LEF1 and TCF and disruption of their normal roles in hair follicle 
formation. Further, the alopecia that K14creP.Δ3β-catflx/wt mice usually exhibit can be 
explained by the finding that, despite the increased formation of hair placode due Δ3β-catenin 
activation, most of the initiated HFs fail to produce normal hair due to incorrect control of 
Wnt/β-catenin signalling (Närhi, et al., 2008). Thus, HF tumors arise such as trichofolliculoma 
and again observed here following K14creP.Δ3β-catflx/wt overexpression (Gat et al., 1998; 
Chan et al., 1999 Grigoryan et al., 2008), which have also been reported also reported in 
human SCC as result of similar gain of function mutations the β-catenin gene that lead to its 
overexpression (Grigoryan et al., 2008; Chan et al., 1999).   
The effects on body size and limb abnormalities can be attributed to the major roles that 
canonical Wnt/β-catenin signalling plays in embryonic and juvenile stages of development. 
Embryonically Wnt/β-catenin signalling is highly involved in the formation of the body 
anterior and posterior axis, hence why null mutation of β-catenin induced embryonic lethality 
as it resulted in a failure in forming body axis in mouse studies (Närhi et al 2008; Grigoryan 
et al., 2008). For instance, Wnt/β-catenin activation up regulates Bone Morphogenic Protein 
[BMP] thus the leaked K14creP.Δ3β-catflx/wt would alter epithelial signalling needed for 





Aside from these constitutive activations of β-catenin phenotypes, effects of K14creP.Δ3β-
catflx/wt on the IFE manifest as minimal hyperplasia and a alteration to epidermal terminal 
differentiation evidenced by anomalous and to date a unique profile of K1 & K6α 
differentiation marker expression. This altered epidermal differentiation was attributed to 
elevated levels of basal layer p53/p21 expression which halted proliferation and induce 
differentiation whilst exhibiting strengthened cell-cell adhesion evident by elevated 
membranous β-catenin/E-cadherin together with nuclear localization of β-catenin that alter 
regulation of pluripotent stem epidermal cells that are needed for terminal differentiation or 
hair follicle differentiation (Watt and Collins, 2008; Grigoryan et al., 2008). 
Indeed, later in this study this p53 response was found to be a major contributor to the 
epidermal responses to β-catenin, as conditional knockout of p53 in K14creP.Δ3β-
catflx/wt.p53flx/flx resulted in a significant reduction in the severity of Δ3β-catenin associated 
phenotypes. This too indicated that p53 response was not exclusive to halting IFE 
tumorigenesis and these data may also suggest that p53 status plays a major role in regulating 
Δ3β-catenin anomalies, which appeared necessary for the HF anomalies observed in previous 
studies of constitutive β-catenin activation. 
One of the major findings in this study was that when K14creP.Δ3β-catflx/wt mice were crossed 
with HK1.ras mice the vast majority of HK1.ras-K14creP.Δ3β-catflx/wt lacked papilloma 
development, whereas HK1.ras controls developed papillomma within 6-8 weeks of ear tag 
wounding. This intriguing result does not fit the current dogma reported in the literature 
(Morin, 1999; Grigoryan et al., 2008) as in reverse, conditional knockout of β-catenin resulted 
in the inhibition of DMBA/TPA tumours that possessed similar ras Ha activation, indicating 
that β-catenin expression was necessary for SCC development (Malanchi et al., 2008; 
Grigoryan et al., 2008) consistent with HK1.ras/fos-K14creP.Δ5PTENflx/flx where in both cases 
p53 loss was also implicated.  
However, this paradoxical lack of tumours in HK1.ras-K14creP.Δ3β-catflx/wt , was not due to a 
loss of HK1.ras expression as the pups exhibited typical HK1.ras phenotypes and there was 
increased levels of severity of Δ3β-catenin in terms of increased scruffiness and increased 
hyperkeratosis in back skin. This was also consistent histologically as the hair follicle 
abnormalities such as formation of more cysts and hair follicle tumours was clearly more 
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severe with increased interfollicular hyperplasia accompanied by abnormal and confused 
differentiation.  
Thus, it may be that adding HK1.ras activation to these Δ3β-catenin phenotypes invoked 
increased elevated levels of p53/p21 resulting in more confused and disturbed IFE and a block 
of the events that initiated papillomatogenesis, given that HK1.ras, HK1.fos and HK1.ras/fos 
mice all exhibited suprabasal levels of β-catenin and only minimal p53 p21 expression until an 
overt papilloma had formed. Thus, they collectively inhibited conversion until p53 was lost in 
HK1.ras/fos-K14creP.Δ5PTENflx/flx and β-catenin became nuclear to drive further progression 
alongside E-cadherin. In addition, another factor helping to inhibit papillomatogenesis in 
HK1.ras-K14creP.Δ3β-catflx/wt , may centre on cytoplasmic E-cadherin/β-catenin interactions 
as E-cadherin can act as a sponge providing further regulation of β-catenin levels (Huels et al., 
2015). Thus, the elevated expression observed in HK1.ras-K14creP.Δ3β-catflx/wt that seemed to 
be strengthened by Δ3β-catenin activation [as observed in colon carcinogenesis (Huels et al., 
2015), would help inhibit papilloma formation. This would be coupled to the excess 
membranous expression of β-catenin/ E-cadherin that together increased the cell-cell adhesion 
in the hyperplastic basal layers that would also inhibit the early formation of papillomas. 
 This inhibition of papilloma formation was also supported by the fact that the epidermal 
differentiation was highly disturbed indicated by K1 confused and patchy expression which 
could attributed to excess expression of p21 (Di Cunto et al., 1998) and this coupled to basal 
layer expression of p53 helped accelerated epidermal terminal differentiation, as seen in 
HK1.fos-K14creP.Δ5PTENflx/flx  KA (Topley et al., 1999; Yao et al., 2008) and again in a 
recent study in ROCK-mediated β-catenin activation (Masre et al., 2020). However, the 
hyperproliferation marker K6α was completely absent from the epidermis, whereas usually it 
is strongly expressed in HK1.ras hyperplastic controls, thus again indicating that possibly the 
anti-proliferative roles of p53 and the pro differentiation roles for p21 contributed to 
papillomatogenesis inhibition.  
Here of note, another possible mechanism for this aberrant K6α expression is a study that 
concluded the ability of constitutive activation of β-catenin to remodel the developed mouse 
dermis into a neonatal state (Collins et al., 2011). In neonates the epidermis is naturally 
hyperplastic but lack K6 expression which remains confine to developing HFs (Rothnagel et 
al., 1999). Thus, as increased Wnt/β-catenin signalling affects the correct control of stem cell 
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niche, it alters the keratin expression profiles leading to a continuously altered differentiation 
programme fate resulting in confused transit amplifying cells as evidenced by formation of K1 
positive cysts which would also divert keratinocytes away from papilloma formation.  
Furthermore, the analysis of the only two mice that developed papillomas in HK1.ras-
K14creP.Δ3β-catflx/wt may confirm that many of the epidermal responses and paradoxical 
tumour inhibition derived from altered developmental responses to β-catenin overexpression. 
ie this was an anomalous deregulation of the natural hyperplasia/hyperkeratosis state and HF 
formation that normally appears during development. Thus, these mice also looked bigger and 
were less phenotypic than the majority of HK1.ras-K14creP.Δ3β-catflx/wt mice that did not 
develop the tumours. This indicate that probably the cre switch did not leak early whether in 
neonatal or juvenile development and only became activated post RU486 treatment, which 
gave HK1.ras effects enough time to develop the foundations of papilloma formation before 
the responses to Δ3β-catenin activation [p53/p21/excess E-cadherin] were deployed in an adult 
epidermis. 
Once formed in an adult skin more closely resembling that of HK1.ras controls, the eventual 
papillomas grossly and histologically looked smaller and less aggressive compared to a typical 
HK1.ras papillomas. This was still contrary to the widely assumed notion that overexpression 
of β-catenin/Wnt signalling leads to more aggressive tumours and possibly malignant 
progression but again these mice did exhibit the Δ3β-catenin activated response following 
RU486 treatment p53/p21/excess E-cadherin suggesting that even in the rare event where 
papillomas avoided the paradoxical block in HK1.ras-K14creP.Δ3β-catflx/wt mice, they could 
not progress to more aggressive tumours and possibly with more time could even be 
regressing. Hence whilst HK1.ras-K14creP.Δ3β-catflx/wt , papillomas showed increased nuclear 
localization the increased membranous β-catenin/E-cadherin expression and strong p53/p21 
aided in halting malignant progression similar to that observed in HK1.fos-
K14creP.Δ5PTENflx/flx KA (Yao et al., 2008).  
Another piece of evidence suggesting that an adult epidermis needed to form correctly prior to 
β-catenin deregulation was supported by a normal K1 expression confined to the suprabasal 
layer appeared in HK1.ras-K14creP.Δ3β-catflx/wt papillomas as always observed in HK1.ras 
papillomas. However, the hyperproliferation marker K6α showed strong expression as well 
but interestingly was lacking in basal layers, a finding exclusive to HK1.ras-K14creP.Δ3β-
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catflx/wt papillomas and not seen in HK1.ras controls that echoes K6α expression in the non-
tumour baring mice. Thus, whilst K1 expression confirms their benign nature, K6α expression 
may indicates that these tumours are not the same type of papilloma as seen in HK1.ras 
controls. These maybe the beginnings of the more aggressive type 2 papillomas hence their 
ability to overcome the paradoxical tumour block. Nonetheless this correlation between TSGs 
expression and cell-cell adhesion seemed to be the key to the protective responses induced in 
response to β-catenin nuclear localization. Thus, conditional knockout of p53 was tested in 
HK1.ras-K14creP.Δ3β-catflx/wt co-operation. 
 
9.3 p53 is essential to develop K14creP.Δ3β-catflx/wt phenotypes and loss 
cannot overcome the paradoxical lack of HK1.ras-K14creP.Δ3β-catflx/wt  
tumours. 
To validate the roles of p53 as suggested by the lack of tumours in Δ3β-catenin phenotypes, 
conditional knockout of p53 was introduced first in K14creP.Δ3β-catflx/wt then in HK1.ras-
K14creP.Δ3β-catflx/wt . Here another major unexpected finding showed that p53 loss resulted in 
a significant reduction in the severity of K14creP.Δ3β-catflx/wt.p53fl/flx phenotypes. This centred 
on skin phenotypes, as p53 loss had minimal effect on body size and extremities. At 3 weeks 
old [~24d] all mice exhibited little effects of Δ3β-catenin; whilst at 8 weeks following RU486 
treatment, only mild levels of Δ3β-catenin phenotype appeared and histologically  
K14creP.Δ3β-catflx/wt .p53flx/flx skin reflected this milder phenotype, which was also paralleled 
by a reduction in  hair follicle abnormalities and thus tumours such as Trichofolliculoma that 
were seen in heterozygous or wild type p53 K14creP.Δ3β-catflx/wt mice (Gat et al., 1998; Celso 
et al., 2003). 
These data clearly implicated p53 roles in both the appearance and the intensity of Δ3β-
catenin phenotypes as well as in the reduced degree of follicular tumours associated with Δ3β-
catenin overexpression. The reasons for this unique and potent block of Δ3β-catenin 
phenotypes by p53 loss are again very unclear but this does appear to be a very important 
finding. Given that p53 normally regulates embryonic stem cell proliferation via activating 
canonical Wnt signalling [β-catenin dependent] among other pathways (Lee et al., 2010), it 
now appears that during juvenile development, similar responses require a competent p53 
305 
 
system and are lacking in both K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx genotypes.  Thus, the epidermis cannot mount the differentiation responses to 
deregulated overexpression of Δ3β-catenin at this juvenile stage (Gat et al., 1998; Van Mater 
et al., 2003; Grigoryan et al., 2008).  
These data suggest that expression responses to p53 loss which altered keratinocyte 
proliferation/differentiation derived from effects of deregulated β-catenin on the stem 
cell/KPC populations (Lee et al., 2010) and these normal roles which are subverted by 
deregulated Δ3β-catenin overexpression requires a competent p53 system to sense the 
problems caused. Hence in developing juvenile K14creP.Δ3β-catflx/wt genotypes it is the 
overexpression of p53, in response to Δ3β-catenin, that plays an unavoidable but essential role 
in the induction of these phenotypes. As outlined above [Chapter 6], a feedback loop maybe 
established whereby elevated levels of p53 activate Wnt signalling receptors which results in 
anomalous proliferation/differentiation, cysts and HF anomalies via adding heterozygous 
endogenous β-catenin expression to that of Δ3β-catenin activation; which in turn induced 
more p53 (Gat et al., 1998; Niemann et al., 2002Van Mater et al., 2003; Grigoryan et al., 
2008; Lee et al., 2010; Kretzschmar et al., 2015). Thus, the lack of this elevated p53 
expression in K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  
genotypes led to a less dramatic, potent response with less alopecia and scruffiness, resulting 
in a more normal looking hair follicles and bigger body size.  
This too may involve the increased levels of E-cadherin observed and this may not only 
increase cell adhesion but the proposed function of E-cadherin to act as a sponge to provide 
additional regulation of β-catenin (Huels et al., 2015) may act as a sink to help remove excess 
β catenin and further minimised phenotype [see below]. In addition, the induction of p63 and 
p73 expression responses would again alter overall IFE and HF keratinocyte 
proliferation/differentiation profiles in response to p53 loss, with major effects on the stem cell 
/KPC populations as indicated by K15 expression. Further this inhibition of Δ3β-catenin 
activation centres exclusively on p53 as this was not observed in p21 nor PTEN co-operation 
experiments, but did appear to be very potent as it also prevented the excessive differentiation 
observed in HK1.fos-K14creP.Δ3β-catwt/flx experiments [below].   
This unexpected result following p53 loss was also observed in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx mice with an identical reduction in juvenile Δ3β-catenin phenotypes, but the 
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most striking finding was the continued lack of tumour development in the vast majority of 
mice, except for the two mice that developed accelerated aggressive SCC [discussed below]. 
This result challenges the current dogma in the literature where β-catenin nuclear localization 
and p53 loss facilitate tumour invasion and metastasis (Polakis 2000; Gunther et al., 2003) as 
seen also in HK1.ras/fos-K14creP.Δ5PTENflx/flx SCCs (Macdonald et al., 2014). Indeed, a 
paradoxical lack of benign papillomas following p53 loss has been present in this model for 
many years (Greenhalgh et al., 1996) without resolution and it was hoped that given the links 
between β-catenin and p53 signalling, this approach employing β-catenin overexpression may 
have been the key to unlocking this paradox, but not so. Nonetheless, given these links it 
suggests that a common block of early stage papillomatogenesis is deployed in both cases, 
which may be similar involving changes to the feedback loops as discussed above; or a 
separate more generic response to p53 loss as it appears in HK1.ras, HK1 fos and HK1.TGFα 
models (Greenhalgh et al., 1996) and most recently manifest again in separate models of 14-3-
3σ/ras co-operation [McMenemy and Greenhalgh, manuscript in preparation.].  
However, the data indicated two possibilities: one of which is that responses to the loss of p53 
protection co-operated with those deployed against constitutive activation β-catenin in 
HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  such as p63/p73 and increased E-cadherin [below] 
acted to prevent the onset of benign tumour development in most cases. Alternatively, in this 
epidermal context possibly tumorigenesis paradoxically required the expression of p53, as 
papillomatogenesis were lacking in both genotype an idea supported by the requirement for 
p53 to engender the epidermal responses to β-catenin in HK1.ras-K14creP.Δ3β-catflx/wt 
cohorts.  
 
This latter, dogma challenging suggestion (Wahl, 2006) is also supported to some extent by the 
observation that in HK1.ras-K14creP.p53flx/flx controls, if RU486 treatment was delayed by 10 
-14 days small papillomas did eventually appear and moreover once established these were 
prone to convert to aggressive SCC; as seen in the rare examples of HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx carcinogenesis [below]. This again echoes the theory outlined above that p53 
creates a feedback loop necessary to elicit β-catenin phenotypes and the fact that a relatively 
normal epidermis appeared to be required to begin the rare instances of papillomatogenesis in 
both HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and HK1.ras-K14creP.Δ3β-catflx/wt cohorts 
coupled to the fact that hyperplastic HK1.ras skin expresses low levels of p53 yet papillomas 
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have very high levels. Thus, this inhibitory compensatory mechanism to p53 loss maybe 
generic, hence a lack of early papillomas in both contexts and that β-catenin overexpression 
cannot overcome the paradoxical inhibition of papillomas following p53 loss in HK1.ras-
K14creP.p53flx/flx mice (Greenhalgh et al., 1996). 
 
Overall, in the majority of cases, the β-catenin expression profile in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx again demonstrated increased nuclear localization with increased cell-cell 
adhesion signalling [β-catenin/E-cadherin expression] that probably helped prevent papillomas 
similar to HK1.ras-K14creP.Δ3β-catflx/wt findings. This indicated that increased cell-cell 
adhesions in HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx were not dependent on p53 expression, 
unlike the conclusions from HK1.ras-K14creP.Δ3β-catflx/wt data; yet if both were present, such 
as in HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology, this β-catenin/E-cadherin mediated 
increased in cell-cell adhesion, coupled to strong expression of p53, was quite potent in 
preventing further progression, consistent with the results observed for  HK1.ras/fos-
K14creP.Δ5PTENflx/flx SSC where p53 loss, nuclear β-catenin and the lack of membranous E-
cadherin contributed to malignant progression and invasion. However, despite the loss of p53, 
β-catenin/E-cadherin interactions appeared to maintain cell-cell adhesion in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx epidermis and E-cadherin may actually increase to aid in the 
inhibition of papilloma formation. In addition, the proposed function of E-cadherin to act as a 
sponge to provide additional regulation of β-catenin (Huels et al., 2015) remained intact such 
that together with increased β-catenin/E-cadherin mediated cell-cell adhesion in basal layers, it 
helped prevented the permissive epidermal context that gave rise to papillomatogenesis.  
Another potent response following p53 loss centred on attempts to regulate Δ3β-catenin 
effects via elevated p21 expression in its cell cycle regulatory roles as HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx IFE hyperplasia was less than that of HK1.ras-K14creP.Δ3β-catflx/wt , as 
determine by BrdU labelling. This increased p21 expression in response to p53 loss also 
appears to have led to more complex responses such as the increased numbers of dead-end 
cysts rather than increased differentiation. This idea was suggested by reduced K1 expression 
despite the increased basal layer p21 which usually promotes keratinocyte commitment to 
epidermal differentiation- but this may reflect increased levels of p63 [below] and its role in 
maintaining a basal layer rather than commit to differentiate. Similarly, lack of K6α 
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expression could be attributed to reduced proliferation given high levels of basal layer p21 
expression, similar to that observed in HK1.ras-K14creP.Δ3β-catflx/wt mice. 
 
This lack of aberrant differentiation and papilloma formation may also involve potential 
responses that changed the regulation of stem cell niches and Keratinocyte Precursor Cells 
[KPCs] populations via compensatory responses mediated by p63/p73 and indicated by K15 
expression. p63 and p73 share many functional similarities to p53 in terms of maintaining the 
cell cycle, inducing roles that maintain epidermal proliferation, terminal differentiation and 
hair follicles morphogenesis (Moll and Slade 2004; Koster et al., 2007; Botchkarev et al., 
2014) rather than p53 responses to stress. 
 
Already links to βcatenin are suggested by the fact that p63 loss causes the epidermis to fail to 
stratify, disrupts HF formation and effects limb development which echoes the phenotypes 
induced by β-catenin deregulation (Mills et al., 1999; Koster et al., 2004; Koster and Roop 
2007). In particular the ΔNp63 isoform is essential to maintaining basal layer proliferation and 
geared to inhibit premature differentiation via repression of genes such as p21 and PTEN 
(Westfall et al. 2003; Moll and Slade 2004; Nguyen et al., 2006; Leonard et al., 2011; 
Botchkarev and Flores, 2014), hence the disruption to K1 expression mediated by p63 
responses to p53 loss that involved p21 [above]. The p63 roles in HF development may also 
account for the general reduction in HF abnormalities and tumours in HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx and elevated expression p63 [and p73] in HFs maybe a key inhibitor of Δ3β-
catenin phenotypes as opposed to a requirement for p53 functions.  
The intense p63/p73 expression also suggest changes to stem cell populations maintenance, as 
for p63 an interesting expression profile appeared in both in HK1.ras-K14creP.Δ3β-catflx/wt 
and HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx suggesting a direct effects on regulation of KPC. 
Here, strands of p63-postive keratinocytes appeared similar to the patchy K1 expression 
pattern, suggesting K1 inhibition in these specific epidermal stem cell units. In agreement 
HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx IFE possessed more strands of positive p63 basal cells 
with even less K1 expression and this could be attributed to p63 in repressing epidermal 
differentiation that may also counterbalance elevated levels of p21 in HK1.ras-K14creP.Δ3β-
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catflx/wt.p53flx/flx in attempts to provide sufficient cells to maintain the barrier given weaker 
hyperplasia.  
Further, these blocks of p63 positive keratinocytes may demark specific subpopulations of 
KPC cells, as also suggested by β-catenin lineage experiments (Watt and Collins, 2008) that 
would be also consistent with the abrupt lateral edges to both K1 and K6 expression made by 
specific stem cell units in the IFE (Porter et al., 2000). Although the isoform is not known this 
result would be consistent ΔNp63 inhibition of premature differentiation via repression of 
Notch (Koster and Roop, 2007; Crum and McKeon, 2010; Leonard et al., 2011; Botchkarev 
and Flores, 2014), and the resulting Notch inhibition leads to increased β-catenin expression 
(Proweller et al 2006);  thus another feed back loop becomes, established which links p63 to 
β-catenin but this cannot overcome the requirement for p53. Alternately the TAp63 isoform 
keeps KPC/stem cells in a quiescent state to avoid their depletion and provide cells for 
wounding and thus suppress tumourigenesis from mutated stem cells (Su et al. 2009b; 2013; 
Romano et al. 2012). This isoform helps account for papillomas inhibition as Δ3β-catenin is 
expressed in stem cells from the K14 promoter [chapter 1: Fig. 8]. Interestingly, neither 
HK1.ras nor HK1.ras-K14creP.p53flx/flx hyperplasia exhibited this p63 expression, indicating 
that this p63 response is specific to Δ3β-catenin expression. Therefore, this result [as with p73 
below] suggests that the inhibitory responses to p53 loss that inhibit HK.ras.p53flx/flx  
papilloma formation are more generic; and perhaps even separate to those observed in the 
context of Δ3β-catenin models. 
For p73 few studies have actually been reported, but it is likely that the repressive ΔNp73 and 
transcriptionally active TAp73 isoforms exert completely differing functions. The TAp73 
isoform exhibits pro-apoptotic functions following DNA damage (Irwin et al., 2003) and 
suppressor properties (Rocco et al., 2006) are supported as p73 expression is often lost through 
methylation, and transgenic mice heterozygous for p53 and p73 develop cutaneous SCC 
(Flores et al., 2005); yet in human cutaneous SCCs p73 remains strongly expressed indicating 
an oncogenic function (Moll and Slade, 2004), or a failed attempt at inhibition given p53 was 
lost also. Thus, the intense increase of p73 in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx basal 
layer IFE clearly supports the idea that this p53 family member was closely allied to the 
presence of p53 hence it may be that the p73 response was perhaps more effective in blocking 




This maybe so, as a comparison to HK1.ras-K14creP.Δ3β-catflx/wt skin, whilst p73 expression 
was similar and strongly expressed in the transformed HFs yet in the hyperplastic IFE, p73 
expression appeared more closely associated with keratinocytes emerging from the HFs. This 
result would be consistent with p73 roles in general epidermal development and the 
localisation to keratinocytes emerging from HFs is very interesting as it may reflect roles for 
the TAp73 isoform in regulating HF bulge stem cell decisions to enter anagen as its ablation 
results stops follicle formation (Rufini et al., 2012). Thus, here it would help combat the 
deregulated Δ3β-catenin expression in juvenile epidermis as the first hair cycle begins. Also, 
this TAp73 depletion accelerates cellular aging and this links to a return to the theme that Δ3β-
catenin expression may return an epidermis to an earlier neonatal/juvenile state (Collins et al., 
2011) as explored further in vitro. 
However, the striking p73 expression increase in HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx  basal 
layers, and which was not seen in HK1.ras-K14creP.Δ3β-catflx/wt and is constant with the TSG 
roles mainly attributed to p73 (Rocco et al., 2006; DeYoung and Ellisen, 2007). Significant 
levels of p73 expression appeared in most keratinocyte nuclei and p73 was very strongly 
expressed in the HFs. In contrast, HK1.ras and also HK1.ras-K14creP.p53flx/flx hyperplasia 
lacked such compensatory p73 expression again supporting the idea that inhibitory responses 
to p53 loss which inhibited HK.ras.p53flx/flx  papilloma formation are separate to those 
observed in these Δ3β-catenin models.   These data are also consistent with the idea that β-
catenin expression had to become basal before the p53 family members reacted to its 
anomalous expression, i.e. this p73 response was specific to β-catenin and lack of basal layer 
β-catenin in HK1.ras or HK1.ras-K14creP.p53flx/flx hyperplasia resulted in a lack of 
compensatory p73 [and p63] expression. If so, this may account for p73 appearance in human 
SCCs (Moll and Slade, 2004; DeYoung and Ellisen, 2007) as following Notch repression by 
ΔNp63 (Koster and Roop, 2007; Botchkarev and Flores, 2014) the resulting β-catenin 
overexpression may have elicited a p73 response.  
This proposed alteration to KPCs populations by TSGs response led to investigating K15 as a 
stem cell marker and interestingly K15 was not expressed in the IFE in either HK1.ras-
K14creP.Δ3β-catflx/wt or HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice. This suggests that Δ3β-
catenin alters the stem cell niches such that the cells migrate out of this niche to reduce the 
numbers of KPC targets for papilloma formation. This lack of IFE K15 expression was also 
constant with the reduced hyperplasia and low mitotic index of HK1.ras-K14creP.Δ3β-
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catflx/wt.p53flx/flx   cells and together with the HK1.ras-K14creP.Δ3β-catflx/wt data it suggests that 
in early-stage hyperplasia Δ3β-catenin activation invokes TSGs responses involving p21/p53 
and/or p63/p73 following p53 loss to protect theses KPC populations. This does not appear in 
early stages in HK1.ras hyperplasia as β-catenin remains suprabasal and the HK1 vector is not 
expressed in HFs, so that these HF niches remain unaffected and K15 expression remains 
relatively normal; however, the precursor cells for papilloma formation are beginning to form 
hence the gradual increase in p53 which becomes uniform in overt papilloma appearing later 
to prevent progression to SCC. 
Hence K15 expression developed in the rare papillomas exhibited by both HK1.ras-
K14creP.Δ3β-catflx/wt and the SCCs developed in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx unlike 
HK1.ras papillomas. This expression of K15 therefore seems to be exclusive to tumours 
developed in genotype carrying Δ3β-catenin which could be a key marker in understanding the 
development of tumours in these genotypes and again suggests a disruption to stem/PCK 
physiology. This idea is also supported by reports that K15-positive cells derived from hair 
follicle stem cells contribute to papilloma devolvement (Li et al., 2013). Thus, tumours that 
developed in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx mice 
may derive from such excess stem cell proliferation initially mediated by ΔNp63 expression 
that escaped the early p73 TSGs responses due to cre leakage of Δ3β-catenin.  
Moreover, the rare papillomas that developed in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx mice had a more logical and distinctly different outcome as p53 
null papillomas converted to SCCs. Also, these SCCs displayed a reduced membranous β-
catenin/E-cadherin more consistent with loss of cell-cell adhesion in basal layers that aided in 
tumour invasion; whilst nuclear localization of β-catenin in almost all cells of basal layers, 
coupled to p53 loss, showed a similar β-catenin/E-cadherin expression profile to that of 
malignant conversion/progression in HK1.ras/fos-K14creP.Δ5PTENflx/flx mice (Macdonald et 
al., 2014). A result finally consistent with the literature dogma (Polakis 2000; Gunther et al., 
2003; Yao et al., 2008; Jeanes et al., 2008).  
Thus, HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and similarly HK1.ras/fos-K14creP.Δ5PTENflx/flx 
SCC both lost p21 expression, unlike papilloma of HK1.ras-K14creP.Δ3β-catflx/wt or tumour 
free HK1.ras-K14creP.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx epidermis with 
high levels of p21. This again indicates that p21 exerts a protective response even at later 
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stages of tumour progression and losing p21 would facilitate malignant progression rather than 
conversion (Macdonald et al., 2014). The SCCs developed in HK1.ras-K14creP.Δ3β-catflx/wt 
.p53flx/flx also exhibited high levels of p63/p73 and this was gain consistent with the potential 
oncogenic roles assigned to p63 and the failed TSG roles for p73 discussed above. Thus, as 
this was also reported in human cutaneous SCCs (Moll and Slade 2004; Koster et al., 2007; 
Botchkarev et al., 2014) this model may be a close relevant mimic.    
These implications of p21 roles in halting tumour development and loss being associated with 
SCC development as seen HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx and in HK1.ras/fos-
K14creP.Δ5PTENflx/flx SCCs, an on-going experiment investigated p21 knockout (Martı et al., 
2001). Preliminary HK1.ras-K14creP.Δ3β-catflx/wt.p21KO data indicated that p21 loss also 
failed to facilitate papillomatogenesis as these mice remained tumour free 12 weeks consistent 
with later p21 roles in tumourigenesis. However, the other major finding was that p21 
knockout in K14creP.Δ3β-catflx/wt.p21ko and HK1.ras-K14creP.Δ3β-catflx/wt .p21KO did not 
show any delay or reduction in the onset of juvenile Δ3β-catenin phenotypes. Thus, the 
responses to Δ3β-catenin overexpression were specifically associated with p53 loss and 
experiments are on going to assess the roles of p63/73 and also explore AKT status in the p21 
knockout genotypes, given the apparent AKT1/p21 antagonism in HK1.ras/fos-
K14creP.Δ5PTENflx/flx malignant progression (Macdonald et al., 2014) and the axis of 
AKT/GSK3β/β-catenin.    
 
9.4 HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt co-operation blocks tumour 
development via keratinocyte differentiation giving a novel skin phenotype. 
Analysis of HK1.fos–Δ5PTENflx KA formation demonstrated that loss of PTEN-mediated 
AKT regulation led to AKT-mediated GSK3β inactivation which triggered compensatory 
p53/p21 expression to divert excess keratinocyte proliferation to the massive differentiation 
that gives the keratosis of classic KA (Yao et al., 2008). Indeed, it was this set of experiments 
that prompted analysis of β-catenin overexpression in this project, as it was assumed that β-
catenin played a significant role in this mechanism. This proved to be correct as endogenous 
β-catenin levels in HK1.fos-K14creP.Δ5PTENflx/flx KA increased with strong membranous β-
catenin/E-cadherin expression and nuclear localization that correlated with induction of 
compensatory p53/p21, as seen in the Δ3β-catenin models. Together with E-cadherin 
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expression, strong membranous β-catenin expression leading in cell-cell adhesion which led to 
a KA outcome rather than invasive SCC (Yao et al., 2008) and confirmed direct β-catenin 
involvement in KA aetiology as a consequence of Δ5PTEN-medaited AKT activation and 
associated GSK3-β inactivation Further, in HK1.ras /fos–Δ5PTENflx mice, basal layer β-
catenin expression became increasingly nuclear and keratinocytes expressed less membranous 
β-catenin paralleled loss of E-cadherin at the invasive front and reduced cell-cell 
adhesion(Alyamani et al., manuscript in preparation). Therefore, it was expected that 
K14creP.Δ3β-catflx/wt  in HK1.fos mice would lead to a similar KA outcome as Δ3β-catenin 
expression was now independent of deregulated PTEN/AKT/GSK3β signalling; and since the 
fos transcription factor AP1 is also a target of Wnt signalling (Toualbi et al., 2007; Saadeddin 
et al., 2009) another feedback loop may become established that leads to SCC if p53 or p21 
became compromised or were experimentally introduced in this model.   
Once again, establishment of HK1.fos-K14creP.Δ3β-catflx/wt, HK1.ras/fos-K14creP.Δ3β-
catflx/wt and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt genotypes resulted in a lack of benign 
tumours of any kind, neither papilloma nor KA. This reinforced the idea that early Δ3β-
catenin activation triggers a general protective response in the epidermis, even in the presence 
of several potent oncogenes: fos, Δ3β-catenin or loss of PTEN-mediated AKT inhibition. In 
terms of HF tumourigenesis a major finding identified novel co-operation between PTEN 
mutation and β-catenin in the aetiology of trichochleomas, one of the many tumour types 
affecting Cowden’s Disease patients that are already heterozygous for familial mutations in 
PTEN.  
Another hallmark of these genotypes was the novel epidermal response giving a skin 
phenotype of an overlapping and highly keratotic bands or scales with a concentric geometric 
harlequin pattern. This pattern results from the keratinocyte proliferation that gives a 
papillomatous hyperplasia, i.e., a folded epidermis, where the keratinocytes subsequently 
differentiated giving rise to overlapping keratosis and hardened scales resembling a pangolin 
skin [the only scaled mammal]. This suggests that the keratotic responses observed in KA 
aetiology appeared here at an earlier stage of juvenile development. This then provided an 
underlying mechanism for the development of this novel pangolin like-skin phenotype 
specifically associated with epidermal responses to dysfunctional Δ3β-catenin and HK1.fos 
interactions on normal skin homeostasis; eg those β-catenin roles in regulating stem cells, 
terminal differentiation and hair follicle formation  (Gat et al., 1998; Niemann et al., 2002; 
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Grigoryan et al., 2008;  Kretzschmar et al., 2015) combined with those of c-fos that in the 
commitment to terminal differentiation (Fisher et al., 1991; Greenhalgh et al., 1993b; Basset-
Seguin et al., 1994;  Angel et al., 2001; Candi et al., 2006) and the HF stem cell decisions to 
form IFE, sebocytes or HF cells (Gerdes et al., 2006).  
Astonishingly, experiments again found that this potent skin phenotype was effectively 
blocked by p53 loss in the IFE of these mice showing again the necessity for a functional p53 
to elicit these specific effects of Δ3β-catenin. Nonetheless, the development of the pangolin-
like skin response in all HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt genotypes suggested that 
in these contexts tumourigenesis was inhibited via aggressive differentiation of the 
keratinocyte proliferation elicited by fos/Δ5PTEN/Δ3β-catenin interaction as juvenile skin 
developed i.e., this diversion into differentiation the prevented KA conversion here prevented 
overt tumour formation. Overall, experiments found that in each genotype tumor inhibition 
was again associated with p53 and p21 expression as seen with HK1.ras-K14creP.Δ3β-catflx/wt 
mice, but here the histotype and K1 and K6 expression analysis demonstrated that a unique 
differentiation profile appears to be the most significant. These experiments also suggest that 
Δ3β-catenin enhanced the HK1.fos-mediated interference of normal differentiation giving a 
dominance of spinus layer keratinocytes that explained the general acanthosis observed in the 
IFE.  
Furthermore, c-fos has major roles in the regulation of keratinocyte cornification in supra-
basal layers (Candi et al., 2006) and this may be quite important when overlaid on fos/β-
catenin-mediated co-operation in suprabasal layers that accelerated differentiation, but 
premature cornification would give rise to early keratosis, such that each fold became a scale-
like structure. Supporting this idea, strands of K1 expression now appeared in basal layer 
keratinocytes, suggesting a premature commitment of basal layer keratinocytes to terminal 
differentiation, a result also found in KA aetiology (Macdonald et al., 2014) and possibly 
amplified by increased HK1.fos expression in parallel with premature basal K1 expression 
(Fisher at al.,1991; Greenhalgh et al., 1993b; Basset-Seguin et al., 1994). In contrast K6α 
expression remained diminished which may also indicate an effect of accelerated 
differentiation and possibly diversion of proliferation into cyst formation which appeared to be 
another anti-tumorigenic mechanism in this HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt 
genotype [below].  
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Therefore, for the first time these HK1.fos-K14creP.Δ5PTENflx/flx and HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice identified a direct link between fos and β-catenin 
activation in regulation of keratinocyte differentiation, consistent with earlier photo-
carcinogenesis studies that associated  epidermal c-fos responses following UV-B exposure with 
AKT activation and GSK3 inactivation (Gonzales and Bowden, 2002) whilst UV-B-mediated 
p53 mutation and subsequent PTEN inhibition increased p-AKT/p-GSK3β/nuclear β-catenin to 
induce differentiation responses mediated by fos/jun/AP1  expression (Wang et al., 2005). This 
latter point strengthens co-operation given PTEN-mediated AKT regulation of downstream 
GSK3β/β-catenin signalling already co-operated with activated HK1.fos to induce KA; and 
K14.Δ5PTEN expression gives blooms of hyperkeratosis (Macdonald et al., 2014) [the classic 
sign of pre-tumours in Cowden’s patients ( Liaw et al., 1997; Fistarol et al., 2002)] which 
would also contribute to premature differentiation thus giving the most extreme examples of 
pangolin-like skin in HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt  mice. Indeed, the lipo-
phosphatase functions of PTEN that act as a scaffolding protein at the cell membrane aid 
assembly of adherence junctions and cell-matrix interactions (Tamura et al., 1998; Subauste et 
al., 2005) and this helped explained the increased E-cadherin observed in the IFE that would 
also add to the degree of keratosis and inhibit the onset of tumorigenesis.  
This mechanism of co-operation in the IFE appears to be deployed in the aetiology of the 
novel trichilemmomas produced in Cowden’s disease, (Liaw et al 1997; Fistarol et al., 2002; 
Suzuki et al., 2003). This again is a logical finding, consistent with the fact that deregulation of 
both these proteins induces HF anomalies in transgenic mice (Gat et al., 1998; Niemann et al., 
2002; Grigoryan et al., 2008; Kretzschmar et al., 2015; Suzuki et al., 2003). Here again the 
deregulation of the AKT/GSK3β/β-cat axis mediated by PTEN loss would add to that from 
constitutive Δ3β-catenin to begin the HF anomalies; whilst the additional functions, such as 
the scaffolding roles in AJ formation, may explain increased E-cadherin observed in the HFs. 
Indeed, this may be of significance in the aetiology of trichilemmomas, a tumour of the ORS 
keratinocytes vs that of the more common folliculoma and the production of cysts another 
feature of Cowden disease skin. This idea is supported by K6α analysis given in HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt trichilemmomas expression was lower than expression seen 
in HK1.fos-K14creP.Δ3β-catwt/flx folliculomas. This suggests a less developed, less 
differentiated HF which may induce the response to divert odd anomalous HF cell 
proliferation into cyst formation, and not just in the HFs as K1 expression was identified 
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showing cyst formation is a general response to the greatly disturbed differentiation and 
originate from both IFE and HF sources. This is a logical conclusion as cyst formation is 
likely to be a common response to divert anomalous from tumour formation and into this dead 
end (Young et al., 2003) as observed in early HK1.ras/fosΔ5PTEN hyperplasia (Macdonald et 
al., 2014) and later in KA aetiology to prevent further progression (Yao et al., 2008).  
Thus, in all of these genotypes, one way or another, the membranous β-catenin component, 
and increased E-cadherin that strengthened cell-cell adhesion helped divert excess PCK 
proliferation into differentiation. This was again paralleled by increased p53/p21, which 
together with accelerated differentiation combined to minimise IFE hyperplasia as exemplified 
by the return of sporadic K1 expression in the HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt IFE 
which was often fairly thin. This correlated with elevated levels of p53/p21 expression, similar 
to that seen previously in HK1.fos-K14creP.Δ5PTENflx/flx KA (Macdonald et al., 2014); and in 
analysis of HK1.ras-K14creP.Δ3β-catflx/wt or K14creP.Δ3β-catflx/wt skin. Thus, to block the 
beginnings of tumour formation, early elevated p53/p21 expression responding to excess β-
catenin/E-cadherin initiated a far more accelerated and premature differentiation program in 
juvenile HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin. This gave rise to an odd, ragged K1 
expression in patches of acanthosis that reflects the role of fos [and PTEN] in cornification 
(Candi et al., 2006) that are now subverted by HK1.fos-K14creP.Δ5PTENflx/flx expression.   
 
In HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt or HK1.fos-K14creP.Δ5PTENflx/flx epidermis the 
timing of β-catenin activation seems to be the key element that governed this massive 
keratosis. In this context p53-mediated proliferation and increased p21-mediated 
differentiation aided the developing pangolin like-skin and preventing further progression via 
cyst production. This was similar to the conclusions made in HK1.ras-K14creP.Δ3β-catflx/wt 
analysis, where p53/p21 responses to Δ3β-catenin appeared to be the main reasons for 
blocking tumours formation. Another possible mechanism centres on the idea that constitutive 
activation of β-catenin returns an adult skin to a neonatal/juvenile state (Collins et al., 2011)-
as suggested in Scatter Assays [below]. In neonatal skin for the first 5-6 days the epidermis is 
naturally hyperplastic but e.g., lacks K6α expression and p-AKT is uniformly expressed in the 
suprabasal layer (Masre et al., 2020). By day 4-6 HK development begins, thus in leaky 
HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt skin so many new HFs are being created in 
juveniles due to the effects of Δ3β-catenin expression that are then further compromised by 
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K14.Δ5PTEN expression such that p53 and p21 responses to AKT and βcatenin are deployed 
in to avoid rapid degeneration of the IFE hence the acanthosis and keratosis to protect the 
barrier function and divert failing HF into cysts collectively again inhibiting the onset of early 
tumorigenesis.    
 
Again, the p53 roles in these findings were tested and, adding more complexity to these 
models, as in HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx conditional p53 loss in the context of 
HK1.fos-K14creP.Δ3β-catflx/wt -p53flx/flx mice completely blocked the Δ3β-catenin IFE 
responses. There was a total disappearance of pangolin-like phenotype and again the HK1.fos-
K14creP.Δ3β-catflx/wt.p53flx/flx mice suggest that it is a general p53-mediated response to β-
catenin deregulation in IFE.  Indeed, despite repeated RU486 treatments Δ3β-catenin 
phenotypes were blocked over longer periods of time; yet without facilitating tumorigenesis, 
as to date no KAs have been observed, even in full sized mice.  
The reasons remain quite unclear. It appears clear that p53 functions are essential to trigger 
this overall response as observed in HK1.fos-K14creP.Δ5PTENflx/flx KA aetiology and this is 
lacking in p53 null HK1.ras/fos.K14.Δ5PTEN papillomas that convert to SCC. As discussed 
above, p63/p73 expression profiles may alter the PCK niches to return the epidermis to a more 
normalised state and negates Δ3β-catenin effects in the HK1.fos models as observed in 
HK1.ras and thus there is no reason for an epidermis to respond with induction of an excessive 
commitment to terminal differentiation. That this is targeted to differentiation reinforced by 
the complete block of differentiation in fos vs the partial block in ras that maybe due to the 
roles for fos in the commitment to differentiate. This again returns to the central p53 paradox: 
that p53 loss blocks HK1.ras or HK1.fos papilloma formation (Greenhalgh et al., 1996) and 
this cannot be overcome by β-catenin activation in ras or fos models as seen in HK1.fos-
K14creP.Δ3β-catflx/wt -p53flx/flx and most cases of HK1.ras-K14creP.Δ3β-catflx/wt .p53flx/flx . 
However, further experimentation will be required to increase animal numbers to assess if any 
individual can bi-pass this tumour inhibition, assess histopathology and differentiation 
markers and determine whether p63/p73/K15 observations also appear in 




9.5 β-catenin activation in vitro induces keratinocyte transformation, 
resistance to calcium-induced differentiation and a neonatal phenotype.  
 
The in vivo analysis of constitutive β-catenin activation in HK1.ras, HK1.fos and 
Δp53/Δ5PTEN/p21KO genotypes resulted in a paradoxical blockage of tumour development 
contrary to the original hypothesis that evolved from β-catenin analysis in HK1.ras/fos-
K14creP.Δ5PTENflx/flx mice and the literature dogma that predicted β-catenin overexpression 
would facilitate tumourigenesis (Morin, 1999; Polakis, 1999; Doglioni et al., 2003; Grigoryan 
et al., 2008; Krishnamurthy and Kurzrock, 2018). In contrast in vitro experiments that further 
explored Δ3β-catenin signalling and effect on keratinocyte transformation and differentiation 
gave results more consistent with this original hypothesis. The consequences of Δ3β-catenin 
activation were assessed in a variety of genotypes was tested in three different experiments. 
The first experiments assessed differentiation responses to calcium-induced terminal 
differentiation via a challenge with 0.125mM Ca2+ [High calcium] medium. The second 
tested the ability to grow clonally again as an indication of immortalisation and partial 
transformation. Finally, a third series of experiments tested the seeding ability and cell 
motility, not only as an indication of invasive potential but also to test the idea that Δ3β-
catenin expression maintains neonatal/juvenile phenotype, as suggested in previous studies 
that investigated β-catenin expression on keratinocytes and the ECM (Collins et al., 2011) as 
well as β-catenin effects on the emerging variety of KPC/stem cell niches (Watt and Collins 
2008; Kretzschmar et al 2015).  
 
In the first experiment of classic calcium induced terminal differentiation assays (Hennings et 
al., 1980; Greenhalgh et al., 1989; Morgan et al., 1992), Δ3β-catenin co-operation with other 
oncogenes displayed resistance to calcium-induced differentiation in all compound lines 
consistent with their rapid growth and oncogenes activation in addition to Δ3β-catenin. These 
data indicated that Δ3β-catenin activation induced transformation via overexpressing the 
canonical Wnt signalling pathway resulting in increased proliferation and a delay or resistance 
to normal epidermal differentiation which was also constant with the literature dogma that β-
catenin gain of function would facilitate tumorigenesis (Morin, 1999; Polakis, 1999; Doglioni 
et al., 2003; Grigoryan et al., 2008; Krishnamurthy and Kurzrock, 2018). Although, there 
were subtle differences, for instance HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lines 
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exhibited a transformed morphology at confluence but possessed numerous squames and 
many floating cells suggesting attempts to differentiate in Low Cal media that would be 
consistent with the excessive differentiation observed in vivo. In addition, whilst these 
keratinocytes resisted forming spinus cells in 0.075mM Ca2+ consistent with a highly 
transformed phenotype; in Hi Cal these cells did differentiate now producing the cornified 
cells and squamous of highly differentiated cells again consistent with the excess keratosis 
observed in vivo and the return of K1. Thus under proliferative conditions fos/PTEN/βcatenin 
co-operation inhibits differentiation but in Hi Cal these cells have a significant excess 
response to elevated calcium. This seemed to imitate the confused differentiation signals and 
aberrant differentiation evoked in vivo consistent with the excess of floating cells continually 
observed in low Cal media, and the granular/squames in Hi Cal which may reflect attempts to 
de-differentiated into cysts and die, which was a highlighted feature in vivo HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice.  
 
Similarly, whilst HK1.ras-K14creP.Δ3β-catflx/wt lines adopted a typical spinus morphology in 
0.075mM Ca2+; in Hi Cal these cells continued to grow in Hi calcium consistent with a fully 
transformed malignant line and lack of K1 expression in vivo. This would be the equivalent of 
the rare SCC tumours of HK1.ras-K14creP.Δ3β-catflx/wt.p53flx/flx  p53 null mice. As often in 
vitro p53 could be lost/mutated as cells become immortalised and transformed e.g., in the 
immortalised human HaCaT keratinocyte cell line (Boelsma et al., 1999). Further 
compounding these results was the finding that whilst K14creP.Δ3β-catflx/wt  lines exhibited a 
normal, cobblestone basal layer morphology in Low Cal 0.05mM Ca2+ media and committed 
to differentiate in 0.075mM Ca2+ media differentiation stalled at this spinus morphology stage 
and in Hi Cal media these cells failed to stratify and undergo cornification to produce 
squames. This result might be mimicking the sporadic differentiation suggested by K1 
expression giving a relatively thin IFE as the supra-basal roles of β-catenin in regulating 
terminal differentiation are altered by Δ3β-catenin and this prevented the final stages of 
differentiation (Grigoryan et al., 2008). It would have been interesting to see the levels of p63 
in this line to assess whether this result echoed the p63 roles in limiting terminal 
differentiation.    
 
Another classic carcinogenicity assay tested cell line ability to grow from clonal density in 
both low and high calcium concentrations. This assessed the stem-like or KPC phenotypes that 
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may have been maintained or reactivated by β-catenin overexpression as suggested in previous 
studies (Watt and Collins, 2008) and epidermal lineage studies (Kretzschmar et al., 2015). 
Typically, the ability to clonally grow in Low calcium but not Hi calcium was previously 
associate with a benign phenotype producing papillomas when grafted onto nude mice; whilst 
growth in High calcium gave lines producing SCC and metastasis in this assay (Strickland et 
al., 1998; Greenhalgh and Yuspa, 1998; Greenhalgh et al., 1989; 1990; Morgan et al., 1992). 
Generally, Δ3β-catenin induced a transformed but benign phenotype as most cell line grew in 
Low Cal media, and only HK1.ras-K14creP.Δ3β-catflx/wt and HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt lines were able to grow from clonal density in Hi Cal media 
which indicated a probably malignant phenotype. These data suggested that deregulation of 
K14creP.Δ3β-catflx/wt alone achieves a benign hit and at least in vitro, co-operation with other 
oncogenes [HK1.ras-K14creP.Δ3β-catflx/wt and HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt] 
results in a malignant phenotype to fit the current dogma of β-catenin oncogenicity (Morin, 
1999; Polakis, 1999; Doglioni et al., 2003; Grigoryan et al., 2008; Krishnamurthy and 
Kurzrock, 2018). 
 
Given the roles for β-catenin and E-cadherin in cell-cell adhesion and the evidence that in vivo 
nuclear β-catenin expression and loss of E-cadherin at the invasive front, an experiment was 
designed to not only assess migration but also test cell line abilities to seed satellite colonies as 
a determinant of transformation and invasion (Hesse et al., 2016). In this experiment all 
K14creP.Δ3β-catflx/wt lines were able to seed/scatter to some extent in proliferative Low Cal 
conditions but only the fully transformed potentially malignant lines HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt were able to seed in Hi 
Cal media. In contrast, lines without Δ3β-catenin activation were unable to seed in this assay. 
This observation for lines in Low Cal would again be consistent with a stem cell –like or PCK 
phenotype would be consistent with endogenous β-catenin activation altering p63 and p73 in 
vivo and the expression of K15- although westerns and IF remain to be done in this Scatter 
assay to confirm. These seeding data are also in agreement with the rare HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx  SCCs and carcinomas in HK1.ras/fos-K14cre.Δ5PTEN that 
showed followingp53 loss, β-catenin became less membranous and together with reduced E-
cadherin resulted in a loss of focal adhesions to facilitate the invasion. Again, IF experiments 
on the migrating and seeding colonies will be required to confirm this idea as a model of 




These experiments also tested the reported potential of Δ3β-catenin expression to return an 
adult epidermis to a more juvenile state which was also suggested by in vivo analysis of K6α 
and p63/K15 expression profiles. This approach was suggested by previous studies that 
concluded in vivo, constitutive β-catenin over expression affected the dermal extra cellular 
matrix and appeared to return the skin to neonatal state (Collins et al., 2011). In these seeding 
experiments typical immortalised keratinocyte cell lines by passage 3-5 do not efficiently seed 
(Greenhalgh et al., 1989) as seen in normal non-cre Δ3β-catenin β-1-3; ICR-1 or Wt-1 lines, 
unlike their normal primary counterparts were seeding satellite colonies is a common property 
given the presence of more numerous stem–like/PCK populations derived from newborn vs. 
adult mice (Morris et al., 2004). Therefore, the ability of all K14creP.Δ3β-catflx/wt lines to seed 
distant colonies, even K14creP.Δ3β-catflx/wt alone cells, as observed in all primary neonatal 
keratinocyte cultures would be consistent with β-catenin overexpression resulting in a return to 
juvenile/neonatal primary cell phenotypes. This conclusion would also be supported in this 
current model by the findings of β-catenin effects on the decisions of stem cells/ PCK cells 
that appear to centre on juvenile epidermal development rather than adults as exemplified by 
those mice that were full sized and had an epidermis which developed relatively normally eg 
following p53 loss and the roles for proteins such as p63 and 73 that directly regulate early 
epidermal and HF development.  
 
Collectively, these data suggest that all Δ3β-catenin lines are transformed to some extent or 
even malignant and demonstrates the major differences between in vivo and in vitro 
experimentation which lacks the tissue homeostasis needed to elicit the biological spectrum of 
responses observed. However, clonal growth and seeding in Low Cal would be consistent with 
Δ3β-catenin mediated influences on stem cells or a return to a more stem-like PCK phenotype; 
whilst growth in Hi Cal demonstrate that these combinations can co-operate with β-catenin to 
fulfil the criteria required for a malignant phenotype in classic keratinocyte transformation 
assays and are thus more consistent with the endogenous β-catenin oncogenicity observed in 
the original HK1.ras/fos/PTEN SCC model and the literature associated with β-catenin in 





9.6 Conclusion and future directions  
This study was conducted to help unravel the exact causal roles for constitutive β-catenin 
activation in development of SCCs employing a well characterised transgenic mouse model of 
multi-stage carcinogenesis. The findings of this study were intriguing and shed light on several 
aspects that can be pursued in the future to gain understanding and fill the void in the current 
literature concerning the causal roles for β-catenin overexpression in cutaneous 
carcinogenesis. Clearly if an epidermis was allowed to develop normally, endogenous β-
catenin in conjunction with HK1.ras, HK1.fos and PTEN loss, plays a significant role in the 
conversion of papillomas to carcinomas as suggested by knockout in classic chemical 
carcinogenesis experiments and the cell line phenotypes derived in this study. In the rare 
instances of tumour formation these roles again appear and demonstrate that they directly 
contribute to SCCs due to incorrect control of β-catenin (Malanchi, et al., 2008) in a two fold 
manner; one involving β-catenin maintenance of the cell-cell adhesion by binding to E-
cadherin, as impairment of this function facilitated malignant progression in HK1.ras-
K14creP.Δ3β-catflx/wt.p53flx/flx  SCCs and carcinomas in HK1.ras/fos-K14cre.Δ5PTEN (Jeanes 
et al., 2008; Macdonald et al., 2014); the second depending upon basal layer expression of 
nuclear β-catenin and thus deregulation of canonical Wnt signalling and disruption of the stem 
cell niches (Watt and Collins, 2008).  
 
Given this integral role in regulation of the HF bulge stem cells niche and the KPC 
populations that reside in the IFE the premature activation of Δ3β-catenin in the juvenile skin 
of this HK1 study led to incorrect control of stem cell niche/KPC, which is integral component 
in maintaining epidermal haematosis and keratinocyte differentiation, thus compensatory 
TSGS [p53/p21/p73/p63] levels were elevated to suppress the susceptibility to IFE tumours 
and this depended upon a functional p53, as exemplified by the novel unique co-operation 
between fos and β-catenin deregulation which generated the pangolin-like skin of HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt mice being completely blocked in HK1.fos-K14creP.Δ3β-
catflx/wt .p53flx/flx mice.   
 
These compensatory responses of TSGs led to aberrant alteration in epidermal terminal 
differentiation and these alteration were more potent in co-operation of Δ3β-catenin with other 
oncogenes resulting in aggressive skin phenotype in term of keratosis and HF abnormalities 
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but no IFE tumours as seen in HK1.ras-K14creP.Δ3β-catflx/wt and HK1.fos-
K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt   cohorts even following p53 loss. Indeed, p53 mediated 
responses seemed to be the key in driving these juvenile skin phenotypes in response to Δ3β-
catenin, as they were blocked by conditional loss of p53 Δ3β-catenin associated skin 
phenotypes in both HK1.fos-K14creP.Δ3β-catflx/wt -p53flx/flx and HK1.ras-K14creP.Δ3β-
catflx/wt.p53flx/flx models; and this was p53 specific not being observed with p21ko. However, 
and more consistent with the original aims if the K14.cre regulator did not leak the delayed 
activation of Δ3β-catenin in a fully developed adult epidermis provided enough time to 
establish a context where papillomas could develop and which converted rapidly to SCC 
following loss of p53 as observed in HK1.ras/fos-K14Δ5PTEN mice. Thus again reinforcing 
the idea that Δ3β-catenin associated phenotypes derived from deregulation of β-catenin during 
epidermal development, and that losing p53 makes the adult skin more susceptibility to IFE 
tumours; whist in juvenile stages, Δ3β-catenin oncogenic activation can be overcome by 
possibly other TSGs [p21, p63,p73], however later stages of tumour development p53 loss in 
conjunction with Δ3β-catenin facilitate SCC development.  
 
The in vitro activation of Δ3β-catenin was more in line with literature finding in term of 
inducing transformation and malignant phenotypes in co-operation with other oncogenes such 
as HK1.fos-K14creP.Δ5PTENflx/flx.Δ3β-catflx/wt and HK1.ras-K14creP.Δ3β-catflx/wt cell lines. 
However, another most interesting observation in the in vitro part of the study was the ability 
of β-catenin to re-programme the epidermis to a more neonatal/juvenile state. This indicated 
the affect Δ3β-catenin could be context dependent and many aspects could be investigated to 
understand these paradoxical results further.  
 
Future Directions  
  
To extrapolate these findings both in vivo and in vitro several actions can be taken in terms of 
protein analysis to determine the mechanism further via completion of the western analysis. 
Given the large amount of data complied, the induction of new transgenes that interact with 
these Δ3β-catenin effect on the epidermis would also answer several of the questions posed by 
these studies such as the following:  
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- Western blot protein analysis and immunocytochemistry analysis in vitro analysis is an 
essential future analysis to contrasts in vivo results in terms of protein expressions such 
as K1,K6,K15,p53,p21,p63,p73,E-cadherin, β-catenin and AKT 
- Investigating an ongoing study to test induction of p53 conditional loss together with 
embryonic knockout of p21 in HK1.ras.K14.Δ3β-cat-p53flx/flx.p21KO to assess their 
effect on papilloma development, epidermal differentiation and reduced/increased 
severity of Δ3β-catenin phenotype. This most likely would have to be performed with 
the now non leaky XJ5 creP regulator. 
- Due to the early cre leak K14creP.Δ3β-catflx/wt , same cohorts will be repeated again 
using XJK5creP* gene switch which initially showed no early cre leak indicted by the 
lack of Δ3β-catenin phenotype in these mice; although to date these appear to require 
extensive, prolonged RU486 treatment and more time to produce phenotypes. 
- Given the implications in the responses to p53 loss in terms of  KPC proliferation and 
differentiation in this study, another interesting approach would be to investigate 
K14creP.Δ3β-catflx/wt -p63KO  and K14creP.Δ3β-catflx/wt -p73KO to assess their effect 
on altering differentiation and again in conjunction with HK1.ras activation to assess 
their effect on papilloma formation. Similarly in conjunction with K14creP.Δ3β-catflx/wt 
-ΔN63 and K14creP.Δ3β-catflx/wt -ΔN73   
- Investigating inducible E-cadherin knock out in co-operation with Δ3β-catenin is a 
experiment that will be performed in the near future, in conjunction also with HK1.ras 
and p53 loss, to assess how the epidermis will cope with E-cadherin loss and Δ3β-
catenin activation in regard to cell-cell adhesion and whether it will facilitate 
tumorigenesis. 
- Given the reported ability of β-catenin to reprogramme the epidermis to a more 
neonatal/juvenile state (Collins et al., 2011), which was an affect suggested in this 
study in both vivo and in vitro, assessing extra cellular matrix protein marker such as 
integrins and Tenascin-C (Yoshida et al., 2015) would give a further insight into how 
β-catenin effects the dermis-epidermis interaction. 
- One of the main analysis to be conducted on the different genotypes of this study is 
assessing stem cell markers other than K15 such as CD34 and LGR5/6. Although an 
attempt was already made to test LGR5/6 the analysis was inconclusive due cross 
reactivity of the antibodies used. 
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- Another target to be analysed in this study is perhaps BCL-2 as several studies 
suggested that β-catenin overexpression could influence apoptosis via overexpressing 
BCL2 (Ming et al., 2012) which could be interesting to see given β-catenin effect on 
apoptosis associated TSGs p53/p73/p63.  
- Given the implicated ability of K14creP.Δ3β-catflx/wt cultured cells to return the 
epidermis to neonatal/juvenile state, it would be interesting to see if these cultured cells 
would have wound healing ability, for example as skin grafts by testing onto nude 
mice. 
 
- Finally, a series of genomic and proteomic analysis of frozen skin biopsies may 





An epidermis in being most exposed to environmental carcinogens has many options to 
prevent benign tumour formation; which may become lost in aggressive papillomas leading to 
conversion. This model shows the importance of both context and temporal expression of 
oncogenic tumour promotion events vs. endogenous TSGs responses that will determine the 
phenotypic outcome. These potent responses to β-catenin deregulation maybe be quite general 
given they appear in response to ras/β-catenin/p53; fos β-catenin/p53; ras/p53 and fos/p53 
models and thus could be equally applicable to internal epithelia in the inhibition of early 
benign tumour [papilloma/KA] aetiology which are circumvented during malignant 
conversion /progression. In the final analysis it will be important to exploit these findings to 
discover exactly what is achieving this tumour inhibition and find new targets for new 
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